pmid
stringlengths 5
8
| title
stringlengths 17
342
| abstract
stringlengths 1
4.53k
| all_entity_list
listlengths 2
73
| label
sequencelengths 1
80
| intra-sentence
sequencelengths 1
80
| head_gene_entity
listlengths 1
80
| tail_diease_entity
listlengths 1
80
| head_name
sequencelengths 1
80
| tail_name
sequencelengths 1
80
|
|---|---|---|---|---|---|---|---|---|---|
10451710 | Loss of NF1 allele in Schwann cells but not in fibroblasts derived from an NF1-associated neurofibroma. | Neurofibromas, the hallmark of neurofibromatosis 1, are composed mainly of Schwann cells and fibroblasts. Inactivation of both NF1 alleles is the cause of these benign tumors, but it is unknown which cell type is the progenitor. In this study, we selectively cultured Schwann cells from an NF1-associated neurofibroma. Fibroblasts were also obtained by culturing the tumor cells under standard conditions. Using four intragenic markers, we genotyped the NF1 locus in the original tumor and in the derived Schwann cells and fibroblasts. Loss of heterozygosity for two informative markers, which indicates loss of one NF1 allele, was found in Schwann cells but not in fibroblasts. This result suggests that genetic alterations of the NF1 gene in Schwann cells are responsible for the development of neurofibromas. | [
{
"begin_idx": "265",
"end_idx": "278",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "benign tumors"
},
{
"begin_idx": "471",
"end_idx": "476",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumor"
},
{
"begin_idx": "584",
"end_idx": "589",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumor"
},
{
"begin_idx": "90",
"end_idx": "102",
"entity_id": "D009455",
"entity_type": "Disease",
"text_name": "neurofibroma"
},
{
"begin_idx": "104",
"end_idx": "117",
"entity_id": "D009455",
"entity_type": "Disease",
"text_name": "Neurofibromas"
},
{
"begin_idx": "409",
"end_idx": "421",
"entity_id": "D009455",
"entity_type": "Disease",
"text_name": "neurofibroma"
},
{
"begin_idx": "901",
"end_idx": "914",
"entity_id": "D009455",
"entity_type": "Disease",
"text_name": "neurofibromas"
},
{
"begin_idx": "8",
"end_idx": "11",
"entity_id": "4763",
"entity_type": "Gene",
"text_name": "NF1"
},
{
"begin_idx": "75",
"end_idx": "78",
"entity_id": "4763",
"entity_type": "Gene",
"text_name": "NF1"
},
{
"begin_idx": "135",
"end_idx": "154",
"entity_id": "4763",
"entity_type": "Gene",
"text_name": "neurofibromatosis 1"
},
{
"begin_idx": "231",
"end_idx": "234",
"entity_id": "4763",
"entity_type": "Gene",
"text_name": "NF1"
},
{
"begin_idx": "394",
"end_idx": "397",
"entity_id": "4763",
"entity_type": "Gene",
"text_name": "NF1"
},
{
"begin_idx": "558",
"end_idx": "561",
"entity_id": "4763",
"entity_type": "Gene",
"text_name": "NF1"
},
{
"begin_idx": "720",
"end_idx": "723",
"entity_id": "4763",
"entity_type": "Gene",
"text_name": "NF1"
},
{
"begin_idx": "836",
"end_idx": "839",
"entity_id": "4763",
"entity_type": "Gene",
"text_name": "NF1"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "135",
"end_idx": "154",
"entity_id": "4763",
"entity_type": "Gene",
"text_name": "neurofibromatosis 1"
},
{
"begin_idx": "394",
"end_idx": "397",
"entity_id": "4763",
"entity_type": "Gene",
"text_name": "NF1"
}
] | [
{
"begin_idx": "104",
"end_idx": "117",
"entity_id": "D009455",
"entity_type": "Disease",
"text_name": "Neurofibromas"
},
{
"begin_idx": "471",
"end_idx": "476",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumor"
}
] | [
"neurofibromatosis 1",
"NF1"
] | [
"Neurofibromas",
"tumor"
] |
10451958 | [The association of HLA-DR4 gene subtypes with Vogt-Koyanagi-Harada syndrome]. | OBJECTIVE: To investigate the association of HLA-DR4 subtypes with Vogt-Koyanagi-Harada (VKH) syndrome and to clarify immune genetic mechanism underlying the susceptibility/resistance to VKH syndrome. METHODS: HLA-DR4 alleles of 54 patients with VKH and 106 healthy controls were amplified and subtyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). RESULTS: A selective amplification of the DR4 alleles of 263 bp was higher in patients with VKH than in the controls. The frequency of DR4-DRB1 alleles was 70% (38/54) in VKH group and was 19% (20/106) in the control group, relative rish (RR) = 10.21, P < 0.005. The genotyping of DR4 alleles showed that DRB1 * 0405 was more frequent in VKH group (35/38, 92%) than in the control group [6/20, 30%, RR = 27.2, P = 0.0,000,017, corrected pvalue (Pc) = 0.0,000,103]. CONCLUSIONS: It is suggested that DRB1 * 0405 be a susceptible subtype to VKH and the specific amino acid residue Ser (serine) at position 57 play an important role in the development of VKH syndrome. The molecular biological technique we used may be useful in studying the immunogenetic mechanism of VKH. | [
{
"begin_idx": "47",
"end_idx": "76",
"entity_id": "D014607",
"entity_type": "Disease",
"text_name": "Vogt-Koyanagi-Harada syndrome"
},
{
"begin_idx": "146",
"end_idx": "181",
"entity_id": "D014607",
"entity_type": "Disease",
"text_name": "Vogt-Koyanagi-Harada (VKH) syndrome"
},
{
"begin_idx": "266",
"end_idx": "278",
"entity_id": "D014607",
"entity_type": "Disease",
"text_name": "VKH syndrome"
},
{
"begin_idx": "1116",
"end_idx": "1128",
"entity_id": "D014607",
"entity_type": "Disease",
"text_name": "VKH syndrome"
},
{
"begin_idx": "603",
"end_idx": "607",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "DRB1"
},
{
"begin_idx": "769",
"end_idx": "773",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "DRB1"
},
{
"begin_idx": "963",
"end_idx": "967",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "DRB1"
},
{
"begin_idx": "24",
"end_idx": "27",
"entity_id": "3126",
"entity_type": "Gene",
"text_name": "DR4"
},
{
"begin_idx": "128",
"end_idx": "131",
"entity_id": "3126",
"entity_type": "Gene",
"text_name": "DR4"
},
{
"begin_idx": "293",
"end_idx": "296",
"entity_id": "3126",
"entity_type": "Gene",
"text_name": "DR4"
},
{
"begin_idx": "506",
"end_idx": "509",
"entity_id": "3126",
"entity_type": "Gene",
"text_name": "DR4"
},
{
"begin_idx": "599",
"end_idx": "602",
"entity_id": "3126",
"entity_type": "Gene",
"text_name": "DR4"
},
{
"begin_idx": "745",
"end_idx": "748",
"entity_id": "3126",
"entity_type": "Gene",
"text_name": "DR4"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "603",
"end_idx": "607",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "DRB1"
},
{
"begin_idx": "128",
"end_idx": "131",
"entity_id": "3126",
"entity_type": "Gene",
"text_name": "DR4"
}
] | [
{
"begin_idx": "146",
"end_idx": "181",
"entity_id": "D014607",
"entity_type": "Disease",
"text_name": "Vogt-Koyanagi-Harada (VKH) syndrome"
},
{
"begin_idx": "266",
"end_idx": "278",
"entity_id": "D014607",
"entity_type": "Disease",
"text_name": "VKH syndrome"
}
] | [
"DRB1",
"DR4"
] | [
"Vogt-Koyanagi-Harada (VKH) syndrome",
"VKH syndrome"
] |
10453738 | Association of the human NPPS gene with ossification of the posterior longitudinal ligament of the spine (OPLL). | OPLL (ossification of the posterior longitudinal ligament of the spine) is a common form of human myelopathy with a prevalence of as much as 4% in a variety of ethnic groups. To clarify the genetic factors that predispose to OPLL, we have studied ttw (tiptoe walking), a mouse model that presents ectopic ossification of the spinal ligaments similar to OPLL and have found that the ttw phenotype is caused by the nonsense mutation of the gene encoding nucleotide pyrophosphatase (NPPS), a membrane-bound glycoprotein thought to produce inorganic pyrophosphate, a major inhibitor of calcification and mineralization. To investigate a possible role of NPPS in the etiology of OPLL, we have examined its genetic variations in OPLL patients. A total of 323 OPLL patients was screened by means of polymerase chain reaction/single-strand conformation polymorphism analysis covering all the exons and their surrounding introns, plus about 1.5-kb of the promoter region. We identified ten nucleotide variations in the NPPS gene; five of the alterations caused amino-acid substitutions, and two of them were found specifically in OPLL patients. Subsequently, we performed an association study using these variations and found a significant association of an allele, viz., a deletion of T at a position 11 nucleotides upstream from the splice acceptor site of intron 20 (IVS20-11delT), with OPLL; the proportion of the individuals having this deletion was significantly higher (P = 0.0029) in OPLL patients than in controls, indicating that those who have this variation may be more susceptible to the abnormal ossification of the spinal ligaments. Thus, our study suggests that NPPS plays an important role in the etiology of human OPLL. | [
{
"begin_idx": "40",
"end_idx": "104",
"entity_id": "C537143",
"entity_type": "Disease",
"text_name": "ossification of the posterior longitudinal ligament of the spine"
},
{
"begin_idx": "106",
"end_idx": "110",
"entity_id": "C537143",
"entity_type": "Disease",
"text_name": "OPLL"
},
{
"begin_idx": "113",
"end_idx": "117",
"entity_id": "C537143",
"entity_type": "Disease",
"text_name": "OPLL"
},
{
"begin_idx": "119",
"end_idx": "183",
"entity_id": "C537143",
"entity_type": "Disease",
"text_name": "ossification of the posterior longitudinal ligament of the spine"
},
{
"begin_idx": "338",
"end_idx": "342",
"entity_id": "C537143",
"entity_type": "Disease",
"text_name": "OPLL"
},
{
"begin_idx": "466",
"end_idx": "470",
"entity_id": "C537143",
"entity_type": "Disease",
"text_name": "OPLL"
},
{
"begin_idx": "787",
"end_idx": "791",
"entity_id": "C537143",
"entity_type": "Disease",
"text_name": "OPLL"
},
{
"begin_idx": "836",
"end_idx": "840",
"entity_id": "C537143",
"entity_type": "Disease",
"text_name": "OPLL"
},
{
"begin_idx": "866",
"end_idx": "870",
"entity_id": "C537143",
"entity_type": "Disease",
"text_name": "OPLL"
},
{
"begin_idx": "1234",
"end_idx": "1238",
"entity_id": "C537143",
"entity_type": "Disease",
"text_name": "OPLL"
},
{
"begin_idx": "1494",
"end_idx": "1498",
"entity_id": "C537143",
"entity_type": "Disease",
"text_name": "OPLL"
},
{
"begin_idx": "1596",
"end_idx": "1600",
"entity_id": "C537143",
"entity_type": "Disease",
"text_name": "OPLL"
},
{
"begin_idx": "1836",
"end_idx": "1840",
"entity_id": "C537143",
"entity_type": "Disease",
"text_name": "OPLL"
},
{
"begin_idx": "25",
"end_idx": "29",
"entity_id": "C566309",
"entity_type": "Disease",
"text_name": "NPPS"
},
{
"begin_idx": "565",
"end_idx": "591",
"entity_id": "C566309",
"entity_type": "Disease",
"text_name": "nucleotide pyrophosphatase"
},
{
"begin_idx": "593",
"end_idx": "597",
"entity_id": "C566309",
"entity_type": "Disease",
"text_name": "NPPS"
},
{
"begin_idx": "763",
"end_idx": "767",
"entity_id": "C566309",
"entity_type": "Disease",
"text_name": "NPPS"
},
{
"begin_idx": "1123",
"end_idx": "1127",
"entity_id": "C566309",
"entity_type": "Disease",
"text_name": "NPPS"
},
{
"begin_idx": "1782",
"end_idx": "1786",
"entity_id": "C566309",
"entity_type": "Disease",
"text_name": "NPPS"
},
{
"begin_idx": "410",
"end_idx": "430",
"entity_id": "D009999",
"entity_type": "Disease",
"text_name": "ectopic ossification"
},
{
"begin_idx": "211",
"end_idx": "221",
"entity_id": "D013118",
"entity_type": "Disease",
"text_name": "myelopathy"
},
{
"begin_idx": "25",
"end_idx": "29",
"entity_id": "5167",
"entity_type": "Gene",
"text_name": "NPPS"
},
{
"begin_idx": "565",
"end_idx": "591",
"entity_id": "5167",
"entity_type": "Gene",
"text_name": "nucleotide pyrophosphatase"
},
{
"begin_idx": "593",
"end_idx": "597",
"entity_id": "5167",
"entity_type": "Gene",
"text_name": "NPPS"
},
{
"begin_idx": "763",
"end_idx": "767",
"entity_id": "5167",
"entity_type": "Gene",
"text_name": "NPPS"
},
{
"begin_idx": "1123",
"end_idx": "1127",
"entity_id": "5167",
"entity_type": "Gene",
"text_name": "NPPS"
},
{
"begin_idx": "1782",
"end_idx": "1786",
"entity_id": "5167",
"entity_type": "Gene",
"text_name": "NPPS"
},
{
"begin_idx": "106",
"end_idx": "110",
"entity_id": "7933",
"entity_type": "Gene",
"text_name": "OPLL"
},
{
"begin_idx": "113",
"end_idx": "117",
"entity_id": "7933",
"entity_type": "Gene",
"text_name": "OPLL"
},
{
"begin_idx": "338",
"end_idx": "342",
"entity_id": "7933",
"entity_type": "Gene",
"text_name": "OPLL"
},
{
"begin_idx": "466",
"end_idx": "470",
"entity_id": "7933",
"entity_type": "Gene",
"text_name": "OPLL"
},
{
"begin_idx": "787",
"end_idx": "791",
"entity_id": "7933",
"entity_type": "Gene",
"text_name": "OPLL"
},
{
"begin_idx": "836",
"end_idx": "840",
"entity_id": "7933",
"entity_type": "Gene",
"text_name": "OPLL"
},
{
"begin_idx": "866",
"end_idx": "870",
"entity_id": "7933",
"entity_type": "Gene",
"text_name": "OPLL"
},
{
"begin_idx": "1234",
"end_idx": "1238",
"entity_id": "7933",
"entity_type": "Gene",
"text_name": "OPLL"
},
{
"begin_idx": "1494",
"end_idx": "1498",
"entity_id": "7933",
"entity_type": "Gene",
"text_name": "OPLL"
},
{
"begin_idx": "1596",
"end_idx": "1600",
"entity_id": "7933",
"entity_type": "Gene",
"text_name": "OPLL"
},
{
"begin_idx": "1836",
"end_idx": "1840",
"entity_id": "7933",
"entity_type": "Gene",
"text_name": "OPLL"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "565",
"end_idx": "591",
"entity_id": "5167",
"entity_type": "Gene",
"text_name": "nucleotide pyrophosphatase"
},
{
"begin_idx": "466",
"end_idx": "470",
"entity_id": "7933",
"entity_type": "Gene",
"text_name": "OPLL"
}
] | [
{
"begin_idx": "40",
"end_idx": "104",
"entity_id": "C537143",
"entity_type": "Disease",
"text_name": "ossification of the posterior longitudinal ligament of the spine"
},
{
"begin_idx": "1494",
"end_idx": "1498",
"entity_id": "C537143",
"entity_type": "Disease",
"text_name": "OPLL"
}
] | [
"nucleotide pyrophosphatase",
"OPLL"
] | [
"ossification of the posterior longitudinal ligament of the spine",
"OPLL"
] |
10453740 | Comparison of complementary and genomic DNA sequencing for the detection of mutations in the HMBS gene in British patients with acute intermittent porphyria: identification of 25 novel mutations. | Acute intermittent porphyria (AIP) is a low-penetrant autosomal dominant disorder caused by mutations in the hydroxymethylbilane synthase (HMBS) gene. Direct detection of mutations is becoming the method of choice for the accurate identification of asymptomatic affected individuals within AIP families so that they can be advised to avoid drugs and other compounds that provoke the life-threatening acute neurovisceral crises that characterise the condition. We describe a prospective comparison of direct automated sequencing of cDNA (29 patients) or genomic DNA (28 patients) to identify HMBS mutations in 57 patients referred consecutively for mutational analysis; 39 different mutations were identified in 54 patients. The sensitivity of the cDNA and genomic DNA methods was 69% and 95%, respectively, indicating that analysis of genomic DNA provides a higher mutation detection rate. Thirty mutations were restricted to a single family; only one (R173W) occurred in more than three families. Of the mutations (6 missense, 8 splice defects, 10 frameshifts, 1 nonsense), 25 have not been reported previously. One novel mutation (344+33G-->T) was located in a putative intron splice enhancer in intron7. Our results define the extent of allelic heterogeneity and the types (41% missense; 59% truncating) and distribution (35% in exons 10, 12, 14) of HMBS mutations, for AIP in the United Kingdom. | [
{
"begin_idx": "147",
"end_idx": "156",
"entity_id": "D011164",
"entity_type": "Disease",
"text_name": "porphyria"
},
{
"begin_idx": "93",
"end_idx": "97",
"entity_id": "D017118",
"entity_type": "Disease",
"text_name": "HMBS"
},
{
"begin_idx": "196",
"end_idx": "224",
"entity_id": "D017118",
"entity_type": "Disease",
"text_name": "Acute intermittent porphyria"
},
{
"begin_idx": "226",
"end_idx": "229",
"entity_id": "D017118",
"entity_type": "Disease",
"text_name": "AIP"
},
{
"begin_idx": "305",
"end_idx": "333",
"entity_id": "D017118",
"entity_type": "Disease",
"text_name": "hydroxymethylbilane synthase"
},
{
"begin_idx": "335",
"end_idx": "339",
"entity_id": "D017118",
"entity_type": "Disease",
"text_name": "HMBS"
},
{
"begin_idx": "486",
"end_idx": "489",
"entity_id": "D017118",
"entity_type": "Disease",
"text_name": "AIP"
},
{
"begin_idx": "787",
"end_idx": "791",
"entity_id": "D017118",
"entity_type": "Disease",
"text_name": "HMBS"
},
{
"begin_idx": "1549",
"end_idx": "1553",
"entity_id": "D017118",
"entity_type": "Disease",
"text_name": "HMBS"
},
{
"begin_idx": "1569",
"end_idx": "1572",
"entity_id": "D017118",
"entity_type": "Disease",
"text_name": "AIP"
},
{
"begin_idx": "250",
"end_idx": "277",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal dominant disorder"
},
{
"begin_idx": "93",
"end_idx": "97",
"entity_id": "3145",
"entity_type": "Gene",
"text_name": "HMBS"
},
{
"begin_idx": "305",
"end_idx": "333",
"entity_id": "3145",
"entity_type": "Gene",
"text_name": "hydroxymethylbilane synthase"
},
{
"begin_idx": "335",
"end_idx": "339",
"entity_id": "3145",
"entity_type": "Gene",
"text_name": "HMBS"
},
{
"begin_idx": "787",
"end_idx": "791",
"entity_id": "3145",
"entity_type": "Gene",
"text_name": "HMBS"
},
{
"begin_idx": "1549",
"end_idx": "1553",
"entity_id": "3145",
"entity_type": "Gene",
"text_name": "HMBS"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "305",
"end_idx": "333",
"entity_id": "3145",
"entity_type": "Gene",
"text_name": "hydroxymethylbilane synthase"
},
{
"begin_idx": "1549",
"end_idx": "1553",
"entity_id": "3145",
"entity_type": "Gene",
"text_name": "HMBS"
}
] | [
{
"begin_idx": "196",
"end_idx": "224",
"entity_id": "D017118",
"entity_type": "Disease",
"text_name": "Acute intermittent porphyria"
},
{
"begin_idx": "250",
"end_idx": "277",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal dominant disorder"
}
] | [
"hydroxymethylbilane synthase",
"HMBS"
] | [
"Acute intermittent porphyria",
"autosomal dominant disorder"
] |
10458483 | Point mutations in the steroid-binding domain of the androgen receptor gene of five Japanese patients with androgen insensitivity syndrome. | We analyzed the androgen receptor (AR) gene in five Japanese patients diagnosed with androgen insensitivity syndrome (AIS). All AR genes from the five patients had single-nucleotide substitutions, which introduced a premature termination codon in three patients (Gln640, Arg752, and Gln640 and Trp751), and a single amino acid substitution in two patients (Arg831 to Gln, and Leu812 to Phe). All the mutations occurred in the steroid-binding domain, comprising exons D through G. The three patients with the premature termination codon(s) and the one patient with Arg831Gln were clinically diagnosed as having complete AIS, while the patient with Leu812Phe had a partial form of AIS. Pubic skin fibroblasts from four of the five patients did not show detectable androgen binding. These data on mutations that have not been reported previously, provide valuable information for the further characterization of structural and functional relationships in the steroid-binding domain of the AR protein. | [
{
"begin_idx": "107",
"end_idx": "138",
"entity_id": "D013734",
"entity_type": "Disease",
"text_name": "androgen insensitivity syndrome"
},
{
"begin_idx": "225",
"end_idx": "256",
"entity_id": "D013734",
"entity_type": "Disease",
"text_name": "androgen insensitivity syndrome"
},
{
"begin_idx": "258",
"end_idx": "261",
"entity_id": "D013734",
"entity_type": "Disease",
"text_name": "AIS"
},
{
"begin_idx": "759",
"end_idx": "762",
"entity_id": "D013734",
"entity_type": "Disease",
"text_name": "AIS"
},
{
"begin_idx": "819",
"end_idx": "822",
"entity_id": "D013734",
"entity_type": "Disease",
"text_name": "AIS"
},
{
"begin_idx": "53",
"end_idx": "70",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "androgen receptor"
},
{
"begin_idx": "156",
"end_idx": "173",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "androgen receptor"
},
{
"begin_idx": "175",
"end_idx": "177",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "AR"
},
{
"begin_idx": "268",
"end_idx": "270",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "AR"
},
{
"begin_idx": "1126",
"end_idx": "1128",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "AR"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "53",
"end_idx": "70",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "androgen receptor"
}
] | [
{
"begin_idx": "107",
"end_idx": "138",
"entity_id": "D013734",
"entity_type": "Disease",
"text_name": "androgen insensitivity syndrome"
}
] | [
"androgen receptor"
] | [
"androgen insensitivity syndrome"
] |
10459572 | A common mutation in the methylenetetrahydrofolate reductase gene is a determinant of hyperhomocysteinemia in epileptic patients receiving anticonvulsants. | Hyperhomocysteinemia is a condition caused by both genetic and nongenetic factors. To determine whether a common methylenetetrahydrofolate reductase (MTHFR) variant is related to elevated homocysteine concentrations in epileptic patients receiving anticonvulsants, we investigated the plasma total homocysteine (tHcy) level, folate level, and MTHFR 677 C --> T mutation using a polymerase chain reaction (PCR) and restriction fragment length polymorphism analysis with HinfI digestion in 103 patients with epilepsy and 103 normal controls. The prevalence of hyperhomocysteinemia (> or = 11.4 micromol/L, 90th percentile of control group) was higher in patients than in controls (25% v 10.0%, P = .007). The homozygosity for the 677 C --> T mutation of MTHFR was associated with elevated tHcy and low folate levels. The magnitude of hyperhomocysteinemia in MTHFR TT homozygotes was more pronounced in epileptic patients than in controls (18.2 +/- 1.6 v 9.1 +/- 1.2 micromol/L, P = .04). In epileptic patients, hyperhomocysteinemia was more frequent in MTHFR TT genotypes versus CT or CC genotypes (58% v 17% and 16%, P < .001). Multiple logistic regression analysis showed that MTHFR TT genotype was an independent predictor of hyperhomocysteinemia in epileptic patients receiving anticonvulsants (phenytoin and carbamazepine but not valproic acid), suggesting that gene-drug interactions induce hyperhomocysteinemia. These findings indicate that epileptic patients receiving anticonvulsants may have a higher folate requirement to maintain a normal tHcy level, especially homozygotes for MTHFR 677 C --> T mutation. | [
{
"begin_idx": "25",
"end_idx": "60",
"entity_id": "C537357",
"entity_type": "Disease",
"text_name": "methylenetetrahydrofolate reductase"
},
{
"begin_idx": "269",
"end_idx": "304",
"entity_id": "C537357",
"entity_type": "Disease",
"text_name": "methylenetetrahydrofolate reductase"
},
{
"begin_idx": "306",
"end_idx": "311",
"entity_id": "C537357",
"entity_type": "Disease",
"text_name": "MTHFR"
},
{
"begin_idx": "499",
"end_idx": "504",
"entity_id": "C537357",
"entity_type": "Disease",
"text_name": "MTHFR"
},
{
"begin_idx": "908",
"end_idx": "913",
"entity_id": "C537357",
"entity_type": "Disease",
"text_name": "MTHFR"
},
{
"begin_idx": "1012",
"end_idx": "1017",
"entity_id": "C537357",
"entity_type": "Disease",
"text_name": "MTHFR"
},
{
"begin_idx": "1207",
"end_idx": "1212",
"entity_id": "C537357",
"entity_type": "Disease",
"text_name": "MTHFR"
},
{
"begin_idx": "1333",
"end_idx": "1338",
"entity_id": "C537357",
"entity_type": "Disease",
"text_name": "MTHFR"
},
{
"begin_idx": "1744",
"end_idx": "1749",
"entity_id": "C537357",
"entity_type": "Disease",
"text_name": "MTHFR"
},
{
"begin_idx": "110",
"end_idx": "119",
"entity_id": "D004827",
"entity_type": "Disease",
"text_name": "epileptic"
},
{
"begin_idx": "375",
"end_idx": "384",
"entity_id": "D004827",
"entity_type": "Disease",
"text_name": "epileptic"
},
{
"begin_idx": "662",
"end_idx": "670",
"entity_id": "D004827",
"entity_type": "Disease",
"text_name": "epilepsy"
},
{
"begin_idx": "1056",
"end_idx": "1065",
"entity_id": "D004827",
"entity_type": "Disease",
"text_name": "epileptic"
},
{
"begin_idx": "1145",
"end_idx": "1154",
"entity_id": "D004827",
"entity_type": "Disease",
"text_name": "epileptic"
},
{
"begin_idx": "1407",
"end_idx": "1416",
"entity_id": "D004827",
"entity_type": "Disease",
"text_name": "epileptic"
},
{
"begin_idx": "1602",
"end_idx": "1611",
"entity_id": "D004827",
"entity_type": "Disease",
"text_name": "epileptic"
},
{
"begin_idx": "86",
"end_idx": "106",
"entity_id": "D020138",
"entity_type": "Disease",
"text_name": "hyperhomocysteinemia"
},
{
"begin_idx": "156",
"end_idx": "176",
"entity_id": "D020138",
"entity_type": "Disease",
"text_name": "Hyperhomocysteinemia"
},
{
"begin_idx": "714",
"end_idx": "734",
"entity_id": "D020138",
"entity_type": "Disease",
"text_name": "hyperhomocysteinemia"
},
{
"begin_idx": "988",
"end_idx": "1008",
"entity_id": "D020138",
"entity_type": "Disease",
"text_name": "hyperhomocysteinemia"
},
{
"begin_idx": "1165",
"end_idx": "1185",
"entity_id": "D020138",
"entity_type": "Disease",
"text_name": "hyperhomocysteinemia"
},
{
"begin_idx": "1383",
"end_idx": "1403",
"entity_id": "D020138",
"entity_type": "Disease",
"text_name": "hyperhomocysteinemia"
},
{
"begin_idx": "1551",
"end_idx": "1571",
"entity_id": "D020138",
"entity_type": "Disease",
"text_name": "hyperhomocysteinemia"
},
{
"begin_idx": "25",
"end_idx": "60",
"entity_id": "4524",
"entity_type": "Gene",
"text_name": "methylenetetrahydrofolate reductase"
},
{
"begin_idx": "269",
"end_idx": "304",
"entity_id": "4524",
"entity_type": "Gene",
"text_name": "methylenetetrahydrofolate reductase"
},
{
"begin_idx": "306",
"end_idx": "311",
"entity_id": "4524",
"entity_type": "Gene",
"text_name": "MTHFR"
},
{
"begin_idx": "499",
"end_idx": "504",
"entity_id": "4524",
"entity_type": "Gene",
"text_name": "MTHFR"
},
{
"begin_idx": "908",
"end_idx": "913",
"entity_id": "4524",
"entity_type": "Gene",
"text_name": "MTHFR"
},
{
"begin_idx": "1012",
"end_idx": "1017",
"entity_id": "4524",
"entity_type": "Gene",
"text_name": "MTHFR"
},
{
"begin_idx": "1207",
"end_idx": "1212",
"entity_id": "4524",
"entity_type": "Gene",
"text_name": "MTHFR"
},
{
"begin_idx": "1333",
"end_idx": "1338",
"entity_id": "4524",
"entity_type": "Gene",
"text_name": "MTHFR"
},
{
"begin_idx": "1744",
"end_idx": "1749",
"entity_id": "4524",
"entity_type": "Gene",
"text_name": "MTHFR"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "25",
"end_idx": "60",
"entity_id": "4524",
"entity_type": "Gene",
"text_name": "methylenetetrahydrofolate reductase"
},
{
"begin_idx": "269",
"end_idx": "304",
"entity_id": "4524",
"entity_type": "Gene",
"text_name": "methylenetetrahydrofolate reductase"
}
] | [
{
"begin_idx": "86",
"end_idx": "106",
"entity_id": "D020138",
"entity_type": "Disease",
"text_name": "hyperhomocysteinemia"
},
{
"begin_idx": "269",
"end_idx": "304",
"entity_id": "C537357",
"entity_type": "Disease",
"text_name": "methylenetetrahydrofolate reductase"
}
] | [
"methylenetetrahydrofolate reductase",
"methylenetetrahydrofolate reductase"
] | [
"hyperhomocysteinemia",
"methylenetetrahydrofolate reductase"
] |
10462014 | Changes in endothelium-derived vascular regulatory factors during dobutamine-stress-induced silent myocardial ischemia in patients with Kawasaki disease. | The changes in endothelium-derived vascular regulatory factors during dobutamine (DOB)-induced myocardial ischemia (MI) were investigated in 21 patients with Kawasaki disease aged from 11 months to 18 years. They were classified into an ischemia group (8 patients) and a non-ischemia group (13 patients) based on the results of 99mTc myocardial scintigraphy and DOB stress 99mTc myocardial scintigraphy. In the ischemia group, MI was relatively mild, because there were ischemic changes on the electrocardiogram and no significant symptoms during DOB stress. Catheters were positioned near the orifice of the coronary artery (Ao) and at the coronary sinus (CS). Hemodynamics and the blood concentrations of lactic acid and endothelin-1, as well as NO3-, 6-keto-prostaglandin F1alpha, and thromboxane B2, (which are inactive metabolites of nitric oxide, prostaglandin I2 and thromboxane A2, respectively), were measured at rest and after DOB stress (maximum dose: 30 microg x kg(-1) x min(-1)). The CS/Ao ratio was determined for all parameters. The rate-pressure product, an index of work load, and the cardiac index were significantly increased by DOB stress in both groups. Coronary angiography showed no vasospasm of the epicardial coronary arteries before or after DOB stress in either group. The plasma concentrations of endothelin-1 and 6-keto-prostaglandin F1alpha were significantly increased after DOB stress in the ischemia group, but the serum concentration of NO did not increase. The lack of an increase in NO production during DOB stress may have contributed to the worsening of MI in patients with Kawasaki disease. | [
{
"begin_idx": "136",
"end_idx": "152",
"entity_id": "C537014",
"entity_type": "Disease",
"text_name": "Kawasaki disease"
},
{
"begin_idx": "312",
"end_idx": "328",
"entity_id": "C537014",
"entity_type": "Disease",
"text_name": "Kawasaki disease"
},
{
"begin_idx": "1767",
"end_idx": "1783",
"entity_id": "C537014",
"entity_type": "Disease",
"text_name": "Kawasaki disease"
},
{
"begin_idx": "391",
"end_idx": "399",
"entity_id": "D007511",
"entity_type": "Disease",
"text_name": "ischemia"
},
{
"begin_idx": "429",
"end_idx": "437",
"entity_id": "D007511",
"entity_type": "Disease",
"text_name": "ischemia"
},
{
"begin_idx": "565",
"end_idx": "573",
"entity_id": "D007511",
"entity_type": "Disease",
"text_name": "ischemia"
},
{
"begin_idx": "1579",
"end_idx": "1587",
"entity_id": "D007511",
"entity_type": "Disease",
"text_name": "ischemia"
},
{
"begin_idx": "488",
"end_idx": "511",
"entity_id": "D009202",
"entity_type": "Disease",
"text_name": "myocardial scintigraphy"
},
{
"begin_idx": "533",
"end_idx": "556",
"entity_id": "D009202",
"entity_type": "Disease",
"text_name": "myocardial scintigraphy"
},
{
"begin_idx": "99",
"end_idx": "118",
"entity_id": "D017202",
"entity_type": "Disease",
"text_name": "myocardial ischemia"
},
{
"begin_idx": "249",
"end_idx": "268",
"entity_id": "D017202",
"entity_type": "Disease",
"text_name": "myocardial ischemia"
},
{
"begin_idx": "270",
"end_idx": "272",
"entity_id": "D017202",
"entity_type": "Disease",
"text_name": "MI"
},
{
"begin_idx": "581",
"end_idx": "583",
"entity_id": "D017202",
"entity_type": "Disease",
"text_name": "MI"
},
{
"begin_idx": "1747",
"end_idx": "1749",
"entity_id": "D017202",
"entity_type": "Disease",
"text_name": "MI"
},
{
"begin_idx": "1361",
"end_idx": "1370",
"entity_id": "D020301",
"entity_type": "Disease",
"text_name": "vasospasm"
},
{
"begin_idx": "877",
"end_idx": "889",
"entity_id": "1906",
"entity_type": "Gene",
"text_name": "endothelin-1"
},
{
"begin_idx": "1480",
"end_idx": "1492",
"entity_id": "1906",
"entity_type": "Gene",
"text_name": "endothelin-1"
}
] | [
"Yes",
"No"
] | [
false,
true
] | [
{
"begin_idx": "877",
"end_idx": "889",
"entity_id": "1906",
"entity_type": "Gene",
"text_name": "endothelin-1"
},
{
"begin_idx": "877",
"end_idx": "889",
"entity_id": "1906",
"entity_type": "Gene",
"text_name": "endothelin-1"
}
] | [
{
"begin_idx": "99",
"end_idx": "118",
"entity_id": "D017202",
"entity_type": "Disease",
"text_name": "myocardial ischemia"
},
{
"begin_idx": "391",
"end_idx": "399",
"entity_id": "D007511",
"entity_type": "Disease",
"text_name": "ischemia"
}
] | [
"endothelin-1",
"endothelin-1"
] | [
"myocardial ischemia",
"ischemia"
] |
10462600 | Two Novel Mutations in the Cystathionine beta-synthase Gene of Homocystinuric Patients. | Background: The continued identfication of new mutations in the cystathionine beta-synthase (CBS) gene is important in correlating the genotype/phenotype of patients with classic homocystinuria and in assessing whether heterozygosity of CBS deficiency is an important cause of mild hyperhomocysteinemia, an independent risk factor for occlusive vascular diseases. Methods and Results: Single-strand polymorphism and direct nucleotide sequencing were used to detect two novel mutations in the CBS gene of three homocystinuric patients from two unrelated families. The first mutation, a G-to-A transistion at nucleotide 1316 in exon 12, results in an amino acid substitution of arginine by glutamine at codon 439. The second mutation is a G-to-A transition at nucleotide 1109 in exon 10 and results in an amino acid substitution of cysteine by tyrosine at codon 370. All three patients are apparently compound heterozygotes, with one of the two novel mutations on one allele and the T(833)C mutation on the other allele. Conclusions: The absence of the G(1316)A and G(1109)A in 216 control alleles demonstrates that these two novel mutations do not represent common polymorphisms, but rather are responsible for the defective CBS enzyme activities encoded by one of the two alleles of the CBS gene in each of the two families. | [
{
"begin_idx": "267",
"end_idx": "281",
"entity_id": "D006712",
"entity_type": "Disease",
"text_name": "homocystinuria"
},
{
"begin_idx": "325",
"end_idx": "339",
"entity_id": "D006712",
"entity_type": "Disease",
"text_name": "CBS deficiency"
},
{
"begin_idx": "433",
"end_idx": "450",
"entity_id": "D014652",
"entity_type": "Disease",
"text_name": "vascular diseases"
},
{
"begin_idx": "370",
"end_idx": "390",
"entity_id": "D020138",
"entity_type": "Disease",
"text_name": "hyperhomocysteinemia"
},
{
"begin_idx": "27",
"end_idx": "54",
"entity_id": "875",
"entity_type": "Gene",
"text_name": "Cystathionine beta-synthase"
},
{
"begin_idx": "152",
"end_idx": "179",
"entity_id": "875",
"entity_type": "Gene",
"text_name": "cystathionine beta-synthase"
},
{
"begin_idx": "181",
"end_idx": "184",
"entity_id": "875",
"entity_type": "Gene",
"text_name": "CBS"
},
{
"begin_idx": "580",
"end_idx": "583",
"entity_id": "875",
"entity_type": "Gene",
"text_name": "CBS"
},
{
"begin_idx": "1312",
"end_idx": "1315",
"entity_id": "875",
"entity_type": "Gene",
"text_name": "CBS"
},
{
"begin_idx": "1375",
"end_idx": "1378",
"entity_id": "875",
"entity_type": "Gene",
"text_name": "CBS"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "27",
"end_idx": "54",
"entity_id": "875",
"entity_type": "Gene",
"text_name": "Cystathionine beta-synthase"
},
{
"begin_idx": "152",
"end_idx": "179",
"entity_id": "875",
"entity_type": "Gene",
"text_name": "cystathionine beta-synthase"
}
] | [
{
"begin_idx": "267",
"end_idx": "281",
"entity_id": "D006712",
"entity_type": "Disease",
"text_name": "homocystinuria"
},
{
"begin_idx": "370",
"end_idx": "390",
"entity_id": "D020138",
"entity_type": "Disease",
"text_name": "hyperhomocysteinemia"
}
] | [
"Cystathionine beta-synthase",
"cystathionine beta-synthase"
] | [
"homocystinuria",
"hyperhomocysteinemia"
] |
10464147 | Biliary fibrosis associated with altered bile composition in a mouse model of erythropoietic protoporphyria. | BACKGROUND _ AIMS: Reduced activity of ferrochelatase in erythropoietic protoporphyria (EPP) results in protoporphyrin (PP) accumulation in erythrocytes and liver. Liver disease may occur in patients with EPP, some of whom develop progressive liver failure that necessitates transplantation. We investigated the mechanisms underlying EPP-associated liver disease in a mouse model of EPP. METHODS: Liver histology, indicators of lipid peroxidation, plasma parameters of liver function, and bile composition were studied in mice homozygous (fch/fch) for a point mutation in the ferrochelatase gene and in heterozygous (fch/+) and wild-type (+/+) mice. RESULTS: Microscopic examination showed bile duct proliferation and biliary fibrosis with portoportal bridging in fch/fch mice. PP content was 130-fold increased, and thiobarbituric acid-reactive substances (+30%) and conjugated dienes (+75%) were slightly higher in fch/fch than in fch/+ and +/+ livers. Levels of hepatic thiols (-12%) and iron (-52%) were reduced in fch/fch livers. Liver enzymes and plasma bilirubin were markedly increased in the homozygotes. Plasma bile salt levels were 80 times higher in fch/fch than in fch/+ and +/+ mice, probably related to the absence of the Na(+)-taurocholate cotransporting protein (Ntcp) in fch/fch liver. Paradoxically, bile flow was not impaired and biliary bile salt secretion was 4 times higher in fch/fch mice than in controls. Up-regulation of the intestinal Na(+)-dependent bile salt transport system in fch/fch mice may enhance efficiency of bile salt reabsorption. The bile salt/lipid ratio and PP content of fch/fch bile were increased 2-fold and 85-fold, respectively, compared with +/+, whereas biliary glutathione was reduced by 90%. Similar effects on bile formation were caused by griseofulvin-induced inhibition of ferrochelatase activity in control mice. CONCLUSIONS: Bile formation is strongly affected in mice with impaired ferrochelatase activity. Rather than peroxidative processes, formation of cytotoxic bile with high concentrations of bile salts and PP may cause biliary fibrosis in fch/fch mice by damaging bile duct epithelium. | [
{
"begin_idx": "799",
"end_idx": "822",
"entity_id": "D001649",
"entity_type": "Disease",
"text_name": "bile duct proliferation"
},
{
"begin_idx": "8",
"end_idx": "16",
"entity_id": "D005355",
"entity_type": "Disease",
"text_name": "fibrosis"
},
{
"begin_idx": "827",
"end_idx": "843",
"entity_id": "D005355",
"entity_type": "Disease",
"text_name": "biliary fibrosis"
},
{
"begin_idx": "2195",
"end_idx": "2211",
"entity_id": "D005355",
"entity_type": "Disease",
"text_name": "biliary fibrosis"
},
{
"begin_idx": "273",
"end_idx": "286",
"entity_id": "D008107",
"entity_type": "Disease",
"text_name": "Liver disease"
},
{
"begin_idx": "443",
"end_idx": "471",
"entity_id": "D008107",
"entity_type": "Disease",
"text_name": "EPP-associated liver disease"
},
{
"begin_idx": "352",
"end_idx": "365",
"entity_id": "D017093",
"entity_type": "Disease",
"text_name": "liver failure"
},
{
"begin_idx": "78",
"end_idx": "107",
"entity_id": "D046351",
"entity_type": "Disease",
"text_name": "erythropoietic protoporphyria"
},
{
"begin_idx": "166",
"end_idx": "195",
"entity_id": "D046351",
"entity_type": "Disease",
"text_name": "erythropoietic protoporphyria"
},
{
"begin_idx": "197",
"end_idx": "200",
"entity_id": "D046351",
"entity_type": "Disease",
"text_name": "EPP"
},
{
"begin_idx": "314",
"end_idx": "317",
"entity_id": "D046351",
"entity_type": "Disease",
"text_name": "EPP"
},
{
"begin_idx": "492",
"end_idx": "495",
"entity_id": "D046351",
"entity_type": "Disease",
"text_name": "EPP"
},
{
"begin_idx": "148",
"end_idx": "162",
"entity_id": "2235",
"entity_type": "Gene",
"text_name": "ferrochelatase"
},
{
"begin_idx": "685",
"end_idx": "699",
"entity_id": "2235",
"entity_type": "Gene",
"text_name": "ferrochelatase"
},
{
"begin_idx": "1938",
"end_idx": "1952",
"entity_id": "2235",
"entity_type": "Gene",
"text_name": "ferrochelatase"
},
{
"begin_idx": "2050",
"end_idx": "2064",
"entity_id": "2235",
"entity_type": "Gene",
"text_name": "ferrochelatase"
},
{
"begin_idx": "1346",
"end_idx": "1387",
"entity_id": "6554",
"entity_type": "Gene",
"text_name": "Na(+)-taurocholate cotransporting protein"
},
{
"begin_idx": "1389",
"end_idx": "1393",
"entity_id": "6554",
"entity_type": "Gene",
"text_name": "Ntcp"
}
] | [
"Yes",
"Yes",
"Yes",
"No",
"No",
"No"
] | [
false,
true,
false,
false,
false,
false
] | [
{
"begin_idx": "148",
"end_idx": "162",
"entity_id": "2235",
"entity_type": "Gene",
"text_name": "ferrochelatase"
},
{
"begin_idx": "148",
"end_idx": "162",
"entity_id": "2235",
"entity_type": "Gene",
"text_name": "ferrochelatase"
},
{
"begin_idx": "148",
"end_idx": "162",
"entity_id": "2235",
"entity_type": "Gene",
"text_name": "ferrochelatase"
},
{
"begin_idx": "1389",
"end_idx": "1393",
"entity_id": "6554",
"entity_type": "Gene",
"text_name": "Ntcp"
},
{
"begin_idx": "1938",
"end_idx": "1952",
"entity_id": "2235",
"entity_type": "Gene",
"text_name": "ferrochelatase"
},
{
"begin_idx": "685",
"end_idx": "699",
"entity_id": "2235",
"entity_type": "Gene",
"text_name": "ferrochelatase"
}
] | [
{
"begin_idx": "799",
"end_idx": "822",
"entity_id": "D001649",
"entity_type": "Disease",
"text_name": "bile duct proliferation"
},
{
"begin_idx": "78",
"end_idx": "107",
"entity_id": "D046351",
"entity_type": "Disease",
"text_name": "erythropoietic protoporphyria"
},
{
"begin_idx": "827",
"end_idx": "843",
"entity_id": "D005355",
"entity_type": "Disease",
"text_name": "biliary fibrosis"
},
{
"begin_idx": "799",
"end_idx": "822",
"entity_id": "D001649",
"entity_type": "Disease",
"text_name": "bile duct proliferation"
},
{
"begin_idx": "443",
"end_idx": "471",
"entity_id": "D008107",
"entity_type": "Disease",
"text_name": "EPP-associated liver disease"
},
{
"begin_idx": "273",
"end_idx": "286",
"entity_id": "D008107",
"entity_type": "Disease",
"text_name": "Liver disease"
}
] | [
"ferrochelatase",
"ferrochelatase",
"ferrochelatase",
"Ntcp",
"ferrochelatase",
"ferrochelatase"
] | [
"bile duct proliferation",
"erythropoietic protoporphyria",
"biliary fibrosis",
"bile duct proliferation",
"EPP-associated liver disease",
"Liver disease"
] |
10464603 | Is the hemochromatosis gene a modifier locus for cystic fibrosis? | The variable clinical manifestations of cystic fibrosis (CF) suggest the influence of modifier genes. For example, meconium ileus is present in approximately 10-15% of neonates with cystic fibrosis; however, the genetic and, or environmental factors that determine whether an individual will develop this complication have not been determined. We propose the HFE gene as a candidate modifier locus for CF based on (1) the suggestion of an association between the HLA loci and CF phenotypes; (2) the location of the HFE gene near the HLA loci and; (3) the similarity between the gastrointestinal manifestations of hereditary hemochromatosis and CF. We have determined the frequency of the C282Y and H63D mutations in a group of 89 CF patients who were homozygous for delta F508 and for whom meconium ileus status was known. The carrier frequency of C282Y among the CF patients with meconium ileus was significantly different from that of our unaffected control group (19.4% versus 7.7%). However, the difference between the meconium ileus and the nonmeconium ileus groups was not significant (19.4% versus 10.3%). There was no difference in the frequency of the H63D among the three groups that were studied. These data are suggestive of a relationship between the development of meconium ileus or other gastrointestinal diseases in CF and the HFE gene. Further study of a larger group of patients is warranted. | [
{
"begin_idx": "49",
"end_idx": "64",
"entity_id": "D003550",
"entity_type": "Disease",
"text_name": "cystic fibrosis"
},
{
"begin_idx": "106",
"end_idx": "121",
"entity_id": "D003550",
"entity_type": "Disease",
"text_name": "cystic fibrosis"
},
{
"begin_idx": "123",
"end_idx": "125",
"entity_id": "D003550",
"entity_type": "Disease",
"text_name": "CF"
},
{
"begin_idx": "248",
"end_idx": "263",
"entity_id": "D003550",
"entity_type": "Disease",
"text_name": "cystic fibrosis"
},
{
"begin_idx": "468",
"end_idx": "470",
"entity_id": "D003550",
"entity_type": "Disease",
"text_name": "CF"
},
{
"begin_idx": "542",
"end_idx": "544",
"entity_id": "D003550",
"entity_type": "Disease",
"text_name": "CF"
},
{
"begin_idx": "710",
"end_idx": "712",
"entity_id": "D003550",
"entity_type": "Disease",
"text_name": "CF"
},
{
"begin_idx": "796",
"end_idx": "798",
"entity_id": "D003550",
"entity_type": "Disease",
"text_name": "CF"
},
{
"begin_idx": "930",
"end_idx": "932",
"entity_id": "D003550",
"entity_type": "Disease",
"text_name": "CF"
},
{
"begin_idx": "1398",
"end_idx": "1400",
"entity_id": "D003550",
"entity_type": "Disease",
"text_name": "CF"
},
{
"begin_idx": "1369",
"end_idx": "1394",
"entity_id": "D005767",
"entity_type": "Disease",
"text_name": "gastrointestinal diseases"
},
{
"begin_idx": "7",
"end_idx": "22",
"entity_id": "D006432",
"entity_type": "Disease",
"text_name": "hemochromatosis"
},
{
"begin_idx": "679",
"end_idx": "705",
"entity_id": "D006432",
"entity_type": "Disease",
"text_name": "hereditary hemochromatosis"
},
{
"begin_idx": "425",
"end_idx": "428",
"entity_id": "3077",
"entity_type": "Gene",
"text_name": "HFE"
},
{
"begin_idx": "581",
"end_idx": "584",
"entity_id": "3077",
"entity_type": "Gene",
"text_name": "HFE"
},
{
"begin_idx": "1409",
"end_idx": "1412",
"entity_id": "3077",
"entity_type": "Gene",
"text_name": "HFE"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "425",
"end_idx": "428",
"entity_id": "3077",
"entity_type": "Gene",
"text_name": "HFE"
},
{
"begin_idx": "425",
"end_idx": "428",
"entity_id": "3077",
"entity_type": "Gene",
"text_name": "HFE"
}
] | [
{
"begin_idx": "49",
"end_idx": "64",
"entity_id": "D003550",
"entity_type": "Disease",
"text_name": "cystic fibrosis"
},
{
"begin_idx": "679",
"end_idx": "705",
"entity_id": "D006432",
"entity_type": "Disease",
"text_name": "hereditary hemochromatosis"
}
] | [
"HFE",
"HFE"
] | [
"cystic fibrosis",
"hereditary hemochromatosis"
] |
10464662 | Fine mapping of the human 5-HTR2a gene to chromosome 13q14 and identification of two highly polymorphic linked markers suitable for association studies in psychiatric disorders. | The serotonergic system is known to play an important role in a number of psychiatric disorders. Indeed, treatments involving agents that have their pharmacological activities within this system are the mainstay of treatment for disorders such as schizophrenia. It is now widely accepted that many common psychiatric disorders have a familial or genetic component and as a result of this there has been an upsurge in interest in the 5-hydroxytryptamine (5-HT) pathways. A number of groups have attempted to establish whether polymorphism in particular proteins of the serotonergic system may form part of the genetic component of psychiatric disorders, including schizophrenia and anorexia nervosa. However, the data from these studies are conflicting and the problem is compounded by the lack of known polymorphic genetic markers mapping in close proximity to genes encoding proteins envolved directly or indirectly in 5-HT neurotransmission. In the current study, we have fine mapped the gene for 5-HTR2a by radiation hybrid mapping, and we report two new, highly linked, polymorphic markers that are suitable for linkage and association studies. | [
{
"begin_idx": "859",
"end_idx": "875",
"entity_id": "D000856",
"entity_type": "Disease",
"text_name": "anorexia nervosa"
},
{
"begin_idx": "155",
"end_idx": "176",
"entity_id": "D001523",
"entity_type": "Disease",
"text_name": "psychiatric disorders"
},
{
"begin_idx": "252",
"end_idx": "273",
"entity_id": "D001523",
"entity_type": "Disease",
"text_name": "psychiatric disorders"
},
{
"begin_idx": "483",
"end_idx": "504",
"entity_id": "D001523",
"entity_type": "Disease",
"text_name": "psychiatric disorders"
},
{
"begin_idx": "808",
"end_idx": "829",
"entity_id": "D001523",
"entity_type": "Disease",
"text_name": "psychiatric disorders"
},
{
"begin_idx": "425",
"end_idx": "438",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
},
{
"begin_idx": "841",
"end_idx": "854",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
},
{
"begin_idx": "512",
"end_idx": "541",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "familial or genetic component"
},
{
"begin_idx": "28",
"end_idx": "33",
"entity_id": "3356",
"entity_type": "Gene",
"text_name": "HTR2a"
},
{
"begin_idx": "1179",
"end_idx": "1184",
"entity_id": "3356",
"entity_type": "Gene",
"text_name": "HTR2a"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "28",
"end_idx": "33",
"entity_id": "3356",
"entity_type": "Gene",
"text_name": "HTR2a"
},
{
"begin_idx": "1179",
"end_idx": "1184",
"entity_id": "3356",
"entity_type": "Gene",
"text_name": "HTR2a"
}
] | [
{
"begin_idx": "155",
"end_idx": "176",
"entity_id": "D001523",
"entity_type": "Disease",
"text_name": "psychiatric disorders"
},
{
"begin_idx": "512",
"end_idx": "541",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "familial or genetic component"
}
] | [
"HTR2a",
"HTR2a"
] | [
"psychiatric disorders",
"familial or genetic component"
] |
10465499 | Association of vitamin D receptor gene polymorphism with multiple sclerosis in Japanese. | 1,25-Dihydroxyvitamin D3 (1,25(OH)2D3), the biologically active form of vitamin D, exerts an immunosuppressive effect and can completely prevent experimental autoimmune encephalomyelitis (EAE). 1,25(OH)2D3 exerts most of its actions only after it has bound to its specific nuclear receptors. To investigate the possible role of vitamin D receptor gene (VDRG) polymorphism in susceptibility to or disease-modulation of MS, we evaluated 77 Japanese patients with 'conventional' MS and 95 controls. A VDRG allelic polymorphism was assessed by Bsm1 endonuclease restriction after specific PCR amplification. Genotypic polymorphism was clearly defined as BB (absence of restriction site on both alleles), bb (presence of restriction site on both alleles), or Bb (heterozygous). We found overexpression of the b allele (92.9 vs. 84.2%: P=0.0138) and homozygote bb (85.7 vs. 71.6%; P=0.0263) in MS patients compared with controls. The results indicate for the first time an association of MS with VDRG polymorphism, which may be involved in pathogenesis of MS, or in the linkage disequilibrium of VDRG to another pathogenic gene loci. The role of VDR gene polymorphism should be further studied in other populations, and the distribution of other polymorphism, such as Apa I, Taq I, should be also analyzed to confirm another susceptibility gene for MS and to obtain more adequate strategies for treatment of MS. | [
{
"begin_idx": "234",
"end_idx": "275",
"entity_id": "D004681",
"entity_type": "Disease",
"text_name": "experimental autoimmune encephalomyelitis"
},
{
"begin_idx": "277",
"end_idx": "280",
"entity_id": "D004681",
"entity_type": "Disease",
"text_name": "EAE"
},
{
"begin_idx": "57",
"end_idx": "75",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "multiple sclerosis"
},
{
"begin_idx": "507",
"end_idx": "509",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "MS"
},
{
"begin_idx": "565",
"end_idx": "567",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "MS"
},
{
"begin_idx": "977",
"end_idx": "979",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "MS"
},
{
"begin_idx": "1071",
"end_idx": "1073",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "MS"
},
{
"begin_idx": "1139",
"end_idx": "1141",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "MS"
},
{
"begin_idx": "1432",
"end_idx": "1434",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "MS"
},
{
"begin_idx": "1491",
"end_idx": "1493",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "MS"
},
{
"begin_idx": "15",
"end_idx": "33",
"entity_id": "7421",
"entity_type": "Gene",
"text_name": "vitamin D receptor"
},
{
"begin_idx": "417",
"end_idx": "435",
"entity_id": "7421",
"entity_type": "Gene",
"text_name": "vitamin D receptor"
},
{
"begin_idx": "1229",
"end_idx": "1232",
"entity_id": "7421",
"entity_type": "Gene",
"text_name": "VDR"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "15",
"end_idx": "33",
"entity_id": "7421",
"entity_type": "Gene",
"text_name": "vitamin D receptor"
},
{
"begin_idx": "417",
"end_idx": "435",
"entity_id": "7421",
"entity_type": "Gene",
"text_name": "vitamin D receptor"
}
] | [
{
"begin_idx": "57",
"end_idx": "75",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "multiple sclerosis"
},
{
"begin_idx": "234",
"end_idx": "275",
"entity_id": "D004681",
"entity_type": "Disease",
"text_name": "experimental autoimmune encephalomyelitis"
}
] | [
"vitamin D receptor",
"vitamin D receptor"
] | [
"multiple sclerosis",
"experimental autoimmune encephalomyelitis"
] |
10466419 | Mucopolysaccharidosis type I: characterization of novel mutations affecting alpha-L-iduronidase activity. | alpha-L-Iduronidase (IDUA) deficiency (mucopolysaccharidosis type I, MPS I) involves a broad spectrum of clinical severity ranging from a severe Hurler syndrome through an intermediate Hurler Scheie syndrome to a mild Scheie syndrome. To date, a number of mutations of the IDUA gene are known in Hurler syndrome, but only a few in Hurler Scheie or Scheie syndrome. The characterization of novel mutations in two patients with the Hurler-Scheie syndrome is reported on. The novel R619G mutation (C-G transversion in codon 619) was apparently homozygous. In transfected COS-7 cells, R619G caused significant reduction in enzyme activity (1.5% of normal activity), although it did not cause significant reduction in IDUA mRNA or protein level. Conversely, the previously described homozygous T364M mutation (C-T transition in codon 364) caused a decrease in the level of IDUA mRNA. Studies inhibiting RNA synthesis with actinomycin D or inhibiting protein synthesis with cycloheximide demonstrate that the decrease in the latter mutation is attributable to an increased rate of mRNA decay. By examining the stability of IDUA mRNA and protein, studies provide better insight into the effect of mutation on IDUA activity. | [
{
"begin_idx": "0",
"end_idx": "28",
"entity_id": "D008059",
"entity_type": "Disease",
"text_name": "Mucopolysaccharidosis type I"
},
{
"begin_idx": "251",
"end_idx": "266",
"entity_id": "D008059",
"entity_type": "Disease",
"text_name": "Hurler syndrome"
},
{
"begin_idx": "291",
"end_idx": "313",
"entity_id": "D008059",
"entity_type": "Disease",
"text_name": "Hurler Scheie syndrome"
},
{
"begin_idx": "324",
"end_idx": "339",
"entity_id": "D008059",
"entity_type": "Disease",
"text_name": "Scheie syndrome"
},
{
"begin_idx": "402",
"end_idx": "417",
"entity_id": "D008059",
"entity_type": "Disease",
"text_name": "Hurler syndrome"
},
{
"begin_idx": "437",
"end_idx": "450",
"entity_id": "D008059",
"entity_type": "Disease",
"text_name": "Hurler Scheie"
},
{
"begin_idx": "454",
"end_idx": "469",
"entity_id": "D008059",
"entity_type": "Disease",
"text_name": "Scheie syndrome"
},
{
"begin_idx": "536",
"end_idx": "558",
"entity_id": "D008059",
"entity_type": "Disease",
"text_name": "Hurler-Scheie syndrome"
},
{
"begin_idx": "175",
"end_idx": "180",
"entity_id": "D016532",
"entity_type": "Disease",
"text_name": "MPS I"
},
{
"begin_idx": "76",
"end_idx": "95",
"entity_id": "3425",
"entity_type": "Gene",
"text_name": "alpha-L-iduronidase"
},
{
"begin_idx": "106",
"end_idx": "125",
"entity_id": "3425",
"entity_type": "Gene",
"text_name": "alpha-L-Iduronidase"
},
{
"begin_idx": "127",
"end_idx": "131",
"entity_id": "3425",
"entity_type": "Gene",
"text_name": "IDUA"
},
{
"begin_idx": "379",
"end_idx": "383",
"entity_id": "3425",
"entity_type": "Gene",
"text_name": "IDUA"
},
{
"begin_idx": "819",
"end_idx": "823",
"entity_id": "3425",
"entity_type": "Gene",
"text_name": "IDUA"
},
{
"begin_idx": "974",
"end_idx": "978",
"entity_id": "3425",
"entity_type": "Gene",
"text_name": "IDUA"
},
{
"begin_idx": "1223",
"end_idx": "1227",
"entity_id": "3425",
"entity_type": "Gene",
"text_name": "IDUA"
},
{
"begin_idx": "1308",
"end_idx": "1312",
"entity_id": "3425",
"entity_type": "Gene",
"text_name": "IDUA"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "76",
"end_idx": "95",
"entity_id": "3425",
"entity_type": "Gene",
"text_name": "alpha-L-iduronidase"
},
{
"begin_idx": "819",
"end_idx": "823",
"entity_id": "3425",
"entity_type": "Gene",
"text_name": "IDUA"
}
] | [
{
"begin_idx": "0",
"end_idx": "28",
"entity_id": "D008059",
"entity_type": "Disease",
"text_name": "Mucopolysaccharidosis type I"
},
{
"begin_idx": "175",
"end_idx": "180",
"entity_id": "D016532",
"entity_type": "Disease",
"text_name": "MPS I"
}
] | [
"alpha-L-iduronidase",
"IDUA"
] | [
"Mucopolysaccharidosis type I",
"MPS I"
] |
10467420 | Mutation of beta-catenin is an early event in chemically induced mouse hepatocellular carcinogenesis. | beta-catenin activation, and subsequent upregulation of Wnt-signaling, is an important event in the development of certain human and rodent cancers. Recently, mutations in the beta-catenin gene in the region of the serine-threonine glycogen kinase (GSK)-3beta phosphorylation target sites have been identified in hepatocellular neoplasms from humans and transgenic mice. In this study we examined 152 hepatocellular neoplasms from B6C3F1 mice included in five chemical treatment groups and controls for mutations in the beta-catenin gene. Twenty of 29 hepatocellular neoplasms from mice treated with methyleugenol had point mutations at codons 32, 33, 34 or 41, sites which are mutated in colon and other cancers. Likewise, nine of 24 methylene chloride-induced hepatocellular neoplasms and 18 of 42 oxazepam-induced neoplasms exhibited similar mutations. In contrast, only three of 18 vinyl carbamate-induced liver tumors, one of 18 TCDD-induced liver tumors, and two of 22 spontaneous liver neoplasms had mutations in beta-catenin. Thus, there appears to be a chemical specific involvement of beta-catenin activation in mouse hepatocellular carcinogenesis. Expression analyses using Western blot and immunohistochemistry indicate that beta-catenin protein accumulates along cell membranes following mutation. The finding of mutations in both adenomas and carcinomas from diverse chemical treatment groups and the immunostaining of beta-catenin protein in an altered hepatocellular focus suggest that these alterations are early events in mouse hepatocellular carcinogenesis. | [
{
"begin_idx": "1446",
"end_idx": "1454",
"entity_id": "D000236",
"entity_type": "Disease",
"text_name": "adenomas"
},
{
"begin_idx": "1459",
"end_idx": "1469",
"entity_id": "D002277",
"entity_type": "Disease",
"text_name": "carcinomas"
},
{
"begin_idx": "791",
"end_idx": "814",
"entity_id": "D003110",
"entity_type": "Disease",
"text_name": "colon and other cancers"
},
{
"begin_idx": "1012",
"end_idx": "1024",
"entity_id": "D008113",
"entity_type": "Disease",
"text_name": "liver tumors"
},
{
"begin_idx": "1049",
"end_idx": "1061",
"entity_id": "D008113",
"entity_type": "Disease",
"text_name": "liver tumors"
},
{
"begin_idx": "1089",
"end_idx": "1104",
"entity_id": "D008113",
"entity_type": "Disease",
"text_name": "liver neoplasms"
},
{
"begin_idx": "242",
"end_idx": "249",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "cancers"
},
{
"begin_idx": "430",
"end_idx": "439",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "neoplasms"
},
{
"begin_idx": "518",
"end_idx": "527",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "neoplasms"
},
{
"begin_idx": "669",
"end_idx": "678",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "neoplasms"
},
{
"begin_idx": "879",
"end_idx": "888",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "neoplasms"
},
{
"begin_idx": "919",
"end_idx": "928",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "neoplasms"
},
{
"begin_idx": "12",
"end_idx": "24",
"entity_id": "1499",
"entity_type": "Gene",
"text_name": "beta-catenin"
},
{
"begin_idx": "102",
"end_idx": "114",
"entity_id": "1499",
"entity_type": "Gene",
"text_name": "beta-catenin"
},
{
"begin_idx": "278",
"end_idx": "290",
"entity_id": "1499",
"entity_type": "Gene",
"text_name": "beta-catenin"
},
{
"begin_idx": "622",
"end_idx": "634",
"entity_id": "1499",
"entity_type": "Gene",
"text_name": "beta-catenin"
},
{
"begin_idx": "1122",
"end_idx": "1134",
"entity_id": "1499",
"entity_type": "Gene",
"text_name": "beta-catenin"
},
{
"begin_idx": "1197",
"end_idx": "1209",
"entity_id": "1499",
"entity_type": "Gene",
"text_name": "beta-catenin"
},
{
"begin_idx": "1339",
"end_idx": "1351",
"entity_id": "1499",
"entity_type": "Gene",
"text_name": "beta-catenin"
},
{
"begin_idx": "1535",
"end_idx": "1547",
"entity_id": "1499",
"entity_type": "Gene",
"text_name": "beta-catenin"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "12",
"end_idx": "24",
"entity_id": "1499",
"entity_type": "Gene",
"text_name": "beta-catenin"
},
{
"begin_idx": "1122",
"end_idx": "1134",
"entity_id": "1499",
"entity_type": "Gene",
"text_name": "beta-catenin"
}
] | [
{
"begin_idx": "1089",
"end_idx": "1104",
"entity_id": "D008113",
"entity_type": "Disease",
"text_name": "liver neoplasms"
},
{
"begin_idx": "669",
"end_idx": "678",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "neoplasms"
}
] | [
"beta-catenin",
"beta-catenin"
] | [
"liver neoplasms",
"neoplasms"
] |
10467834 | Prognostic value of serum C-reactive protein in kala-azar. | The currently recommended protocol for treatment of kala-azar (KA) necessitates repeated bone marrow/splenic aspiration to monitor the response and duration of therapy as well as to detect resistance and change to alternative drugs. These procedures being invasive, there is a pressing need for less invasive diagnostic tools for this purpose. We have evaluated the role of C-reactive protein (CRP) in 201 children with visceral leishmaniasis at different stages of the disease to work out the relationship, if any, between CRP levels and disease activity, including response to therapy. The subjects belonged to the 2-12 year age group in whom CRP estimation was done on admission, every 5th day during treatment, and repeated on follow-up at 2 and 6 months. The levels were compared with those of 50 randomly chosen age-matched healthy children who served as controls. The mean serum CRP value in the study group before the commencement of treatment was 62.96 +/- 1.03 mg/l, which was significantly higher (p < 0.001) in comparison to the control group. Commencement of treatment resulted in a simultaneous decline in serum CRP. Parasitic clearance from the spleen was faster in patients with an initial low serum CRP level (< 60 mg/l) in comparison to patients with high levels (> 60 mg/l). During treatment, mean serum CRP levels were significantly higher in late responders than in early responders (p < 0.001). Correlation of CRP levels to indicate the presence or absence of parasites suggested a cut-off level of 12 mg/l by day 10, with a sensitivity of 82.5 per cent, specificity of 78.5 per cent, positive predictive value of 92 per cent, and negative predictive value of 60.2 per cent. Our observations suggest a promising role for CRP estimation every 5-10 days during therapy in visceral leishmaniasis for monitoring the response to therapy and to detect possible resistance. | [
{
"begin_idx": "48",
"end_idx": "57",
"entity_id": "D007898",
"entity_type": "Disease",
"text_name": "kala-azar"
},
{
"begin_idx": "111",
"end_idx": "120",
"entity_id": "D007898",
"entity_type": "Disease",
"text_name": "kala-azar"
},
{
"begin_idx": "122",
"end_idx": "124",
"entity_id": "D007898",
"entity_type": "Disease",
"text_name": "KA"
},
{
"begin_idx": "479",
"end_idx": "501",
"entity_id": "D007898",
"entity_type": "Disease",
"text_name": "visceral leishmaniasis"
},
{
"begin_idx": "1851",
"end_idx": "1873",
"entity_id": "D007898",
"entity_type": "Disease",
"text_name": "visceral leishmaniasis"
},
{
"begin_idx": "26",
"end_idx": "44",
"entity_id": "1401",
"entity_type": "Gene",
"text_name": "C-reactive protein"
},
{
"begin_idx": "433",
"end_idx": "451",
"entity_id": "1401",
"entity_type": "Gene",
"text_name": "C-reactive protein"
},
{
"begin_idx": "453",
"end_idx": "456",
"entity_id": "1401",
"entity_type": "Gene",
"text_name": "CRP"
},
{
"begin_idx": "583",
"end_idx": "586",
"entity_id": "1401",
"entity_type": "Gene",
"text_name": "CRP"
},
{
"begin_idx": "704",
"end_idx": "707",
"entity_id": "1401",
"entity_type": "Gene",
"text_name": "CRP"
},
{
"begin_idx": "945",
"end_idx": "948",
"entity_id": "1401",
"entity_type": "Gene",
"text_name": "CRP"
},
{
"begin_idx": "1185",
"end_idx": "1188",
"entity_id": "1401",
"entity_type": "Gene",
"text_name": "CRP"
},
{
"begin_idx": "1275",
"end_idx": "1278",
"entity_id": "1401",
"entity_type": "Gene",
"text_name": "CRP"
},
{
"begin_idx": "1382",
"end_idx": "1385",
"entity_id": "1401",
"entity_type": "Gene",
"text_name": "CRP"
},
{
"begin_idx": "1491",
"end_idx": "1494",
"entity_id": "1401",
"entity_type": "Gene",
"text_name": "CRP"
},
{
"begin_idx": "1802",
"end_idx": "1805",
"entity_id": "1401",
"entity_type": "Gene",
"text_name": "CRP"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "26",
"end_idx": "44",
"entity_id": "1401",
"entity_type": "Gene",
"text_name": "C-reactive protein"
}
] | [
{
"begin_idx": "479",
"end_idx": "501",
"entity_id": "D007898",
"entity_type": "Disease",
"text_name": "visceral leishmaniasis"
}
] | [
"C-reactive protein"
] | [
"visceral leishmaniasis"
] |
10468508 | HLA-DPB1*0501-associated opticospinal multiple sclerosis: clinical, neuroimaging and immunogenetic studies. | In order to clarify the relationship between the clinical phenotype and the human leucocyte antigen (HLA) in multiple sclerosis in Asians, 93 Japanese patients with clinically definite multiple sclerosis underwent clinical MRI and HLA-DPB1 gene typing studies. According to a neurological examination, 29 patients were classified as opticospinal multiple sclerosis, 17 as spinal multiple sclerosis and 47 as Western type multiple sclerosis showing the involvement of multiple sites in the CNS including either the cerebrum, cerebellum or brainstem. The opticospinal multiple sclerosis showed a significantly higher age of onset, higher expanded disability status scale scores and higher CSF cell counts and protein content than the Western type multiple sclerosis. On brain and spinal cord MRI, the opticospinal multiple sclerosis showed a significantly lower number of brain lesions, but a higher frequency of gadolinium-enhancement of the optic nerve and a higher frequency of spinal cord atrophy than in Western type multiple sclerosis. The frequency of the HLA-DPB1*0501 allele was found to be significantly greater in opticospinal multiple sclerosis (93%) than in healthy controls (63%, corrected P value = 0.0091 and relative risk = 7.9), but not in Western type multiple sclerosis (66%) or spinal multiple sclerosis (82%). The marked differences in the clinical and MRI findings as well as in the immunogenetic backgrounds between the opticospinal multiple sclerosis and Western-type multiple sclerosis together suggest that HLA-DPB1*0501-associated opticospinal multiple sclerosis is a distinct subtype of multiple sclerosis. | [
{
"begin_idx": "25",
"end_idx": "56",
"entity_id": "C580329",
"entity_type": "Disease",
"text_name": "opticospinal multiple sclerosis"
},
{
"begin_idx": "441",
"end_idx": "472",
"entity_id": "C580329",
"entity_type": "Disease",
"text_name": "opticospinal multiple sclerosis"
},
{
"begin_idx": "661",
"end_idx": "692",
"entity_id": "C580329",
"entity_type": "Disease",
"text_name": "opticospinal multiple sclerosis"
},
{
"begin_idx": "907",
"end_idx": "938",
"entity_id": "C580329",
"entity_type": "Disease",
"text_name": "opticospinal multiple sclerosis"
},
{
"begin_idx": "1231",
"end_idx": "1262",
"entity_id": "C580329",
"entity_type": "Disease",
"text_name": "opticospinal multiple sclerosis"
},
{
"begin_idx": "1550",
"end_idx": "1581",
"entity_id": "C580329",
"entity_type": "Disease",
"text_name": "opticospinal multiple sclerosis"
},
{
"begin_idx": "1665",
"end_idx": "1696",
"entity_id": "C580329",
"entity_type": "Disease",
"text_name": "opticospinal multiple sclerosis"
},
{
"begin_idx": "978",
"end_idx": "991",
"entity_id": "D001927",
"entity_type": "Disease",
"text_name": "brain lesions"
},
{
"begin_idx": "217",
"end_idx": "235",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "multiple sclerosis"
},
{
"begin_idx": "293",
"end_idx": "311",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "multiple sclerosis"
},
{
"begin_idx": "480",
"end_idx": "505",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "spinal multiple sclerosis"
},
{
"begin_idx": "516",
"end_idx": "547",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "Western type multiple sclerosis"
},
{
"begin_idx": "840",
"end_idx": "871",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "Western type multiple sclerosis"
},
{
"begin_idx": "1115",
"end_idx": "1146",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "Western type multiple sclerosis"
},
{
"begin_idx": "1364",
"end_idx": "1395",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "Western type multiple sclerosis"
},
{
"begin_idx": "1405",
"end_idx": "1430",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "spinal multiple sclerosis"
},
{
"begin_idx": "1599",
"end_idx": "1617",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "multiple sclerosis"
},
{
"begin_idx": "1722",
"end_idx": "1740",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "multiple sclerosis"
},
{
"begin_idx": "1087",
"end_idx": "1106",
"entity_id": "D013118",
"entity_type": "Disease",
"text_name": "spinal cord atrophy"
},
{
"begin_idx": "0",
"end_idx": "8",
"entity_id": "3115",
"entity_type": "Gene",
"text_name": "HLA-DPB1"
},
{
"begin_idx": "339",
"end_idx": "347",
"entity_id": "3115",
"entity_type": "Gene",
"text_name": "HLA-DPB1"
},
{
"begin_idx": "1169",
"end_idx": "1177",
"entity_id": "3115",
"entity_type": "Gene",
"text_name": "HLA-DPB1"
},
{
"begin_idx": "1640",
"end_idx": "1648",
"entity_id": "3115",
"entity_type": "Gene",
"text_name": "HLA-DPB1"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "0",
"end_idx": "8",
"entity_id": "3115",
"entity_type": "Gene",
"text_name": "HLA-DPB1"
},
{
"begin_idx": "1640",
"end_idx": "1648",
"entity_id": "3115",
"entity_type": "Gene",
"text_name": "HLA-DPB1"
}
] | [
{
"begin_idx": "516",
"end_idx": "547",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "Western type multiple sclerosis"
},
{
"begin_idx": "1665",
"end_idx": "1696",
"entity_id": "C580329",
"entity_type": "Disease",
"text_name": "opticospinal multiple sclerosis"
}
] | [
"HLA-DPB1",
"HLA-DPB1"
] | [
"Western type multiple sclerosis",
"opticospinal multiple sclerosis"
] |
10468973 | Association of the large multifunctional proteasome (LMP2) gene with Graves' disease is a result of linkage disequilibrium with the HLA haplotype DRB1*0304-DQB1*02-DQA1*0501. | OBJECTIVE: The large multifunctional proteasome (LMP) molecules are over expressed in thyrocytes, the target cells of Graves' disease, and the LMP genes are found within the MHC class II region. The LMP genes may therefore play a role in susceptibility to Graves' disease. The aim of this this study was to determine whether polymorphisms of the LMP genes, LMP 2 and LMP 7 are in linkage disequilibrium with Graves' disease. DESIGN: Target DNA was amplified using the polymerase chain reaction. The distribution of an Arg-His polymorphism in the LMP 2 gene and a G/T polymorphism in the LMP 7 gene, both of which lead to the presence of an HhaI restriction site, were investigated in a population based case control and family based study in patients with Graves' disease. PATIENTS: We obtained DNA from 306 patients with Graves' disease and 364 control subjects for the population based case-control study. In an independent family based study, DNA was obtained from 129 families including both parents, an affected sibling with Graves' disease and an unaffected sibling. All families, patients and control subjects were white caucasians. MEASUREMENTS: Frequencies of the alleles and genotypes of the LMP 2 and LMP 7 genes were compared between patients and control subjects using the chi2 test. Transmission of alleles from heterozygous parents to affected and unaffected offspring was assessed using the transmission disequilibrium test (TDT). RESULTS: In the case control study, no difference in allele or genotype frequency was seen between patients and control subjects at the LMP7 locus. At the LMP2 locus the R allele and the RH genotype were increased in subjects with Graves' disease when compared with control subjects (R allele: 36.3% vs. 29.5%, pc = 0. 0164; RH genotype: 56.5% vs. 45%, pc = 0.0102). However, the R allele was in linkage disequilibrium with the associated HLA DRB1*0304-DQB1*02-DQA1*0501 haplotype, delta = 0.102. Within the family based study, no preferential allelic transmission was seen from heterozygote parents to offspring at either loci. CONCLUSION: These results show that association of the LMP 2 locus with Graves' disease is due to linkage disequilibrium with the associated HLA haplotype DRB1*0304-DQB1*02-DQA1*0501. | [
{
"begin_idx": "69",
"end_idx": "84",
"entity_id": "D006111",
"entity_type": "Disease",
"text_name": "Graves' disease"
},
{
"begin_idx": "293",
"end_idx": "308",
"entity_id": "D006111",
"entity_type": "Disease",
"text_name": "Graves' disease"
},
{
"begin_idx": "431",
"end_idx": "446",
"entity_id": "D006111",
"entity_type": "Disease",
"text_name": "Graves' disease"
},
{
"begin_idx": "583",
"end_idx": "598",
"entity_id": "D006111",
"entity_type": "Disease",
"text_name": "Graves' disease"
},
{
"begin_idx": "931",
"end_idx": "946",
"entity_id": "D006111",
"entity_type": "Disease",
"text_name": "Graves' disease"
},
{
"begin_idx": "997",
"end_idx": "1012",
"entity_id": "D006111",
"entity_type": "Disease",
"text_name": "Graves' disease"
},
{
"begin_idx": "1205",
"end_idx": "1220",
"entity_id": "D006111",
"entity_type": "Disease",
"text_name": "Graves' disease"
},
{
"begin_idx": "1853",
"end_idx": "1868",
"entity_id": "D006111",
"entity_type": "Disease",
"text_name": "Graves' disease"
},
{
"begin_idx": "2323",
"end_idx": "2338",
"entity_id": "D006111",
"entity_type": "Disease",
"text_name": "Graves' disease"
},
{
"begin_idx": "156",
"end_idx": "160",
"entity_id": "3119",
"entity_type": "Gene",
"text_name": "DQB1"
},
{
"begin_idx": "2075",
"end_idx": "2079",
"entity_id": "3119",
"entity_type": "Gene",
"text_name": "DQB1"
},
{
"begin_idx": "2416",
"end_idx": "2420",
"entity_id": "3119",
"entity_type": "Gene",
"text_name": "DQB1"
},
{
"begin_idx": "146",
"end_idx": "150",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "DRB1"
},
{
"begin_idx": "2061",
"end_idx": "2069",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "HLA DRB1"
},
{
"begin_idx": "2406",
"end_idx": "2410",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "DRB1"
},
{
"begin_idx": "542",
"end_idx": "547",
"entity_id": "5696",
"entity_type": "Gene",
"text_name": "LMP 7"
},
{
"begin_idx": "762",
"end_idx": "767",
"entity_id": "5696",
"entity_type": "Gene",
"text_name": "LMP 7"
},
{
"begin_idx": "1387",
"end_idx": "1392",
"entity_id": "5696",
"entity_type": "Gene",
"text_name": "LMP 7"
},
{
"begin_idx": "1758",
"end_idx": "1762",
"entity_id": "5696",
"entity_type": "Gene",
"text_name": "LMP7"
},
{
"begin_idx": "53",
"end_idx": "57",
"entity_id": "5698",
"entity_type": "Gene",
"text_name": "LMP2"
},
{
"begin_idx": "532",
"end_idx": "537",
"entity_id": "5698",
"entity_type": "Gene",
"text_name": "LMP 2"
},
{
"begin_idx": "721",
"end_idx": "726",
"entity_id": "5698",
"entity_type": "Gene",
"text_name": "LMP 2"
},
{
"begin_idx": "1377",
"end_idx": "1382",
"entity_id": "5698",
"entity_type": "Gene",
"text_name": "LMP 2"
},
{
"begin_idx": "1777",
"end_idx": "1781",
"entity_id": "5698",
"entity_type": "Gene",
"text_name": "LMP2"
},
{
"begin_idx": "2306",
"end_idx": "2311",
"entity_id": "5698",
"entity_type": "Gene",
"text_name": "LMP 2"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "532",
"end_idx": "537",
"entity_id": "5698",
"entity_type": "Gene",
"text_name": "LMP 2"
},
{
"begin_idx": "542",
"end_idx": "547",
"entity_id": "5696",
"entity_type": "Gene",
"text_name": "LMP 7"
}
] | [
{
"begin_idx": "69",
"end_idx": "84",
"entity_id": "D006111",
"entity_type": "Disease",
"text_name": "Graves' disease"
},
{
"begin_idx": "431",
"end_idx": "446",
"entity_id": "D006111",
"entity_type": "Disease",
"text_name": "Graves' disease"
}
] | [
"LMP 2",
"LMP 7"
] | [
"Graves' disease",
"Graves' disease"
] |
10469306 | Combined analysis of polymorphisms of the tumor necrosis factor-alpha and interleukin-10 promoter regions and polymorphic xenobiotic metabolizing enzymes in psoriasis. | Environmental and genetic factors are thought to interact in the manifestation of psoriasis, but knowledge about the involved genes and antigens is incomplete. This study has focused on the association between psoriasis and inherited variations in xenobiotic metabolism and cytokine production as two components that may influence cutaneous immune responses to foreign substances. Polymorphisms of N-acetyltransferase 2, glutathione S-transferases T1 and M1, and promoter polymorphisms of the genes encoding for tumor necrosis factor-alpha and interleukin-10 were investigated in 151 Caucasian patients with psoriasis (100 with type I and 51 with type II psoriasis) and in 123 healthy controls. Polymorphisms were detected by polymerase chain reaction-based methods, restriction enzyme analysis, and direct sequencing. There were no significant differences in the distribution of enzyme polymorphisms or point mutations at position -1082 of the interleukin-10 promoter between the psoriasis groups and the control group. The G-->A polymorphism at position -238 of the tumor necrosis factor-alpha promoter (TNF alpha-238*A allele) was more common in type I psoriasis (27%) than in the controls [9.8%; odds ratio 3.4 (95% confidence interval 1.6-7.2); p = 0.0012; pcorr = 0.018]. Surprisingly, this overrepresentation of the tumor necrosis factor alpha-238*A allele was observed in male patients [4.1 (1.5-11.0); p = 0.0046; pcorr = 0.064] but not in female patients [1.8 (0.5-6.5); p = 0.5]. The G-->A polymorphism at position -308 of the tumor necrosis factor-alpha promoter was less frequent in type I psoriasis (23%) compared with controls (35.7%), although the negative association was weak [0.54 (0.3-0.97); p = 0.041; pcorr = not significant]. The distribution of the TNF alpha-238*A and TNF alpha-238*A alleles was similar in type II patients and controls. Our results suggest that male carriers of the G-->A polymorphism at position -238 of the tumor necrosis factor-alpha promoter are at an increased risk to develop early-onset psoriasis. | [
{
"begin_idx": "157",
"end_idx": "166",
"entity_id": "D011565",
"entity_type": "Disease",
"text_name": "psoriasis"
},
{
"begin_idx": "250",
"end_idx": "259",
"entity_id": "D011565",
"entity_type": "Disease",
"text_name": "psoriasis"
},
{
"begin_idx": "378",
"end_idx": "387",
"entity_id": "D011565",
"entity_type": "Disease",
"text_name": "psoriasis"
},
{
"begin_idx": "776",
"end_idx": "785",
"entity_id": "D011565",
"entity_type": "Disease",
"text_name": "psoriasis"
},
{
"begin_idx": "815",
"end_idx": "832",
"entity_id": "D011565",
"entity_type": "Disease",
"text_name": "type II psoriasis"
},
{
"begin_idx": "1149",
"end_idx": "1158",
"entity_id": "D011565",
"entity_type": "Disease",
"text_name": "psoriasis"
},
{
"begin_idx": "1317",
"end_idx": "1333",
"entity_id": "D011565",
"entity_type": "Disease",
"text_name": "type I psoriasis"
},
{
"begin_idx": "1764",
"end_idx": "1780",
"entity_id": "D011565",
"entity_type": "Disease",
"text_name": "type I psoriasis"
},
{
"begin_idx": "2205",
"end_idx": "2214",
"entity_id": "D011565",
"entity_type": "Disease",
"text_name": "psoriasis"
},
{
"begin_idx": "566",
"end_idx": "587",
"entity_id": "10",
"entity_type": "Gene",
"text_name": "N-acetyltransferase 2"
},
{
"begin_idx": "74",
"end_idx": "88",
"entity_id": "3586",
"entity_type": "Gene",
"text_name": "interleukin-10"
},
{
"begin_idx": "712",
"end_idx": "726",
"entity_id": "3586",
"entity_type": "Gene",
"text_name": "interleukin-10"
},
{
"begin_idx": "1113",
"end_idx": "1127",
"entity_id": "3586",
"entity_type": "Gene",
"text_name": "interleukin-10"
},
{
"begin_idx": "42",
"end_idx": "69",
"entity_id": "7124",
"entity_type": "Gene",
"text_name": "tumor necrosis factor-alpha"
},
{
"begin_idx": "680",
"end_idx": "707",
"entity_id": "7124",
"entity_type": "Gene",
"text_name": "tumor necrosis factor-alpha"
},
{
"begin_idx": "1236",
"end_idx": "1263",
"entity_id": "7124",
"entity_type": "Gene",
"text_name": "tumor necrosis factor-alpha"
},
{
"begin_idx": "1274",
"end_idx": "1283",
"entity_id": "7124",
"entity_type": "Gene",
"text_name": "TNF alpha"
},
{
"begin_idx": "1491",
"end_idx": "1518",
"entity_id": "7124",
"entity_type": "Gene",
"text_name": "tumor necrosis factor alpha"
},
{
"begin_idx": "1706",
"end_idx": "1733",
"entity_id": "7124",
"entity_type": "Gene",
"text_name": "tumor necrosis factor-alpha"
},
{
"begin_idx": "1941",
"end_idx": "1950",
"entity_id": "7124",
"entity_type": "Gene",
"text_name": "TNF alpha"
},
{
"begin_idx": "1961",
"end_idx": "1970",
"entity_id": "7124",
"entity_type": "Gene",
"text_name": "TNF alpha"
},
{
"begin_idx": "2120",
"end_idx": "2147",
"entity_id": "7124",
"entity_type": "Gene",
"text_name": "tumor necrosis factor-alpha"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "74",
"end_idx": "88",
"entity_id": "3586",
"entity_type": "Gene",
"text_name": "interleukin-10"
},
{
"begin_idx": "2120",
"end_idx": "2147",
"entity_id": "7124",
"entity_type": "Gene",
"text_name": "tumor necrosis factor-alpha"
}
] | [
{
"begin_idx": "815",
"end_idx": "832",
"entity_id": "D011565",
"entity_type": "Disease",
"text_name": "type II psoriasis"
},
{
"begin_idx": "815",
"end_idx": "832",
"entity_id": "D011565",
"entity_type": "Disease",
"text_name": "type II psoriasis"
}
] | [
"interleukin-10",
"tumor necrosis factor-alpha"
] | [
"type II psoriasis",
"type II psoriasis"
] |
10469321 | X-linked anhidrotic (hypohidrotic) ectodermal dysplasia caused by a novel mutation in EDA1 gene: 406T > G (Leu55Arg) | [
{
"begin_idx": "0",
"end_idx": "55",
"entity_id": "D053358",
"entity_type": "Disease",
"text_name": "X-linked anhidrotic (hypohidrotic) ectodermal dysplasia"
},
{
"begin_idx": "86",
"end_idx": "90",
"entity_id": "1896",
"entity_type": "Gene",
"text_name": "EDA1"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "86",
"end_idx": "90",
"entity_id": "1896",
"entity_type": "Gene",
"text_name": "EDA1"
}
] | [
{
"begin_idx": "0",
"end_idx": "55",
"entity_id": "D053358",
"entity_type": "Disease",
"text_name": "X-linked anhidrotic (hypohidrotic) ectodermal dysplasia"
}
] | [
"EDA1"
] | [
"X-linked anhidrotic (hypohidrotic) ectodermal dysplasia"
] |
|
10471058 | Cytochrome P450 CYP2D6 genotypes: association with hair colour, Breslow thickness and melanocyte stimulating hormone receptor alleles in patients with malignant melanoma. | We previously identified associations between polymorphism in the cytochrome P450 CYP2D6 gene and outcome in several cancers. We have now examined the hypothesis that homozygosity for the mutant alleles, CYP2D6*4 and CYP2D6*3, is associated with susceptibility and outcome in malignant melanoma. Outcome was assessed by Breslow thickness. We first confirmed previous reports that these mutant alleles are associated with increased susceptibility to malignant melanoma. For example, the frequency of homozygosity for CYP2D6*4 was significantly greater (P = 0.006, chi-squared 1 d.f. = 7.4, odds ratio 2.2, 95% confidence interval 1.2, 3.9) in cases (9.1%) than in control individuals (4.3%). The frequency of homozygosity for the mutant alleles was next examined in the malignant melanoma cases grouped on the basis of characteristics associated with malignant melanoma risk. Homozygosity was significantly more common (P = 0.038) in cases with red/blonde hair than in those with brown/black hair. We found no associations between the CYP2D6 genotype and sex, skin type or eye colour. The possible association of CYP2D6 with outcome was assessed by comparing genotype frequencies in patients with tumours of Breslow thickness < 1.5 mm with those whose tumours were > or = 1.5 mm. In patients with red/blonde, but not brown or black hair, homozygosity for CYP2D6*4 was significantly associated with thicker lesions in a multivariate model (P = 0.036). We further examined the association of CYP2D6*4 homozygosity with red/blonde hair by classifying patients on the basis of homo- or heterozygosity for wild-type or val92met, asp294his or asp84glu melanocyte stimulating hormone receptor (MC1R) alleles. None of the nine patients with brown/black hair with the asp294his allele were homozygotes for CYP2D6*4. By contrast, in the patients with red/blonde hair, three of five cases with asp294his were homozygotes for the mutant CYP2D6 allele. The difference in the frequency of CYP2D6*4 homozygotes in the red/blonde cases with wild-type MC1R alleles compared with those with asp294his was significant (exact P = 0.029). No associations between val92his or asp84glu and CYP2D6 alleles were identified. | [
{
"begin_idx": "151",
"end_idx": "169",
"entity_id": "D008545",
"entity_type": "Disease",
"text_name": "malignant melanoma"
},
{
"begin_idx": "447",
"end_idx": "465",
"entity_id": "D008545",
"entity_type": "Disease",
"text_name": "malignant melanoma"
},
{
"begin_idx": "620",
"end_idx": "638",
"entity_id": "D008545",
"entity_type": "Disease",
"text_name": "malignant melanoma"
},
{
"begin_idx": "940",
"end_idx": "958",
"entity_id": "D008545",
"entity_type": "Disease",
"text_name": "malignant melanoma"
},
{
"begin_idx": "1021",
"end_idx": "1039",
"entity_id": "D008545",
"entity_type": "Disease",
"text_name": "malignant melanoma"
},
{
"begin_idx": "1378",
"end_idx": "1399",
"entity_id": "D009135",
"entity_type": "Disease",
"text_name": "Breslow thickness < 1"
},
{
"begin_idx": "288",
"end_idx": "295",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "cancers"
},
{
"begin_idx": "1367",
"end_idx": "1374",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumours"
},
{
"begin_idx": "1422",
"end_idx": "1429",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumours"
},
{
"begin_idx": "1230",
"end_idx": "1253",
"entity_id": "D012868",
"entity_type": "Disease",
"text_name": "skin type or eye colour"
},
{
"begin_idx": "16",
"end_idx": "22",
"entity_id": "1565",
"entity_type": "Gene",
"text_name": "CYP2D6"
},
{
"begin_idx": "253",
"end_idx": "259",
"entity_id": "1565",
"entity_type": "Gene",
"text_name": "CYP2D6"
},
{
"begin_idx": "375",
"end_idx": "381",
"entity_id": "1565",
"entity_type": "Gene",
"text_name": "CYP2D6"
},
{
"begin_idx": "388",
"end_idx": "394",
"entity_id": "1565",
"entity_type": "Gene",
"text_name": "CYP2D6"
},
{
"begin_idx": "687",
"end_idx": "693",
"entity_id": "1565",
"entity_type": "Gene",
"text_name": "CYP2D6"
},
{
"begin_idx": "1205",
"end_idx": "1211",
"entity_id": "1565",
"entity_type": "Gene",
"text_name": "CYP2D6"
},
{
"begin_idx": "1283",
"end_idx": "1289",
"entity_id": "1565",
"entity_type": "Gene",
"text_name": "CYP2D6"
},
{
"begin_idx": "1525",
"end_idx": "1531",
"entity_id": "1565",
"entity_type": "Gene",
"text_name": "CYP2D6"
},
{
"begin_idx": "1660",
"end_idx": "1666",
"entity_id": "1565",
"entity_type": "Gene",
"text_name": "CYP2D6"
},
{
"begin_idx": "1967",
"end_idx": "1973",
"entity_id": "1565",
"entity_type": "Gene",
"text_name": "CYP2D6"
},
{
"begin_idx": "2095",
"end_idx": "2101",
"entity_id": "1565",
"entity_type": "Gene",
"text_name": "CYP2D6"
},
{
"begin_idx": "2145",
"end_idx": "2151",
"entity_id": "1565",
"entity_type": "Gene",
"text_name": "CYP2D6"
},
{
"begin_idx": "2337",
"end_idx": "2343",
"entity_id": "1565",
"entity_type": "Gene",
"text_name": "CYP2D6"
},
{
"begin_idx": "1857",
"end_idx": "1861",
"entity_id": "4157",
"entity_type": "Gene",
"text_name": "MC1R"
},
{
"begin_idx": "2205",
"end_idx": "2209",
"entity_id": "4157",
"entity_type": "Gene",
"text_name": "MC1R"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "16",
"end_idx": "22",
"entity_id": "1565",
"entity_type": "Gene",
"text_name": "CYP2D6"
},
{
"begin_idx": "1857",
"end_idx": "1861",
"entity_id": "4157",
"entity_type": "Gene",
"text_name": "MC1R"
}
] | [
{
"begin_idx": "151",
"end_idx": "169",
"entity_id": "D008545",
"entity_type": "Disease",
"text_name": "malignant melanoma"
},
{
"begin_idx": "151",
"end_idx": "169",
"entity_id": "D008545",
"entity_type": "Disease",
"text_name": "malignant melanoma"
}
] | [
"CYP2D6",
"MC1R"
] | [
"malignant melanoma",
"malignant melanoma"
] |
10471507 | Mutations in the CCN gene family member WISP3 cause progressive pseudorheumatoid dysplasia. | Members of the CCN (for CTGF, cyr61/cef10, nov) gene family encode cysteine-rich secreted proteins with roles in cell growth and differentiation. Cell-specific and tissue-specific differences in the expression and function of different CCN family members suggest they have non-redundant roles. Using a positional-candidate approach, we found that mutations in the CCN family member WISP3 are associated with the autosomal recessive skeletal disorder progressive pseudorheumatoid dysplasia (PPD; MIM 208230). PPD is an autosomal recessive disorder that may be initially misdiagnosed as juvenile rheumatoid arthritis. Its population incidence has been estimated at 1 per million in the United Kingdom, but it is likely to be higher in the Middle East and Gulf States. Affected individuals are asymptomatic in early childhood. Signs and symptoms of disease typically develop between three and eight years of age. Clinically and radiographically, patients experience continued cartilage loss and destructive bone changes as they age, in several instances necessitating joint replacement surgery by the third decade of life. Extraskeletal manifestations have not been reported in PPD. Cartilage appears to be the primary affected tissue, and in one patient, a biopsy of the iliac crest revealed abnormal nests of chondrocytes and loss of normal cell columnar organization in growth zones. We have identified nine different WISP3 mutations in unrelated, affected individuals, indicating that the gene is essential for normal post-natal skeletal growth and cartilage homeostasis. | [
{
"begin_idx": "52",
"end_idx": "90",
"entity_id": "C535387",
"entity_type": "Disease",
"text_name": "progressive pseudorheumatoid dysplasia"
},
{
"begin_idx": "542",
"end_idx": "580",
"entity_id": "C535387",
"entity_type": "Disease",
"text_name": "progressive pseudorheumatoid dysplasia"
},
{
"begin_idx": "582",
"end_idx": "585",
"entity_id": "C535387",
"entity_type": "Disease",
"text_name": "PPD"
},
{
"begin_idx": "600",
"end_idx": "603",
"entity_id": "C535387",
"entity_type": "Disease",
"text_name": "PPD"
},
{
"begin_idx": "1267",
"end_idx": "1270",
"entity_id": "C535387",
"entity_type": "Disease",
"text_name": "PPD"
},
{
"begin_idx": "677",
"end_idx": "706",
"entity_id": "D001172",
"entity_type": "Disease",
"text_name": "juvenile rheumatoid arthritis"
},
{
"begin_idx": "504",
"end_idx": "541",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal recessive skeletal disorder"
},
{
"begin_idx": "610",
"end_idx": "638",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal recessive disorder"
},
{
"begin_idx": "116",
"end_idx": "120",
"entity_id": "1490",
"entity_type": "Gene",
"text_name": "CTGF"
},
{
"begin_idx": "122",
"end_idx": "127",
"entity_id": "3491",
"entity_type": "Gene",
"text_name": "cyr61"
},
{
"begin_idx": "135",
"end_idx": "138",
"entity_id": "4856",
"entity_type": "Gene",
"text_name": "nov"
},
{
"begin_idx": "40",
"end_idx": "45",
"entity_id": "8838",
"entity_type": "Gene",
"text_name": "WISP3"
},
{
"begin_idx": "474",
"end_idx": "479",
"entity_id": "8838",
"entity_type": "Gene",
"text_name": "WISP3"
},
{
"begin_idx": "1510",
"end_idx": "1515",
"entity_id": "8838",
"entity_type": "Gene",
"text_name": "WISP3"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "40",
"end_idx": "45",
"entity_id": "8838",
"entity_type": "Gene",
"text_name": "WISP3"
},
{
"begin_idx": "122",
"end_idx": "127",
"entity_id": "3491",
"entity_type": "Gene",
"text_name": "cyr61"
}
] | [
{
"begin_idx": "52",
"end_idx": "90",
"entity_id": "C535387",
"entity_type": "Disease",
"text_name": "progressive pseudorheumatoid dysplasia"
},
{
"begin_idx": "582",
"end_idx": "585",
"entity_id": "C535387",
"entity_type": "Disease",
"text_name": "PPD"
}
] | [
"WISP3",
"cyr61"
] | [
"progressive pseudorheumatoid dysplasia",
"PPD"
] |
10477430 | Screening for mutations in the uroporphyrinogen decarboxylase gene using denaturing gradient gel electrophoresis. Identification and characterization of six novel mutations associated with familial PCT. | The two porphyrias, familial porphyria cutanea tarda (fPCT) and hepatoerythropoietic porphyria (HEP), are associated with mutations in the gene encoding the enzyme uroporphyrinogen decarboxylase (UROD). Several mutations, most of which are private, have been identified in HEP and fPCT patients, confirming the heterogeneity of the underlying genetic defects of these diseases. We have established a denaturing gradient gel electrophoresis (DGGE) assay for mutation detection in the UROD gene, enabling the simultaneous screening for known and unknown mutations. The established assay has proved able to detect the underlying UROD mutation in 10 previously characterized DNA samples as well as a new mutation in each of six previously unexamined PCT patients. The six novel UROD mutations comprise three missense mutations (M01T, F229L, and M324T), two splice mutations (IVS3-2A-->T and IVS5-2A-->G) leading to exon skipping, and a 2-bp deletion (415-416delTA) resulting in a frameshift and the introduction of a premature stop codon. Heterologous expression and enzymatic studies of the mutant proteins demonstrate that the three mutations leading to shortening or truncation of the UROD protein have no residual catalytic activity, whereas the two missense mutants retained some residual activity. Furthermore, the missense mutants exhibited a considerable increase in thermolability. The six new mutations bring to a total of 29 the number of disease-related mutations in the UROD gene. The DGGE assay presented greatly improves the genetic diagnosis of fPCT and HEP, thereby facilitating the detection of familial UROD deficient patients as well as the discrimination between familial and sporadic PCT cases. | [
{
"begin_idx": "189",
"end_idx": "201",
"entity_id": "D017119",
"entity_type": "Disease",
"text_name": "familial PCT"
},
{
"begin_idx": "223",
"end_idx": "255",
"entity_id": "D017119",
"entity_type": "Disease",
"text_name": "familial porphyria cutanea tarda"
},
{
"begin_idx": "257",
"end_idx": "261",
"entity_id": "D017119",
"entity_type": "Disease",
"text_name": "fPCT"
},
{
"begin_idx": "484",
"end_idx": "488",
"entity_id": "D017119",
"entity_type": "Disease",
"text_name": "fPCT"
},
{
"begin_idx": "949",
"end_idx": "952",
"entity_id": "D017119",
"entity_type": "Disease",
"text_name": "PCT"
},
{
"begin_idx": "1760",
"end_idx": "1764",
"entity_id": "D017119",
"entity_type": "Disease",
"text_name": "fPCT"
},
{
"begin_idx": "1905",
"end_idx": "1908",
"entity_id": "D017119",
"entity_type": "Disease",
"text_name": "PCT"
},
{
"begin_idx": "267",
"end_idx": "297",
"entity_id": "D017121",
"entity_type": "Disease",
"text_name": "hepatoerythropoietic porphyria"
},
{
"begin_idx": "299",
"end_idx": "302",
"entity_id": "D017121",
"entity_type": "Disease",
"text_name": "HEP"
},
{
"begin_idx": "476",
"end_idx": "479",
"entity_id": "D017121",
"entity_type": "Disease",
"text_name": "HEP"
},
{
"begin_idx": "1769",
"end_idx": "1772",
"entity_id": "D017121",
"entity_type": "Disease",
"text_name": "HEP"
},
{
"begin_idx": "31",
"end_idx": "61",
"entity_id": "7389",
"entity_type": "Gene",
"text_name": "uroporphyrinogen decarboxylase"
},
{
"begin_idx": "367",
"end_idx": "397",
"entity_id": "7389",
"entity_type": "Gene",
"text_name": "uroporphyrinogen decarboxylase"
},
{
"begin_idx": "399",
"end_idx": "403",
"entity_id": "7389",
"entity_type": "Gene",
"text_name": "UROD"
},
{
"begin_idx": "686",
"end_idx": "690",
"entity_id": "7389",
"entity_type": "Gene",
"text_name": "UROD"
},
{
"begin_idx": "829",
"end_idx": "833",
"entity_id": "7389",
"entity_type": "Gene",
"text_name": "UROD"
},
{
"begin_idx": "977",
"end_idx": "981",
"entity_id": "7389",
"entity_type": "Gene",
"text_name": "UROD"
},
{
"begin_idx": "1387",
"end_idx": "1391",
"entity_id": "7389",
"entity_type": "Gene",
"text_name": "UROD"
},
{
"begin_idx": "1682",
"end_idx": "1686",
"entity_id": "7389",
"entity_type": "Gene",
"text_name": "UROD"
},
{
"begin_idx": "1821",
"end_idx": "1825",
"entity_id": "7389",
"entity_type": "Gene",
"text_name": "UROD"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "31",
"end_idx": "61",
"entity_id": "7389",
"entity_type": "Gene",
"text_name": "uroporphyrinogen decarboxylase"
},
{
"begin_idx": "1821",
"end_idx": "1825",
"entity_id": "7389",
"entity_type": "Gene",
"text_name": "UROD"
}
] | [
{
"begin_idx": "223",
"end_idx": "255",
"entity_id": "D017119",
"entity_type": "Disease",
"text_name": "familial porphyria cutanea tarda"
},
{
"begin_idx": "267",
"end_idx": "297",
"entity_id": "D017121",
"entity_type": "Disease",
"text_name": "hepatoerythropoietic porphyria"
}
] | [
"uroporphyrinogen decarboxylase",
"UROD"
] | [
"familial porphyria cutanea tarda",
"hepatoerythropoietic porphyria"
] |
10477432 | Identification of 12 novel mutations and two new polymorphisms in the arylsulfatase A gene: haplotype and genotype-phenotype correlation studies in Spanish metachromatic leukodystrophy patients. | Arylsulfatase A (ARSA) deficiency is the main cause of metachromatic leukodystrophy (MLD), a lysosomal disorder with no specific treatment. In view of the importance of genetic counseling, analyses of mutations and polymorphisms, including the ARSA pseudodeficiency allele, were carried out in 18 unrelated Spanish MLD patients. A systematic search allowed us to identify 100% of the alleles involving 17 different mutations, 12 of which are novel: G32S, L68P, R84W, P94A, G99V, P136S, W193X, H227Y, R288H, G308D, T327I, and IVS6-12C-->G. Two new polymorphisms, 2033C>T and 2059C>T, were identified in intron 6 which, in combination with two polymorphisms previously described (2161C>G and 2213C>G), gave rise to four different haplotypes in the control population. In addition, we also studied polymorphism 842G>T. Linkage disequilibrium was detected between mutations IVS2+1G-->A, D255H, and T327I and specific haplotypes, suggesting a unique origin for these mutations. Moreover, mutation T327I was always associated with the T allele of the new rare variant A210A (893C>T). The distribution of mutation D255H (frequency 19.4%) among patients with different MLD clinical presentation revealed a clear genotype-phenotype correlation paralleling that reported for mutation IVS2+1G-->A (frequency 25%). Among the novel mutations, only P136S and R288H occurred on a background of the ARSA pseudodeficiency allele. Screening 182 normal chromosomes identified a frequency of 8.8% of this allele; moreover, we identified two unrelated subjects with the polyA- mutation in the absence of the N350S mutation, and this infrequent haplotype reinforced the heterogeneity of conditions with ARSA deficiency. | [
{
"begin_idx": "156",
"end_idx": "184",
"entity_id": "D007966",
"entity_type": "Disease",
"text_name": "metachromatic leukodystrophy"
},
{
"begin_idx": "250",
"end_idx": "278",
"entity_id": "D007966",
"entity_type": "Disease",
"text_name": "metachromatic leukodystrophy"
},
{
"begin_idx": "280",
"end_idx": "283",
"entity_id": "D007966",
"entity_type": "Disease",
"text_name": "MLD"
},
{
"begin_idx": "510",
"end_idx": "513",
"entity_id": "D007966",
"entity_type": "Disease",
"text_name": "MLD"
},
{
"begin_idx": "1356",
"end_idx": "1359",
"entity_id": "D007966",
"entity_type": "Disease",
"text_name": "MLD"
},
{
"begin_idx": "1876",
"end_idx": "1891",
"entity_id": "D007966",
"entity_type": "Disease",
"text_name": "ARSA deficiency"
},
{
"begin_idx": "288",
"end_idx": "306",
"entity_id": "D016464",
"entity_type": "Disease",
"text_name": "lysosomal disorder"
},
{
"begin_idx": "70",
"end_idx": "85",
"entity_id": "410",
"entity_type": "Gene",
"text_name": "arylsulfatase A"
},
{
"begin_idx": "195",
"end_idx": "210",
"entity_id": "410",
"entity_type": "Gene",
"text_name": "Arylsulfatase A"
},
{
"begin_idx": "212",
"end_idx": "216",
"entity_id": "410",
"entity_type": "Gene",
"text_name": "ARSA"
},
{
"begin_idx": "439",
"end_idx": "443",
"entity_id": "410",
"entity_type": "Gene",
"text_name": "ARSA"
},
{
"begin_idx": "1578",
"end_idx": "1582",
"entity_id": "410",
"entity_type": "Gene",
"text_name": "ARSA"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "70",
"end_idx": "85",
"entity_id": "410",
"entity_type": "Gene",
"text_name": "arylsulfatase A"
},
{
"begin_idx": "1578",
"end_idx": "1582",
"entity_id": "410",
"entity_type": "Gene",
"text_name": "ARSA"
}
] | [
{
"begin_idx": "156",
"end_idx": "184",
"entity_id": "D007966",
"entity_type": "Disease",
"text_name": "metachromatic leukodystrophy"
},
{
"begin_idx": "288",
"end_idx": "306",
"entity_id": "D016464",
"entity_type": "Disease",
"text_name": "lysosomal disorder"
}
] | [
"arylsulfatase A",
"ARSA"
] | [
"metachromatic leukodystrophy",
"lysosomal disorder"
] |
10477434 | Molecular basis of late-life globoid cell leukodystrophy. | Globoid cell leukodystrophy is an autosomal recessive inherited disease caused by deficiency of the lysosomal enzyme galactocerebrosidase (GALC). Although the severe, rapidly progressing infantile form is the most common, late-onset forms have been described. We investigated the molecular basis of GALC deficiency in a patient with a late-life mild form of globoid cell leukodystrophy who survived into the eighth decade. Since material suitable for mutation analysis was no longer available from the proband, her GALC genotype was reconstructed by analyzing this gene in her six obligate carrier offspring. One allele contained the mutation 809G>A (G270D) in the 1637C background, while the other allele contained three sequence variants: 1609G>A (G537R), 1873G>A (A625T), and 1650T>A (V550V) in the 1637T background. These mutations were confirmed in the proband's genomic DNA isolated from a sural nerve biopsy. Expression studies indicated that the G537R is a disease-causing mutation, as it resulted in no GALC activity, either alone or together with the A625T. This A625T sequence variant did not affect the enzyme activity, at least when expressed in the 1637T background. The mild clinical phenotype was likely to be associated with the 809G>A, since residual GALC activity, about 17% of the control activity, was detected in the expression studies of this mutation. This mutation has been found in several other patients with late-onset GLD. | [
{
"begin_idx": "19",
"end_idx": "56",
"entity_id": "D007965",
"entity_type": "Disease",
"text_name": "late-life globoid cell leukodystrophy"
},
{
"begin_idx": "58",
"end_idx": "85",
"entity_id": "D007965",
"entity_type": "Disease",
"text_name": "Globoid cell leukodystrophy"
},
{
"begin_idx": "357",
"end_idx": "372",
"entity_id": "D007965",
"entity_type": "Disease",
"text_name": "GALC deficiency"
},
{
"begin_idx": "408",
"end_idx": "443",
"entity_id": "D007965",
"entity_type": "Disease",
"text_name": "form of globoid cell leukodystrophy"
},
{
"begin_idx": "1505",
"end_idx": "1508",
"entity_id": "D007965",
"entity_type": "Disease",
"text_name": "GLD"
},
{
"begin_idx": "140",
"end_idx": "195",
"entity_id": "D008661",
"entity_type": "Disease",
"text_name": "deficiency of the lysosomal enzyme galactocerebrosidase"
},
{
"begin_idx": "112",
"end_idx": "129",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "inherited disease"
},
{
"begin_idx": "175",
"end_idx": "195",
"entity_id": "2581",
"entity_type": "Gene",
"text_name": "galactocerebrosidase"
},
{
"begin_idx": "197",
"end_idx": "201",
"entity_id": "2581",
"entity_type": "Gene",
"text_name": "GALC"
},
{
"begin_idx": "573",
"end_idx": "577",
"entity_id": "2581",
"entity_type": "Gene",
"text_name": "GALC"
},
{
"begin_idx": "1070",
"end_idx": "1074",
"entity_id": "2581",
"entity_type": "Gene",
"text_name": "GALC"
},
{
"begin_idx": "1327",
"end_idx": "1331",
"entity_id": "2581",
"entity_type": "Gene",
"text_name": "GALC"
}
] | [
"Yes",
"No"
] | [
false,
true
] | [
{
"begin_idx": "175",
"end_idx": "195",
"entity_id": "2581",
"entity_type": "Gene",
"text_name": "galactocerebrosidase"
},
{
"begin_idx": "1070",
"end_idx": "1074",
"entity_id": "2581",
"entity_type": "Gene",
"text_name": "GALC"
}
] | [
{
"begin_idx": "19",
"end_idx": "56",
"entity_id": "D007965",
"entity_type": "Disease",
"text_name": "late-life globoid cell leukodystrophy"
},
{
"begin_idx": "112",
"end_idx": "129",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "inherited disease"
}
] | [
"galactocerebrosidase",
"GALC"
] | [
"late-life globoid cell leukodystrophy",
"inherited disease"
] |
10479408 | Interleukin 10 mitigates the development of the zymosan-induced multiple organ dysfunction syndrome in mice. | We investigated the effect of interleukin 10 on the development of zymosan-induced multiple organ dysfunction syndrome (MODS) and on plasma concentrations and production capacity of tumour necrosis factor (TNF)-alpha by peritoneal cells. Groups of C57BL/6 mice received a single intraperitoneal injection with zymosan, a cell wall component of Saccharomyces cerevisiae, at day 0. Daily doses of human recombinant interleukin 10 (IL-10: 10 or 50 microg/kg) were given intraperitoneally either starting directly before administration of zymosan (day 0), or 5 or 8 days after administration of zymosan. The animals were monitored for survival, condition, body weight and temperature. On day 12 all surviving animals were killed to obtain plasma, organs and peritoneal cells. Plasma concentrations of TNF-alpha and lipopolysaccharide-stimulated production of TNF-alpha by peritoneal cells were measured; organ weights were registered as an indicator for organ damage. IL-10 improves survival and clinical condition and also reduces organ damage, but only at the highest dose used and only when started simultaneously with the administration of zymosan. Circulating TNF-alpha concentrations 12 days after zymosan are not affected by any of the IL-10 schedules used. However, lipopolysaccharide-stimulated production of TNF-alpha by peritoneal cells is increased, in a dose- and time-dependent fashion. The anti-inflammatory cytokine IL-10 is able to attenuate the development of MODS in this model, but only when given simultaneously with zymosan, and in high dosages. | [
{
"begin_idx": "64",
"end_idx": "99",
"entity_id": "D009102",
"entity_type": "Disease",
"text_name": "multiple organ dysfunction syndrome"
},
{
"begin_idx": "192",
"end_idx": "227",
"entity_id": "D009102",
"entity_type": "Disease",
"text_name": "multiple organ dysfunction syndrome"
},
{
"begin_idx": "229",
"end_idx": "233",
"entity_id": "D009102",
"entity_type": "Disease",
"text_name": "MODS"
},
{
"begin_idx": "1583",
"end_idx": "1587",
"entity_id": "D009102",
"entity_type": "Disease",
"text_name": "MODS"
},
{
"begin_idx": "298",
"end_idx": "306",
"entity_id": "D009336",
"entity_type": "Disease",
"text_name": "necrosis"
},
{
"begin_idx": "291",
"end_idx": "297",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumour"
},
{
"begin_idx": "0",
"end_idx": "14",
"entity_id": "3586",
"entity_type": "Gene",
"text_name": "Interleukin 10"
},
{
"begin_idx": "139",
"end_idx": "153",
"entity_id": "3586",
"entity_type": "Gene",
"text_name": "interleukin 10"
},
{
"begin_idx": "522",
"end_idx": "536",
"entity_id": "3586",
"entity_type": "Gene",
"text_name": "interleukin 10"
},
{
"begin_idx": "538",
"end_idx": "543",
"entity_id": "3586",
"entity_type": "Gene",
"text_name": "IL-10"
},
{
"begin_idx": "1073",
"end_idx": "1078",
"entity_id": "3586",
"entity_type": "Gene",
"text_name": "IL-10"
},
{
"begin_idx": "1348",
"end_idx": "1353",
"entity_id": "3586",
"entity_type": "Gene",
"text_name": "IL-10"
},
{
"begin_idx": "1537",
"end_idx": "1542",
"entity_id": "3586",
"entity_type": "Gene",
"text_name": "IL-10"
},
{
"begin_idx": "315",
"end_idx": "325",
"entity_id": "7124",
"entity_type": "Gene",
"text_name": "TNF)-alpha"
},
{
"begin_idx": "906",
"end_idx": "915",
"entity_id": "7124",
"entity_type": "Gene",
"text_name": "TNF-alpha"
},
{
"begin_idx": "964",
"end_idx": "973",
"entity_id": "7124",
"entity_type": "Gene",
"text_name": "TNF-alpha"
},
{
"begin_idx": "1270",
"end_idx": "1279",
"entity_id": "7124",
"entity_type": "Gene",
"text_name": "TNF-alpha"
},
{
"begin_idx": "1423",
"end_idx": "1432",
"entity_id": "7124",
"entity_type": "Gene",
"text_name": "TNF-alpha"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "0",
"end_idx": "14",
"entity_id": "3586",
"entity_type": "Gene",
"text_name": "Interleukin 10"
},
{
"begin_idx": "315",
"end_idx": "325",
"entity_id": "7124",
"entity_type": "Gene",
"text_name": "TNF)-alpha"
}
] | [
{
"begin_idx": "64",
"end_idx": "99",
"entity_id": "D009102",
"entity_type": "Disease",
"text_name": "multiple organ dysfunction syndrome"
},
{
"begin_idx": "1583",
"end_idx": "1587",
"entity_id": "D009102",
"entity_type": "Disease",
"text_name": "MODS"
}
] | [
"Interleukin 10",
"TNF)-alpha"
] | [
"multiple organ dysfunction syndrome",
"MODS"
] |
10479479 | Trimethylaminuria is caused by mutations of the FMO3 gene in a North American cohort. | Trimethylaminuria (TMAuria) (McKusick 602079) first described in 1970 is an autosomal recessive condition caused by a partial or total incapacity to catalyze the N-oxygenation of the odorous compound trimethylamine (TMA). The result is a severe body odor and associated psychosocial conditions. This inborn error of metabolism, previously thought to be rare, is now being increasingly detected in severe and milder presentations. Mutations of a phase 1 detoxicating gene, flavin-containing monooxygenase 3 (FMO3), have been shown to cause TMAuria. Herein we describe a cohort of individuals ascertained in North America with severe TMAuria, defined by a reduction of TMA oxidation below 50% of normal with genotype-phenotype correlations. We detected four new FMO3 mutations; two were missense (A52T and R387L), one was nonsense (E314X). The fourth allele is apparently composed of two relatively common polymorphisms (K158-G308) found in the general population. On the basis of this study we conclude that one common mutation and an increasing number of private mutations in individuals of different ethnic origins cause TMAuria in this cohort. | [
{
"begin_idx": "0",
"end_idx": "17",
"entity_id": "C536561",
"entity_type": "Disease",
"text_name": "Trimethylaminuria"
},
{
"begin_idx": "86",
"end_idx": "103",
"entity_id": "C536561",
"entity_type": "Disease",
"text_name": "Trimethylaminuria"
},
{
"begin_idx": "105",
"end_idx": "112",
"entity_id": "C536561",
"entity_type": "Disease",
"text_name": "TMAuria"
},
{
"begin_idx": "625",
"end_idx": "632",
"entity_id": "C536561",
"entity_type": "Disease",
"text_name": "TMAuria"
},
{
"begin_idx": "718",
"end_idx": "725",
"entity_id": "C536561",
"entity_type": "Disease",
"text_name": "TMAuria"
},
{
"begin_idx": "1208",
"end_idx": "1215",
"entity_id": "C536561",
"entity_type": "Disease",
"text_name": "TMAuria"
},
{
"begin_idx": "386",
"end_idx": "412",
"entity_id": "D008661",
"entity_type": "Disease",
"text_name": "inborn error of metabolism"
},
{
"begin_idx": "162",
"end_idx": "191",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal recessive condition"
},
{
"begin_idx": "48",
"end_idx": "52",
"entity_id": "2328",
"entity_type": "Gene",
"text_name": "FMO3"
},
{
"begin_idx": "558",
"end_idx": "591",
"entity_id": "2328",
"entity_type": "Gene",
"text_name": "flavin-containing monooxygenase 3"
},
{
"begin_idx": "593",
"end_idx": "597",
"entity_id": "2328",
"entity_type": "Gene",
"text_name": "FMO3"
},
{
"begin_idx": "846",
"end_idx": "850",
"entity_id": "2328",
"entity_type": "Gene",
"text_name": "FMO3"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "558",
"end_idx": "591",
"entity_id": "2328",
"entity_type": "Gene",
"text_name": "flavin-containing monooxygenase 3"
},
{
"begin_idx": "48",
"end_idx": "52",
"entity_id": "2328",
"entity_type": "Gene",
"text_name": "FMO3"
}
] | [
{
"begin_idx": "0",
"end_idx": "17",
"entity_id": "C536561",
"entity_type": "Disease",
"text_name": "Trimethylaminuria"
},
{
"begin_idx": "162",
"end_idx": "191",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal recessive condition"
}
] | [
"flavin-containing monooxygenase 3",
"FMO3"
] | [
"Trimethylaminuria",
"autosomal recessive condition"
] |
10480364 | X-linked adrenomyeloneuropathy associated with 14 novel ALD-gene mutations: no correlation between type of mutation and age of onset. | Adrenomyeloneuropathy (AMN) represents a milder form of X-linked adrenoleukodystrophy (ALD), the most frequent peroxisomal disorder. The disease is characterised by an abnormal accumulation of saturated, very long chain, fatty acids, because of altered peroxisomal beta-oxidation that concomitantly leads to demyelination in the central and peripheral nervous systems. ALD shows a highly variable phenotypic expression and extensive mutation analysis in ALD patients has failed to establish a genotype-phenotype correlation, even in the presence of the same ALD-gene defect. Therefore, we have looked for a relationship between the molecular lesion and the age of onset in 19 patients with a well-classified clinical course of AMN. The nearly complete novel spectrum of ALD gene mutations identified has revealed no obvious correlation between the type of mutation and age of AMN onset in this small series. However, intrafamiliar concordance could be observed with respect to the occurrence of adrenocortical insufficiency. This supports the idea of one (or more) additional gene(s) contributing to the phenotypic expression of ALD. | [
{
"begin_idx": "1129",
"end_idx": "1157",
"entity_id": "D000224",
"entity_type": "Disease",
"text_name": "adrenocortical insufficiency"
},
{
"begin_idx": "56",
"end_idx": "59",
"entity_id": "D000326",
"entity_type": "Disease",
"text_name": "ALD"
},
{
"begin_idx": "134",
"end_idx": "155",
"entity_id": "D000326",
"entity_type": "Disease",
"text_name": "Adrenomyeloneuropathy"
},
{
"begin_idx": "157",
"end_idx": "160",
"entity_id": "D000326",
"entity_type": "Disease",
"text_name": "AMN"
},
{
"begin_idx": "190",
"end_idx": "219",
"entity_id": "D000326",
"entity_type": "Disease",
"text_name": "X-linked adrenoleukodystrophy"
},
{
"begin_idx": "221",
"end_idx": "224",
"entity_id": "D000326",
"entity_type": "Disease",
"text_name": "ALD"
},
{
"begin_idx": "503",
"end_idx": "506",
"entity_id": "D000326",
"entity_type": "Disease",
"text_name": "ALD"
},
{
"begin_idx": "588",
"end_idx": "591",
"entity_id": "D000326",
"entity_type": "Disease",
"text_name": "ALD"
},
{
"begin_idx": "692",
"end_idx": "695",
"entity_id": "D000326",
"entity_type": "Disease",
"text_name": "ALD"
},
{
"begin_idx": "861",
"end_idx": "864",
"entity_id": "D000326",
"entity_type": "Disease",
"text_name": "AMN"
},
{
"begin_idx": "904",
"end_idx": "907",
"entity_id": "D000326",
"entity_type": "Disease",
"text_name": "ALD"
},
{
"begin_idx": "1010",
"end_idx": "1013",
"entity_id": "D000326",
"entity_type": "Disease",
"text_name": "AMN"
},
{
"begin_idx": "1263",
"end_idx": "1266",
"entity_id": "D000326",
"entity_type": "Disease",
"text_name": "ALD"
},
{
"begin_idx": "442",
"end_idx": "455",
"entity_id": "D003711",
"entity_type": "Disease",
"text_name": "demyelination"
},
{
"begin_idx": "245",
"end_idx": "265",
"entity_id": "D018901",
"entity_type": "Disease",
"text_name": "peroxisomal disorder"
},
{
"begin_idx": "0",
"end_idx": "30",
"entity_id": "D040181",
"entity_type": "Disease",
"text_name": "X-linked adrenomyeloneuropathy"
},
{
"begin_idx": "56",
"end_idx": "59",
"entity_id": "215",
"entity_type": "Gene",
"text_name": "ALD"
},
{
"begin_idx": "221",
"end_idx": "224",
"entity_id": "215",
"entity_type": "Gene",
"text_name": "ALD"
},
{
"begin_idx": "503",
"end_idx": "506",
"entity_id": "215",
"entity_type": "Gene",
"text_name": "ALD"
},
{
"begin_idx": "588",
"end_idx": "591",
"entity_id": "215",
"entity_type": "Gene",
"text_name": "ALD"
},
{
"begin_idx": "692",
"end_idx": "695",
"entity_id": "215",
"entity_type": "Gene",
"text_name": "ALD"
},
{
"begin_idx": "904",
"end_idx": "907",
"entity_id": "215",
"entity_type": "Gene",
"text_name": "ALD"
},
{
"begin_idx": "1263",
"end_idx": "1266",
"entity_id": "215",
"entity_type": "Gene",
"text_name": "ALD"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "56",
"end_idx": "59",
"entity_id": "215",
"entity_type": "Gene",
"text_name": "ALD"
},
{
"begin_idx": "1263",
"end_idx": "1266",
"entity_id": "215",
"entity_type": "Gene",
"text_name": "ALD"
}
] | [
{
"begin_idx": "190",
"end_idx": "219",
"entity_id": "D000326",
"entity_type": "Disease",
"text_name": "X-linked adrenoleukodystrophy"
},
{
"begin_idx": "0",
"end_idx": "30",
"entity_id": "D040181",
"entity_type": "Disease",
"text_name": "X-linked adrenomyeloneuropathy"
}
] | [
"ALD",
"ALD"
] | [
"X-linked adrenoleukodystrophy",
"X-linked adrenomyeloneuropathy"
] |
10482956 | Molecular analysis of cystinosis: probable Irish origin of the most common French Canadian mutation. | Infantile nephropathic cystinosis, an autosomal recessive disease characterized by a lysosomal accumulation of cystine, presents as failure to thrive, rickets and proximal renal tubular acidosis. The cystinosis gene, CTNS, which maps to chromosome 17p13, encodes a predicted 55 kDa protein with characteristics of a lysosomal membrane protein. We have conducted extensive linkage analysis in a French Canadian cystinosis cohort identifying a founding haplotype present in approximately half (21/40) of the chromosomes studied. Subsequent mutational analysis, in addition to identifying two novel mutations, has unexpectedly revealed a mutation which has been previously found in Irish (but not French) cystinotic families on these 21 French Canadian chromosomes. Haplotype analysis of two Irish families with this mutation supports the hypothesis that Celtic chromosomes represent an extensive portion of cystinosis chromosomes in French Canada. Our analysis underlines the genetic heterogeneity of the French Canadian population, reflecting a frequently unrecognized contribution from non-Gallic sources including the Irish. | [
{
"begin_idx": "22",
"end_idx": "32",
"entity_id": "D003554",
"entity_type": "Disease",
"text_name": "cystinosis"
},
{
"begin_idx": "111",
"end_idx": "134",
"entity_id": "D003554",
"entity_type": "Disease",
"text_name": "nephropathic cystinosis"
},
{
"begin_idx": "301",
"end_idx": "311",
"entity_id": "D003554",
"entity_type": "Disease",
"text_name": "cystinosis"
},
{
"begin_idx": "511",
"end_idx": "521",
"entity_id": "D003554",
"entity_type": "Disease",
"text_name": "cystinosis"
},
{
"begin_idx": "1006",
"end_idx": "1016",
"entity_id": "D003554",
"entity_type": "Disease",
"text_name": "cystinosis"
},
{
"begin_idx": "233",
"end_idx": "259",
"entity_id": "D005183",
"entity_type": "Disease",
"text_name": "failure to thrive, rickets"
},
{
"begin_idx": "264",
"end_idx": "295",
"entity_id": "D007674",
"entity_type": "Disease",
"text_name": "proximal renal tubular acidosis"
},
{
"begin_idx": "139",
"end_idx": "166",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal recessive disease"
},
{
"begin_idx": "318",
"end_idx": "322",
"entity_id": "1497",
"entity_type": "Gene",
"text_name": "CTNS"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "318",
"end_idx": "322",
"entity_id": "1497",
"entity_type": "Gene",
"text_name": "CTNS"
},
{
"begin_idx": "318",
"end_idx": "322",
"entity_id": "1497",
"entity_type": "Gene",
"text_name": "CTNS"
}
] | [
{
"begin_idx": "111",
"end_idx": "134",
"entity_id": "D003554",
"entity_type": "Disease",
"text_name": "nephropathic cystinosis"
},
{
"begin_idx": "264",
"end_idx": "295",
"entity_id": "D007674",
"entity_type": "Disease",
"text_name": "proximal renal tubular acidosis"
}
] | [
"CTNS",
"CTNS"
] | [
"nephropathic cystinosis",
"proximal renal tubular acidosis"
] |
10482963 | Recessive Romano-Ward syndrome associated with compound heterozygosity for two mutations in the KVLQT1 gene. | We describe a Swedish family with the proband and his brother suffering from severe Romano-Ward syndome (RWS) associated with compound heterozygosity for two mutations in the KVLQT1 (also known as KCNQ1 and KCNA9) gene (R518X and A525T). The mutations were found to segregate as heterozygotes in the maternal and the paternal lineage, respectively. None of the heterozygotes exhibited clinical long QT syndrome (LQTS). No hearing defects were found in the proband. The data strongly indicates that the compound heterozygosity for R518X and A525T is the cause of an autosomal recessive form of RWS in this family. Our findings support the implication of a higher frequency of gene carriers than previously expected. We suggest that relatives of 'sporadic RWS' patients should be considered potential carriers, at risk of dying suddenly from drug-induced LQTS. | [
{
"begin_idx": "503",
"end_idx": "519",
"entity_id": "D008133",
"entity_type": "Disease",
"text_name": "long QT syndrome"
},
{
"begin_idx": "521",
"end_idx": "525",
"entity_id": "D008133",
"entity_type": "Disease",
"text_name": "LQTS"
},
{
"begin_idx": "962",
"end_idx": "966",
"entity_id": "D008133",
"entity_type": "Disease",
"text_name": "LQTS"
},
{
"begin_idx": "10",
"end_idx": "30",
"entity_id": "D029597",
"entity_type": "Disease",
"text_name": "Romano-Ward syndrome"
},
{
"begin_idx": "193",
"end_idx": "212",
"entity_id": "D029597",
"entity_type": "Disease",
"text_name": "Romano-Ward syndome"
},
{
"begin_idx": "214",
"end_idx": "217",
"entity_id": "D029597",
"entity_type": "Disease",
"text_name": "RWS"
},
{
"begin_idx": "702",
"end_idx": "705",
"entity_id": "D029597",
"entity_type": "Disease",
"text_name": "RWS"
},
{
"begin_idx": "863",
"end_idx": "866",
"entity_id": "D029597",
"entity_type": "Disease",
"text_name": "RWS"
},
{
"begin_idx": "531",
"end_idx": "546",
"entity_id": "D034381",
"entity_type": "Disease",
"text_name": "hearing defects"
},
{
"begin_idx": "96",
"end_idx": "102",
"entity_id": "3784",
"entity_type": "Gene",
"text_name": "KVLQT1"
},
{
"begin_idx": "284",
"end_idx": "290",
"entity_id": "3784",
"entity_type": "Gene",
"text_name": "KVLQT1"
},
{
"begin_idx": "306",
"end_idx": "311",
"entity_id": "3784",
"entity_type": "Gene",
"text_name": "KCNQ1"
},
{
"begin_idx": "316",
"end_idx": "321",
"entity_id": "3784",
"entity_type": "Gene",
"text_name": "KCNA9"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "96",
"end_idx": "102",
"entity_id": "3784",
"entity_type": "Gene",
"text_name": "KVLQT1"
},
{
"begin_idx": "96",
"end_idx": "102",
"entity_id": "3784",
"entity_type": "Gene",
"text_name": "KVLQT1"
}
] | [
{
"begin_idx": "10",
"end_idx": "30",
"entity_id": "D029597",
"entity_type": "Disease",
"text_name": "Romano-Ward syndrome"
},
{
"begin_idx": "962",
"end_idx": "966",
"entity_id": "D008133",
"entity_type": "Disease",
"text_name": "LQTS"
}
] | [
"KVLQT1",
"KVLQT1"
] | [
"Romano-Ward syndrome",
"LQTS"
] |
10484772 | Coats' disease of the retina (unilateral retinal telangiectasis) caused by somatic mutation in the NDP gene: a role for norrin in retinal angiogenesis. | Coats' disease is characterized by abnormal retinal vascular development (so-called 'retinal telangiectasis') which results in massive intraretinal and subretinal lipid accumulation (exudative retinal detachment). The classical form of Coats' disease is almost invariably isolated, unilateral and seen in males. A female with a unilateral variant of Coats' disease gave birth to a son affected by Norrie disease. Both carried a missense mutation within the NDP gene on chromosome Xp11.2. Subsequently analysis of the retinas of nine enucleated eyes from males with Coats' disease demonstrated in one a somatic mutation in the NDP gene which was not present within non-retinal tissue. We suggest that Coats' telangiectasis is secondary to somatic mutation in the NDP gene which results in a deficiency of norrin (the protein product of the NDP gene) within the developing retina. This supports recent observations that the protein is critical for normal retinal vasculogenesis. | [
{
"begin_idx": "549",
"end_idx": "563",
"entity_id": "C537849",
"entity_type": "Disease",
"text_name": "Norrie disease"
},
{
"begin_idx": "287",
"end_idx": "333",
"entity_id": "D006949",
"entity_type": "Disease",
"text_name": "intraretinal and subretinal lipid accumulation"
},
{
"begin_idx": "335",
"end_idx": "363",
"entity_id": "D012163",
"entity_type": "Disease",
"text_name": "exudative retinal detachment"
},
{
"begin_idx": "187",
"end_idx": "224",
"entity_id": "D012164",
"entity_type": "Disease",
"text_name": "abnormal retinal vascular development"
},
{
"begin_idx": "0",
"end_idx": "14",
"entity_id": "D058456",
"entity_type": "Disease",
"text_name": "Coats' disease"
},
{
"begin_idx": "30",
"end_idx": "63",
"entity_id": "D058456",
"entity_type": "Disease",
"text_name": "unilateral retinal telangiectasis"
},
{
"begin_idx": "152",
"end_idx": "166",
"entity_id": "D058456",
"entity_type": "Disease",
"text_name": "Coats' disease"
},
{
"begin_idx": "237",
"end_idx": "259",
"entity_id": "D058456",
"entity_type": "Disease",
"text_name": "retinal telangiectasis"
},
{
"begin_idx": "388",
"end_idx": "402",
"entity_id": "D058456",
"entity_type": "Disease",
"text_name": "Coats' disease"
},
{
"begin_idx": "502",
"end_idx": "516",
"entity_id": "D058456",
"entity_type": "Disease",
"text_name": "Coats' disease"
},
{
"begin_idx": "717",
"end_idx": "731",
"entity_id": "D058456",
"entity_type": "Disease",
"text_name": "Coats' disease"
},
{
"begin_idx": "852",
"end_idx": "873",
"entity_id": "D058456",
"entity_type": "Disease",
"text_name": "Coats' telangiectasis"
},
{
"begin_idx": "99",
"end_idx": "102",
"entity_id": "4693",
"entity_type": "Gene",
"text_name": "NDP"
},
{
"begin_idx": "120",
"end_idx": "126",
"entity_id": "4693",
"entity_type": "Gene",
"text_name": "norrin"
},
{
"begin_idx": "609",
"end_idx": "612",
"entity_id": "4693",
"entity_type": "Gene",
"text_name": "NDP"
},
{
"begin_idx": "778",
"end_idx": "781",
"entity_id": "4693",
"entity_type": "Gene",
"text_name": "NDP"
},
{
"begin_idx": "914",
"end_idx": "917",
"entity_id": "4693",
"entity_type": "Gene",
"text_name": "NDP"
},
{
"begin_idx": "956",
"end_idx": "962",
"entity_id": "4693",
"entity_type": "Gene",
"text_name": "norrin"
},
{
"begin_idx": "991",
"end_idx": "994",
"entity_id": "4693",
"entity_type": "Gene",
"text_name": "NDP"
}
] | [
"Yes",
"No"
] | [
false,
false
] | [
{
"begin_idx": "120",
"end_idx": "126",
"entity_id": "4693",
"entity_type": "Gene",
"text_name": "norrin"
},
{
"begin_idx": "99",
"end_idx": "102",
"entity_id": "4693",
"entity_type": "Gene",
"text_name": "NDP"
}
] | [
{
"begin_idx": "549",
"end_idx": "563",
"entity_id": "C537849",
"entity_type": "Disease",
"text_name": "Norrie disease"
},
{
"begin_idx": "287",
"end_idx": "333",
"entity_id": "D006949",
"entity_type": "Disease",
"text_name": "intraretinal and subretinal lipid accumulation"
}
] | [
"norrin",
"NDP"
] | [
"Norrie disease",
"intraretinal and subretinal lipid accumulation"
] |
10486317 | Variegate porphyria in Western Europe: identification of PPOX gene mutations in 104 families, extent of allelic heterogeneity, and absence of correlation between phenotype and type of mutation. | Variegate porphyria (VP) is a low-penetrance, autosomal dominant disorder characterized clinically by skin lesions and acute neurovisceral attacks that occur separately or together. It results from partial deficiency of protoporphyrinogen oxidase encoded by the PPOX gene. VP is relatively common in South Africa, where most patients have inherited the same mutation in the PPOX gene from a common ancestor, but few families from elsewhere have been studied. Here we describe the molecular basis and clinical features of 108 unrelated patients from France and the United Kingdom. Mutations in the PPOX gene were identified by a combination of screening (denaturing gradient gel electrophoresis, heteroduplex analysis, or denaturing high-performance liquid chromatography) and direct automated sequencing of amplified genomic DNA. A total of 60 novel and 6 previously reported mutations (25 missense, 24 frameshift, 10 splice site, and 7 nonsense) were identified in 104 (96%) of these unrelated patients, together with 3 previously unrecognized single-nucleotide polymorphisms. VP is less heterogeneous than other acute porphyrias; 5 mutations were present in 28 (26%) of the families, whereas 47 mutations were restricted to 1 family; only 2 mutations were found in both countries. The pattern of clinical presentation was identical to that reported from South Africa and was not influenced by type of mutation. Our results define the molecular genetics of VP in western Europe, demonstrate its allelic heterogeneity outside South Africa, and show that genotype is not a significant determinant of mode of presentation. | [
{
"begin_idx": "400",
"end_idx": "440",
"entity_id": "C538659",
"entity_type": "Disease",
"text_name": "deficiency of protoporphyrinogen oxidase"
},
{
"begin_idx": "296",
"end_idx": "308",
"entity_id": "D012871",
"entity_type": "Disease",
"text_name": "skin lesions"
},
{
"begin_idx": "1308",
"end_idx": "1324",
"entity_id": "D017118",
"entity_type": "Disease",
"text_name": "acute porphyrias"
},
{
"begin_idx": "240",
"end_idx": "267",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal dominant disorder"
},
{
"begin_idx": "0",
"end_idx": "19",
"entity_id": "D046350",
"entity_type": "Disease",
"text_name": "Variegate porphyria"
},
{
"begin_idx": "194",
"end_idx": "213",
"entity_id": "D046350",
"entity_type": "Disease",
"text_name": "Variegate porphyria"
},
{
"begin_idx": "215",
"end_idx": "217",
"entity_id": "D046350",
"entity_type": "Disease",
"text_name": "VP"
},
{
"begin_idx": "467",
"end_idx": "469",
"entity_id": "D046350",
"entity_type": "Disease",
"text_name": "VP"
},
{
"begin_idx": "1272",
"end_idx": "1274",
"entity_id": "D046350",
"entity_type": "Disease",
"text_name": "VP"
},
{
"begin_idx": "1652",
"end_idx": "1654",
"entity_id": "D046350",
"entity_type": "Disease",
"text_name": "VP"
},
{
"begin_idx": "57",
"end_idx": "61",
"entity_id": "5498",
"entity_type": "Gene",
"text_name": "PPOX"
},
{
"begin_idx": "414",
"end_idx": "440",
"entity_id": "5498",
"entity_type": "Gene",
"text_name": "protoporphyrinogen oxidase"
},
{
"begin_idx": "456",
"end_idx": "460",
"entity_id": "5498",
"entity_type": "Gene",
"text_name": "PPOX"
},
{
"begin_idx": "568",
"end_idx": "572",
"entity_id": "5498",
"entity_type": "Gene",
"text_name": "PPOX"
},
{
"begin_idx": "791",
"end_idx": "795",
"entity_id": "5498",
"entity_type": "Gene",
"text_name": "PPOX"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "414",
"end_idx": "440",
"entity_id": "5498",
"entity_type": "Gene",
"text_name": "protoporphyrinogen oxidase"
},
{
"begin_idx": "791",
"end_idx": "795",
"entity_id": "5498",
"entity_type": "Gene",
"text_name": "PPOX"
}
] | [
{
"begin_idx": "0",
"end_idx": "19",
"entity_id": "D046350",
"entity_type": "Disease",
"text_name": "Variegate porphyria"
},
{
"begin_idx": "240",
"end_idx": "267",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal dominant disorder"
}
] | [
"protoporphyrinogen oxidase",
"PPOX"
] | [
"Variegate porphyria",
"autosomal dominant disorder"
] |
10487631 | Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations. | Two biallelic polymorphisms in introns 3 and 6 of the p53 gene were analysed for a possible risk-modifying effect for ovarian cancer. Germline DNA was genotyped from 310 German Caucasian ovarian cancer patients and 364 healthy controls. We also typed 124 affected and 276 unaffected female carriers with known deleterious BRCA1 or BRCA2 germline mutation from high-risk breast-ovarian cancer families. Genotyping was based on PCR and high-resolution gel electrophoresis. German ovarian cancer patients who carried the rare allele of the MspI restriction fragment length polymorphism (RELP) in intron 6 were found to have an overall 1.93-fold increased risk (95% confidence internal (CI) 1.27-2.91) which further increased with the age at diagnosis of 41-60 years (odds ratio (OR) 2.71, 95% CI 1.10-6.71 for 41-50 and OR 2.44, 95% CI 1.12-5.28 for 51-60). The 16 bp duplication polymorphism in intron 3 was in a strong linkage to the MspI RFLP. In BRCA1 or BRCA2 mutation carriers, no difference in allele frequency was observed for carriers affected or unaffected with ovarian cancer. Our data suggest that intronic polymorphisms of the p53 gene modify the risk for ovarian cancer patients but not in carriers with BRCA1 or BRCA2 mutations. | [
{
"begin_idx": "71",
"end_idx": "85",
"entity_id": "D010051",
"entity_type": "Disease",
"text_name": "ovarian cancer"
},
{
"begin_idx": "262",
"end_idx": "276",
"entity_id": "D010051",
"entity_type": "Disease",
"text_name": "ovarian cancer"
},
{
"begin_idx": "331",
"end_idx": "345",
"entity_id": "D010051",
"entity_type": "Disease",
"text_name": "ovarian cancer"
},
{
"begin_idx": "622",
"end_idx": "636",
"entity_id": "D010051",
"entity_type": "Disease",
"text_name": "ovarian cancer"
},
{
"begin_idx": "1213",
"end_idx": "1227",
"entity_id": "D010051",
"entity_type": "Disease",
"text_name": "ovarian cancer"
},
{
"begin_idx": "1310",
"end_idx": "1324",
"entity_id": "D010051",
"entity_type": "Disease",
"text_name": "ovarian cancer"
},
{
"begin_idx": "514",
"end_idx": "535",
"entity_id": "D061325",
"entity_type": "Disease",
"text_name": "breast-ovarian cancer"
},
{
"begin_idx": "109",
"end_idx": "114",
"entity_id": "672",
"entity_type": "Gene",
"text_name": "BRCA1"
},
{
"begin_idx": "466",
"end_idx": "471",
"entity_id": "672",
"entity_type": "Gene",
"text_name": "BRCA1"
},
{
"begin_idx": "1091",
"end_idx": "1096",
"entity_id": "672",
"entity_type": "Gene",
"text_name": "BRCA1"
},
{
"begin_idx": "1359",
"end_idx": "1364",
"entity_id": "672",
"entity_type": "Gene",
"text_name": "BRCA1"
},
{
"begin_idx": "118",
"end_idx": "123",
"entity_id": "675",
"entity_type": "Gene",
"text_name": "BRCA2"
},
{
"begin_idx": "475",
"end_idx": "480",
"entity_id": "675",
"entity_type": "Gene",
"text_name": "BRCA2"
},
{
"begin_idx": "1100",
"end_idx": "1105",
"entity_id": "675",
"entity_type": "Gene",
"text_name": "BRCA2"
},
{
"begin_idx": "1368",
"end_idx": "1373",
"entity_id": "675",
"entity_type": "Gene",
"text_name": "BRCA2"
},
{
"begin_idx": "23",
"end_idx": "26",
"entity_id": "7157",
"entity_type": "Gene",
"text_name": "p53"
},
{
"begin_idx": "198",
"end_idx": "201",
"entity_id": "7157",
"entity_type": "Gene",
"text_name": "p53"
},
{
"begin_idx": "1281",
"end_idx": "1284",
"entity_id": "7157",
"entity_type": "Gene",
"text_name": "p53"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "23",
"end_idx": "26",
"entity_id": "7157",
"entity_type": "Gene",
"text_name": "p53"
},
{
"begin_idx": "109",
"end_idx": "114",
"entity_id": "672",
"entity_type": "Gene",
"text_name": "BRCA1"
}
] | [
{
"begin_idx": "71",
"end_idx": "85",
"entity_id": "D010051",
"entity_type": "Disease",
"text_name": "ovarian cancer"
},
{
"begin_idx": "1213",
"end_idx": "1227",
"entity_id": "D010051",
"entity_type": "Disease",
"text_name": "ovarian cancer"
}
] | [
"p53",
"BRCA1"
] | [
"ovarian cancer",
"ovarian cancer"
] |
10487664 | A novel parathyroid hormone (PTH)/PTH-related peptide receptor mutation in Jansen's metaphyseal chondrodysplasia. | Two heterozygous PTH/PTH-related peptide (PTHrP) receptor missense mutations were previously identified in patients with Jansen's metaphyseal chondrodysplasia (JMC), a rare form of short limb dwarfism associated with hypercalcemia and normal or undetectable levels of PTH and PTHrP. Both mutations, H223R and T410P, resulted in constitutive activation of the cAMP signaling pathway and provided a plausible explanation for the abnormalities in skeletal development and mineral ion homeostasis. In the present study we analyzed genomic DNA from four additional sporadic cases with JMC to search for novel activating mutations in the PTH/PTHrP receptor, to determine the frequency of the two previously identified missense mutations, H223R and T410P, and to determine whether different mutations present with different severity of the disease. The H223R mutation was identified in three novel JMC patients and is, therefore, to date the most frequent cause of JMC. In the fourth patient, a novel heterozygous missense mutation was found that changes isoleucine 458 in the receptor's seventh membrane-spanning region to arginine (I458R). In COS-7 cells expressing the human PTH/PTHrP receptor with the I458R mutation, basal cAMP accumulation was approximately 8 times higher than that in cells expressing the wild-type receptor despite impaired surface expression of the mutant receptor. Furthermore, the I458R mutant showed higher responsiveness to PTH than the wild-type receptor in its ability to activate both downstream effectors, adenylyl cyclase and phospholipase C. Like the H223R and the T410P mutants, the I458R mutant had no detectable effect on basal inositol phosphate accumulation. Overall, the patient with the I458R mutation exhibited clinical and biochemical abnormalities similar to those in patients with the previously identified H223R and T410P mutations. | [
{
"begin_idx": "75",
"end_idx": "112",
"entity_id": "C537564",
"entity_type": "Disease",
"text_name": "Jansen's metaphyseal chondrodysplasia"
},
{
"begin_idx": "235",
"end_idx": "272",
"entity_id": "C537564",
"entity_type": "Disease",
"text_name": "Jansen's metaphyseal chondrodysplasia"
},
{
"begin_idx": "274",
"end_idx": "277",
"entity_id": "C537564",
"entity_type": "Disease",
"text_name": "JMC"
},
{
"begin_idx": "694",
"end_idx": "697",
"entity_id": "C537564",
"entity_type": "Disease",
"text_name": "JMC"
},
{
"begin_idx": "1005",
"end_idx": "1008",
"entity_id": "C537564",
"entity_type": "Disease",
"text_name": "JMC"
},
{
"begin_idx": "1072",
"end_idx": "1075",
"entity_id": "C537564",
"entity_type": "Disease",
"text_name": "JMC"
},
{
"begin_idx": "331",
"end_idx": "344",
"entity_id": "D006934",
"entity_type": "Disease",
"text_name": "hypercalcemia"
},
{
"begin_idx": "8",
"end_idx": "27",
"entity_id": "5741",
"entity_type": "Gene",
"text_name": "parathyroid hormone"
},
{
"begin_idx": "29",
"end_idx": "32",
"entity_id": "5741",
"entity_type": "Gene",
"text_name": "PTH"
},
{
"begin_idx": "131",
"end_idx": "134",
"entity_id": "5741",
"entity_type": "Gene",
"text_name": "PTH"
},
{
"begin_idx": "382",
"end_idx": "385",
"entity_id": "5741",
"entity_type": "Gene",
"text_name": "PTH"
},
{
"begin_idx": "1561",
"end_idx": "1564",
"entity_id": "5741",
"entity_type": "Gene",
"text_name": "PTH"
},
{
"begin_idx": "34",
"end_idx": "53",
"entity_id": "5744",
"entity_type": "Gene",
"text_name": "PTH-related peptide"
},
{
"begin_idx": "135",
"end_idx": "154",
"entity_id": "5744",
"entity_type": "Gene",
"text_name": "PTH-related peptide"
},
{
"begin_idx": "156",
"end_idx": "161",
"entity_id": "5744",
"entity_type": "Gene",
"text_name": "PTHrP"
},
{
"begin_idx": "390",
"end_idx": "395",
"entity_id": "5744",
"entity_type": "Gene",
"text_name": "PTHrP"
},
{
"begin_idx": "746",
"end_idx": "764",
"entity_id": "5745",
"entity_type": "Gene",
"text_name": "PTH/PTHrP receptor"
},
{
"begin_idx": "1285",
"end_idx": "1303",
"entity_id": "5745",
"entity_type": "Gene",
"text_name": "PTH/PTHrP receptor"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "746",
"end_idx": "764",
"entity_id": "5745",
"entity_type": "Gene",
"text_name": "PTH/PTHrP receptor"
},
{
"begin_idx": "1561",
"end_idx": "1564",
"entity_id": "5741",
"entity_type": "Gene",
"text_name": "PTH"
}
] | [
{
"begin_idx": "75",
"end_idx": "112",
"entity_id": "C537564",
"entity_type": "Disease",
"text_name": "Jansen's metaphyseal chondrodysplasia"
},
{
"begin_idx": "274",
"end_idx": "277",
"entity_id": "C537564",
"entity_type": "Disease",
"text_name": "JMC"
}
] | [
"PTH/PTHrP receptor",
"PTH"
] | [
"Jansen's metaphyseal chondrodysplasia",
"JMC"
] |
10487688 | Differences in allelic distribution of two polymorphisms in the VHL-associated gene CUL2 in pheochromocytoma patients without somatic CUL2 mutations. | Although the two major familial forms of pheochromocytomas, multiple endocrine neoplasia type 2 and von-Hippel-Lindau disease (VHL), have been associated with mutations of the RET and VHL genes, respectively, the molecular pathogenesis of sporadic pheochromocytomas is largely unknown. Recently, a putative tumor suppressor gene has been identified, CUL2, whose product has been shown to interact with the VHL tumor suppressor. To examine whether CUL2 plays a role in pheochromocytoma pathogenesis, we analyzed a series of 26 distinct tumor samples for mutations in the whole coding region of this gene. There were no somatic pathogenic mutations in CUL2, except for 1 sporadic tumor that had a hemizygous gene deletion. We also found 3 novel polymorphisms in the gene. One of these variants, IVS5-6C/T, as well as another previously described one, c.2057G/A, were overrepresented among the pheochromocytoma patients compared to that in a control population (P < 0.005 and P < 0.01, respectively). Although our findings suggest that CUL2 does not play a major role in the pathogenesis of pheochromocytomas, it is still unknown whether epigenetic mechanisms are involved in its inactivation in VHL-associated tumors. Furthermore, the potential role for the overrepresented alleles in the pheochromocytoma group requires further investigation. | [
{
"begin_idx": "64",
"end_idx": "67",
"entity_id": "D006623",
"entity_type": "Disease",
"text_name": "VHL"
},
{
"begin_idx": "250",
"end_idx": "275",
"entity_id": "D006623",
"entity_type": "Disease",
"text_name": "von-Hippel-Lindau disease"
},
{
"begin_idx": "277",
"end_idx": "280",
"entity_id": "D006623",
"entity_type": "Disease",
"text_name": "VHL"
},
{
"begin_idx": "334",
"end_idx": "337",
"entity_id": "D006623",
"entity_type": "Disease",
"text_name": "VHL"
},
{
"begin_idx": "556",
"end_idx": "565",
"entity_id": "D006623",
"entity_type": "Disease",
"text_name": "VHL tumor"
},
{
"begin_idx": "1343",
"end_idx": "1364",
"entity_id": "D006623",
"entity_type": "Disease",
"text_name": "VHL-associated tumors"
},
{
"begin_idx": "457",
"end_idx": "462",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumor"
},
{
"begin_idx": "685",
"end_idx": "690",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumor"
},
{
"begin_idx": "828",
"end_idx": "833",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumor"
},
{
"begin_idx": "92",
"end_idx": "108",
"entity_id": "D010673",
"entity_type": "Disease",
"text_name": "pheochromocytoma"
},
{
"begin_idx": "191",
"end_idx": "208",
"entity_id": "D010673",
"entity_type": "Disease",
"text_name": "pheochromocytomas"
},
{
"begin_idx": "389",
"end_idx": "415",
"entity_id": "D010673",
"entity_type": "Disease",
"text_name": "sporadic pheochromocytomas"
},
{
"begin_idx": "618",
"end_idx": "634",
"entity_id": "D010673",
"entity_type": "Disease",
"text_name": "pheochromocytoma"
},
{
"begin_idx": "1041",
"end_idx": "1057",
"entity_id": "D010673",
"entity_type": "Disease",
"text_name": "pheochromocytoma"
},
{
"begin_idx": "1238",
"end_idx": "1255",
"entity_id": "D010673",
"entity_type": "Disease",
"text_name": "pheochromocytomas"
},
{
"begin_idx": "1437",
"end_idx": "1453",
"entity_id": "D010673",
"entity_type": "Disease",
"text_name": "pheochromocytoma"
},
{
"begin_idx": "210",
"end_idx": "245",
"entity_id": "D018813",
"entity_type": "Disease",
"text_name": "multiple endocrine neoplasia type 2"
},
{
"begin_idx": "326",
"end_idx": "329",
"entity_id": "5979",
"entity_type": "Gene",
"text_name": "RET"
},
{
"begin_idx": "64",
"end_idx": "67",
"entity_id": "7428",
"entity_type": "Gene",
"text_name": "VHL"
},
{
"begin_idx": "250",
"end_idx": "275",
"entity_id": "7428",
"entity_type": "Gene",
"text_name": "von-Hippel-Lindau disease"
},
{
"begin_idx": "277",
"end_idx": "280",
"entity_id": "7428",
"entity_type": "Gene",
"text_name": "VHL"
},
{
"begin_idx": "334",
"end_idx": "337",
"entity_id": "7428",
"entity_type": "Gene",
"text_name": "VHL"
},
{
"begin_idx": "84",
"end_idx": "88",
"entity_id": "8453",
"entity_type": "Gene",
"text_name": "CUL2"
},
{
"begin_idx": "134",
"end_idx": "138",
"entity_id": "8453",
"entity_type": "Gene",
"text_name": "CUL2"
},
{
"begin_idx": "500",
"end_idx": "504",
"entity_id": "8453",
"entity_type": "Gene",
"text_name": "CUL2"
},
{
"begin_idx": "597",
"end_idx": "601",
"entity_id": "8453",
"entity_type": "Gene",
"text_name": "CUL2"
},
{
"begin_idx": "800",
"end_idx": "804",
"entity_id": "8453",
"entity_type": "Gene",
"text_name": "CUL2"
},
{
"begin_idx": "1183",
"end_idx": "1187",
"entity_id": "8453",
"entity_type": "Gene",
"text_name": "CUL2"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "84",
"end_idx": "88",
"entity_id": "8453",
"entity_type": "Gene",
"text_name": "CUL2"
},
{
"begin_idx": "326",
"end_idx": "329",
"entity_id": "5979",
"entity_type": "Gene",
"text_name": "RET"
}
] | [
{
"begin_idx": "389",
"end_idx": "415",
"entity_id": "D010673",
"entity_type": "Disease",
"text_name": "sporadic pheochromocytomas"
},
{
"begin_idx": "556",
"end_idx": "565",
"entity_id": "D006623",
"entity_type": "Disease",
"text_name": "VHL tumor"
}
] | [
"CUL2",
"RET"
] | [
"sporadic pheochromocytomas",
"VHL tumor"
] |
10488958 | Angiotensinogen T174M and M235T gene polymorphisms are associated with the extent of coronary atherosclerosis. | BACKGROUND: The relations of the angiotensinogen (AGT) T174M and M235T gene polymorphisms to the risk of coronary heart disease (CHD) have been investigated in only a few studies with conflicting results. RESULTS: Therefore, we analysed the relationship of the AGT gene polymorphisms to the presence and extent of CHD in 2250 male Caucasians whose coronary anatomy was defined by means of coronary angiography. The relative frequencies of the T and M alleles of the T174M and of the M235T gene variation did not significantly differ between patients without or with single-, double- or triple-vessel disease and between subjects without or with myocardial infarction (MI). In contrast the mean CHD score--defined by Gensini--was higher within MM homozygotes of the T174M gene variation than within TT genotypes; TM subjects had intermediate values. In M235T genotypes, mean CHD scores were similar in the total sample and in older individuals (> or = 62 years), whereas in younger individuals (< 62 years) a higher CHD score was found within AGT 235 T allele carriers than within MM homozygotes. In younger individuals with high apoAI plasma levels, the mean CHD score was clearly higher within TT homozygotes of the M235T gene variation than within MM genotypes; MT subjects had intermediate values. An interaction between both angiotensinogen gene polymorphisms on the extent of CHD or on the risk of non-fatal MI were not observed when the M allele of AGT T174M was combined either with the T allele or the TT genotype of M235T. CONCLUSIONS: The present study strengthens the hypothesis of an association of both angiotensinogen gene polymorphisms with the extent of coronary heart disease. | [
{
"begin_idx": "85",
"end_idx": "109",
"entity_id": "D003324",
"entity_type": "Disease",
"text_name": "coronary atherosclerosis"
},
{
"begin_idx": "216",
"end_idx": "238",
"entity_id": "D003327",
"entity_type": "Disease",
"text_name": "coronary heart disease"
},
{
"begin_idx": "240",
"end_idx": "243",
"entity_id": "D003327",
"entity_type": "Disease",
"text_name": "CHD"
},
{
"begin_idx": "425",
"end_idx": "428",
"entity_id": "D003327",
"entity_type": "Disease",
"text_name": "CHD"
},
{
"begin_idx": "805",
"end_idx": "808",
"entity_id": "D003327",
"entity_type": "Disease",
"text_name": "CHD"
},
{
"begin_idx": "985",
"end_idx": "988",
"entity_id": "D003327",
"entity_type": "Disease",
"text_name": "CHD"
},
{
"begin_idx": "1126",
"end_idx": "1129",
"entity_id": "D003327",
"entity_type": "Disease",
"text_name": "CHD"
},
{
"begin_idx": "1270",
"end_idx": "1273",
"entity_id": "D003327",
"entity_type": "Disease",
"text_name": "CHD"
},
{
"begin_idx": "1492",
"end_idx": "1495",
"entity_id": "D003327",
"entity_type": "Disease",
"text_name": "CHD"
},
{
"begin_idx": "1781",
"end_idx": "1803",
"entity_id": "D003327",
"entity_type": "Disease",
"text_name": "coronary heart disease"
},
{
"begin_idx": "697",
"end_idx": "718",
"entity_id": "D004194",
"entity_type": "Disease",
"text_name": "triple-vessel disease"
},
{
"begin_idx": "756",
"end_idx": "777",
"entity_id": "D009203",
"entity_type": "Disease",
"text_name": "myocardial infarction"
},
{
"begin_idx": "779",
"end_idx": "781",
"entity_id": "D009203",
"entity_type": "Disease",
"text_name": "MI"
},
{
"begin_idx": "1514",
"end_idx": "1526",
"entity_id": "D009203",
"entity_type": "Disease",
"text_name": "non-fatal MI"
},
{
"begin_idx": "0",
"end_idx": "15",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "Angiotensinogen"
},
{
"begin_idx": "144",
"end_idx": "159",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "angiotensinogen"
},
{
"begin_idx": "161",
"end_idx": "164",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "AGT"
},
{
"begin_idx": "372",
"end_idx": "375",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "AGT"
},
{
"begin_idx": "1153",
"end_idx": "1156",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "AGT"
},
{
"begin_idx": "1440",
"end_idx": "1455",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "angiotensinogen"
},
{
"begin_idx": "1566",
"end_idx": "1569",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "AGT"
},
{
"begin_idx": "1727",
"end_idx": "1742",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "angiotensinogen"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "0",
"end_idx": "15",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "Angiotensinogen"
},
{
"begin_idx": "0",
"end_idx": "15",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "Angiotensinogen"
}
] | [
{
"begin_idx": "85",
"end_idx": "109",
"entity_id": "D003324",
"entity_type": "Disease",
"text_name": "coronary atherosclerosis"
},
{
"begin_idx": "1126",
"end_idx": "1129",
"entity_id": "D003327",
"entity_type": "Disease",
"text_name": "CHD"
}
] | [
"Angiotensinogen",
"Angiotensinogen"
] | [
"coronary atherosclerosis",
"CHD"
] |
10489052 | Myelin uncompaction in Charcot-Marie-Tooth neuropathy type 1A with a point mutation of peripheral myelin protein-22. | BACKGROUND: The peripheral myelin protein-22 (PMP22) gene has four transmembrane domains, two extracellular loops, and a short cytoplasmic tail. Its roles in the peripheral nervous system remain unclear. The most common cause of Charcot-Marie-Tooth neuropathy type 1A (CMT1A) is a PMP22 gene duplication. Missense point mutations in the transmembrane domains are rare alternative causes that have undetermined pathogenetic mechanisms. OBJECTIVE: To investigate the phenotype-to-genotype correlations in a pedigree with unusual CMT1A. METHODS: We identified a pedigree with an autosomal dominant motor-sensory neuropathy and severely reduced nerve conduction velocities who did not have the PMP22 duplication. Specimens from sural nerve biopsies from two patients of different ages were evaluated morphometrically. By automated direct nucleotide sequencing we analyzed PMP22 and the gene of the major structural myelin protein zero (P0). RESULTS: Nucleotide 159 of PMP22 showed an A-to-T heterozygous mutation, predicted to cause an aspartate-to-valine substitution at codon 37 in the first extracellular loop of the protein. The mutation co-segregated with the disease in the pedigree and was absent in 80 healthy controls. The histopathologic phenotype was a de-remyelinating neuropathy with onion bulb formations, characterized by prominent uncompaction of the myelin sheath in the majority of fibers and by frequent tomacula. CONCLUSION: We have described a novel mutation in the first extracellular loop of PMP22 associated with an atypical CMT1A that overlaps pathologically with CMT1B caused by point mutations in the extracellular domain of P0. | [
{
"begin_idx": "23",
"end_idx": "61",
"entity_id": "D002607",
"entity_type": "Disease",
"text_name": "Charcot-Marie-Tooth neuropathy type 1A"
},
{
"begin_idx": "346",
"end_idx": "384",
"entity_id": "D002607",
"entity_type": "Disease",
"text_name": "Charcot-Marie-Tooth neuropathy type 1A"
},
{
"begin_idx": "386",
"end_idx": "391",
"entity_id": "D002607",
"entity_type": "Disease",
"text_name": "CMT1A"
},
{
"begin_idx": "644",
"end_idx": "649",
"entity_id": "D002607",
"entity_type": "Disease",
"text_name": "CMT1A"
},
{
"begin_idx": "1662",
"end_idx": "1667",
"entity_id": "D002607",
"entity_type": "Disease",
"text_name": "CMT1A"
},
{
"begin_idx": "1702",
"end_idx": "1707",
"entity_id": "D002607",
"entity_type": "Disease",
"text_name": "CMT1B"
},
{
"begin_idx": "1394",
"end_idx": "1404",
"entity_id": "D009422",
"entity_type": "Disease",
"text_name": "neuropathy"
},
{
"begin_idx": "693",
"end_idx": "736",
"entity_id": "D010523",
"entity_type": "Disease",
"text_name": "autosomal dominant motor-sensory neuropathy"
},
{
"begin_idx": "1702",
"end_idx": "1707",
"entity_id": "4359",
"entity_type": "Gene",
"text_name": "CMT1B"
},
{
"begin_idx": "87",
"end_idx": "115",
"entity_id": "5376",
"entity_type": "Gene",
"text_name": "peripheral myelin protein-22"
},
{
"begin_idx": "133",
"end_idx": "161",
"entity_id": "5376",
"entity_type": "Gene",
"text_name": "peripheral myelin protein-22"
},
{
"begin_idx": "163",
"end_idx": "168",
"entity_id": "5376",
"entity_type": "Gene",
"text_name": "PMP22"
},
{
"begin_idx": "398",
"end_idx": "403",
"entity_id": "5376",
"entity_type": "Gene",
"text_name": "PMP22"
},
{
"begin_idx": "807",
"end_idx": "812",
"entity_id": "5376",
"entity_type": "Gene",
"text_name": "PMP22"
},
{
"begin_idx": "985",
"end_idx": "990",
"entity_id": "5376",
"entity_type": "Gene",
"text_name": "PMP22"
},
{
"begin_idx": "1081",
"end_idx": "1086",
"entity_id": "5376",
"entity_type": "Gene",
"text_name": "PMP22"
},
{
"begin_idx": "1628",
"end_idx": "1633",
"entity_id": "5376",
"entity_type": "Gene",
"text_name": "PMP22"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "87",
"end_idx": "115",
"entity_id": "5376",
"entity_type": "Gene",
"text_name": "peripheral myelin protein-22"
},
{
"begin_idx": "1628",
"end_idx": "1633",
"entity_id": "5376",
"entity_type": "Gene",
"text_name": "PMP22"
}
] | [
{
"begin_idx": "23",
"end_idx": "61",
"entity_id": "D002607",
"entity_type": "Disease",
"text_name": "Charcot-Marie-Tooth neuropathy type 1A"
},
{
"begin_idx": "1394",
"end_idx": "1404",
"entity_id": "D009422",
"entity_type": "Disease",
"text_name": "neuropathy"
}
] | [
"peripheral myelin protein-22",
"PMP22"
] | [
"Charcot-Marie-Tooth neuropathy type 1A",
"neuropathy"
] |
10489105 | Quantitative association between a newly identified molecular variant in the endothelin-2 gene and human essential hypertension. | BACKGROUND: Essential hypertension is a multifactorial disease in which the genetic contribution is probably the result of a number of genes acting in combination. Recent work has incriminated endothelin-2 (ET2) as a candidate gene for human essential hypertension. This study sought to (i) determine the existence of any molecular variants in the ET2 gene; (ii) undertake an allelic-association study of any such variants found in a large group of well characterized hypertensive and control populations; and (iii) assess any quantitative relationship between the molecular variant and pretreatment blood presure. METHODS: The ET2 gene was subjected to single strand conformation polymorphism (SSCP) analysis in order to identify novel molecular variants. Well-characterized subjects recruited from our local population were used in our association study. Two hundred and forty-four hypertensive patients with pre-treatment blood pressure (range 139/94-237/133 mmHg) were well matched with 228 controls from our local population of 30000 healthy subjects (range 96/62-160/85 mmHg). All subjects were Caucasian. RESULTS: Polymerase chain reaction-SSCP identified a single A985G base change in 3'-UTR of the ET2 gene which was confirmed by direct sequencing. A restriction site for the enzyme BsmA1 was either created (+) or removed (-) with this polymorphism. Analysis of variance showed that the ET2 genotype was an independent predictor of pre-treatment diastolic blood pressure (DBP) in the hypertensive (P< 0.001) but not normotensive group with higher pressures tracking with the (-) allele. Other covariates such as age, sex, alcohol, cigarette smoking, body mass index and cholesterol showed no significant relationship with this genotype. The genotype frequencies for the hypertensive and control population were (-/-: -/+: +/+) 178 :58:8 and 168:55: 5, respectively (not significant). Subjects from the top and tail quartiles of measurement of blood pressure in both groups were selected for genotype and allele frequency comparison. Both genotype and allele differences were highly significant between the two extreme groups for DBP (genotype P< 0.001, alleles P< 0.01) distribution. A search for potential functional variants in linkage disequilibrium with A985G found one further variant in the 5'-UTR, C44T. Conditional haplotype probabilities in 214 chromosomes show that this polymorphism is not in linkage disequilibrium with the 3'-UTR. No other variants were found on a molecular screen of the transcribed portion of the ET2 gene. CONCLUSION: This newly identified polymorphism of the ET2 gene tracked significantly in hypertensives when blood pressure was assessed as a quantitative trait. The difference in genotype and allele frequencies between the extremes of blood pressure suggest that the ET2 locus influences the severity rather than the initial development of hypertension. | [
{
"begin_idx": "169",
"end_idx": "191",
"entity_id": "D004194",
"entity_type": "Disease",
"text_name": "multifactorial disease"
},
{
"begin_idx": "115",
"end_idx": "127",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertension"
},
{
"begin_idx": "151",
"end_idx": "163",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertension"
},
{
"begin_idx": "381",
"end_idx": "393",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertension"
},
{
"begin_idx": "597",
"end_idx": "609",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertensive"
},
{
"begin_idx": "1013",
"end_idx": "1025",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertensive"
},
{
"begin_idx": "1623",
"end_idx": "1635",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertensive"
},
{
"begin_idx": "1909",
"end_idx": "1921",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertensive"
},
{
"begin_idx": "2766",
"end_idx": "2779",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertensives"
},
{
"begin_idx": "3017",
"end_idx": "3029",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertension"
},
{
"begin_idx": "77",
"end_idx": "89",
"entity_id": "1907",
"entity_type": "Gene",
"text_name": "endothelin-2"
},
{
"begin_idx": "322",
"end_idx": "334",
"entity_id": "1907",
"entity_type": "Gene",
"text_name": "endothelin-2"
},
{
"begin_idx": "336",
"end_idx": "339",
"entity_id": "1907",
"entity_type": "Gene",
"text_name": "ET2"
},
{
"begin_idx": "477",
"end_idx": "480",
"entity_id": "1907",
"entity_type": "Gene",
"text_name": "ET2"
},
{
"begin_idx": "757",
"end_idx": "760",
"entity_id": "1907",
"entity_type": "Gene",
"text_name": "ET2"
},
{
"begin_idx": "1336",
"end_idx": "1339",
"entity_id": "1907",
"entity_type": "Gene",
"text_name": "ET2"
},
{
"begin_idx": "1526",
"end_idx": "1529",
"entity_id": "1907",
"entity_type": "Gene",
"text_name": "ET2"
},
{
"begin_idx": "2668",
"end_idx": "2671",
"entity_id": "1907",
"entity_type": "Gene",
"text_name": "ET2"
},
{
"begin_idx": "2732",
"end_idx": "2735",
"entity_id": "1907",
"entity_type": "Gene",
"text_name": "ET2"
},
{
"begin_idx": "2944",
"end_idx": "2947",
"entity_id": "1907",
"entity_type": "Gene",
"text_name": "ET2"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "77",
"end_idx": "89",
"entity_id": "1907",
"entity_type": "Gene",
"text_name": "endothelin-2"
},
{
"begin_idx": "2668",
"end_idx": "2671",
"entity_id": "1907",
"entity_type": "Gene",
"text_name": "ET2"
}
] | [
{
"begin_idx": "2766",
"end_idx": "2779",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertensives"
},
{
"begin_idx": "169",
"end_idx": "191",
"entity_id": "D004194",
"entity_type": "Disease",
"text_name": "multifactorial disease"
}
] | [
"endothelin-2",
"ET2"
] | [
"hypertensives",
"multifactorial disease"
] |
10490706 | Haplotype relative risk study of catechol-O-methyltransferase (COMT) and attention deficit hyperactivity disorder (ADHD): association of the high-enzyme activity Val allele with ADHD impulsive-hyperactive phenotype. | Attention deficit hyperactivity disorder (ADHD) is a developmental syndrome expressed along three domains: inattention, hyperactive-impulsive, and combined type. Both environmental and genetic factors contribute to the etiology of this complex disease. In the current investigation, a catechol-O-methyltransferase (COMT) polymorphism that codes for a high versus low enzyme COMT activity was examined using family-based methods for a role in ADHD. Using a haplotype relative risk design and a parent-to-proband allele transmission test with 48 ADHD triads, we found an association between COMT and illness (chi(2) = 4.72, p = 0.03, df = 1). In particular, the impulsive-hyperactive type of ADHD (excluding inattention) ascertained by Diagnostic and Statistical Manual of Mental Disorders (DSM IV) criteria (chi(2) = 8.34, p = 0.004, df = 1), by the Conners Teaching Rating Hyperactivity scale (Pearson chi(2) = 5.32, p = 0.02, df = 1) as well as by the Continuous Performance Test False Alarm scale (chi(2) = 2.78, p = 0.096, df = 1) were associated with the high enzyme activity COMT val allele. Similar results were obtained if genotype frequencies were compared. It should be noted that the association between the high-enzyme activity COMT val allele that increases CNS dopamine (and norepinephrine) clearance is consistent with the use of methylphenidate, an agent that increases dopamine (and norepinephrine) turnover, in the treatment of this disorder. These provisional findings suggest that newly developed COMT inhibitors such as tolcapone, applied in Parkinson's disease, might in due time be considered in the treatment of ADHD. | [
{
"begin_idx": "83",
"end_idx": "113",
"entity_id": "D001289",
"entity_type": "Disease",
"text_name": "deficit hyperactivity disorder"
},
{
"begin_idx": "115",
"end_idx": "119",
"entity_id": "D001289",
"entity_type": "Disease",
"text_name": "ADHD"
},
{
"begin_idx": "178",
"end_idx": "182",
"entity_id": "D001289",
"entity_type": "Disease",
"text_name": "ADHD"
},
{
"begin_idx": "216",
"end_idx": "256",
"entity_id": "D001289",
"entity_type": "Disease",
"text_name": "Attention deficit hyperactivity disorder"
},
{
"begin_idx": "258",
"end_idx": "262",
"entity_id": "D001289",
"entity_type": "Disease",
"text_name": "ADHD"
},
{
"begin_idx": "658",
"end_idx": "662",
"entity_id": "D001289",
"entity_type": "Disease",
"text_name": "ADHD"
},
{
"begin_idx": "760",
"end_idx": "764",
"entity_id": "D001289",
"entity_type": "Disease",
"text_name": "ADHD"
},
{
"begin_idx": "906",
"end_idx": "910",
"entity_id": "D001289",
"entity_type": "Disease",
"text_name": "ADHD"
},
{
"begin_idx": "1851",
"end_idx": "1855",
"entity_id": "D001289",
"entity_type": "Disease",
"text_name": "ADHD"
},
{
"begin_idx": "987",
"end_idx": "1003",
"entity_id": "D001523",
"entity_type": "Disease",
"text_name": "Mental Disorders"
},
{
"begin_idx": "1089",
"end_idx": "1102",
"entity_id": "D006948",
"entity_type": "Disease",
"text_name": "Hyperactivity"
},
{
"begin_idx": "1778",
"end_idx": "1797",
"entity_id": "D010300",
"entity_type": "Disease",
"text_name": "Parkinson's disease"
},
{
"begin_idx": "33",
"end_idx": "61",
"entity_id": "1312",
"entity_type": "Gene",
"text_name": "catechol-O-methyltransferase"
},
{
"begin_idx": "63",
"end_idx": "67",
"entity_id": "1312",
"entity_type": "Gene",
"text_name": "COMT"
},
{
"begin_idx": "501",
"end_idx": "529",
"entity_id": "1312",
"entity_type": "Gene",
"text_name": "catechol-O-methyltransferase"
},
{
"begin_idx": "531",
"end_idx": "535",
"entity_id": "1312",
"entity_type": "Gene",
"text_name": "COMT"
},
{
"begin_idx": "590",
"end_idx": "594",
"entity_id": "1312",
"entity_type": "Gene",
"text_name": "COMT"
},
{
"begin_idx": "805",
"end_idx": "809",
"entity_id": "1312",
"entity_type": "Gene",
"text_name": "COMT"
},
{
"begin_idx": "1296",
"end_idx": "1300",
"entity_id": "1312",
"entity_type": "Gene",
"text_name": "COMT"
},
{
"begin_idx": "1455",
"end_idx": "1459",
"entity_id": "1312",
"entity_type": "Gene",
"text_name": "COMT"
},
{
"begin_idx": "1732",
"end_idx": "1736",
"entity_id": "1312",
"entity_type": "Gene",
"text_name": "COMT"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "33",
"end_idx": "61",
"entity_id": "1312",
"entity_type": "Gene",
"text_name": "catechol-O-methyltransferase"
},
{
"begin_idx": "1455",
"end_idx": "1459",
"entity_id": "1312",
"entity_type": "Gene",
"text_name": "COMT"
}
] | [
{
"begin_idx": "216",
"end_idx": "256",
"entity_id": "D001289",
"entity_type": "Disease",
"text_name": "Attention deficit hyperactivity disorder"
},
{
"begin_idx": "1089",
"end_idx": "1102",
"entity_id": "D006948",
"entity_type": "Disease",
"text_name": "Hyperactivity"
}
] | [
"catechol-O-methyltransferase",
"COMT"
] | [
"Attention deficit hyperactivity disorder",
"Hyperactivity"
] |
10490711 | Tyrosine hydroxylase polymorphism and phenotypic heterogeneity in bipolar affective disorder: a multicenter association study. | Tyrosine hydroxylase (TH), the rate-limiting enzyme in the metabolism of catecholamines, is considered a candidate gene in bipolar affective disorder (BPAD) and has been the subject of numerous linkage and association studies. Taken together, most results do not support a major gene effect for the TH gene in BPAD. Genetic and phenotypic heterogeneity may partially explain the difficulty of confirming the exact role of this gene using both association and linkage methods. Four hundred one BPAD patients and 401 unrelated matched controls were recruited within a European collaborative project (BIOMED1 project in the area of brain research, European Community grant number CT 92-1217, project leader: J. Mendlewicz) involving 14 centers for a case-control association study with a tetranucleotide polymorphism in the TH gene. Patients and controls were carefully matched for geographical origin. Phenotypic heterogeneity was considered and subgroup analyses were performed with relevant variables: age at onset, family history, and diagnostic stability. No association was observed in the total sample or for subgroups according to age at onset (n = 172), family history alone (n = 159), or high degree of diagnostic stability and a positive family history (n = 131). The results of this association study do not confirm the possible implication of TH polymorphism in the susceptibility to BPAD. | [
{
"begin_idx": "66",
"end_idx": "92",
"entity_id": "D001714",
"entity_type": "Disease",
"text_name": "bipolar affective disorder"
},
{
"begin_idx": "250",
"end_idx": "276",
"entity_id": "D001714",
"entity_type": "Disease",
"text_name": "bipolar affective disorder"
},
{
"begin_idx": "278",
"end_idx": "282",
"entity_id": "D001714",
"entity_type": "Disease",
"text_name": "BPAD"
},
{
"begin_idx": "437",
"end_idx": "441",
"entity_id": "D001714",
"entity_type": "Disease",
"text_name": "BPAD"
},
{
"begin_idx": "620",
"end_idx": "624",
"entity_id": "D001714",
"entity_type": "Disease",
"text_name": "BPAD"
},
{
"begin_idx": "1521",
"end_idx": "1525",
"entity_id": "D001714",
"entity_type": "Disease",
"text_name": "BPAD"
},
{
"begin_idx": "278",
"end_idx": "282",
"entity_id": "100188844",
"entity_type": "Gene",
"text_name": "BPAD"
},
{
"begin_idx": "437",
"end_idx": "441",
"entity_id": "100188844",
"entity_type": "Gene",
"text_name": "BPAD"
},
{
"begin_idx": "620",
"end_idx": "624",
"entity_id": "100188844",
"entity_type": "Gene",
"text_name": "BPAD"
},
{
"begin_idx": "1521",
"end_idx": "1525",
"entity_id": "100188844",
"entity_type": "Gene",
"text_name": "BPAD"
},
{
"begin_idx": "0",
"end_idx": "20",
"entity_id": "7054",
"entity_type": "Gene",
"text_name": "Tyrosine hydroxylase"
},
{
"begin_idx": "127",
"end_idx": "147",
"entity_id": "7054",
"entity_type": "Gene",
"text_name": "Tyrosine hydroxylase"
},
{
"begin_idx": "149",
"end_idx": "151",
"entity_id": "7054",
"entity_type": "Gene",
"text_name": "TH"
},
{
"begin_idx": "426",
"end_idx": "428",
"entity_id": "7054",
"entity_type": "Gene",
"text_name": "TH"
},
{
"begin_idx": "948",
"end_idx": "950",
"entity_id": "7054",
"entity_type": "Gene",
"text_name": "TH"
},
{
"begin_idx": "1480",
"end_idx": "1482",
"entity_id": "7054",
"entity_type": "Gene",
"text_name": "TH"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "0",
"end_idx": "20",
"entity_id": "7054",
"entity_type": "Gene",
"text_name": "Tyrosine hydroxylase"
},
{
"begin_idx": "437",
"end_idx": "441",
"entity_id": "100188844",
"entity_type": "Gene",
"text_name": "BPAD"
}
] | [
{
"begin_idx": "66",
"end_idx": "92",
"entity_id": "D001714",
"entity_type": "Disease",
"text_name": "bipolar affective disorder"
},
{
"begin_idx": "437",
"end_idx": "441",
"entity_id": "D001714",
"entity_type": "Disease",
"text_name": "BPAD"
}
] | [
"Tyrosine hydroxylase",
"BPAD"
] | [
"bipolar affective disorder",
"BPAD"
] |
10490712 | Human chromosomes 11p15 and 4p12 and alcohol dependence: possible association with the GABRB1 gene. | To determine the role of genes in the chromosomal regions 11p15 and 4p12 in the development of alcohol dependence, a sample of alcoholics (n = 133) and normal controls (n = 89) were screened using polymorphisms in the dopamine D4 receptor (DRD4), tyrosine hydroxylase (TH), and GABA receptor beta1 (GABRbeta1) genes. Comparison of total alcoholics with normal controls for GABRbeta1 gene was highly significant (p = 0.004). The difference between type II alcoholics and normal controls for the same allele frequencies was also significant (p = 0.029). The allele distributions of the polymorphisms in the DRD4 and TH genes in alcoholics and normal controls were similar and their differences were not significant. Our association studies indicate that the GABRbeta1 gene may play a role in the development of alcoholism. Therefore, it is important to screen a sample of well-characterized alcoholics with functional polymorphisms in all of the GABAalpha receptor subunit genes and determine their relationship with alcoholism phenotypes. Results with TH and DRD4 genes indicate that these two genes may not play major roles in the development of alcoholism. | [
{
"begin_idx": "37",
"end_idx": "55",
"entity_id": "D000437",
"entity_type": "Disease",
"text_name": "alcohol dependence"
},
{
"begin_idx": "195",
"end_idx": "213",
"entity_id": "D000437",
"entity_type": "Disease",
"text_name": "alcohol dependence"
},
{
"begin_idx": "909",
"end_idx": "919",
"entity_id": "D000437",
"entity_type": "Disease",
"text_name": "alcoholism"
},
{
"begin_idx": "1115",
"end_idx": "1125",
"entity_id": "D000437",
"entity_type": "Disease",
"text_name": "alcoholism"
},
{
"begin_idx": "1246",
"end_idx": "1256",
"entity_id": "D000437",
"entity_type": "Disease",
"text_name": "alcoholism"
},
{
"begin_idx": "318",
"end_idx": "338",
"entity_id": "1815",
"entity_type": "Gene",
"text_name": "dopamine D4 receptor"
},
{
"begin_idx": "340",
"end_idx": "344",
"entity_id": "1815",
"entity_type": "Gene",
"text_name": "DRD4"
},
{
"begin_idx": "705",
"end_idx": "709",
"entity_id": "1815",
"entity_type": "Gene",
"text_name": "DRD4"
},
{
"begin_idx": "1158",
"end_idx": "1162",
"entity_id": "1815",
"entity_type": "Gene",
"text_name": "DRD4"
},
{
"begin_idx": "87",
"end_idx": "93",
"entity_id": "2560",
"entity_type": "Gene",
"text_name": "GABRB1"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "87",
"end_idx": "93",
"entity_id": "2560",
"entity_type": "Gene",
"text_name": "GABRB1"
},
{
"begin_idx": "340",
"end_idx": "344",
"entity_id": "1815",
"entity_type": "Gene",
"text_name": "DRD4"
}
] | [
{
"begin_idx": "37",
"end_idx": "55",
"entity_id": "D000437",
"entity_type": "Disease",
"text_name": "alcohol dependence"
},
{
"begin_idx": "909",
"end_idx": "919",
"entity_id": "D000437",
"entity_type": "Disease",
"text_name": "alcoholism"
}
] | [
"GABRB1",
"DRD4"
] | [
"alcohol dependence",
"alcoholism"
] |
10491309 | Nonpathogenic common variants of IFNGR1 and IFNGR2 in association with total serum IgE levels. | Atopy is an immune disorder in which a Th2 dominant mechanism leads to high IgE levels and the clinical disorder asthma. It has been postulated that the Th1 cytokine IFNgamma, acting through its heterodimeric receptors, IFNgammaR1 and IFNgammaR2, in the induction/proliferation of Th1 cells, might suppress the Th2 responses that may underlie atopic asthma. However, neither murine nor human variants of IFNgamma associate with atopy. Several dysfunctional mutations have been identified in IFNgamma receptor genes (IFNGR1 and IFNGR2) in relation to severe and selective infections with poorly pathogenic organisms. However, little is known about common polymorphisms and their functional role in atopy. To test whether such variants of IFNGR1 and IFNGR2 relate to atopic asthma, we conducted a genetic association study in both British (n = 300) and Japanese (n = 200) populations. An intronic variant of IFNGR1 showed marginal association with total serum IgE levels in the British population compared with those with total IgE levels <30 IU/ml and those with >120-500 IU/ml [odds ratio = 2.00 (95% CI 1. 00-4.07), P = 0.048]. A coding variant, Gln64Arg of the IFNGR2, also associated with total serum IgE levels in the British population [chi(2) = 5.08, P = 0.024]. Further genetic and functional analyses are needed to clarify the role of variants of IFNgamma receptor genes in atopic immune disorder among different ethnic groups. | [
{
"begin_idx": "523",
"end_idx": "528",
"entity_id": "C564133",
"entity_type": "Disease",
"text_name": "atopy"
},
{
"begin_idx": "792",
"end_idx": "797",
"entity_id": "C564133",
"entity_type": "Disease",
"text_name": "atopy"
},
{
"begin_idx": "438",
"end_idx": "451",
"entity_id": "C565292",
"entity_type": "Disease",
"text_name": "atopic asthma"
},
{
"begin_idx": "860",
"end_idx": "873",
"entity_id": "C565292",
"entity_type": "Disease",
"text_name": "atopic asthma"
},
{
"begin_idx": "208",
"end_idx": "214",
"entity_id": "D001249",
"entity_type": "Disease",
"text_name": "asthma"
},
{
"begin_idx": "107",
"end_idx": "122",
"entity_id": "D007154",
"entity_type": "Disease",
"text_name": "immune disorder"
},
{
"begin_idx": "1477",
"end_idx": "1499",
"entity_id": "D007154",
"entity_type": "Disease",
"text_name": "atopic immune disorder"
},
{
"begin_idx": "261",
"end_idx": "269",
"entity_id": "3458",
"entity_type": "Gene",
"text_name": "IFNgamma"
},
{
"begin_idx": "499",
"end_idx": "507",
"entity_id": "3458",
"entity_type": "Gene",
"text_name": "IFNgamma"
},
{
"begin_idx": "586",
"end_idx": "594",
"entity_id": "3458",
"entity_type": "Gene",
"text_name": "IFNgamma"
},
{
"begin_idx": "1450",
"end_idx": "1458",
"entity_id": "3458",
"entity_type": "Gene",
"text_name": "IFNgamma"
},
{
"begin_idx": "33",
"end_idx": "39",
"entity_id": "3459",
"entity_type": "Gene",
"text_name": "IFNGR1"
},
{
"begin_idx": "315",
"end_idx": "325",
"entity_id": "3459",
"entity_type": "Gene",
"text_name": "IFNgammaR1"
},
{
"begin_idx": "611",
"end_idx": "617",
"entity_id": "3459",
"entity_type": "Gene",
"text_name": "IFNGR1"
},
{
"begin_idx": "832",
"end_idx": "838",
"entity_id": "3459",
"entity_type": "Gene",
"text_name": "IFNGR1"
},
{
"begin_idx": "1001",
"end_idx": "1007",
"entity_id": "3459",
"entity_type": "Gene",
"text_name": "IFNGR1"
},
{
"begin_idx": "44",
"end_idx": "50",
"entity_id": "3460",
"entity_type": "Gene",
"text_name": "IFNGR2"
},
{
"begin_idx": "330",
"end_idx": "340",
"entity_id": "3460",
"entity_type": "Gene",
"text_name": "IFNgammaR2"
},
{
"begin_idx": "622",
"end_idx": "628",
"entity_id": "3460",
"entity_type": "Gene",
"text_name": "IFNGR2"
},
{
"begin_idx": "843",
"end_idx": "849",
"entity_id": "3460",
"entity_type": "Gene",
"text_name": "IFNGR2"
},
{
"begin_idx": "1258",
"end_idx": "1264",
"entity_id": "3460",
"entity_type": "Gene",
"text_name": "IFNGR2"
},
{
"begin_idx": "248",
"end_idx": "251",
"entity_id": "51497",
"entity_type": "Gene",
"text_name": "Th1"
},
{
"begin_idx": "376",
"end_idx": "379",
"entity_id": "51497",
"entity_type": "Gene",
"text_name": "Th1"
}
] | [
"Yes",
"No"
] | [
false,
true
] | [
{
"begin_idx": "330",
"end_idx": "340",
"entity_id": "3460",
"entity_type": "Gene",
"text_name": "IFNgammaR2"
},
{
"begin_idx": "330",
"end_idx": "340",
"entity_id": "3460",
"entity_type": "Gene",
"text_name": "IFNgammaR2"
}
] | [
{
"begin_idx": "208",
"end_idx": "214",
"entity_id": "D001249",
"entity_type": "Disease",
"text_name": "asthma"
},
{
"begin_idx": "438",
"end_idx": "451",
"entity_id": "C565292",
"entity_type": "Disease",
"text_name": "atopic asthma"
}
] | [
"IFNgammaR2",
"IFNgammaR2"
] | [
"asthma",
"atopic asthma"
] |
10491406 | Fibroblast growth factor-2 mediates pressure-induced hypertrophic response. | In vitro, fibroblast growth factor-2 (FGF2) has been implicated in cardiomyocyte growth and reexpression of fetal contractile genes, both markers of hypertrophy. However, its in vivo role in cardiac hypertrophy during pressure overload is not well characterized. Mice with or without FGF2 (Fgf2(+/+) and Fgf2(-/-), respectively) were subjected to transverse aortic coarctation (AC). Left ventricular (LV) mass and wall thickness were assessed by echocardiography preoperatively and once a week postoperatively for 10 weeks. In vivo LV function during dobutamine stimulation, cardiomyocyte cross-sectional area, and recapitulation of fetal cardiac genes were also measured. AC Fgf2(-/-) mice develop significantly less hypertrophy (4-24% increase) compared with AC Fgf2(+/+) mice (41-52% increase). Cardiomyocyte cross-sectional area is significantly reduced in AC Fgf2(-/-) mice. Noncoarcted (NC) and AC Fgf2(-/-) mice have similar beta-adrenergic responses, but those of AC Fgf2(+/+) mice are blunted. A lack of mitotic growth in both AC Fgf2(+/+) and Fgf2(-/-) hearts indicates a hypertrophic response of cardiomyocytes. Consequently, FGF2 plays a major role in cardiac hypertrophy. Comparison of alpha- and beta-cardiac myosin heavy chain mRNA and protein levels in NC and AC Fgf2(+/+) and Fgf2(-/-) mice indicates that myosin heavy chain composition depends on hemodynamic stress rather than on FGF2 or hypertrophy, and that isoform switching is transcriptionally, not posttranscriptionally, regulated. | [
{
"begin_idx": "434",
"end_idx": "452",
"entity_id": "D001017",
"entity_type": "Disease",
"text_name": "aortic coarctation"
},
{
"begin_idx": "454",
"end_idx": "456",
"entity_id": "D001017",
"entity_type": "Disease",
"text_name": "AC"
},
{
"begin_idx": "749",
"end_idx": "751",
"entity_id": "D001017",
"entity_type": "Disease",
"text_name": "AC"
},
{
"begin_idx": "837",
"end_idx": "839",
"entity_id": "D001017",
"entity_type": "Disease",
"text_name": "AC"
},
{
"begin_idx": "937",
"end_idx": "939",
"entity_id": "D001017",
"entity_type": "Disease",
"text_name": "AC"
},
{
"begin_idx": "977",
"end_idx": "979",
"entity_id": "D001017",
"entity_type": "Disease",
"text_name": "AC"
},
{
"begin_idx": "1048",
"end_idx": "1050",
"entity_id": "D001017",
"entity_type": "Disease",
"text_name": "AC"
},
{
"begin_idx": "1112",
"end_idx": "1114",
"entity_id": "D001017",
"entity_type": "Disease",
"text_name": "AC"
},
{
"begin_idx": "1352",
"end_idx": "1354",
"entity_id": "D001017",
"entity_type": "Disease",
"text_name": "AC"
},
{
"begin_idx": "267",
"end_idx": "286",
"entity_id": "D006332",
"entity_type": "Disease",
"text_name": "cardiac hypertrophy"
},
{
"begin_idx": "1240",
"end_idx": "1259",
"entity_id": "D006332",
"entity_type": "Disease",
"text_name": "cardiac hypertrophy"
},
{
"begin_idx": "53",
"end_idx": "65",
"entity_id": "D006984",
"entity_type": "Disease",
"text_name": "hypertrophic"
},
{
"begin_idx": "225",
"end_idx": "236",
"entity_id": "D006984",
"entity_type": "Disease",
"text_name": "hypertrophy"
},
{
"begin_idx": "794",
"end_idx": "805",
"entity_id": "D006984",
"entity_type": "Disease",
"text_name": "hypertrophy"
},
{
"begin_idx": "1158",
"end_idx": "1170",
"entity_id": "D006984",
"entity_type": "Disease",
"text_name": "hypertrophic"
},
{
"begin_idx": "1483",
"end_idx": "1494",
"entity_id": "D006984",
"entity_type": "Disease",
"text_name": "hypertrophy"
},
{
"begin_idx": "0",
"end_idx": "26",
"entity_id": "2247",
"entity_type": "Gene",
"text_name": "Fibroblast growth factor-2"
},
{
"begin_idx": "86",
"end_idx": "112",
"entity_id": "2247",
"entity_type": "Gene",
"text_name": "fibroblast growth factor-2"
},
{
"begin_idx": "114",
"end_idx": "118",
"entity_id": "2247",
"entity_type": "Gene",
"text_name": "FGF2"
},
{
"begin_idx": "360",
"end_idx": "364",
"entity_id": "2247",
"entity_type": "Gene",
"text_name": "FGF2"
},
{
"begin_idx": "366",
"end_idx": "370",
"entity_id": "2247",
"entity_type": "Gene",
"text_name": "Fgf2"
},
{
"begin_idx": "380",
"end_idx": "384",
"entity_id": "2247",
"entity_type": "Gene",
"text_name": "Fgf2"
},
{
"begin_idx": "752",
"end_idx": "756",
"entity_id": "2247",
"entity_type": "Gene",
"text_name": "Fgf2"
},
{
"begin_idx": "840",
"end_idx": "844",
"entity_id": "2247",
"entity_type": "Gene",
"text_name": "Fgf2"
},
{
"begin_idx": "940",
"end_idx": "944",
"entity_id": "2247",
"entity_type": "Gene",
"text_name": "Fgf2"
},
{
"begin_idx": "980",
"end_idx": "984",
"entity_id": "2247",
"entity_type": "Gene",
"text_name": "Fgf2"
},
{
"begin_idx": "1051",
"end_idx": "1055",
"entity_id": "2247",
"entity_type": "Gene",
"text_name": "Fgf2"
},
{
"begin_idx": "1115",
"end_idx": "1119",
"entity_id": "2247",
"entity_type": "Gene",
"text_name": "Fgf2"
},
{
"begin_idx": "1129",
"end_idx": "1133",
"entity_id": "2247",
"entity_type": "Gene",
"text_name": "Fgf2"
},
{
"begin_idx": "1213",
"end_idx": "1217",
"entity_id": "2247",
"entity_type": "Gene",
"text_name": "FGF2"
},
{
"begin_idx": "1355",
"end_idx": "1359",
"entity_id": "2247",
"entity_type": "Gene",
"text_name": "Fgf2"
},
{
"begin_idx": "1369",
"end_idx": "1373",
"entity_id": "2247",
"entity_type": "Gene",
"text_name": "Fgf2"
},
{
"begin_idx": "1475",
"end_idx": "1479",
"entity_id": "2247",
"entity_type": "Gene",
"text_name": "FGF2"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "0",
"end_idx": "26",
"entity_id": "2247",
"entity_type": "Gene",
"text_name": "Fibroblast growth factor-2"
},
{
"begin_idx": "752",
"end_idx": "756",
"entity_id": "2247",
"entity_type": "Gene",
"text_name": "Fgf2"
}
] | [
{
"begin_idx": "267",
"end_idx": "286",
"entity_id": "D006332",
"entity_type": "Disease",
"text_name": "cardiac hypertrophy"
},
{
"begin_idx": "794",
"end_idx": "805",
"entity_id": "D006984",
"entity_type": "Disease",
"text_name": "hypertrophy"
}
] | [
"Fibroblast growth factor-2",
"Fgf2"
] | [
"cardiac hypertrophy",
"hypertrophy"
] |
10494094 | Epidermolysis bullosa simplex with mottled pigmentation: clinical aspects and confirmation of the P24L mutation in the KRT5 gene in further patients. | Epidermolysis bullosa simplex with mottled pigmentation (EBS-MP) is a rare dermatologic disorder of autosomal dominant inheritance with intraepidermal blistering after minor trauma, reticular hyperpigmentation unrelated to the blistering, nail dystrophy, and mild palmoplantar keratosis. Keratin 5 and keratin 14 are known to be essential for the basal keratinocyte cytoskeleton and are defective in several forms of epidermolysis bullosa simplex. Recently, a 71C-->T transition in the keratin 5 gene (KRT5) causing a P24L substitution was identified in some patients with EBS-MP. We present a family with three affected members and a sporadic patient with EBS-MP. They exemplify clinically mild expression with intrafamilial variability and the possibility of improvement with time. In all of them, mutation analysis of the KRT5 gene showed the P24L mutation. So far, other mutations in the same or in other genes have not been reported in patients with EBS-MP. | [
{
"begin_idx": "0",
"end_idx": "55",
"entity_id": "C535959",
"entity_type": "Disease",
"text_name": "Epidermolysis bullosa simplex with mottled pigmentation"
},
{
"begin_idx": "150",
"end_idx": "205",
"entity_id": "C535959",
"entity_type": "Disease",
"text_name": "Epidermolysis bullosa simplex with mottled pigmentation"
},
{
"begin_idx": "207",
"end_idx": "213",
"entity_id": "C535959",
"entity_type": "Disease",
"text_name": "EBS-MP"
},
{
"begin_idx": "723",
"end_idx": "729",
"entity_id": "C535959",
"entity_type": "Disease",
"text_name": "EBS-MP"
},
{
"begin_idx": "807",
"end_idx": "813",
"entity_id": "C535959",
"entity_type": "Disease",
"text_name": "EBS-MP"
},
{
"begin_idx": "1105",
"end_idx": "1111",
"entity_id": "C535959",
"entity_type": "Disease",
"text_name": "EBS-MP"
},
{
"begin_idx": "332",
"end_idx": "387",
"entity_id": "D001768",
"entity_type": "Disease",
"text_name": "reticular hyperpigmentation unrelated to the blistering"
},
{
"begin_idx": "414",
"end_idx": "436",
"entity_id": "D007645",
"entity_type": "Disease",
"text_name": "palmoplantar keratosis"
},
{
"begin_idx": "389",
"end_idx": "403",
"entity_id": "D009260",
"entity_type": "Disease",
"text_name": "nail dystrophy"
},
{
"begin_idx": "324",
"end_idx": "330",
"entity_id": "D014947",
"entity_type": "Disease",
"text_name": "trauma"
},
{
"begin_idx": "225",
"end_idx": "246",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "dermatologic disorder"
},
{
"begin_idx": "119",
"end_idx": "123",
"entity_id": "3852",
"entity_type": "Gene",
"text_name": "KRT5"
},
{
"begin_idx": "652",
"end_idx": "656",
"entity_id": "3852",
"entity_type": "Gene",
"text_name": "KRT5"
},
{
"begin_idx": "975",
"end_idx": "979",
"entity_id": "3852",
"entity_type": "Gene",
"text_name": "KRT5"
},
{
"begin_idx": "452",
"end_idx": "462",
"entity_id": "3861",
"entity_type": "Gene",
"text_name": "keratin 14"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "119",
"end_idx": "123",
"entity_id": "3852",
"entity_type": "Gene",
"text_name": "KRT5"
},
{
"begin_idx": "652",
"end_idx": "656",
"entity_id": "3852",
"entity_type": "Gene",
"text_name": "KRT5"
}
] | [
{
"begin_idx": "0",
"end_idx": "55",
"entity_id": "C535959",
"entity_type": "Disease",
"text_name": "Epidermolysis bullosa simplex with mottled pigmentation"
},
{
"begin_idx": "414",
"end_idx": "436",
"entity_id": "D007645",
"entity_type": "Disease",
"text_name": "palmoplantar keratosis"
}
] | [
"KRT5",
"KRT5"
] | [
"Epidermolysis bullosa simplex with mottled pigmentation",
"palmoplantar keratosis"
] |
10500062 | Functional and ethnic association of allele 2 of the interleukin-1 receptor antagonist gene in ulcerative colitis. | BACKGROUND _ AIMS: The role of the interleukin (IL)-1 receptor antagonist (IL-1ra) in predisposing an individual to inflammatory bowel disease (IBD) is controversial. This study aimed to determine the association between intron 2 IL-1ra polymorphism and IBD by performing a multiethnic case-control study and to assess its functional significance. METHODS: A total of 236 patients with ulcerative colitis (UC), 196 patients with Crohn's disease (CD), and 338 ethnically matched control patients treated at LAC-USC and Cedars-Sinai Medical Centers and the University of Milan Medical Center were genotyped for a variable length polymorphism in intron 2 of the IL-1ra gene (IL-1RN). Total IL-1ra protein production rates in peripheral blood mononuclear cells (PBMCs) were correlated with carriage of allele 2 of the IL-1RN gene (IL-1RN*2). RESULTS: In the LAC-USC group, UC patients (n = 60) had an increased frequency of at least 1 copy of IL-1RN*2 compared with controls (n = 129) (70% vs. 33%; P < 0.01; odds ratio [OR], 4.7). The frequency of IL-1RN*2 carriage in the Cedars-Sinai group was 59% in UC, 45% in CD, and 42% in controls (P < 0.01; OR, 2.0). A significant difference was observed only in the Jewish subgroup (P = 0.003; OR, 5.0). The association was not detected in UC or CD patients treated at the University of Milan. The ORs of 4.7 and 5.0 appear to be the highest reported in any UC population for any genetic markers. Further, carriage of IL-1RN*2 was associated with decreased production of total IL-1ra protein in cultured PBMCs from both UC patients and controls. CONCLUSIONS: These results provide further evidence that IL-1ra is important in the predisposition to UC, there may be genetic or pathogenetic heterogeneity between different ethnic groups, and UC and CD are genetically distinct diseases. | [
{
"begin_idx": "95",
"end_idx": "113",
"entity_id": "D003093",
"entity_type": "Disease",
"text_name": "ulcerative colitis"
},
{
"begin_idx": "501",
"end_idx": "519",
"entity_id": "D003093",
"entity_type": "Disease",
"text_name": "ulcerative colitis"
},
{
"begin_idx": "521",
"end_idx": "523",
"entity_id": "D003093",
"entity_type": "Disease",
"text_name": "UC"
},
{
"begin_idx": "984",
"end_idx": "986",
"entity_id": "D003093",
"entity_type": "Disease",
"text_name": "UC"
},
{
"begin_idx": "1215",
"end_idx": "1217",
"entity_id": "D003093",
"entity_type": "Disease",
"text_name": "UC"
},
{
"begin_idx": "1395",
"end_idx": "1397",
"entity_id": "D003093",
"entity_type": "Disease",
"text_name": "UC"
},
{
"begin_idx": "1513",
"end_idx": "1515",
"entity_id": "D003093",
"entity_type": "Disease",
"text_name": "UC"
},
{
"begin_idx": "1675",
"end_idx": "1677",
"entity_id": "D003093",
"entity_type": "Disease",
"text_name": "UC"
},
{
"begin_idx": "1803",
"end_idx": "1805",
"entity_id": "D003093",
"entity_type": "Disease",
"text_name": "UC"
},
{
"begin_idx": "1895",
"end_idx": "1897",
"entity_id": "D003093",
"entity_type": "Disease",
"text_name": "UC"
},
{
"begin_idx": "544",
"end_idx": "559",
"entity_id": "D003424",
"entity_type": "Disease",
"text_name": "Crohn's disease"
},
{
"begin_idx": "561",
"end_idx": "563",
"entity_id": "D003424",
"entity_type": "Disease",
"text_name": "CD"
},
{
"begin_idx": "1226",
"end_idx": "1228",
"entity_id": "D003424",
"entity_type": "Disease",
"text_name": "CD"
},
{
"begin_idx": "1401",
"end_idx": "1403",
"entity_id": "D003424",
"entity_type": "Disease",
"text_name": "CD"
},
{
"begin_idx": "1902",
"end_idx": "1904",
"entity_id": "D003424",
"entity_type": "Disease",
"text_name": "CD"
},
{
"begin_idx": "231",
"end_idx": "257",
"entity_id": "D015212",
"entity_type": "Disease",
"text_name": "inflammatory bowel disease"
},
{
"begin_idx": "259",
"end_idx": "262",
"entity_id": "D015212",
"entity_type": "Disease",
"text_name": "IBD"
},
{
"begin_idx": "369",
"end_idx": "372",
"entity_id": "D015212",
"entity_type": "Disease",
"text_name": "IBD"
},
{
"begin_idx": "53",
"end_idx": "86",
"entity_id": "3557",
"entity_type": "Gene",
"text_name": "interleukin-1 receptor antagonist"
},
{
"begin_idx": "150",
"end_idx": "188",
"entity_id": "3557",
"entity_type": "Gene",
"text_name": "interleukin (IL)-1 receptor antagonist"
},
{
"begin_idx": "190",
"end_idx": "196",
"entity_id": "3557",
"entity_type": "Gene",
"text_name": "IL-1ra"
},
{
"begin_idx": "345",
"end_idx": "351",
"entity_id": "3557",
"entity_type": "Gene",
"text_name": "IL-1ra"
},
{
"begin_idx": "774",
"end_idx": "780",
"entity_id": "3557",
"entity_type": "Gene",
"text_name": "IL-1ra"
},
{
"begin_idx": "787",
"end_idx": "793",
"entity_id": "3557",
"entity_type": "Gene",
"text_name": "IL-1RN"
},
{
"begin_idx": "802",
"end_idx": "808",
"entity_id": "3557",
"entity_type": "Gene",
"text_name": "IL-1ra"
},
{
"begin_idx": "929",
"end_idx": "935",
"entity_id": "3557",
"entity_type": "Gene",
"text_name": "IL-1RN"
},
{
"begin_idx": "942",
"end_idx": "948",
"entity_id": "3557",
"entity_type": "Gene",
"text_name": "IL-1RN"
},
{
"begin_idx": "1054",
"end_idx": "1060",
"entity_id": "3557",
"entity_type": "Gene",
"text_name": "IL-1RN"
},
{
"begin_idx": "1160",
"end_idx": "1166",
"entity_id": "3557",
"entity_type": "Gene",
"text_name": "IL-1RN"
},
{
"begin_idx": "1573",
"end_idx": "1579",
"entity_id": "3557",
"entity_type": "Gene",
"text_name": "IL-1RN"
},
{
"begin_idx": "1632",
"end_idx": "1638",
"entity_id": "3557",
"entity_type": "Gene",
"text_name": "IL-1ra"
},
{
"begin_idx": "1758",
"end_idx": "1764",
"entity_id": "3557",
"entity_type": "Gene",
"text_name": "IL-1ra"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "150",
"end_idx": "188",
"entity_id": "3557",
"entity_type": "Gene",
"text_name": "interleukin (IL)-1 receptor antagonist"
},
{
"begin_idx": "345",
"end_idx": "351",
"entity_id": "3557",
"entity_type": "Gene",
"text_name": "IL-1ra"
}
] | [
{
"begin_idx": "95",
"end_idx": "113",
"entity_id": "D003093",
"entity_type": "Disease",
"text_name": "ulcerative colitis"
},
{
"begin_idx": "561",
"end_idx": "563",
"entity_id": "D003424",
"entity_type": "Disease",
"text_name": "CD"
}
] | [
"interleukin (IL)-1 receptor antagonist",
"IL-1ra"
] | [
"ulcerative colitis",
"CD"
] |
10501358 | Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. | BACKGROUND: Prostate cancer is a very common disease in more-developed countries, but its cause is largely unknown. It is an androgen-dependent cancer, and androgens have been proposed as having a substantial role in predisposition to the disease. Thus, variations in androgen metabolism genes may affect risk of this disease. METHODS: We screened 216 African-American and 172 Hispanic men with prostate cancer, and 261 African-American and 200 Hispanic healthy men (controls), from a large prospective cohort study (the Hawaii-Los Angeles Multiethnic Cohort Study) for a mis-sense substitution in the human prostatic (or type II) steroid 5alpha-reductase (SRD5A2) gene, the product of which controls metabolic activation of testosterone to dihydrotestosterone. This mis-sense substitution results in an alanine residue at codon 49 being replaced with threonine (A49T). We also reconstructed this mutation in the SRD5A2 cDNA, and overexpressed the enzyme in mammalian tissue culture cells. FINDINGS: The A49T aminoacid substitution in the SRD5A2 gene increased the risk of clinically significant disease 7.2-fold in African-American men (95% CI=2.17-27.91; p=0.001) and 3.6-fold in Hispanic men (1.09-12.27; p=0.04). The mutant enzyme had a higher in-vitro Vmax than the normal enzyme (9.9 vs 1.9 nmol min(-1) mg(-1)). INTERPRETATION: The A49T variant of the SRD5A2 gene may be a significant contributor to the incidence of prostate cancer in African-American and Hispanic men in Los Angeles. We estimate that the population attributable risk due to this aminoacid substitution for clinically significant disease is about 8% in both populations. Increased conversion of testosterone to dihydrotestosterone catalysed by this variant steroid 5alpha-reductase enzyme may be the cause of the increased risk. | [
{
"begin_idx": "276",
"end_idx": "282",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "cancer"
},
{
"begin_idx": "58",
"end_idx": "73",
"entity_id": "D011471",
"entity_type": "Disease",
"text_name": "prostate cancer"
},
{
"begin_idx": "144",
"end_idx": "159",
"entity_id": "D011471",
"entity_type": "Disease",
"text_name": "Prostate cancer"
},
{
"begin_idx": "527",
"end_idx": "542",
"entity_id": "D011471",
"entity_type": "Disease",
"text_name": "prostate cancer"
},
{
"begin_idx": "1556",
"end_idx": "1571",
"entity_id": "D011471",
"entity_type": "Disease",
"text_name": "prostate cancer"
},
{
"begin_idx": "41",
"end_idx": "47",
"entity_id": "6716",
"entity_type": "Gene",
"text_name": "SRD5A2"
},
{
"begin_idx": "789",
"end_idx": "795",
"entity_id": "6716",
"entity_type": "Gene",
"text_name": "SRD5A2"
},
{
"begin_idx": "1045",
"end_idx": "1051",
"entity_id": "6716",
"entity_type": "Gene",
"text_name": "SRD5A2"
},
{
"begin_idx": "1171",
"end_idx": "1177",
"entity_id": "6716",
"entity_type": "Gene",
"text_name": "SRD5A2"
},
{
"begin_idx": "1491",
"end_idx": "1497",
"entity_id": "6716",
"entity_type": "Gene",
"text_name": "SRD5A2"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "41",
"end_idx": "47",
"entity_id": "6716",
"entity_type": "Gene",
"text_name": "SRD5A2"
},
{
"begin_idx": "789",
"end_idx": "795",
"entity_id": "6716",
"entity_type": "Gene",
"text_name": "SRD5A2"
}
] | [
{
"begin_idx": "58",
"end_idx": "73",
"entity_id": "D011471",
"entity_type": "Disease",
"text_name": "prostate cancer"
},
{
"begin_idx": "276",
"end_idx": "282",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "cancer"
}
] | [
"SRD5A2",
"SRD5A2"
] | [
"prostate cancer",
"cancer"
] |
10502720 | Androgen receptor polymorphisms: association with prostate cancer risk, relapse and overall survival. | Several reports have suggested that one or both of the trinucleotide repeat polymorphisms in the human androgen receptor (hAR) gene, (CAG)n coding for polyglutamine and (GGC)n coding for polyglycine, may be associated with prostate cancer risk; but no study has investigated their association with disease progression. We present here a study of both hAR trinucleotide repeat polymorphisms not only as they relate to the initial diagnosis but also as they are associated with disease progression after therapy. Lymphocyte DNA samples from 178 British Caucasian prostate cancer patients and 195 control individuals were genotyped by PCR for the (CAG)n and (GGC)n polymorphisms in hAR. Univariate Cox proportional hazard analysis indicated that stage, grade and GGC repeat length were individually significant factors associated with disease-free survival (DFS) and overall survival (OS). The relative risk (RR) of relapse for men with more than 16 GGC repeats was 1.74 (95% CI 1. 08-2.79) and of dying from any cause, 1.98 (1.13-3.45). Adjusting for stage and grade, GGC effects remained but were not significant (RR(DFS)= 1.60, p = 0.052; RR(OS)= 1.65, p = 0.088). The greatest effects were in stage T1-T2 (RR(DFS)= 3.56, 95% CI 1.13-11.21) and grade 1 (RR(DFS)= 6.47, 95% CI 0.57-72.8) tumours. No differences between patient and control allele distributions were found by odds-ratio analysis, nor were trends with stage or grade evident in the proportion of short CAG alleles. Non-significant trends with stage and grade were found in the proportion of short GGC alleles. The (GGC)n polymorphism in this population is a significant predictor of disease outcome. Since the (GGC)(n) effect is strongest in early-stage tumours, this marker may help forecast aggressive behaviour and could be used to identify those patients meriting more radical treatment. | [
{
"begin_idx": "1850",
"end_idx": "1879",
"entity_id": "D001523",
"entity_type": "Disease",
"text_name": "forecast aggressive behaviour"
},
{
"begin_idx": "862",
"end_idx": "879",
"entity_id": "D007870",
"entity_type": "Disease",
"text_name": "GGC repeat length"
},
{
"begin_idx": "1389",
"end_idx": "1396",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumours"
},
{
"begin_idx": "1820",
"end_idx": "1827",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumours"
},
{
"begin_idx": "50",
"end_idx": "65",
"entity_id": "D011471",
"entity_type": "Disease",
"text_name": "prostate cancer"
},
{
"begin_idx": "325",
"end_idx": "340",
"entity_id": "D011471",
"entity_type": "Disease",
"text_name": "prostate cancer"
},
{
"begin_idx": "653",
"end_idx": "678",
"entity_id": "D011471",
"entity_type": "Disease",
"text_name": "Caucasian prostate cancer"
},
{
"begin_idx": "224",
"end_idx": "227",
"entity_id": "10894",
"entity_type": "Gene",
"text_name": "hAR"
},
{
"begin_idx": "453",
"end_idx": "456",
"entity_id": "10894",
"entity_type": "Gene",
"text_name": "hAR"
},
{
"begin_idx": "781",
"end_idx": "784",
"entity_id": "10894",
"entity_type": "Gene",
"text_name": "hAR"
},
{
"begin_idx": "0",
"end_idx": "17",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "Androgen receptor"
},
{
"begin_idx": "205",
"end_idx": "222",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "androgen receptor"
},
{
"begin_idx": "272",
"end_idx": "275",
"entity_id": "79017",
"entity_type": "Gene",
"text_name": "GGC"
},
{
"begin_idx": "758",
"end_idx": "761",
"entity_id": "79017",
"entity_type": "Gene",
"text_name": "GGC"
},
{
"begin_idx": "1049",
"end_idx": "1052",
"entity_id": "79017",
"entity_type": "Gene",
"text_name": "GGC"
},
{
"begin_idx": "1168",
"end_idx": "1171",
"entity_id": "79017",
"entity_type": "Gene",
"text_name": "GGC"
},
{
"begin_idx": "1663",
"end_idx": "1666",
"entity_id": "79017",
"entity_type": "Gene",
"text_name": "GGC"
},
{
"begin_idx": "1681",
"end_idx": "1684",
"entity_id": "79017",
"entity_type": "Gene",
"text_name": "GGC"
},
{
"begin_idx": "1777",
"end_idx": "1780",
"entity_id": "79017",
"entity_type": "Gene",
"text_name": "GGC"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "0",
"end_idx": "17",
"entity_id": "367",
"entity_type": "Gene",
"text_name": "Androgen receptor"
},
{
"begin_idx": "224",
"end_idx": "227",
"entity_id": "10894",
"entity_type": "Gene",
"text_name": "hAR"
}
] | [
{
"begin_idx": "653",
"end_idx": "678",
"entity_id": "D011471",
"entity_type": "Disease",
"text_name": "Caucasian prostate cancer"
},
{
"begin_idx": "1850",
"end_idx": "1879",
"entity_id": "D001523",
"entity_type": "Disease",
"text_name": "forecast aggressive behaviour"
}
] | [
"Androgen receptor",
"hAR"
] | [
"Caucasian prostate cancer",
"forecast aggressive behaviour"
] |
10502831 | Identification of a cytogenetic deletion and of four novel mutations (Q69X, I172F, G188V, G197R) affecting the gene for ornithine transcarbamylase (OTC) in Spanish patients with OTC deficiency. | A deletion of at least 11.5 cM in the paternal X chromosome mapping between microsatellites DXS989 and DXS1003 and encompassing the genes for ornithine transcarbamylase (OTC), retinitis pigmentosa GTPase regulator (RPGR) and dystrophin, was associated with the loss of band Xp21 in a female patient with OTC deficiency. Another four female patients were heterozygous for point mutations in the OTC gene: the nonsense mutation Q69X or the missense mutations I172F, G188V and G197R. In the OTC amino acid sequence, I172 and G197 are proximate to residues involved in catalysis, and G188 is within a loop joining helix 5 and strand 6 in the core of the ornithine-bindingdomain. Therefore, the mutations of these residues may cause structural changes affecting catalysis and/or the architecture of the ornithine domain. The mutation appeared "de novo" in the patients or, in one case, in the mother of the patient, in agreement with the predominance of "de novo" mutations in female patients of OTC deficiency. There was full agreement between the results of mutational analysis and of allopurinol testing in the patients and their female relatives, supporting the value of the allopurinol test in the detection of carriers of OTC deficiency. This deficiency is a genetically heterogeneous X-linked condition. | [
{
"begin_idx": "370",
"end_idx": "390",
"entity_id": "D012174",
"entity_type": "Disease",
"text_name": "retinitis pigmentosa"
},
{
"begin_idx": "178",
"end_idx": "192",
"entity_id": "D020163",
"entity_type": "Disease",
"text_name": "OTC deficiency"
},
{
"begin_idx": "498",
"end_idx": "512",
"entity_id": "D020163",
"entity_type": "Disease",
"text_name": "OTC deficiency"
},
{
"begin_idx": "1185",
"end_idx": "1199",
"entity_id": "D020163",
"entity_type": "Disease",
"text_name": "OTC deficiency"
},
{
"begin_idx": "1417",
"end_idx": "1431",
"entity_id": "D020163",
"entity_type": "Disease",
"text_name": "OTC deficiency"
},
{
"begin_idx": "1480",
"end_idx": "1498",
"entity_id": "D040181",
"entity_type": "Disease",
"text_name": "X-linked condition"
},
{
"begin_idx": "120",
"end_idx": "146",
"entity_id": "5009",
"entity_type": "Gene",
"text_name": "ornithine transcarbamylase"
},
{
"begin_idx": "148",
"end_idx": "151",
"entity_id": "5009",
"entity_type": "Gene",
"text_name": "OTC"
},
{
"begin_idx": "336",
"end_idx": "362",
"entity_id": "5009",
"entity_type": "Gene",
"text_name": "ornithine transcarbamylase"
},
{
"begin_idx": "364",
"end_idx": "367",
"entity_id": "5009",
"entity_type": "Gene",
"text_name": "OTC"
},
{
"begin_idx": "588",
"end_idx": "591",
"entity_id": "5009",
"entity_type": "Gene",
"text_name": "OTC"
},
{
"begin_idx": "682",
"end_idx": "685",
"entity_id": "5009",
"entity_type": "Gene",
"text_name": "OTC"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "120",
"end_idx": "146",
"entity_id": "5009",
"entity_type": "Gene",
"text_name": "ornithine transcarbamylase"
},
{
"begin_idx": "682",
"end_idx": "685",
"entity_id": "5009",
"entity_type": "Gene",
"text_name": "OTC"
}
] | [
{
"begin_idx": "178",
"end_idx": "192",
"entity_id": "D020163",
"entity_type": "Disease",
"text_name": "OTC deficiency"
},
{
"begin_idx": "1480",
"end_idx": "1498",
"entity_id": "D040181",
"entity_type": "Disease",
"text_name": "X-linked condition"
}
] | [
"ornithine transcarbamylase",
"OTC"
] | [
"OTC deficiency",
"X-linked condition"
] |
10504484 | A novel 18-amino acid deletion in apolipoprotein E associated with lipoprotein glomerulopathy. | BACKGROUND: Lipoprotein glomerulopathy (LPG) is a novel disease characterized by proteinuria, lipoprotein thrombi in glomeruli, and an increased concentration of plasma apolipoprotein (apo) E. Previous studies have shown that a genetic disorder of apo E may be associated with the genesis of this disease. METHODS: An apo E mutation was analyzed in a 57-year-old Japanese male with LPG and systemic atherosclerotic complications. Apo E phenotypes were analyzed by isoelectric focusing and immunoblotting. Apo E genotypes were determined by restriction fragment isotyping with HhaI. Polymerase chain reaction (PCR) products of apo E coding region exons 3 and 4 were cloned into pT7Blue-T-vector and were sequenced. RESULTS: A novel apo E mutation was identified in this patient and his family. There was a discrepancy between an apo E phenotype (E1/3) and genotype (E3/3). Sequence analysis showed a 54 bp deletion in exon 4 of the apo E gene, causing the 18-amino acid deletion (Gln 156-Gly 173-->0). This deletion mutation was further confirmed by the detection of a short fragment of PCR-amplified DNA using polyacrylamide gel electrophoresis. The patient was a heterozygote with apo E1, and this mutation was determined to be the structural basis for the apo E1 phenotype. One of two daughters was a heterozygous carrier of apo E1, although she did not have proteinuria or atherosclerotic diseases. CONCLUSIONS: Apo E1 (Gln 156-Gly 173-->0) is a novel mutation of apo E that may be etiologically related to LPG and to the development of atherosclerosis. The result of this family study suggests that the occurrence of LPG may involve other genetic or environmental factors. | [
{
"begin_idx": "67",
"end_idx": "93",
"entity_id": "C567089",
"entity_type": "Disease",
"text_name": "lipoprotein glomerulopathy"
},
{
"begin_idx": "107",
"end_idx": "133",
"entity_id": "C567089",
"entity_type": "Disease",
"text_name": "Lipoprotein glomerulopathy"
},
{
"begin_idx": "135",
"end_idx": "138",
"entity_id": "C567089",
"entity_type": "Disease",
"text_name": "LPG"
},
{
"begin_idx": "477",
"end_idx": "480",
"entity_id": "C567089",
"entity_type": "Disease",
"text_name": "LPG"
},
{
"begin_idx": "1605",
"end_idx": "1608",
"entity_id": "C567089",
"entity_type": "Disease",
"text_name": "LPG"
},
{
"begin_idx": "1716",
"end_idx": "1719",
"entity_id": "C567089",
"entity_type": "Disease",
"text_name": "LPG"
},
{
"begin_idx": "176",
"end_idx": "187",
"entity_id": "D011507",
"entity_type": "Disease",
"text_name": "proteinuria"
},
{
"begin_idx": "1456",
"end_idx": "1467",
"entity_id": "D011507",
"entity_type": "Disease",
"text_name": "proteinuria"
},
{
"begin_idx": "323",
"end_idx": "339",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "genetic disorder"
},
{
"begin_idx": "485",
"end_idx": "523",
"entity_id": "D050197",
"entity_type": "Disease",
"text_name": "systemic atherosclerotic complications"
},
{
"begin_idx": "1471",
"end_idx": "1495",
"entity_id": "D050197",
"entity_type": "Disease",
"text_name": "atherosclerotic diseases"
},
{
"begin_idx": "1635",
"end_idx": "1650",
"entity_id": "D050197",
"entity_type": "Disease",
"text_name": "atherosclerosis"
},
{
"begin_idx": "34",
"end_idx": "50",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "apolipoprotein E"
},
{
"begin_idx": "343",
"end_idx": "348",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "apo E"
},
{
"begin_idx": "413",
"end_idx": "418",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "apo E"
},
{
"begin_idx": "525",
"end_idx": "530",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "Apo E"
},
{
"begin_idx": "600",
"end_idx": "605",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "Apo E"
},
{
"begin_idx": "721",
"end_idx": "726",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "apo E"
},
{
"begin_idx": "826",
"end_idx": "831",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "apo E"
},
{
"begin_idx": "923",
"end_idx": "928",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "apo E"
},
{
"begin_idx": "1026",
"end_idx": "1031",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "apo E"
},
{
"begin_idx": "1562",
"end_idx": "1567",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "apo E"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "34",
"end_idx": "50",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "apolipoprotein E"
},
{
"begin_idx": "525",
"end_idx": "530",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "Apo E"
}
] | [
{
"begin_idx": "67",
"end_idx": "93",
"entity_id": "C567089",
"entity_type": "Disease",
"text_name": "lipoprotein glomerulopathy"
},
{
"begin_idx": "323",
"end_idx": "339",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "genetic disorder"
}
] | [
"apolipoprotein E",
"Apo E"
] | [
"lipoprotein glomerulopathy",
"genetic disorder"
] |
10505747 | Analysis of an IFN-gamma gene (IFNG) polymorphism in multiple sclerosis in Europe: effect of population structure on association with disease. | An intronic dinucleotide polymorphism in the IFN-gamma gene (IFNG) was used as a marker for testing association with multiple sclerosis (MS). Disease association was analyzed in case-control sets sampled from four geographically separate European populations (Germany, Northern Italy, Sardinia, and Sweden). Only in the Swedish was a weak disease association of the IFNG allele pattern found, mainly due to a higher frequency of IFNG allele I1 in MS patients. No evidence for association was found in the German or Northern Italian populations. These results contrast with the situation in Sardinia. We have recently reported transmission disequilibrium of IFNG allele I2 in Sardinian MS siblings not carrying the predisposing DRB1 *03 or *04 alleles (Ann. Neurol. 44, 841-842, 1998). Further analysis now shows that I2 is significantly more often transmitted to DRB1 *03-/*04- males, than to DRB1 *03-/*04- females. The odds ratio (OR) for IFNG-associated susceptibility to MS in the total Sardinian DRB1*03-/*04- group was 1.88 for I2 heterozygotes but amounted to 8.235 for I2 homozygotes, suggestive of a recessive mode of inheritance. Score test-based statistics pointed to an I2 allele dosage effect acting in susceptibility. Comparison of the IFNG allele frequencies in seven European populations (Northern Finnish, Southern Finnish, Swedish, Danish, German, Italian, and Sardinian) revealed a highly different distribution pattern. We introduced latitude as a score variable in order to test for trend in binomial proportions. This test statistic showed that for both most common alleles, I1 and I2 (compiled allele frequency about 85%), a significant opposite north-to-south trend is seen throughout Europe. This effect is primarily due to the extreme values found in the outlier populations of Finland and Sardinia. Our findings are discussed with respect to recent literature pertinent to the role of the IFNG chromosome region in autoimmune diseases. | [
{
"begin_idx": "2085",
"end_idx": "2104",
"entity_id": "D001327",
"entity_type": "Disease",
"text_name": "autoimmune diseases"
},
{
"begin_idx": "53",
"end_idx": "71",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "multiple sclerosis"
},
{
"begin_idx": "260",
"end_idx": "278",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "multiple sclerosis"
},
{
"begin_idx": "280",
"end_idx": "282",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "MS"
},
{
"begin_idx": "590",
"end_idx": "592",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "MS"
},
{
"begin_idx": "828",
"end_idx": "830",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "MS"
},
{
"begin_idx": "1118",
"end_idx": "1120",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "MS"
},
{
"begin_idx": "870",
"end_idx": "874",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "DRB1"
},
{
"begin_idx": "1006",
"end_idx": "1010",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "DRB1"
},
{
"begin_idx": "1036",
"end_idx": "1040",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "DRB1"
},
{
"begin_idx": "1144",
"end_idx": "1148",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "DRB1"
},
{
"begin_idx": "15",
"end_idx": "24",
"entity_id": "3458",
"entity_type": "Gene",
"text_name": "IFN-gamma"
},
{
"begin_idx": "31",
"end_idx": "35",
"entity_id": "3458",
"entity_type": "Gene",
"text_name": "IFNG"
},
{
"begin_idx": "188",
"end_idx": "197",
"entity_id": "3458",
"entity_type": "Gene",
"text_name": "IFN-gamma"
},
{
"begin_idx": "204",
"end_idx": "208",
"entity_id": "3458",
"entity_type": "Gene",
"text_name": "IFNG"
},
{
"begin_idx": "509",
"end_idx": "513",
"entity_id": "3458",
"entity_type": "Gene",
"text_name": "IFNG"
},
{
"begin_idx": "572",
"end_idx": "576",
"entity_id": "3458",
"entity_type": "Gene",
"text_name": "IFNG"
},
{
"begin_idx": "800",
"end_idx": "804",
"entity_id": "3458",
"entity_type": "Gene",
"text_name": "IFNG"
},
{
"begin_idx": "1084",
"end_idx": "1088",
"entity_id": "3458",
"entity_type": "Gene",
"text_name": "IFNG"
},
{
"begin_idx": "1393",
"end_idx": "1397",
"entity_id": "3458",
"entity_type": "Gene",
"text_name": "IFNG"
},
{
"begin_idx": "2059",
"end_idx": "2063",
"entity_id": "3458",
"entity_type": "Gene",
"text_name": "IFNG"
},
{
"begin_idx": "1740",
"end_idx": "1749",
"entity_id": "5502",
"entity_type": "Gene",
"text_name": "I1 and I2"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "15",
"end_idx": "24",
"entity_id": "3458",
"entity_type": "Gene",
"text_name": "IFN-gamma"
},
{
"begin_idx": "870",
"end_idx": "874",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "DRB1"
}
] | [
{
"begin_idx": "53",
"end_idx": "71",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "multiple sclerosis"
},
{
"begin_idx": "53",
"end_idx": "71",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "multiple sclerosis"
}
] | [
"IFN-gamma",
"DRB1"
] | [
"multiple sclerosis",
"multiple sclerosis"
] |
10506123 | Molecular basis for the progeroid variant of Ehlers-Danlos syndrome. Identification and characterization of two mutations in galactosyltransferase I gene. | Progeroid type Ehlers-Danlos (E-D) syndrome was reported to be caused by defects in galactosyltransferase I (EC 2.4.1.133), which is involved in the synthesis of common linkage regions of proteoglycans. Recently, we isolated cDNA of the galactosyltransferase I (XGalT-1) (Okajima, T., Yoshida, K., Kondo, T., and Furukawa, K. (1999) J. Biol. Chem. 274, 22915-22918). Therefore, we analyzed mutations in this gene of a patient with progeroid type E-D syndrome by reverse transcription polymerase chain reaction and direct sequencing. Two changes of G and T to A and C at 186 and 206, respectively, were detected. Then, we determined the genomic DNA sequences encompassing the A186D and L206P mutations, revealing that the unaffected parents and two siblings were heterozygous for either one of the two different mutations and normal, while the patient had both of two different mutant genes. Enzymatic functions of cDNA clones of XGalT-1 containing the individual mutations were examined, elucidating that L206P clone completely lost the activity, while A186D retained approximately 50% or 10% of the activity when analyzed with extracts from cDNA transfectant cells or recombinant soluble enzymes, respectively. Moreover, L206P enzyme showed diffuse staining in the cytoplasm of transfectant cells, while the wild type or A186D clones showed Golgi pattern. These results indicated that the mutations in XGalT-1 were at least one of main molecular basis for progeroid type E-D syndrome. | [
{
"begin_idx": "228",
"end_idx": "262",
"entity_id": "C536201",
"entity_type": "Disease",
"text_name": "defects in galactosyltransferase I"
},
{
"begin_idx": "45",
"end_idx": "67",
"entity_id": "D004535",
"entity_type": "Disease",
"text_name": "Ehlers-Danlos syndrome"
},
{
"begin_idx": "125",
"end_idx": "148",
"entity_id": "11285",
"entity_type": "Gene",
"text_name": "galactosyltransferase I"
},
{
"begin_idx": "239",
"end_idx": "262",
"entity_id": "11285",
"entity_type": "Gene",
"text_name": "galactosyltransferase I"
},
{
"begin_idx": "392",
"end_idx": "415",
"entity_id": "11285",
"entity_type": "Gene",
"text_name": "galactosyltransferase I"
},
{
"begin_idx": "417",
"end_idx": "424",
"entity_id": "11285",
"entity_type": "Gene",
"text_name": "XGalT-1"
},
{
"begin_idx": "1084",
"end_idx": "1091",
"entity_id": "11285",
"entity_type": "Gene",
"text_name": "XGalT-1"
},
{
"begin_idx": "1558",
"end_idx": "1565",
"entity_id": "11285",
"entity_type": "Gene",
"text_name": "XGalT-1"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "125",
"end_idx": "148",
"entity_id": "11285",
"entity_type": "Gene",
"text_name": "galactosyltransferase I"
},
{
"begin_idx": "1084",
"end_idx": "1091",
"entity_id": "11285",
"entity_type": "Gene",
"text_name": "XGalT-1"
}
] | [
{
"begin_idx": "228",
"end_idx": "262",
"entity_id": "C536201",
"entity_type": "Disease",
"text_name": "defects in galactosyltransferase I"
},
{
"begin_idx": "45",
"end_idx": "67",
"entity_id": "D004535",
"entity_type": "Disease",
"text_name": "Ehlers-Danlos syndrome"
}
] | [
"galactosyltransferase I",
"XGalT-1"
] | [
"defects in galactosyltransferase I",
"Ehlers-Danlos syndrome"
] |
10506726 | Erythropoietin reduces anemia and transfusions: A randomized trial with or without erythropoietin during chemotherapy. | BACKGROUND: Anemia has been reported to develop during preoperative chemotherapy with paclitaxel and carboplatin. The use of recombinant human erythropoietin (EPO) has been shown to reduce anemia and subsequent packed red blood cell transfusions. The current study is a report of a Phase III, prospective, randomized trial with or without EPO that confirms the original observations of less anemia and fewer transfusions in those patients randomized to receive EPO concurrently with paclitaxel and carboplatin. METHODS: Thirty patients with advanced head and neck or lung carcinoma were treated with 2 courses of paclitaxel, 230 mg/m(2), and carboplatin, 7.5 mg/mL/minute, repeated every 21 days. The treatment group was comprised of 15 patients randomized to receive concurrent EPO, 150 U/kg, 3 times per week; in patients deemed nonresponsive the dose was increased to 300 U/kg and 450 U/kg in subsequent courses. The control group was comprised of 15 patients randomized not to receive EPO. RESULTS: Twenty-seven patients were evaluable. After 2 courses of chemotherapy the mean hemoglobin decrease was 1.2 g/dL in the EPO group versus 2.8 g/dL in the control group (P = 0.037). There was a highly significant decrease in hemoglobin over time in patients who did not receive EPO (P = 0.008). After 4 courses of chemotherapy, fewer patients were transfused in the EPO arm: 2 of 13 (15%) in the EPO treatment group versus 5 of 14 (36%) in the control group. CONCLUSIONS: There was significantly less anemia and transfusions were reduced by 50% in patients randomized to receive EPO during chemotherapy with paclitaxel and carboplatin. | [
{
"begin_idx": "23",
"end_idx": "29",
"entity_id": "D000740",
"entity_type": "Disease",
"text_name": "anemia"
},
{
"begin_idx": "131",
"end_idx": "137",
"entity_id": "D000740",
"entity_type": "Disease",
"text_name": "Anemia"
},
{
"begin_idx": "308",
"end_idx": "314",
"entity_id": "D000740",
"entity_type": "Disease",
"text_name": "anemia"
},
{
"begin_idx": "510",
"end_idx": "516",
"entity_id": "D000740",
"entity_type": "Disease",
"text_name": "anemia"
},
{
"begin_idx": "1620",
"end_idx": "1626",
"entity_id": "D000740",
"entity_type": "Disease",
"text_name": "anemia"
},
{
"begin_idx": "678",
"end_idx": "700",
"entity_id": "D008175",
"entity_type": "Disease",
"text_name": "neck or lung carcinoma"
},
{
"begin_idx": "0",
"end_idx": "14",
"entity_id": "2056",
"entity_type": "Gene",
"text_name": "Erythropoietin"
},
{
"begin_idx": "83",
"end_idx": "97",
"entity_id": "2056",
"entity_type": "Gene",
"text_name": "erythropoietin"
},
{
"begin_idx": "262",
"end_idx": "276",
"entity_id": "2056",
"entity_type": "Gene",
"text_name": "erythropoietin"
},
{
"begin_idx": "278",
"end_idx": "281",
"entity_id": "2056",
"entity_type": "Gene",
"text_name": "EPO"
},
{
"begin_idx": "458",
"end_idx": "461",
"entity_id": "2056",
"entity_type": "Gene",
"text_name": "EPO"
},
{
"begin_idx": "580",
"end_idx": "583",
"entity_id": "2056",
"entity_type": "Gene",
"text_name": "EPO"
},
{
"begin_idx": "898",
"end_idx": "901",
"entity_id": "2056",
"entity_type": "Gene",
"text_name": "EPO"
},
{
"begin_idx": "1108",
"end_idx": "1111",
"entity_id": "2056",
"entity_type": "Gene",
"text_name": "EPO"
},
{
"begin_idx": "1241",
"end_idx": "1244",
"entity_id": "2056",
"entity_type": "Gene",
"text_name": "EPO"
},
{
"begin_idx": "1397",
"end_idx": "1400",
"entity_id": "2056",
"entity_type": "Gene",
"text_name": "EPO"
},
{
"begin_idx": "1485",
"end_idx": "1488",
"entity_id": "2056",
"entity_type": "Gene",
"text_name": "EPO"
},
{
"begin_idx": "1515",
"end_idx": "1518",
"entity_id": "2056",
"entity_type": "Gene",
"text_name": "EPO"
},
{
"begin_idx": "1698",
"end_idx": "1701",
"entity_id": "2056",
"entity_type": "Gene",
"text_name": "EPO"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "0",
"end_idx": "14",
"entity_id": "2056",
"entity_type": "Gene",
"text_name": "Erythropoietin"
},
{
"begin_idx": "278",
"end_idx": "281",
"entity_id": "2056",
"entity_type": "Gene",
"text_name": "EPO"
}
] | [
{
"begin_idx": "23",
"end_idx": "29",
"entity_id": "D000740",
"entity_type": "Disease",
"text_name": "anemia"
},
{
"begin_idx": "678",
"end_idx": "700",
"entity_id": "D008175",
"entity_type": "Disease",
"text_name": "neck or lung carcinoma"
}
] | [
"Erythropoietin",
"EPO"
] | [
"anemia",
"neck or lung carcinoma"
] |
10508506 | Familial endometrial cancer in female carriers of MSH6 germline mutations. | [
{
"begin_idx": "0",
"end_idx": "27",
"entity_id": "D016889",
"entity_type": "Disease",
"text_name": "Familial endometrial cancer"
},
{
"begin_idx": "50",
"end_idx": "54",
"entity_id": "2956",
"entity_type": "Gene",
"text_name": "MSH6"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "50",
"end_idx": "54",
"entity_id": "2956",
"entity_type": "Gene",
"text_name": "MSH6"
}
] | [
{
"begin_idx": "0",
"end_idx": "27",
"entity_id": "D016889",
"entity_type": "Disease",
"text_name": "Familial endometrial cancer"
}
] | [
"MSH6"
] | [
"Familial endometrial cancer"
] |
|
10508514 | Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. | Rett syndrome (RTT, MIM 312750) is a progressive neurodevelopmental disorder and one of the most common causes of mental retardation in females, with an incidence of 1 in 10,000-15,000 (ref. 2). Patients with classic RTT appear to develop normally until 6-18 months of age, then gradually lose speech and purposeful hand use, and develop microcephaly, seizures, autism, ataxia, intermittent hyperventilation and stereotypic hand movements. After initial regression, the condition stabilizes and patients usually survive into adulthood. As RTT occurs almost exclusively in females, it has been proposed that RTT is caused by an X-linked dominant mutation with lethality in hemizygous males. Previous exclusion mapping studies using RTT families mapped the locus to Xq28 (refs 6,9,10,11). Using a systematic gene screening approach, we have identified mutations in the gene (MECP2 ) encoding X-linked methyl-CpG-binding protein 2 (MeCP2) as the cause of some cases of RTT. MeCP2 selectively binds CpG dinucleotides in the mammalian genome and mediates transcriptional repression through interaction with histone deacetylase and the corepressor SIN3A (refs 12,13). In 5 of 21 sporadic patients, we found 3 de novo missense mutations in the region encoding the highly conserved methyl-binding domain (MBD) as well as a de novo frameshift and a de novo nonsense mutation, both of which disrupt the transcription repression domain (TRD). In two affected half-sisters of a RTT family, we found segregation of an additional missense mutation not detected in their obligate carrier mother. This suggests that the mother is a germline mosaic for this mutation. Our study reports the first disease-causing mutations in RTT and points to abnormal epigenetic regulation as the mechanism underlying the pathogenesis of RTT. | [
{
"begin_idx": "1369",
"end_idx": "1390",
"entity_id": "C535434",
"entity_type": "Disease",
"text_name": "methyl-binding domain"
},
{
"begin_idx": "1392",
"end_idx": "1395",
"entity_id": "C535434",
"entity_type": "Disease",
"text_name": "MBD"
},
{
"begin_idx": "465",
"end_idx": "471",
"entity_id": "D001259",
"entity_type": "Disease",
"text_name": "ataxia"
},
{
"begin_idx": "457",
"end_idx": "463",
"entity_id": "D001321",
"entity_type": "Disease",
"text_name": "autism"
},
{
"begin_idx": "144",
"end_idx": "171",
"entity_id": "D002658",
"entity_type": "Disease",
"text_name": "neurodevelopmental disorder"
},
{
"begin_idx": "209",
"end_idx": "227",
"entity_id": "D008607",
"entity_type": "Disease",
"text_name": "mental retardation"
},
{
"begin_idx": "433",
"end_idx": "445",
"entity_id": "D008831",
"entity_type": "Disease",
"text_name": "microcephaly"
},
{
"begin_idx": "447",
"end_idx": "455",
"entity_id": "D012640",
"entity_type": "Disease",
"text_name": "seizures"
},
{
"begin_idx": "0",
"end_idx": "13",
"entity_id": "D015518",
"entity_type": "Disease",
"text_name": "Rett syndrome"
},
{
"begin_idx": "95",
"end_idx": "108",
"entity_id": "D015518",
"entity_type": "Disease",
"text_name": "Rett syndrome"
},
{
"begin_idx": "110",
"end_idx": "113",
"entity_id": "D015518",
"entity_type": "Disease",
"text_name": "RTT"
},
{
"begin_idx": "312",
"end_idx": "315",
"entity_id": "D015518",
"entity_type": "Disease",
"text_name": "RTT"
},
{
"begin_idx": "634",
"end_idx": "637",
"entity_id": "D015518",
"entity_type": "Disease",
"text_name": "RTT"
},
{
"begin_idx": "702",
"end_idx": "705",
"entity_id": "D015518",
"entity_type": "Disease",
"text_name": "RTT"
},
{
"begin_idx": "826",
"end_idx": "829",
"entity_id": "D015518",
"entity_type": "Disease",
"text_name": "RTT"
},
{
"begin_idx": "1061",
"end_idx": "1064",
"entity_id": "D015518",
"entity_type": "Disease",
"text_name": "RTT"
},
{
"begin_idx": "1561",
"end_idx": "1564",
"entity_id": "D015518",
"entity_type": "Disease",
"text_name": "RTT"
},
{
"begin_idx": "1803",
"end_idx": "1806",
"entity_id": "D015518",
"entity_type": "Disease",
"text_name": "RTT"
},
{
"begin_idx": "1900",
"end_idx": "1903",
"entity_id": "D015518",
"entity_type": "Disease",
"text_name": "RTT"
},
{
"begin_idx": "40",
"end_idx": "54",
"entity_id": "D040181",
"entity_type": "Disease",
"text_name": "X-linked MECP2"
},
{
"begin_idx": "1237",
"end_idx": "1242",
"entity_id": "25942",
"entity_type": "Gene",
"text_name": "SIN3A"
},
{
"begin_idx": "49",
"end_idx": "54",
"entity_id": "4204",
"entity_type": "Gene",
"text_name": "MECP2"
},
{
"begin_idx": "65",
"end_idx": "93",
"entity_id": "4204",
"entity_type": "Gene",
"text_name": "methyl-CpG-binding protein 2"
},
{
"begin_idx": "968",
"end_idx": "973",
"entity_id": "4204",
"entity_type": "Gene",
"text_name": "MECP2"
},
{
"begin_idx": "994",
"end_idx": "1022",
"entity_id": "4204",
"entity_type": "Gene",
"text_name": "methyl-CpG-binding protein 2"
},
{
"begin_idx": "1024",
"end_idx": "1029",
"entity_id": "4204",
"entity_type": "Gene",
"text_name": "MeCP2"
},
{
"begin_idx": "1066",
"end_idx": "1071",
"entity_id": "4204",
"entity_type": "Gene",
"text_name": "MeCP2"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "65",
"end_idx": "93",
"entity_id": "4204",
"entity_type": "Gene",
"text_name": "methyl-CpG-binding protein 2"
},
{
"begin_idx": "1237",
"end_idx": "1242",
"entity_id": "25942",
"entity_type": "Gene",
"text_name": "SIN3A"
}
] | [
{
"begin_idx": "0",
"end_idx": "13",
"entity_id": "D015518",
"entity_type": "Disease",
"text_name": "Rett syndrome"
},
{
"begin_idx": "826",
"end_idx": "829",
"entity_id": "D015518",
"entity_type": "Disease",
"text_name": "RTT"
}
] | [
"methyl-CpG-binding protein 2",
"SIN3A"
] | [
"Rett syndrome",
"RTT"
] |
10508524 | The neuronal ceroid lipofuscinoses in human EPMR and mnd mutant mice are associated with mutations in CLN8. | The neuronal ceroid lipofuscinoses (NCLs) are a genetically heterogeneous group of progressive neurodegenerative disorders characterized by the accumulation of autofluorescent lipopigment in various tissues. Progressive epilepsy with mental retardation (EPMR, MIM 600143) was recently recognized as a new NCL subtype (CLN8). It is an autosomal recessive disorder characterized by onset of generalized seizures between 5 and 10 years, and subsequent progressive mental retardation. Here we report the positional cloning of a novel gene, CLN8, which is mutated in EPMR. It encodes a putative transmembrane protein. EPMR patients were homozygous for a missense mutation (70C-->G, R24G) that was not found in homozygosity in 433 controls. We also cloned the mouse Cln8 sequence. It displays 82% nucleotide identity with CLN8, conservation of the codon harbouring the human mutation and is localized to the same region as the motor neuron degeneration mouse, mnd, a naturally occurring mouse NCL (ref. 4). In mnd/mnd mice, we identified a homozygous 1-bp insertion (267-268insC, codon 90) predicting a frameshift and a truncated protein. Our data demonstrate that mutations in these orthologous genes underlie NCL phenotypes in human and mouse, and represent the first description of the molecular basis of a naturally occurring animal model for NCL. | [
{
"begin_idx": "102",
"end_idx": "106",
"entity_id": "C537952",
"entity_type": "Disease",
"text_name": "CLN8"
},
{
"begin_idx": "426",
"end_idx": "430",
"entity_id": "C537952",
"entity_type": "Disease",
"text_name": "CLN8"
},
{
"begin_idx": "644",
"end_idx": "648",
"entity_id": "C537952",
"entity_type": "Disease",
"text_name": "CLN8"
},
{
"begin_idx": "924",
"end_idx": "928",
"entity_id": "C537952",
"entity_type": "Disease",
"text_name": "CLN8"
},
{
"begin_idx": "44",
"end_idx": "48",
"entity_id": "D008607",
"entity_type": "Disease",
"text_name": "EPMR"
},
{
"begin_idx": "328",
"end_idx": "360",
"entity_id": "D008607",
"entity_type": "Disease",
"text_name": "epilepsy with mental retardation"
},
{
"begin_idx": "362",
"end_idx": "366",
"entity_id": "D008607",
"entity_type": "Disease",
"text_name": "EPMR"
},
{
"begin_idx": "569",
"end_idx": "587",
"entity_id": "D008607",
"entity_type": "Disease",
"text_name": "mental retardation"
},
{
"begin_idx": "670",
"end_idx": "674",
"entity_id": "D008607",
"entity_type": "Disease",
"text_name": "EPMR"
},
{
"begin_idx": "721",
"end_idx": "725",
"entity_id": "D008607",
"entity_type": "Disease",
"text_name": "EPMR"
},
{
"begin_idx": "1035",
"end_idx": "1054",
"entity_id": "D009410",
"entity_type": "Disease",
"text_name": "neuron degeneration"
},
{
"begin_idx": "4",
"end_idx": "34",
"entity_id": "D009472",
"entity_type": "Disease",
"text_name": "neuronal ceroid lipofuscinoses"
},
{
"begin_idx": "112",
"end_idx": "142",
"entity_id": "D009472",
"entity_type": "Disease",
"text_name": "neuronal ceroid lipofuscinoses"
},
{
"begin_idx": "144",
"end_idx": "148",
"entity_id": "D009472",
"entity_type": "Disease",
"text_name": "NCLs"
},
{
"begin_idx": "509",
"end_idx": "517",
"entity_id": "D012640",
"entity_type": "Disease",
"text_name": "seizures"
},
{
"begin_idx": "203",
"end_idx": "230",
"entity_id": "D019636",
"entity_type": "Disease",
"text_name": "neurodegenerative disorders"
},
{
"begin_idx": "442",
"end_idx": "470",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal recessive disorder"
},
{
"begin_idx": "44",
"end_idx": "48",
"entity_id": "2055",
"entity_type": "Gene",
"text_name": "EPMR"
},
{
"begin_idx": "102",
"end_idx": "106",
"entity_id": "2055",
"entity_type": "Gene",
"text_name": "CLN8"
},
{
"begin_idx": "362",
"end_idx": "366",
"entity_id": "2055",
"entity_type": "Gene",
"text_name": "EPMR"
},
{
"begin_idx": "426",
"end_idx": "430",
"entity_id": "2055",
"entity_type": "Gene",
"text_name": "CLN8"
},
{
"begin_idx": "644",
"end_idx": "648",
"entity_id": "2055",
"entity_type": "Gene",
"text_name": "CLN8"
},
{
"begin_idx": "670",
"end_idx": "674",
"entity_id": "2055",
"entity_type": "Gene",
"text_name": "EPMR"
},
{
"begin_idx": "721",
"end_idx": "725",
"entity_id": "2055",
"entity_type": "Gene",
"text_name": "EPMR"
},
{
"begin_idx": "868",
"end_idx": "872",
"entity_id": "2055",
"entity_type": "Gene",
"text_name": "Cln8"
},
{
"begin_idx": "924",
"end_idx": "928",
"entity_id": "2055",
"entity_type": "Gene",
"text_name": "CLN8"
},
{
"begin_idx": "413",
"end_idx": "416",
"entity_id": "4691",
"entity_type": "Gene",
"text_name": "NCL"
},
{
"begin_idx": "1095",
"end_idx": "1098",
"entity_id": "4691",
"entity_type": "Gene",
"text_name": "NCL"
},
{
"begin_idx": "1313",
"end_idx": "1316",
"entity_id": "4691",
"entity_type": "Gene",
"text_name": "NCL"
},
{
"begin_idx": "1449",
"end_idx": "1452",
"entity_id": "4691",
"entity_type": "Gene",
"text_name": "NCL"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "44",
"end_idx": "48",
"entity_id": "2055",
"entity_type": "Gene",
"text_name": "EPMR"
},
{
"begin_idx": "1095",
"end_idx": "1098",
"entity_id": "4691",
"entity_type": "Gene",
"text_name": "NCL"
}
] | [
{
"begin_idx": "102",
"end_idx": "106",
"entity_id": "C537952",
"entity_type": "Disease",
"text_name": "CLN8"
},
{
"begin_idx": "644",
"end_idx": "648",
"entity_id": "C537952",
"entity_type": "Disease",
"text_name": "CLN8"
}
] | [
"EPMR",
"NCL"
] | [
"CLN8",
"CLN8"
] |
10514107 | Association between Alzheimer's disease and the NOS3 gene. | Alzheimer's disease (AD) is the most common form of neurodegenerative disorder of later life. Genetic studies have demonstrated that the apolipoprotein E (ApoE) gene is an important susceptibility locus; however, other environmental and genetic factors operating alone or in combination with ApoE must also be involved. Among candidate genes that may contribute to this residual risk is the endothelial nitric oxide synthase (NOS3) gene. NO release from vascular endothelium accounts in large part for endothelium-derived relaxing factor bioactivity. Abnormalities of cerebral small vessels occur early in AD, and it has been demonstrated recently that beta-amyloid interacts with endothelial cells in blood vessels to produce an excess of superoxide radicals. We have genotyped 122 cases of early-onset AD (EOAD) and 317 cases of late-onset AD (LOAD) as well as 392 controls for a common structural polymorphism Glu/Asp at codon 298 in the NOS3 gene. We find a highly significant enrichment for Glu/Glu homozygotes in LOAD compared with controls. The effect appears to be independent of ApoE status. NOS3 may be a new genetic risk factor for LOAD. | [
{
"begin_idx": "20",
"end_idx": "39",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "Alzheimer's disease"
},
{
"begin_idx": "59",
"end_idx": "78",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "Alzheimer's disease"
},
{
"begin_idx": "80",
"end_idx": "82",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "665",
"end_idx": "667",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "863",
"end_idx": "865",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "901",
"end_idx": "903",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "111",
"end_idx": "137",
"entity_id": "D019636",
"entity_type": "Disease",
"text_name": "neurodegenerative disorder"
},
{
"begin_idx": "196",
"end_idx": "212",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "apolipoprotein E"
},
{
"begin_idx": "214",
"end_idx": "218",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "ApoE"
},
{
"begin_idx": "351",
"end_idx": "355",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "ApoE"
},
{
"begin_idx": "1147",
"end_idx": "1151",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "ApoE"
},
{
"begin_idx": "48",
"end_idx": "52",
"entity_id": "4846",
"entity_type": "Gene",
"text_name": "NOS3"
},
{
"begin_idx": "450",
"end_idx": "483",
"entity_id": "4846",
"entity_type": "Gene",
"text_name": "endothelial nitric oxide synthase"
},
{
"begin_idx": "485",
"end_idx": "489",
"entity_id": "4846",
"entity_type": "Gene",
"text_name": "NOS3"
},
{
"begin_idx": "1000",
"end_idx": "1004",
"entity_id": "4846",
"entity_type": "Gene",
"text_name": "NOS3"
},
{
"begin_idx": "1160",
"end_idx": "1164",
"entity_id": "4846",
"entity_type": "Gene",
"text_name": "NOS3"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "450",
"end_idx": "483",
"entity_id": "4846",
"entity_type": "Gene",
"text_name": "endothelial nitric oxide synthase"
},
{
"begin_idx": "485",
"end_idx": "489",
"entity_id": "4846",
"entity_type": "Gene",
"text_name": "NOS3"
}
] | [
{
"begin_idx": "20",
"end_idx": "39",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "Alzheimer's disease"
},
{
"begin_idx": "111",
"end_idx": "137",
"entity_id": "D019636",
"entity_type": "Disease",
"text_name": "neurodegenerative disorder"
}
] | [
"endothelial nitric oxide synthase",
"NOS3"
] | [
"Alzheimer's disease",
"neurodegenerative disorder"
] |
10515446 | Renal protective effects of blocking the intrarenal renin-angiotensin system. | It has been well demonstrated that angiotensin-converting enzyme inhibitors (ACEIs) can retard the progression of renal failure and kidney sclerosis in patients and animal models with glomerular diseases. The aim of this study was to observe the influences of ACEI on intrarenal Ang II and TGFbeta1 local formation and their relation to renal protective effects. Experimental glomerulosclerosis with nephrotic syndrome was induced in unilateral nephrectomized rats with repeated injections of adriamycin. Rats were randomly divided into three groups: 1) a sham-operated control group (n=8); 2) an NS group treated with ACEI (benazepril 4 mg/kg/d) (n=10), and 3) an NS group not treated (n=10). After 8 wk, serum, urine and renal tissue were collected for study. ACE activity and Ang II concentration in renal tissue were measured by colorimetry and radioimmunoassay, respectively. Immunohistochemistry staining was employed for transforming growth factor-beta1 (TGFbeta1) and extracellular matrix (ECM) examination. TGFbeta1 mRNA was assessed by in situ hybridization. Compared with those of non-treated nephropathy rats, ACE activity (13.39+/-5.02 vs. 49.13+/-12.92 U/ml, p< 0.01) and Ang II (402.61+/-80.22 vs. 751.63+/-137.45 pg/mg/pr p < 0.01) in renal tissue were significantly inhibited in the rats treated with ACEI. At the same time, proteinuria was significantly reduced (155.06+/-103.56 vs. 421.11+/-148.45 mg/24 h, p < 0.01) and renal function improved (Scr 76.3+/-33.1 vs. 107.1+/-71.0, p < 0.05), concomitant with a reduction in the glomerular sclerosis index (30.6+/-19.5 vs. 120.3+/-61.9, p < 0.01) and a reduction in ECM accumulation such as Col IV, III, LN and FN (29.2+/-9.8 vs. 76.8+/-12.4; 29.5+/-12.4 vs. 85.9+/-11.5; 26.0+/-5.1 vs. 69.6+/-1.73; 32.4+/-12.4 vs. 70.5+/-13.5; p< 0.01 in all cases). In the ACEI treated group, these histologic benefits coincided with a reduced expression of TGFbeta1 in both tubular cells and sclerosed glomeruli in protein as well as mRNA level. These findings provide further evidence that ACEI (benazepril) can prevent the progression of renal damage in both the function and morphologic changes which associated with a down-regulation of intrarenal Ang II level through the relative inhibition of renal ACE activity. The blocking of the intrarenal renin angiotensin system (RAS) might contribute to the inhibition of TGFbeta1 local formation and the TGFbeta1-mediated ECM accumulation that are related to the renal protective effects of ACEI. | [
{
"begin_idx": "454",
"end_idx": "472",
"entity_id": "D005921",
"entity_type": "Disease",
"text_name": "glomerulosclerosis"
},
{
"begin_idx": "210",
"end_idx": "226",
"entity_id": "D007674",
"entity_type": "Disease",
"text_name": "kidney sclerosis"
},
{
"begin_idx": "262",
"end_idx": "281",
"entity_id": "D007674",
"entity_type": "Disease",
"text_name": "glomerular diseases"
},
{
"begin_idx": "1182",
"end_idx": "1193",
"entity_id": "D007674",
"entity_type": "Disease",
"text_name": "nephropathy"
},
{
"begin_idx": "1624",
"end_idx": "1644",
"entity_id": "D007674",
"entity_type": "Disease",
"text_name": "glomerular sclerosis"
},
{
"begin_idx": "2172",
"end_idx": "2184",
"entity_id": "D007674",
"entity_type": "Disease",
"text_name": "renal damage"
},
{
"begin_idx": "478",
"end_idx": "496",
"entity_id": "D009404",
"entity_type": "Disease",
"text_name": "nephrotic syndrome"
},
{
"begin_idx": "1420",
"end_idx": "1431",
"entity_id": "D011507",
"entity_type": "Disease",
"text_name": "proteinuria"
},
{
"begin_idx": "192",
"end_idx": "205",
"entity_id": "D051437",
"entity_type": "Disease",
"text_name": "renal failure"
},
{
"begin_idx": "840",
"end_idx": "843",
"entity_id": "1636",
"entity_type": "Gene",
"text_name": "ACE"
},
{
"begin_idx": "1200",
"end_idx": "1203",
"entity_id": "1636",
"entity_type": "Gene",
"text_name": "ACE"
},
{
"begin_idx": "2338",
"end_idx": "2341",
"entity_id": "1636",
"entity_type": "Gene",
"text_name": "ACE"
},
{
"begin_idx": "368",
"end_idx": "376",
"entity_id": "7040",
"entity_type": "Gene",
"text_name": "TGFbeta1"
},
{
"begin_idx": "1006",
"end_idx": "1038",
"entity_id": "7040",
"entity_type": "Gene",
"text_name": "transforming growth factor-beta1"
},
{
"begin_idx": "1040",
"end_idx": "1048",
"entity_id": "7040",
"entity_type": "Gene",
"text_name": "TGFbeta1"
},
{
"begin_idx": "1094",
"end_idx": "1102",
"entity_id": "7040",
"entity_type": "Gene",
"text_name": "TGFbeta1"
},
{
"begin_idx": "1989",
"end_idx": "1997",
"entity_id": "7040",
"entity_type": "Gene",
"text_name": "TGFbeta1"
},
{
"begin_idx": "2452",
"end_idx": "2460",
"entity_id": "7040",
"entity_type": "Gene",
"text_name": "TGFbeta1"
},
{
"begin_idx": "2485",
"end_idx": "2493",
"entity_id": "7040",
"entity_type": "Gene",
"text_name": "TGFbeta1"
}
] | [
"Yes",
"No"
] | [
false,
false
] | [
{
"begin_idx": "1006",
"end_idx": "1038",
"entity_id": "7040",
"entity_type": "Gene",
"text_name": "transforming growth factor-beta1"
},
{
"begin_idx": "2452",
"end_idx": "2460",
"entity_id": "7040",
"entity_type": "Gene",
"text_name": "TGFbeta1"
}
] | [
{
"begin_idx": "478",
"end_idx": "496",
"entity_id": "D009404",
"entity_type": "Disease",
"text_name": "nephrotic syndrome"
},
{
"begin_idx": "210",
"end_idx": "226",
"entity_id": "D007674",
"entity_type": "Disease",
"text_name": "kidney sclerosis"
}
] | [
"transforming growth factor-beta1",
"TGFbeta1"
] | [
"nephrotic syndrome",
"kidney sclerosis"
] |
10515860 | Lymphoproliferative syndrome with autoimmunity: A possible genetic basis for dominant expression of the clinical manifestations. | Fas (CD95/Apo-1) mutations were previously reported as the genetic defect responsible for human lymphoproliferative syndrome associated with autoimmune manifestations (also known as autoimmune lymphoproliferative syndrome or Canale-Smith syndrome). We have identified 14 new heterozygous Fas mutations. Analysis of patients and families allow us to further dissect this syndrome with regards to the relationship between Fas mutations, inheritance pattern, and phenotype as observed on long-term follow-up. In vitro studies show that lymphocytes from all Fas mutant carriers exhibit a Fas-antibody-induced apoptosis defect. However, among the 8 inherited mutations, 4 of 4 Fas missense mutations were associated with high clinical penetrance, whereas 3 of 4 mutations leading to a truncated Fas product were associated with variable clinical penetrance. This suggests that a second defect, in another yet undefined factor involved in apoptosis and/or lymphoproliferation control, is necessary to induce full clinical expression of the disease. These results also indicate that the currently available antibody-mediated in vitro apoptosis assay does not necessarily reflect the in vivo ability of abnormal Fas molecules to trigger lymphocyte death. In addition, we found that lymphoproliferative manifestations resolved with age, whereas immunological disorders [ie, hypergammaglobulinemia and detection of TcR alphabeta(+) CD4(-) CD8(-) lymphocytes] persisted. This observation suggests that Fas-mediated apoptosis plays a more important role in lymphocyte homeostasis in early childhood than later on in life. | [
{
"begin_idx": "34",
"end_idx": "46",
"entity_id": "D001327",
"entity_type": "Disease",
"text_name": "autoimmunity"
},
{
"begin_idx": "1494",
"end_idx": "1516",
"entity_id": "D006942",
"entity_type": "Disease",
"text_name": "hypergammaglobulinemia"
},
{
"begin_idx": "1465",
"end_idx": "1488",
"entity_id": "D007154",
"entity_type": "Disease",
"text_name": "immunological disorders"
},
{
"begin_idx": "0",
"end_idx": "28",
"entity_id": "D008232",
"entity_type": "Disease",
"text_name": "Lymphoproliferative syndrome"
},
{
"begin_idx": "225",
"end_idx": "253",
"entity_id": "D008232",
"entity_type": "Disease",
"text_name": "lymphoproliferative syndrome"
},
{
"begin_idx": "188",
"end_idx": "202",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "genetic defect"
},
{
"begin_idx": "311",
"end_idx": "350",
"entity_id": "D056735",
"entity_type": "Disease",
"text_name": "autoimmune lymphoproliferative syndrome"
},
{
"begin_idx": "354",
"end_idx": "375",
"entity_id": "D056735",
"entity_type": "Disease",
"text_name": "Canale-Smith syndrome"
},
{
"begin_idx": "134",
"end_idx": "138",
"entity_id": "355",
"entity_type": "Gene",
"text_name": "CD95"
},
{
"begin_idx": "139",
"end_idx": "144",
"entity_id": "355",
"entity_type": "Gene",
"text_name": "Apo-1"
},
{
"begin_idx": "1534",
"end_idx": "1537",
"entity_id": "6962",
"entity_type": "Gene",
"text_name": "TcR"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "139",
"end_idx": "144",
"entity_id": "355",
"entity_type": "Gene",
"text_name": "Apo-1"
},
{
"begin_idx": "1534",
"end_idx": "1537",
"entity_id": "6962",
"entity_type": "Gene",
"text_name": "TcR"
}
] | [
{
"begin_idx": "311",
"end_idx": "350",
"entity_id": "D056735",
"entity_type": "Disease",
"text_name": "autoimmune lymphoproliferative syndrome"
},
{
"begin_idx": "1494",
"end_idx": "1516",
"entity_id": "D006942",
"entity_type": "Disease",
"text_name": "hypergammaglobulinemia"
}
] | [
"Apo-1",
"TcR"
] | [
"autoimmune lymphoproliferative syndrome",
"hypergammaglobulinemia"
] |
10519592 | Isolated sulfite oxidase deficiency: review of two cases in one family. | OBJECTIVE: The authors describe two cases of isolated sulfite oxidase deficiency found in one family. This is a rare autosomal-recessive disorder presenting at birth with seizures, severe neurologic disease, and ectopia lentis. It can be easily missed with metabolic screening; however, the finding of lens subluxation stresses the importance of ophthalmic assessment in making the diagnosis. DESIGN: Two observational case reports. INTERVENTION/METHODS: Ophthalmic assessment, biochemical assay for specific urinary and plasma metabolites, magnetic resonance imaging, and gene sequencing were used to make the diagnosis of the disease in the proband. The diagnosis was subsequently recognized in a previously affected sibling after the postmortem neuropathology was reviewed. Mutation analysis was performed on cultured fibroblasts from the proband to identify and categorize the specific mutation responsible for the disease in the family. From this, future prenatal detection of sulfite oxidase deficiency is possible. MAIN OUTCOME MEASURES: The diagnosis of sulfite oxidase deficiency was established in this family, enabling appropriate genetic counseling and recurrence risk estimation. RESULTS: Point mutations were found in both alleles of the sulfite oxidase gene in the proband. The first is a 623C-->A mutation, which predicts an A208D substitution, and the second is a 1109C-->A, which predicts an S370Y substitution. Both residues A208D and S370Y are critical for sulfite oxidase activity. CONCLUSIONS: Isolated sulfite oxidase deficiency is a rare heritable disease for which mutation analysis can allow accurate prenatal screening. It often is difficult to diagnose by clinical presentation alone, but the critical finding of lens subluxation accompanying seizures and diffuse neurologic disease in an infant should alert the physician to the diagnosis. | [
{
"begin_idx": "9",
"end_idx": "35",
"entity_id": "C538141",
"entity_type": "Disease",
"text_name": "sulfite oxidase deficiency"
},
{
"begin_idx": "126",
"end_idx": "152",
"entity_id": "C538141",
"entity_type": "Disease",
"text_name": "sulfite oxidase deficiency"
},
{
"begin_idx": "1054",
"end_idx": "1080",
"entity_id": "C538141",
"entity_type": "Disease",
"text_name": "sulfite oxidase deficiency"
},
{
"begin_idx": "1134",
"end_idx": "1160",
"entity_id": "C538141",
"entity_type": "Disease",
"text_name": "sulfite oxidase deficiency"
},
{
"begin_idx": "1597",
"end_idx": "1623",
"entity_id": "C538141",
"entity_type": "Disease",
"text_name": "sulfite oxidase deficiency"
},
{
"begin_idx": "284",
"end_idx": "298",
"entity_id": "D004479",
"entity_type": "Disease",
"text_name": "ectopia lentis"
},
{
"begin_idx": "260",
"end_idx": "278",
"entity_id": "D009422",
"entity_type": "Disease",
"text_name": "neurologic disease"
},
{
"begin_idx": "1856",
"end_idx": "1882",
"entity_id": "D009422",
"entity_type": "Disease",
"text_name": "diffuse neurologic disease"
},
{
"begin_idx": "243",
"end_idx": "251",
"entity_id": "D012640",
"entity_type": "Disease",
"text_name": "seizures"
},
{
"begin_idx": "1843",
"end_idx": "1851",
"entity_id": "D012640",
"entity_type": "Disease",
"text_name": "seizures"
},
{
"begin_idx": "189",
"end_idx": "217",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal-recessive disorder"
},
{
"begin_idx": "1324",
"end_idx": "1339",
"entity_id": "6821",
"entity_type": "Gene",
"text_name": "sulfite oxidase"
},
{
"begin_idx": "1549",
"end_idx": "1564",
"entity_id": "6821",
"entity_type": "Gene",
"text_name": "sulfite oxidase"
}
] | [
"Yes",
"No"
] | [
false,
false
] | [
{
"begin_idx": "1324",
"end_idx": "1339",
"entity_id": "6821",
"entity_type": "Gene",
"text_name": "sulfite oxidase"
},
{
"begin_idx": "1549",
"end_idx": "1564",
"entity_id": "6821",
"entity_type": "Gene",
"text_name": "sulfite oxidase"
}
] | [
{
"begin_idx": "9",
"end_idx": "35",
"entity_id": "C538141",
"entity_type": "Disease",
"text_name": "sulfite oxidase deficiency"
},
{
"begin_idx": "189",
"end_idx": "217",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal-recessive disorder"
}
] | [
"sulfite oxidase",
"sulfite oxidase"
] | [
"sulfite oxidase deficiency",
"autosomal-recessive disorder"
] |
10519734 | Comparative effects of simvastatin and cholestyramine on plasma lipoproteins and CETP in humans. | Cholesteryl ester transfer protein (CETP) mediates neutral lipid transport in plasma, resulting in a net transfer of cholesteryl ester from high density lipoprotein to very low density lipoprotein. CETP gene expression is regulated by cholesterol, and plasma CETP level increases in patients with hyperlipidemia and with cholesterol feeding. Simvastatin, unlike cholestyramine, reduces hydroxymethylglutaryl coenzyme A reductase activity and may decrease a cellular pool of cholesterol, which is regulatory for CETP gene expression. The effects of simvastatin and cholestyramine on plasma lipids and CETP in 24 male and 19 female patients with primary hypercholesterolemia were compared. Following a four-week placebo period, patients were randomly assigned to receive either simvastatin or cholestyramine. Medication was increased in a stepwise fashion (from 10 to 40 mg for simvastatin and from 8 to 24 g for cholestyramine) as required at six-week intervals to maintain a low density lipoprotein cholesterol (LDL-C) level below 3.4 mmol/L. At the end of the 18-week study, the mean dose of simvastatin was 28.6 mg/day and of cholestyramine 19.3 g/day. Simvastatin was more effective than cholestyramine in lowering LDL-C (-36.8% versus -27. 2%; P=0.031) and triglycerides (-8.5% versus +12.5%; P=0.045). Plasma CETP level decreased by 14.8% following treatment with simvastatin (P=0.003) but did not change following cholestyramine treatment. This study demonstrates that, compared with cholestyramine, simvastatin results in more favourable improvements in the plasma lipoprotein profile and also lowers plasma levels of CETP. | [
{
"begin_idx": "749",
"end_idx": "769",
"entity_id": "D006937",
"entity_type": "Disease",
"text_name": "hypercholesterolemia"
},
{
"begin_idx": "394",
"end_idx": "408",
"entity_id": "D006949",
"entity_type": "Disease",
"text_name": "hyperlipidemia"
},
{
"begin_idx": "81",
"end_idx": "85",
"entity_id": "1071",
"entity_type": "Gene",
"text_name": "CETP"
},
{
"begin_idx": "97",
"end_idx": "131",
"entity_id": "1071",
"entity_type": "Gene",
"text_name": "Cholesteryl ester transfer protein"
},
{
"begin_idx": "133",
"end_idx": "137",
"entity_id": "1071",
"entity_type": "Gene",
"text_name": "CETP"
},
{
"begin_idx": "295",
"end_idx": "299",
"entity_id": "1071",
"entity_type": "Gene",
"text_name": "CETP"
},
{
"begin_idx": "356",
"end_idx": "360",
"entity_id": "1071",
"entity_type": "Gene",
"text_name": "CETP"
},
{
"begin_idx": "608",
"end_idx": "612",
"entity_id": "1071",
"entity_type": "Gene",
"text_name": "CETP"
},
{
"begin_idx": "697",
"end_idx": "701",
"entity_id": "1071",
"entity_type": "Gene",
"text_name": "CETP"
},
{
"begin_idx": "1411",
"end_idx": "1415",
"entity_id": "1071",
"entity_type": "Gene",
"text_name": "CETP"
},
{
"begin_idx": "1722",
"end_idx": "1726",
"entity_id": "1071",
"entity_type": "Gene",
"text_name": "CETP"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "97",
"end_idx": "131",
"entity_id": "1071",
"entity_type": "Gene",
"text_name": "Cholesteryl ester transfer protein"
},
{
"begin_idx": "608",
"end_idx": "612",
"entity_id": "1071",
"entity_type": "Gene",
"text_name": "CETP"
}
] | [
{
"begin_idx": "394",
"end_idx": "408",
"entity_id": "D006949",
"entity_type": "Disease",
"text_name": "hyperlipidemia"
},
{
"begin_idx": "749",
"end_idx": "769",
"entity_id": "D006937",
"entity_type": "Disease",
"text_name": "hypercholesterolemia"
}
] | [
"Cholesteryl ester transfer protein",
"CETP"
] | [
"hyperlipidemia",
"hypercholesterolemia"
] |
10520641 | Association of CCR5 delta32 with reduced risk of asthma. | We report that individuals carrying the CCR5 delta32 mutation, a naturally occurring variant of the C-C chemokine receptor 5 (CCR5), are at reduced risk of developing asthma. These data suggest a possible explanation for the high prevalence of this mutation in the general population. | [
{
"begin_idx": "49",
"end_idx": "55",
"entity_id": "D001249",
"entity_type": "Disease",
"text_name": "asthma"
},
{
"begin_idx": "224",
"end_idx": "230",
"entity_id": "D001249",
"entity_type": "Disease",
"text_name": "asthma"
},
{
"begin_idx": "15",
"end_idx": "19",
"entity_id": "1234",
"entity_type": "Gene",
"text_name": "CCR5"
},
{
"begin_idx": "97",
"end_idx": "101",
"entity_id": "1234",
"entity_type": "Gene",
"text_name": "CCR5"
},
{
"begin_idx": "157",
"end_idx": "181",
"entity_id": "1234",
"entity_type": "Gene",
"text_name": "C-C chemokine receptor 5"
},
{
"begin_idx": "183",
"end_idx": "187",
"entity_id": "1234",
"entity_type": "Gene",
"text_name": "CCR5"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "157",
"end_idx": "181",
"entity_id": "1234",
"entity_type": "Gene",
"text_name": "C-C chemokine receptor 5"
}
] | [
{
"begin_idx": "49",
"end_idx": "55",
"entity_id": "D001249",
"entity_type": "Disease",
"text_name": "asthma"
}
] | [
"C-C chemokine receptor 5"
] | [
"asthma"
] |
10522893 | Evidence for the GluR6 gene associated with younger onset age of Huntington's disease. | Huntington's disease (HD) is attributed to a triplet CAG repeat mutation, and about half of the variation in onset age can be explained by the size of the repeat expansion. Recently, a TAA repeat polymorphism in close linkage to the kainate receptor, GluR6, was reported related to onset age in HD. We examined this polymorphism in 258 unrelated HD-affected persons (172 from a clinic sample and 86 from a postmortem series). This study confirms that the 155 allele is associated with younger onset age of HD and suggests that it is in linkage disequilibrium with a variant of the GluR6 gene or another gene in this region. | [
{
"begin_idx": "65",
"end_idx": "85",
"entity_id": "D006816",
"entity_type": "Disease",
"text_name": "Huntington's disease"
},
{
"begin_idx": "87",
"end_idx": "107",
"entity_id": "D006816",
"entity_type": "Disease",
"text_name": "Huntington's disease"
},
{
"begin_idx": "109",
"end_idx": "111",
"entity_id": "D006816",
"entity_type": "Disease",
"text_name": "HD"
},
{
"begin_idx": "382",
"end_idx": "384",
"entity_id": "D006816",
"entity_type": "Disease",
"text_name": "HD"
},
{
"begin_idx": "433",
"end_idx": "435",
"entity_id": "D006816",
"entity_type": "Disease",
"text_name": "HD"
},
{
"begin_idx": "593",
"end_idx": "595",
"entity_id": "D006816",
"entity_type": "Disease",
"text_name": "HD"
},
{
"begin_idx": "17",
"end_idx": "22",
"entity_id": "2898",
"entity_type": "Gene",
"text_name": "GluR6"
},
{
"begin_idx": "338",
"end_idx": "343",
"entity_id": "2898",
"entity_type": "Gene",
"text_name": "GluR6"
},
{
"begin_idx": "668",
"end_idx": "673",
"entity_id": "2898",
"entity_type": "Gene",
"text_name": "GluR6"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "17",
"end_idx": "22",
"entity_id": "2898",
"entity_type": "Gene",
"text_name": "GluR6"
}
] | [
{
"begin_idx": "65",
"end_idx": "85",
"entity_id": "D006816",
"entity_type": "Disease",
"text_name": "Huntington's disease"
}
] | [
"GluR6"
] | [
"Huntington's disease"
] |
10522904 | Primary association of a TNF gene polymorphism with susceptibility to multiple sclerosis. | The associations of three promoter polymorphisms in the tumor necrosis factor (TNFA) gene have been studied in 238 patients and 324 control subjects. A significant correlation was found between MS susceptibility and the TNFA-376 polymorphism. This association was independent of the human leukocyte antigen (HLA) class II association and the combined inheritance of HLA-DRB1*1501 and the TNFA-376A allele more than additively increased susceptibility to MS. | [
{
"begin_idx": "70",
"end_idx": "88",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "multiple sclerosis"
},
{
"begin_idx": "284",
"end_idx": "286",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "MS"
},
{
"begin_idx": "544",
"end_idx": "546",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "MS"
},
{
"begin_idx": "456",
"end_idx": "464",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "HLA-DRB1"
},
{
"begin_idx": "379",
"end_idx": "411",
"entity_id": "3126",
"entity_type": "Gene",
"text_name": "leukocyte antigen (HLA) class II"
},
{
"begin_idx": "146",
"end_idx": "167",
"entity_id": "7124",
"entity_type": "Gene",
"text_name": "tumor necrosis factor"
},
{
"begin_idx": "169",
"end_idx": "173",
"entity_id": "7124",
"entity_type": "Gene",
"text_name": "TNFA"
},
{
"begin_idx": "310",
"end_idx": "314",
"entity_id": "7124",
"entity_type": "Gene",
"text_name": "TNFA"
},
{
"begin_idx": "478",
"end_idx": "482",
"entity_id": "7124",
"entity_type": "Gene",
"text_name": "TNFA"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "146",
"end_idx": "167",
"entity_id": "7124",
"entity_type": "Gene",
"text_name": "tumor necrosis factor"
},
{
"begin_idx": "379",
"end_idx": "411",
"entity_id": "3126",
"entity_type": "Gene",
"text_name": "leukocyte antigen (HLA) class II"
}
] | [
{
"begin_idx": "70",
"end_idx": "88",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "multiple sclerosis"
},
{
"begin_idx": "284",
"end_idx": "286",
"entity_id": "D009103",
"entity_type": "Disease",
"text_name": "MS"
}
] | [
"tumor necrosis factor",
"leukocyte antigen (HLA) class II"
] | [
"multiple sclerosis",
"MS"
] |
10522989 | A novel case of multiple endocrine neoplasia type 2A associated with two de novo mutations of the RET protooncogene. | We report a novel case of multiple endocrine neoplasia type 2A (MEN 2A) associated with two mutations of the protooncogene RET. One affects codon 634 and causes a cysteine to arginine substitution; the second at codon 640 causes an alanine to glycine substitution in the transmembrane region. The two mutations were present on the same RET allele and were detected in germline and tumor DNA. Both mutations were de novo, i.e. they were not found in the DNA of the parents or relatives. Immunohistochemical and RT-PCR analysis showed that the pheochromocytoma expressed calcitonin as well as both RET alleles. A cell line established from the tumor and propagated in culture sustained the expression of RET and calcitonin, as did the original pheochromocytoma. Because the patient presented with medullary thyroid carcinoma and pheochromocytoma without parathyroid gland involvement, we speculate that this clinical picture could be correlated with the two RET mutations and to the unusual calcitonin production. This is the first report of a MEN 2A case due to two mutations of the RET gene and associated with a calcitonin-producing pheochromocytoma. | [
{
"begin_idx": "498",
"end_idx": "503",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumor"
},
{
"begin_idx": "759",
"end_idx": "764",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumor"
},
{
"begin_idx": "969",
"end_idx": "980",
"entity_id": "D010282",
"entity_type": "Disease",
"text_name": "parathyroid"
},
{
"begin_idx": "659",
"end_idx": "675",
"entity_id": "D010673",
"entity_type": "Disease",
"text_name": "pheochromocytoma"
},
{
"begin_idx": "859",
"end_idx": "875",
"entity_id": "D010673",
"entity_type": "Disease",
"text_name": "pheochromocytoma"
},
{
"begin_idx": "944",
"end_idx": "960",
"entity_id": "D010673",
"entity_type": "Disease",
"text_name": "pheochromocytoma"
},
{
"begin_idx": "1251",
"end_idx": "1267",
"entity_id": "D010673",
"entity_type": "Disease",
"text_name": "pheochromocytoma"
},
{
"begin_idx": "912",
"end_idx": "939",
"entity_id": "D013964",
"entity_type": "Disease",
"text_name": "medullary thyroid carcinoma"
},
{
"begin_idx": "16",
"end_idx": "52",
"entity_id": "D018813",
"entity_type": "Disease",
"text_name": "multiple endocrine neoplasia type 2A"
},
{
"begin_idx": "143",
"end_idx": "179",
"entity_id": "D018813",
"entity_type": "Disease",
"text_name": "multiple endocrine neoplasia type 2A"
},
{
"begin_idx": "181",
"end_idx": "187",
"entity_id": "D018813",
"entity_type": "Disease",
"text_name": "MEN 2A"
},
{
"begin_idx": "1159",
"end_idx": "1165",
"entity_id": "D018813",
"entity_type": "Disease",
"text_name": "MEN 2A"
},
{
"begin_idx": "16",
"end_idx": "52",
"entity_id": "5979",
"entity_type": "Gene",
"text_name": "multiple endocrine neoplasia type 2A"
},
{
"begin_idx": "98",
"end_idx": "101",
"entity_id": "5979",
"entity_type": "Gene",
"text_name": "RET"
},
{
"begin_idx": "143",
"end_idx": "179",
"entity_id": "5979",
"entity_type": "Gene",
"text_name": "multiple endocrine neoplasia type 2A"
},
{
"begin_idx": "181",
"end_idx": "187",
"entity_id": "5979",
"entity_type": "Gene",
"text_name": "MEN 2A"
},
{
"begin_idx": "240",
"end_idx": "243",
"entity_id": "5979",
"entity_type": "Gene",
"text_name": "RET"
},
{
"begin_idx": "453",
"end_idx": "456",
"entity_id": "5979",
"entity_type": "Gene",
"text_name": "RET"
},
{
"begin_idx": "713",
"end_idx": "716",
"entity_id": "5979",
"entity_type": "Gene",
"text_name": "RET"
},
{
"begin_idx": "819",
"end_idx": "822",
"entity_id": "5979",
"entity_type": "Gene",
"text_name": "RET"
},
{
"begin_idx": "1073",
"end_idx": "1076",
"entity_id": "5979",
"entity_type": "Gene",
"text_name": "RET"
},
{
"begin_idx": "1159",
"end_idx": "1165",
"entity_id": "5979",
"entity_type": "Gene",
"text_name": "MEN 2A"
},
{
"begin_idx": "1199",
"end_idx": "1202",
"entity_id": "5979",
"entity_type": "Gene",
"text_name": "RET"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "16",
"end_idx": "52",
"entity_id": "5979",
"entity_type": "Gene",
"text_name": "multiple endocrine neoplasia type 2A"
},
{
"begin_idx": "713",
"end_idx": "716",
"entity_id": "5979",
"entity_type": "Gene",
"text_name": "RET"
}
] | [
{
"begin_idx": "16",
"end_idx": "52",
"entity_id": "D018813",
"entity_type": "Disease",
"text_name": "multiple endocrine neoplasia type 2A"
},
{
"begin_idx": "659",
"end_idx": "675",
"entity_id": "D010673",
"entity_type": "Disease",
"text_name": "pheochromocytoma"
}
] | [
"multiple endocrine neoplasia type 2A",
"RET"
] | [
"multiple endocrine neoplasia type 2A",
"pheochromocytoma"
] |
10523018 | Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. | Peroxisome proliferator-activated receptor-gamma (PPARgamma) is a nuclear receptor that regulates adipocyte differentiation. Variations in the PPARgamma gene may affect the function of the PPARgamma and, therefore, body adipocity. We investigated the frequencies of the Pro12Ala polymorphism in exon B and the silent CAC478CAT polymorphism in exon 6 of the PPARgamma gene and their effects on body weight, body composition, and energy expenditure in obese Finns. One hundred and seventy obese subjects [29 men and 141 women; body mass index (BMI), 35.7 +/- 3.8 kg/m2; age, 43 +/- 8 yr; mean +/- SD) participated in the study. The frequencies of the Ala12 allele in exon B and CAT478 allele in exon 6 were not significantly different between the obese and population-based control subjects (0.14 vs. 0.13 and 0.19 vs. 0.21, respectively). The polymorphisms were associated with increased BMI [Pro12Pro, 34.5 +/- 3.8; Pro12Ala, 34.8 +/- 3.1; Ala12Ala, 39.2 +/- 4.6 kg/m2 (P = 0.011); CAC478CAC, 34.5 +/- 3.8; CAC478CAT, 34.5 +/- 3.3; CAT478CAT, 37.7 +/- 4.1 kg/m2 (P = 0.046)]. In addition, the women with both Ala12Ala and CAT478CAT genotypes (n = 5) were significantly more obese compared with the women having both Pro12Pro and CAC478CAC genotypes (n = 85; BMI, 40.6 +/- 3.3 vs. 34.4 +/- 3.9 kg/m2; P = 0.001), and they had increased fat mass (46.8 +/- 9.1 vs. 36.8 +/- 7.5 kg; P = 0.005). In conclusion, the Pro12Ala and CAC478CAT polymorphisms in the PPARgamma gene are associated with severe overweight and increased fat mass among obese women. | [
{
"begin_idx": "123",
"end_idx": "128",
"entity_id": "D009765",
"entity_type": "Disease",
"text_name": "obese"
},
{
"begin_idx": "586",
"end_idx": "591",
"entity_id": "D009765",
"entity_type": "Disease",
"text_name": "obese"
},
{
"begin_idx": "623",
"end_idx": "628",
"entity_id": "D009765",
"entity_type": "Disease",
"text_name": "obese"
},
{
"begin_idx": "881",
"end_idx": "886",
"entity_id": "D009765",
"entity_type": "Disease",
"text_name": "obese"
},
{
"begin_idx": "1310",
"end_idx": "1315",
"entity_id": "D009765",
"entity_type": "Disease",
"text_name": "obese"
},
{
"begin_idx": "1672",
"end_idx": "1677",
"entity_id": "D009765",
"entity_type": "Disease",
"text_name": "obese"
},
{
"begin_idx": "25",
"end_idx": "73",
"entity_id": "5468",
"entity_type": "Gene",
"text_name": "peroxisome proliferator-activated receptor-gamma"
},
{
"begin_idx": "136",
"end_idx": "184",
"entity_id": "5468",
"entity_type": "Gene",
"text_name": "Peroxisome proliferator-activated receptor-gamma"
},
{
"begin_idx": "186",
"end_idx": "195",
"entity_id": "5468",
"entity_type": "Gene",
"text_name": "PPARgamma"
},
{
"begin_idx": "279",
"end_idx": "288",
"entity_id": "5468",
"entity_type": "Gene",
"text_name": "PPARgamma"
},
{
"begin_idx": "325",
"end_idx": "334",
"entity_id": "5468",
"entity_type": "Gene",
"text_name": "PPARgamma"
},
{
"begin_idx": "493",
"end_idx": "502",
"entity_id": "5468",
"entity_type": "Gene",
"text_name": "PPARgamma"
},
{
"begin_idx": "1590",
"end_idx": "1599",
"entity_id": "5468",
"entity_type": "Gene",
"text_name": "PPARgamma"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "25",
"end_idx": "73",
"entity_id": "5468",
"entity_type": "Gene",
"text_name": "peroxisome proliferator-activated receptor-gamma"
}
] | [
{
"begin_idx": "123",
"end_idx": "128",
"entity_id": "D009765",
"entity_type": "Disease",
"text_name": "obese"
}
] | [
"peroxisome proliferator-activated receptor-gamma"
] | [
"obese"
] |
10523339 | Mutants of 11beta-hydroxysteroid dehydrogenase (11-HSD2) with partial activity: improved correlations between genotype and biochemical phenotype in apparent mineralocorticoid excess. | Mutations in the kidney isozyme of human 11-hydroxysteroid dehydrogenase (11-HSD2) cause apparent mineralocorticoid excess, an autosomal recessive form of familial hypertension. We studied 4 patients with AME, identifying 4 novel and 3 previously reported mutations in the HSD11B2 (HSD11K) gene. Point mutations causing amino acid substitutions were introduced into a pCMV5/11HSD2 expression construct and expressed in mammalian CHOP cells. Mutations L179R and R208H abolished activity in whole cells. Mutants S180F, A237V, and A328V had 19%, 72%, and 25%, respectively, of the activity of the wild-type enzyme in whole cells when cortisol was used as the substrate and 80%, 140%, and 55%, respectively, of wild-type activity when corticosterone was used as the substrate. However, these mutant proteins were only 0.6% to 5.7% as active as the wild-type enzyme in cell lysates, suggesting that these mutations alter stability of the enzyme. In regression analyses of all AME patients with published genotypes, several biochemical and clinical parameters were highly correlated with mutant enzymatic activity, demonstrated in whole cells, when cortisol was used as the substrate. These included the ratio of urinary cortisone to cortisol metabolites (R(2)=0.648, P<0.0001), age at presentation (R(2)=0.614, P<0.0001), and birth weight (R(2)=0.576, P=0.0004). Approximately 5% conversion of cortisol to cortisone is predicted in subjects with mutations that completely inactivate HSD11B2, suggesting that a low level of enzymatic activity is mediated by another enzyme, possibly 11-HSD1. | [
{
"begin_idx": "157",
"end_idx": "181",
"entity_id": "C537422",
"entity_type": "Disease",
"text_name": "mineralocorticoid excess"
},
{
"begin_idx": "281",
"end_idx": "305",
"entity_id": "C537422",
"entity_type": "Disease",
"text_name": "mineralocorticoid excess"
},
{
"begin_idx": "338",
"end_idx": "359",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "familial hypertension"
},
{
"begin_idx": "456",
"end_idx": "463",
"entity_id": "3291",
"entity_type": "Gene",
"text_name": "HSD11B2"
},
{
"begin_idx": "465",
"end_idx": "471",
"entity_id": "3291",
"entity_type": "Gene",
"text_name": "HSD11K"
},
{
"begin_idx": "1661",
"end_idx": "1668",
"entity_id": "3291",
"entity_type": "Gene",
"text_name": "HSD11B2"
}
] | [
"Yes",
"No"
] | [
false,
false
] | [
{
"begin_idx": "456",
"end_idx": "463",
"entity_id": "3291",
"entity_type": "Gene",
"text_name": "HSD11B2"
},
{
"begin_idx": "1661",
"end_idx": "1668",
"entity_id": "3291",
"entity_type": "Gene",
"text_name": "HSD11B2"
}
] | [
{
"begin_idx": "157",
"end_idx": "181",
"entity_id": "C537422",
"entity_type": "Disease",
"text_name": "mineralocorticoid excess"
},
{
"begin_idx": "338",
"end_idx": "359",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "familial hypertension"
}
] | [
"HSD11B2",
"HSD11B2"
] | [
"mineralocorticoid excess",
"familial hypertension"
] |
10526905 | Delayed recovery of hypertension after single dose losartan in angiotensin II-infused conscious rats. | OBJECTIVE: In a conscious unrestrained rat model, it takes approximately 1 week for angiotensin II to increase blood pressure to maximum levels. We investigated the time required for hypertension to fully recover after acute angiotensin II receptor blockade in this angiotensin II dependent hypertensive model. DESIGN: Conscious unrestrained rats (n = 8) infused with 10 ng/kg per min angiotensin II for 21 days received losartan (10 mg/kg) on day 17 of angiotensin II infusion. Mean arterial pressure (MAP) and heart rate were monitored continuously. The acute pressor response to 50 ng/kg per min angiotensin II was monitored for 2 h on days 15, 17, 18, 19 and 20 of angiotensin II infusion. Plasma renin concentration (PRC) was measured daily. RESULTS: Angiotensin II increased MAP acutely by 26 +/- 2 mmHg and by a further 23 +/- 4 mmHg between days 4 and 8. Losartan acutely reduced MAP by 75 +/- 2 mmHg; 24 h later MAP had partially recovered but remained suppressed by 47 +/- 3 mmHg. MAP had not fully recovered 4 days later. Some 2 h after losartan, the acute pressor response to angiotensin II had fallen from 24 +/- 2 mmHg to zero. This recovered to 13 +/- 5 and 28 +/- 2 mmHg 24 and 48 h post losartan. After losartan PRC rose from 0.1 +/- 0.05 to above 1 ng/ml per h for less than 24 h. CONCLUSION: A single dose of losartan reverses both the fast and slow pressor effects of continuous angiotensin II infusions. While losartan is metabolized, the fast vasoconstrictor effect recovers quickly but the slow pressor effect takes almost a week to build up again to maximum levels. Since the slow pressor effect is mediated via the AT1 receptor, any means of blocking the renin-angiotensin system is likely to keep blood pressure below maximum hypertensive levels for several days after the drug has disappeared from the circulation. | [
{
"begin_idx": "20",
"end_idx": "32",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertension"
},
{
"begin_idx": "285",
"end_idx": "297",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertension"
},
{
"begin_idx": "393",
"end_idx": "405",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertensive"
},
{
"begin_idx": "1854",
"end_idx": "1866",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertensive"
},
{
"begin_idx": "63",
"end_idx": "77",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "angiotensin II"
},
{
"begin_idx": "186",
"end_idx": "200",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "angiotensin II"
},
{
"begin_idx": "327",
"end_idx": "341",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "angiotensin II"
},
{
"begin_idx": "368",
"end_idx": "382",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "angiotensin II"
},
{
"begin_idx": "487",
"end_idx": "501",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "angiotensin II"
},
{
"begin_idx": "556",
"end_idx": "570",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "angiotensin II"
},
{
"begin_idx": "701",
"end_idx": "715",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "angiotensin II"
},
{
"begin_idx": "771",
"end_idx": "785",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "angiotensin II"
},
{
"begin_idx": "858",
"end_idx": "872",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "Angiotensin II"
},
{
"begin_idx": "1190",
"end_idx": "1204",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "angiotensin II"
},
{
"begin_idx": "1501",
"end_idx": "1515",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "angiotensin II"
},
{
"begin_idx": "803",
"end_idx": "808",
"entity_id": "5972",
"entity_type": "Gene",
"text_name": "renin"
},
{
"begin_idx": "1782",
"end_idx": "1787",
"entity_id": "5972",
"entity_type": "Gene",
"text_name": "renin"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "63",
"end_idx": "77",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "angiotensin II"
},
{
"begin_idx": "1782",
"end_idx": "1787",
"entity_id": "5972",
"entity_type": "Gene",
"text_name": "renin"
}
] | [
{
"begin_idx": "20",
"end_idx": "32",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertension"
},
{
"begin_idx": "20",
"end_idx": "32",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertension"
}
] | [
"angiotensin II",
"renin"
] | [
"hypertension",
"hypertension"
] |
10526907 | 825T allele of the G-protein beta3 subunit gene (GNB3) is associated with impaired left ventricular diastolic filling in essential hypertension. | OBJECTIVE: Recently, a novel C825T polymorphism in the gene (GNB3) encoding for the G-protein beta3 subunit was identified. The 825T allele is associated with the generation of a novel splice variant, enhanced intracellular signal transduction, and arterial hypertension. In this study, we investigated the impact of the 825T allele on left ventricular structure and function in mild to moderate essential hypertensive subjects. METHODS: In 34 white patients with established mild to moderate essential hypertension (World Health Organization stage I or II, mean age 52 +/- 9 years) genotype analysis of GNB3 C825T polymorphism, insertion/deletion polymorphism of the ACE gene and 1166 A/C polymorphism of the AT1 receptor gene was performed. In each patient, 24 h ambulatory blood pressure measurement (SpaceLabs 90207) and two-dimensional guided M-mode echocardiography combined with Doppler sonography were performed. RESULTS: In our homogenous study group, the GNB3 825T allele was not associated with casual and 24 h ambulatory blood pressure (CC versus TC/TT: 144 +/- 13/92 +/- 8 versus 151 +/- 14/97 +/- 7 and 143 +/- 11/92 +/- 7 versus 150 +/- 16/ 96 +/- 9 mmHg, respectively) or parameters of left ventricular structure (relative wall thickness: CC versus TC/TT, 0.48 +/- 0.1 versus 0.46 +/- 0.1; left ventricular mass: CC versus TC/TT, 281 +/- 65 versus 299 +/- 80 g). However, transmitral flow variables reflecting left ventricular diastolic filling were impaired in patients expressing the TC/TT genotype (ratio of peak late (A) to early (E) velocities: CC versus TC/TT, 0.95 +/- 0.24 versus 1.2 +/- 0.26, P< 0.02; velocity time integrals A/E: CC versus TC/TT, 0.57 +/- 0.16 versus 0.76 +/- 0.23, P< 0.01) while all co-variables such as age, body mass index, ambulatory blood pressure, heart rate and end-diastolic volume were similar between the two groups. If patients were stratified according to the I/D polymorphism of the ACE gene and the A1166C polymorphism of the AT1 receptor gene, no differences in blood pressure, left ventricular structure or systolic and diastolic function of the left ventricle were found between different genotypes. CONCLUSION: The GNB3 825T allele was associated with impaired left ventricular diastolic filling in hypertensive subjects in this study. Since alterations in left ventricular filling have been identified as an early marker of hypertensive heart disease, the GNB3 C825T polymorphism may influence cardiac adaptation to increased afterload. | [
{
"begin_idx": "121",
"end_idx": "143",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "essential hypertension"
},
{
"begin_idx": "403",
"end_idx": "415",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertension"
},
{
"begin_idx": "551",
"end_idx": "563",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertensive"
},
{
"begin_idx": "638",
"end_idx": "660",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "essential hypertension"
},
{
"begin_idx": "2406",
"end_idx": "2418",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertensive"
},
{
"begin_idx": "2532",
"end_idx": "2558",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertensive heart disease"
},
{
"begin_idx": "74",
"end_idx": "117",
"entity_id": "D018487",
"entity_type": "Disease",
"text_name": "impaired left ventricular diastolic filling"
},
{
"begin_idx": "2359",
"end_idx": "2402",
"entity_id": "D018487",
"entity_type": "Disease",
"text_name": "impaired left ventricular diastolic filling"
},
{
"begin_idx": "813",
"end_idx": "816",
"entity_id": "1636",
"entity_type": "Gene",
"text_name": "ACE"
},
{
"begin_idx": "2085",
"end_idx": "2088",
"entity_id": "1636",
"entity_type": "Gene",
"text_name": "ACE"
},
{
"begin_idx": "19",
"end_idx": "34",
"entity_id": "2784",
"entity_type": "Gene",
"text_name": "G-protein beta3"
},
{
"begin_idx": "49",
"end_idx": "53",
"entity_id": "2784",
"entity_type": "Gene",
"text_name": "GNB3"
},
{
"begin_idx": "206",
"end_idx": "210",
"entity_id": "2784",
"entity_type": "Gene",
"text_name": "GNB3"
},
{
"begin_idx": "229",
"end_idx": "244",
"entity_id": "2784",
"entity_type": "Gene",
"text_name": "G-protein beta3"
},
{
"begin_idx": "749",
"end_idx": "753",
"entity_id": "2784",
"entity_type": "Gene",
"text_name": "GNB3"
},
{
"begin_idx": "1110",
"end_idx": "1114",
"entity_id": "2784",
"entity_type": "Gene",
"text_name": "GNB3"
},
{
"begin_idx": "2322",
"end_idx": "2326",
"entity_id": "2784",
"entity_type": "Gene",
"text_name": "GNB3"
},
{
"begin_idx": "2564",
"end_idx": "2568",
"entity_id": "2784",
"entity_type": "Gene",
"text_name": "GNB3"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "19",
"end_idx": "34",
"entity_id": "2784",
"entity_type": "Gene",
"text_name": "G-protein beta3"
},
{
"begin_idx": "813",
"end_idx": "816",
"entity_id": "1636",
"entity_type": "Gene",
"text_name": "ACE"
}
] | [
{
"begin_idx": "2532",
"end_idx": "2558",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertensive heart disease"
},
{
"begin_idx": "2532",
"end_idx": "2558",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertensive heart disease"
}
] | [
"G-protein beta3",
"ACE"
] | [
"hypertensive heart disease",
"hypertensive heart disease"
] |
10528858 | Unreported RSK2 missense mutation in two male sibs with an unusually mild form of Coffin-Lowry syndrome. | An unreported missense mutation of the ribosomal S6 kinase 2 (RSK2) gene has been identified in two male sibs with a mild form of Coffin-Lowry syndrome (CLS) inherited from their healthy mother. They exhibit transient severe hypotonia, macrocephaly, delay in closure of the fontanelles, normal gait, and mild mental retardation, associated in the first sib with transient autistic behaviour. Some dysmorphic features of CLS (in particular forearm fullness and tapering fingers) and many atypical findings (some of which were reminiscent of FG syndrome) were observed as well. The moderate phenotypic expression of this mutation extends the CLS phenotype to include less severe mental retardation and minor, hitherto unreported signs. The missense mutation identified may be less deleterious than those previously described. As this mutation occurs in a protein domain with no predicted function, it could be responsible for a conformational change affecting the protein catalytic function, since a non-polar amino acid is replaced by a charged residue. | [
{
"begin_idx": "645",
"end_idx": "656",
"entity_id": "C537923",
"entity_type": "Disease",
"text_name": "FG syndrome"
},
{
"begin_idx": "502",
"end_idx": "521",
"entity_id": "D000013",
"entity_type": "Disease",
"text_name": "dysmorphic features"
},
{
"begin_idx": "477",
"end_idx": "495",
"entity_id": "D001321",
"entity_type": "Disease",
"text_name": "autistic behaviour"
},
{
"begin_idx": "414",
"end_idx": "432",
"entity_id": "D008607",
"entity_type": "Disease",
"text_name": "mental retardation"
},
{
"begin_idx": "782",
"end_idx": "800",
"entity_id": "D008607",
"entity_type": "Disease",
"text_name": "mental retardation"
},
{
"begin_idx": "330",
"end_idx": "339",
"entity_id": "D009123",
"entity_type": "Disease",
"text_name": "hypotonia"
},
{
"begin_idx": "82",
"end_idx": "103",
"entity_id": "D038921",
"entity_type": "Disease",
"text_name": "Coffin-Lowry syndrome"
},
{
"begin_idx": "235",
"end_idx": "256",
"entity_id": "D038921",
"entity_type": "Disease",
"text_name": "Coffin-Lowry syndrome"
},
{
"begin_idx": "258",
"end_idx": "261",
"entity_id": "D038921",
"entity_type": "Disease",
"text_name": "CLS"
},
{
"begin_idx": "525",
"end_idx": "528",
"entity_id": "D038921",
"entity_type": "Disease",
"text_name": "CLS"
},
{
"begin_idx": "745",
"end_idx": "748",
"entity_id": "D038921",
"entity_type": "Disease",
"text_name": "CLS"
},
{
"begin_idx": "341",
"end_idx": "353",
"entity_id": "D058627",
"entity_type": "Disease",
"text_name": "macrocephaly"
},
{
"begin_idx": "11",
"end_idx": "15",
"entity_id": "6197",
"entity_type": "Gene",
"text_name": "RSK2"
},
{
"begin_idx": "144",
"end_idx": "165",
"entity_id": "6197",
"entity_type": "Gene",
"text_name": "ribosomal S6 kinase 2"
},
{
"begin_idx": "167",
"end_idx": "171",
"entity_id": "6197",
"entity_type": "Gene",
"text_name": "RSK2"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "144",
"end_idx": "165",
"entity_id": "6197",
"entity_type": "Gene",
"text_name": "ribosomal S6 kinase 2"
},
{
"begin_idx": "167",
"end_idx": "171",
"entity_id": "6197",
"entity_type": "Gene",
"text_name": "RSK2"
}
] | [
{
"begin_idx": "82",
"end_idx": "103",
"entity_id": "D038921",
"entity_type": "Disease",
"text_name": "Coffin-Lowry syndrome"
},
{
"begin_idx": "782",
"end_idx": "800",
"entity_id": "D008607",
"entity_type": "Disease",
"text_name": "mental retardation"
}
] | [
"ribosomal S6 kinase 2",
"RSK2"
] | [
"Coffin-Lowry syndrome",
"mental retardation"
] |
10533030 | Two distinct phenotypes caused by two different missense mutations in the same codon of the VHL gene. | We have identified a family segregating von Hippel-Lindau (VHL) disease with a previously unreported T547A mutation in exon 1 of the VHL gene that causes a Tyr112 to Asn missense alteration in the protein. The mutation was identified by nucleotide sequencing and confirmed by restriction enzyme digestion. The mutation cosegregated with the disease in all five tested affected individuals from the extended family. The family consists of more than 100 at-risk individuals over seven generations. To date, we have identified 13 affected individuals of whom seven have had renal cell carcinoma and one has had a pheochromocytoma. No other case of a neuroendocrine tumor of the pancreas or adrenal gland (pheochromocytoma) was found or recognized retrospectively. Other manifestations in this family include retinal angioma and hemangioblastoma of the central nervous system. We also found the T547A mutation in three asymptomatic members of the family, ages 12, 19, and 20. Another mutation, T547C, which causes Tyr112 to His, has been seen at the same position and has been associated with VHL type 2A (pheochromocytoma, but no renal cell carcinoma) in two families with a total of 22 affected individuals [Chen F, Slife L, Kishida T, Mulvihill J, Tisherman SE, Zbar B, 1996: J Med Genet 33:716-717]. Thus, different amino acid changes at the same position can cause very distinct clinical phenotypes. It will be interesting to elucidate the functional differences that underlie the different phenotypes. | [
{
"begin_idx": "673",
"end_idx": "693",
"entity_id": "D002292",
"entity_type": "Disease",
"text_name": "renal cell carcinoma"
},
{
"begin_idx": "1229",
"end_idx": "1249",
"entity_id": "D002292",
"entity_type": "Disease",
"text_name": "renal cell carcinoma"
},
{
"begin_idx": "92",
"end_idx": "95",
"entity_id": "D006623",
"entity_type": "Disease",
"text_name": "VHL"
},
{
"begin_idx": "142",
"end_idx": "173",
"entity_id": "D006623",
"entity_type": "Disease",
"text_name": "von Hippel-Lindau (VHL) disease"
},
{
"begin_idx": "235",
"end_idx": "238",
"entity_id": "D006623",
"entity_type": "Disease",
"text_name": "VHL"
},
{
"begin_idx": "1191",
"end_idx": "1202",
"entity_id": "D006623",
"entity_type": "Disease",
"text_name": "VHL type 2A"
},
{
"begin_idx": "712",
"end_idx": "728",
"entity_id": "D010673",
"entity_type": "Disease",
"text_name": "pheochromocytoma"
},
{
"begin_idx": "804",
"end_idx": "820",
"entity_id": "D010673",
"entity_type": "Disease",
"text_name": "pheochromocytoma"
},
{
"begin_idx": "1204",
"end_idx": "1220",
"entity_id": "D010673",
"entity_type": "Disease",
"text_name": "pheochromocytoma"
},
{
"begin_idx": "907",
"end_idx": "922",
"entity_id": "D012173",
"entity_type": "Disease",
"text_name": "retinal angioma"
},
{
"begin_idx": "927",
"end_idx": "943",
"entity_id": "D018325",
"entity_type": "Disease",
"text_name": "hemangioblastoma"
},
{
"begin_idx": "749",
"end_idx": "785",
"entity_id": "D018358",
"entity_type": "Disease",
"text_name": "neuroendocrine tumor of the pancreas"
},
{
"begin_idx": "92",
"end_idx": "95",
"entity_id": "7428",
"entity_type": "Gene",
"text_name": "VHL"
},
{
"begin_idx": "161",
"end_idx": "164",
"entity_id": "7428",
"entity_type": "Gene",
"text_name": "VHL"
},
{
"begin_idx": "235",
"end_idx": "238",
"entity_id": "7428",
"entity_type": "Gene",
"text_name": "VHL"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "92",
"end_idx": "95",
"entity_id": "7428",
"entity_type": "Gene",
"text_name": "VHL"
},
{
"begin_idx": "235",
"end_idx": "238",
"entity_id": "7428",
"entity_type": "Gene",
"text_name": "VHL"
}
] | [
{
"begin_idx": "142",
"end_idx": "173",
"entity_id": "D006623",
"entity_type": "Disease",
"text_name": "von Hippel-Lindau (VHL) disease"
},
{
"begin_idx": "712",
"end_idx": "728",
"entity_id": "D010673",
"entity_type": "Disease",
"text_name": "pheochromocytoma"
}
] | [
"VHL",
"VHL"
] | [
"von Hippel-Lindau (VHL) disease",
"pheochromocytoma"
] |
10533863 | Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. | BACKGROUND: A low concentration of HDL cholesterol is the most common lipoprotein abnormality in patients with premature atherosclerosis. We have shown that Tangier disease, a rare and severe form of HDL deficiency characterised by a biochemical defect in cellular cholesterol efflux, is caused by mutations in the ATP-binding-cassette (ABC1) gene. This gene codes for the cholesterol-efflux regulatory protein (CERP). We investigated the presence of mutations in this gene in patients with familial HDL deficiency. METHODS: Three French-Canadian families and one Dutch family with familial HDL deficiency were studied. Fibroblasts from the proband of each family were defective in cellular cholesterol efflux. Genomic DNA of each proband was used for mutation detection with primers flanking each exon of the ABC1 gene, and for sequencing of the entire coding region of the gene. PCR and restriction-fragment length polymorphism assays specific to each mutation were used to investigate segregation of the mutation in each family, and to test for absence of the mutation in DNA from normal controls. FINDINGS: A different mutation was detected in ABC1 in each family studied. Each mutation either created a stop codon predicted to result in truncation of CERP, or altered a conserved aminoacid residue. Each mutation segregated with low concentrations of HDL-cholesterol in the family, and was not observed in more than 500 control chromosomes tested. INTERPRETATION: These data show that mutations in ABC1 are the major cause of familial HDL deficiency associated with defective cholesterol efflux, and that CERP has an essential role in the formation of HDL. Our findings highlight the potential of modulation of ABC1 as a new route for increasing HDL concentrations. | [
{
"begin_idx": "159",
"end_idx": "182",
"entity_id": "D004194",
"entity_type": "Disease",
"text_name": "lipoprotein abnormality"
},
{
"begin_idx": "246",
"end_idx": "261",
"entity_id": "D013631",
"entity_type": "Disease",
"text_name": "Tangier disease"
},
{
"begin_idx": "210",
"end_idx": "225",
"entity_id": "D050197",
"entity_type": "Disease",
"text_name": "atherosclerosis"
},
{
"begin_idx": "30",
"end_idx": "53",
"entity_id": "D052456",
"entity_type": "Disease",
"text_name": "familial HDL deficiency"
},
{
"begin_idx": "289",
"end_idx": "303",
"entity_id": "D052456",
"entity_type": "Disease",
"text_name": "HDL deficiency"
},
{
"begin_idx": "580",
"end_idx": "603",
"entity_id": "D052456",
"entity_type": "Disease",
"text_name": "familial HDL deficiency"
},
{
"begin_idx": "671",
"end_idx": "694",
"entity_id": "D052456",
"entity_type": "Disease",
"text_name": "familial HDL deficiency"
},
{
"begin_idx": "1620",
"end_idx": "1643",
"entity_id": "D052456",
"entity_type": "Disease",
"text_name": "familial HDL deficiency"
},
{
"begin_idx": "17",
"end_idx": "21",
"entity_id": "19",
"entity_type": "Gene",
"text_name": "ABC1"
},
{
"begin_idx": "426",
"end_idx": "430",
"entity_id": "19",
"entity_type": "Gene",
"text_name": "ABC1"
},
{
"begin_idx": "462",
"end_idx": "499",
"entity_id": "19",
"entity_type": "Gene",
"text_name": "cholesterol-efflux regulatory protein"
},
{
"begin_idx": "501",
"end_idx": "505",
"entity_id": "19",
"entity_type": "Gene",
"text_name": "CERP"
},
{
"begin_idx": "899",
"end_idx": "903",
"entity_id": "19",
"entity_type": "Gene",
"text_name": "ABC1"
},
{
"begin_idx": "1237",
"end_idx": "1241",
"entity_id": "19",
"entity_type": "Gene",
"text_name": "ABC1"
},
{
"begin_idx": "1345",
"end_idx": "1349",
"entity_id": "19",
"entity_type": "Gene",
"text_name": "CERP"
},
{
"begin_idx": "1592",
"end_idx": "1596",
"entity_id": "19",
"entity_type": "Gene",
"text_name": "ABC1"
},
{
"begin_idx": "1699",
"end_idx": "1703",
"entity_id": "19",
"entity_type": "Gene",
"text_name": "CERP"
},
{
"begin_idx": "1805",
"end_idx": "1809",
"entity_id": "19",
"entity_type": "Gene",
"text_name": "ABC1"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "462",
"end_idx": "499",
"entity_id": "19",
"entity_type": "Gene",
"text_name": "cholesterol-efflux regulatory protein"
},
{
"begin_idx": "1345",
"end_idx": "1349",
"entity_id": "19",
"entity_type": "Gene",
"text_name": "CERP"
}
] | [
{
"begin_idx": "30",
"end_idx": "53",
"entity_id": "D052456",
"entity_type": "Disease",
"text_name": "familial HDL deficiency"
},
{
"begin_idx": "246",
"end_idx": "261",
"entity_id": "D013631",
"entity_type": "Disease",
"text_name": "Tangier disease"
}
] | [
"cholesterol-efflux regulatory protein",
"CERP"
] | [
"familial HDL deficiency",
"Tangier disease"
] |
10534569 | Germline mutations in the MEN1 gene: creation of a new splice acceptor site and insertion of 7 intron nucleotides into the mRNA. | The MEN1 tumor predisposition syndrome is caused by mutations in the MEN1 gene on human chromosome 11q13. We screened MEN1 gene exons 1-10 and flanking intron sequences from four different MEN1 families for mutations. In three families, heterozygous germline mutations within the exons were found, two of these representing novel mutations. In another family, all clinically affected members were heterozygous for a point mutation Gright curved arrow A within intron 4. Sequence analysis of cDNA from lymphocytes of the affected patients revealed that the intron mutation created a new acceptor splice site, leading to the inclusion of 7 bp of intronic sequence into the mRNA. The resulting frameshift generates a premature stop in codon 271. Intron borders should thus be screened for mutations in MEN1 diagnostics and cDNA sequence analysis is helpful in identifying pathophysiological consequences of intron mutations. | [
{
"begin_idx": "133",
"end_idx": "167",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "MEN1 tumor predisposition syndrome"
},
{
"begin_idx": "26",
"end_idx": "30",
"entity_id": "D018761",
"entity_type": "Disease",
"text_name": "MEN1"
},
{
"begin_idx": "198",
"end_idx": "202",
"entity_id": "D018761",
"entity_type": "Disease",
"text_name": "MEN1"
},
{
"begin_idx": "247",
"end_idx": "251",
"entity_id": "D018761",
"entity_type": "Disease",
"text_name": "MEN1"
},
{
"begin_idx": "318",
"end_idx": "322",
"entity_id": "D018761",
"entity_type": "Disease",
"text_name": "MEN1"
},
{
"begin_idx": "928",
"end_idx": "932",
"entity_id": "D018761",
"entity_type": "Disease",
"text_name": "MEN1"
},
{
"begin_idx": "26",
"end_idx": "30",
"entity_id": "4221",
"entity_type": "Gene",
"text_name": "MEN1"
},
{
"begin_idx": "198",
"end_idx": "202",
"entity_id": "4221",
"entity_type": "Gene",
"text_name": "MEN1"
},
{
"begin_idx": "247",
"end_idx": "251",
"entity_id": "4221",
"entity_type": "Gene",
"text_name": "MEN1"
},
{
"begin_idx": "318",
"end_idx": "322",
"entity_id": "4221",
"entity_type": "Gene",
"text_name": "MEN1"
},
{
"begin_idx": "928",
"end_idx": "932",
"entity_id": "4221",
"entity_type": "Gene",
"text_name": "MEN1"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "26",
"end_idx": "30",
"entity_id": "4221",
"entity_type": "Gene",
"text_name": "MEN1"
},
{
"begin_idx": "26",
"end_idx": "30",
"entity_id": "4221",
"entity_type": "Gene",
"text_name": "MEN1"
}
] | [
{
"begin_idx": "26",
"end_idx": "30",
"entity_id": "D018761",
"entity_type": "Disease",
"text_name": "MEN1"
},
{
"begin_idx": "133",
"end_idx": "167",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "MEN1 tumor predisposition syndrome"
}
] | [
"MEN1",
"MEN1"
] | [
"MEN1",
"MEN1 tumor predisposition syndrome"
] |
10541004 | Association between a promoter polymorphism in the dopamine D2 receptor gene and schizophrenia. | Genetic factors and dopamine receptor dysfunction have been implicated in the pathophysiology of schizophrenia. Recently, an association between a putative functional promoter polymorphism (-141C Ins/Del) in the dopamine D2 receptor gene and schizophrenia was reported. We investigated unrelated Swedish schizophrenic patients (n = 129) and control subjects (n = 179) for the same polymorphism. Similarly to a previous Japanese report, the - 141C Del allele frequency was significantly lower in patients than controls (chi2=4.4, 1 df, p<0.05; odds ratio 0.49, 95% confidence interval 0.26-0.91). The present and previous results may indicate that the -141C Ins/Del dopamine D2 receptor gene polymorphism affects susceptibility to schizophrenia. | [
{
"begin_idx": "81",
"end_idx": "94",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
},
{
"begin_idx": "193",
"end_idx": "206",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
},
{
"begin_idx": "338",
"end_idx": "351",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
},
{
"begin_idx": "400",
"end_idx": "413",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenic"
},
{
"begin_idx": "826",
"end_idx": "839",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
},
{
"begin_idx": "51",
"end_idx": "71",
"entity_id": "1813",
"entity_type": "Gene",
"text_name": "dopamine D2 receptor"
},
{
"begin_idx": "308",
"end_idx": "328",
"entity_id": "1813",
"entity_type": "Gene",
"text_name": "dopamine D2 receptor"
},
{
"begin_idx": "761",
"end_idx": "781",
"entity_id": "1813",
"entity_type": "Gene",
"text_name": "dopamine D2 receptor"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "51",
"end_idx": "71",
"entity_id": "1813",
"entity_type": "Gene",
"text_name": "dopamine D2 receptor"
}
] | [
{
"begin_idx": "81",
"end_idx": "94",
"entity_id": "D012559",
"entity_type": "Disease",
"text_name": "schizophrenia"
}
] | [
"dopamine D2 receptor"
] | [
"schizophrenia"
] |
10544227 | Mutation analysis in patients of Mediterranean descent with Wilson disease: identification of 19 novel mutations. | In this study, we report further results of mutation analysis of the ATP7B gene in Wilson disease (WD) patients of Mediterranean origin. A total of 136 WD chromosomes, 73 of which were of Italian, 43 of Turkish, 18 of Sardinian, and two of Spanish origin, were analysed and the mutation characterised in 84.5% of them. We found 50 different mutations of which 19 are novel, including three nonsense, one frameshift, and 15 missense mutations. The mutations detected were rare and mostly found in the compound heterozygous state together with other mutations and only rarely in homozygosity. Most of these mutations lie in the transmembrane and ATP binding loop regions. These data expand our knowledge of both the structure-function relationships of the WD protein and the molecular pathology of WD, thus improving our capability of prevention and genetic counselling. | [
{
"begin_idx": "60",
"end_idx": "74",
"entity_id": "D006527",
"entity_type": "Disease",
"text_name": "Wilson disease"
},
{
"begin_idx": "197",
"end_idx": "211",
"entity_id": "D006527",
"entity_type": "Disease",
"text_name": "Wilson disease"
},
{
"begin_idx": "213",
"end_idx": "215",
"entity_id": "D006527",
"entity_type": "Disease",
"text_name": "WD"
},
{
"begin_idx": "266",
"end_idx": "268",
"entity_id": "D006527",
"entity_type": "Disease",
"text_name": "WD"
},
{
"begin_idx": "868",
"end_idx": "870",
"entity_id": "D006527",
"entity_type": "Disease",
"text_name": "WD"
},
{
"begin_idx": "910",
"end_idx": "912",
"entity_id": "D006527",
"entity_type": "Disease",
"text_name": "WD"
},
{
"begin_idx": "183",
"end_idx": "188",
"entity_id": "540",
"entity_type": "Gene",
"text_name": "ATP7B"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "183",
"end_idx": "188",
"entity_id": "540",
"entity_type": "Gene",
"text_name": "ATP7B"
}
] | [
{
"begin_idx": "60",
"end_idx": "74",
"entity_id": "D006527",
"entity_type": "Disease",
"text_name": "Wilson disease"
}
] | [
"ATP7B"
] | [
"Wilson disease"
] |
10544909 | A flow cytometric assay of platelet activation marker P-selectin (CD62P) distinguishes heparin-induced thrombocytopenia (HIT) from HIT with thrombosis (HITT). | Heparin induced thrombocytopenia (HIT) is a well-known complication of heparin administration but usually resolves upon discontinuation without sequelae. However, a small proportion of HIT patients develop thrombosis associated with HIT, designated as HITT, which is often life-threatening and may lead to gangrene and amputations. Existing laboratory methods of confirming HIT/HITT do not distinguish between HIT and HITT. We report a flow cytometric assay of platelet activation marker CD62P to distinguish the effects of addition of HIT vs. HITT plasma to normal blood. Briefly, normal whole blood was incubated with platelet-poor plasma from 12 patients with HITT, 30 with HIT, and 65 controls, in presence and absence of heparin, and expression of CD62P was assayed by flow cytometry. When the ratios of fluorescent intensity of CD62P with heparin divided by that without heparin were compared, HITT plasma induced significantly higher ratios than HIT plasma (HITT ratios approximately 2.5 vs. HIT ratios approximately 1.2; p <0.001). Eleven of 12 HITT patients were positive by this test but only 5 of 30 HIT patients were positive (p <0.0005). In a case of HIT with silent thrombosis, this assay gave a positive results prior to clinically evident thrombosis. In conclusion, this method distinguishes HITT from HIT and may be clinically useful in the detection of HITT, allowing early intervention for preventing catastrophic thrombosis. | [
{
"begin_idx": "103",
"end_idx": "119",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "thrombocytopenia"
},
{
"begin_idx": "121",
"end_idx": "124",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "HIT"
},
{
"begin_idx": "131",
"end_idx": "150",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "HIT with thrombosis"
},
{
"begin_idx": "152",
"end_idx": "156",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "HITT"
},
{
"begin_idx": "159",
"end_idx": "191",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "Heparin induced thrombocytopenia"
},
{
"begin_idx": "193",
"end_idx": "196",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "HIT"
},
{
"begin_idx": "344",
"end_idx": "347",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "HIT"
},
{
"begin_idx": "392",
"end_idx": "395",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "HIT"
},
{
"begin_idx": "411",
"end_idx": "415",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "HITT"
},
{
"begin_idx": "533",
"end_idx": "536",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "HIT"
},
{
"begin_idx": "537",
"end_idx": "541",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "HITT"
},
{
"begin_idx": "569",
"end_idx": "572",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "HIT"
},
{
"begin_idx": "577",
"end_idx": "581",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "HITT"
},
{
"begin_idx": "695",
"end_idx": "698",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "HIT"
},
{
"begin_idx": "703",
"end_idx": "707",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "HITT"
},
{
"begin_idx": "822",
"end_idx": "826",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "HITT"
},
{
"begin_idx": "836",
"end_idx": "839",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "HIT"
},
{
"begin_idx": "1059",
"end_idx": "1063",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "HITT"
},
{
"begin_idx": "1112",
"end_idx": "1115",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "HIT"
},
{
"begin_idx": "1124",
"end_idx": "1128",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "HITT"
},
{
"begin_idx": "1158",
"end_idx": "1161",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "HIT"
},
{
"begin_idx": "1212",
"end_idx": "1216",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "HITT"
},
{
"begin_idx": "1270",
"end_idx": "1273",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "HIT"
},
{
"begin_idx": "1323",
"end_idx": "1326",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "HIT"
},
{
"begin_idx": "1467",
"end_idx": "1471",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "HITT"
},
{
"begin_idx": "1477",
"end_idx": "1480",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "HIT"
},
{
"begin_idx": "1530",
"end_idx": "1534",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "HITT"
},
{
"begin_idx": "365",
"end_idx": "375",
"entity_id": "D013927",
"entity_type": "Disease",
"text_name": "thrombosis"
},
{
"begin_idx": "1339",
"end_idx": "1349",
"entity_id": "D013927",
"entity_type": "Disease",
"text_name": "thrombosis"
},
{
"begin_idx": "1414",
"end_idx": "1424",
"entity_id": "D013927",
"entity_type": "Disease",
"text_name": "thrombosis"
},
{
"begin_idx": "1592",
"end_idx": "1602",
"entity_id": "D013927",
"entity_type": "Disease",
"text_name": "thrombosis"
},
{
"begin_idx": "54",
"end_idx": "64",
"entity_id": "6403",
"entity_type": "Gene",
"text_name": "P-selectin"
},
{
"begin_idx": "66",
"end_idx": "71",
"entity_id": "6403",
"entity_type": "Gene",
"text_name": "CD62P"
},
{
"begin_idx": "647",
"end_idx": "652",
"entity_id": "6403",
"entity_type": "Gene",
"text_name": "CD62P"
},
{
"begin_idx": "912",
"end_idx": "917",
"entity_id": "6403",
"entity_type": "Gene",
"text_name": "CD62P"
},
{
"begin_idx": "993",
"end_idx": "998",
"entity_id": "6403",
"entity_type": "Gene",
"text_name": "CD62P"
}
] | [
"Yes",
"No"
] | [
false,
true
] | [
{
"begin_idx": "54",
"end_idx": "64",
"entity_id": "6403",
"entity_type": "Gene",
"text_name": "P-selectin"
},
{
"begin_idx": "66",
"end_idx": "71",
"entity_id": "6403",
"entity_type": "Gene",
"text_name": "CD62P"
}
] | [
{
"begin_idx": "365",
"end_idx": "375",
"entity_id": "D013927",
"entity_type": "Disease",
"text_name": "thrombosis"
},
{
"begin_idx": "822",
"end_idx": "826",
"entity_id": "D013921",
"entity_type": "Disease",
"text_name": "HITT"
}
] | [
"P-selectin",
"CD62P"
] | [
"thrombosis",
"HITT"
] |
10544980 | Norrie disease and exudative vitreoretinopathy in families with affected female carriers. | PURPOSE: Norrie disease (ND) is a rare X-linked recessive disorder characterized by congenital blindness, which is often associated with sensorineural hearing loss and mental retardation. X-linked familial exudative vitreoretinopathy (FEVR) is a hereditary disorder characterized by an abnormality of the peripheral retina and is not associated with systemic diseases. X-linked recessive disorders generally do not affect females. Here we show that female carriers can be associated with manifestation of an X-linked disorder. METHODS: A four-generation family with an affected female, and a history of congenital blindness and hearing loss, was identified through the pro-band. A second family, with a full-term female infant, was evaluated through ophthalmic examinations and found to exhibit ocular features, such as retinal folds, retinal detachment and peripheral exudates. Peripheral blood specimens were collected from several affected and unaffected family members. DNA was extracted and analyzed by single-strand conformation polymorphism (SSCP) following polymerase chain reaction (PCR) amplification of the exons of the Norrie disease gene. The amplified products were sequenced by the dideoxy chain termination method. RESULTS: In an X-linked four-generation family, a novel missense (A118D) mutation in the third exon of the Norrie disease gene, was identified. The mutation was transmitted through three generations and cosegregated with the disease. The affected maternal grandmother and the unaffected mother carried the same mutation in one of their alleles. In an unrelated sporadic family, a heterozygous missense mutation (C96Y) was identified in the third exon of the Norrie disease gene in an affected individual. Analysis of exon-1 and 2 of the Norrie disease gene did not reveal any additional sequence alterations in these families. The mutations were not detected in the unaffected family members and the 116 normal unrelated controls, suggesting that they are likely to be the pathogenic mutations. CONCLUSIONS: The results further strengthen the proposal that X-linked disorders can occur in female carriers, due likely to an unfavorable X-inactivation. | [
{
"begin_idx": "174",
"end_idx": "194",
"entity_id": "C536600",
"entity_type": "Disease",
"text_name": "congenital blindness"
},
{
"begin_idx": "693",
"end_idx": "713",
"entity_id": "C536600",
"entity_type": "Disease",
"text_name": "congenital blindness"
},
{
"begin_idx": "0",
"end_idx": "14",
"entity_id": "C537849",
"entity_type": "Disease",
"text_name": "Norrie disease"
},
{
"begin_idx": "99",
"end_idx": "113",
"entity_id": "C537849",
"entity_type": "Disease",
"text_name": "Norrie disease"
},
{
"begin_idx": "115",
"end_idx": "117",
"entity_id": "C537849",
"entity_type": "Disease",
"text_name": "ND"
},
{
"begin_idx": "1221",
"end_idx": "1235",
"entity_id": "C537849",
"entity_type": "Disease",
"text_name": "Norrie disease"
},
{
"begin_idx": "1428",
"end_idx": "1442",
"entity_id": "C537849",
"entity_type": "Disease",
"text_name": "Norrie disease"
},
{
"begin_idx": "1779",
"end_idx": "1793",
"entity_id": "C537849",
"entity_type": "Disease",
"text_name": "Norrie disease"
},
{
"begin_idx": "1858",
"end_idx": "1872",
"entity_id": "C537849",
"entity_type": "Disease",
"text_name": "Norrie disease"
},
{
"begin_idx": "287",
"end_idx": "323",
"entity_id": "C580083",
"entity_type": "Disease",
"text_name": "familial exudative vitreoretinopathy"
},
{
"begin_idx": "325",
"end_idx": "329",
"entity_id": "C580083",
"entity_type": "Disease",
"text_name": "FEVR"
},
{
"begin_idx": "227",
"end_idx": "253",
"entity_id": "D006319",
"entity_type": "Disease",
"text_name": "sensorineural hearing loss"
},
{
"begin_idx": "258",
"end_idx": "276",
"entity_id": "D008607",
"entity_type": "Disease",
"text_name": "mental retardation"
},
{
"begin_idx": "925",
"end_idx": "943",
"entity_id": "D012163",
"entity_type": "Disease",
"text_name": "retinal detachment"
},
{
"begin_idx": "29",
"end_idx": "46",
"entity_id": "D018630",
"entity_type": "Disease",
"text_name": "vitreoretinopathy"
},
{
"begin_idx": "336",
"end_idx": "355",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "hereditary disorder"
},
{
"begin_idx": "718",
"end_idx": "730",
"entity_id": "D034381",
"entity_type": "Disease",
"text_name": "hearing loss"
},
{
"begin_idx": "440",
"end_idx": "457",
"entity_id": "D034721",
"entity_type": "Disease",
"text_name": "systemic diseases"
},
{
"begin_idx": "129",
"end_idx": "156",
"entity_id": "D040181",
"entity_type": "Disease",
"text_name": "X-linked recessive disorder"
},
{
"begin_idx": "459",
"end_idx": "487",
"entity_id": "D040181",
"entity_type": "Disease",
"text_name": "X-linked recessive disorders"
},
{
"begin_idx": "598",
"end_idx": "615",
"entity_id": "D040181",
"entity_type": "Disease",
"text_name": "X-linked disorder"
},
{
"begin_idx": "2178",
"end_idx": "2196",
"entity_id": "D040181",
"entity_type": "Disease",
"text_name": "X-linked disorders"
},
{
"begin_idx": "325",
"end_idx": "329",
"entity_id": "4693",
"entity_type": "Gene",
"text_name": "FEVR"
}
] | [
"Yes",
"No"
] | [
false,
false
] | [
{
"begin_idx": "325",
"end_idx": "329",
"entity_id": "4693",
"entity_type": "Gene",
"text_name": "FEVR"
},
{
"begin_idx": "325",
"end_idx": "329",
"entity_id": "4693",
"entity_type": "Gene",
"text_name": "FEVR"
}
] | [
{
"begin_idx": "0",
"end_idx": "14",
"entity_id": "C537849",
"entity_type": "Disease",
"text_name": "Norrie disease"
},
{
"begin_idx": "598",
"end_idx": "615",
"entity_id": "D040181",
"entity_type": "Disease",
"text_name": "X-linked disorder"
}
] | [
"FEVR",
"FEVR"
] | [
"Norrie disease",
"X-linked disorder"
] |
10545420 | Strain-dependent lung tumor formation in mice transplacentally exposed to 3-methylcholanthrene and post-natally exposed to butylated hydroxytoluene. | The carcinogenic effects of in utero exposure to 3-methylcholanthrene (MC) have been demonstrated in the tumor-resistant C57BL/6 (B6) and DBA (D2) strains of mice. In this study, we determined the effects of in utero exposure to MC in BALB/c mice, a strain which demonstrates greater susceptibility to lung tumor induction, and compared our findings with those previously found in [D2xB6D2F(1)]F(2) mice. In addition, we assessed the molecular pathogenesis of the chemically induced tumors and examined the effects of the putative lung tumor promoter butylated hydroxytoluene (BHT) in BALB/c mice. BALB/c mice were treated on day 17 of gestation with 5, 15 or 45 mg/kg MC and 6 weeks after birth with BHT for 6 consecutive weeks. Mice were killed at 6 months of age. Ki-ras, p16Ink4a and p19ARF gene loci were amplified from paraffin-embedded lung tumor tissue and screened for the presence of point mutations via allele-specific oligonucleotide hybridization and single strand conformation polymorphism (SSCP) analyses. Ki-ras point mutations were found in 56% (20/36) of BALB/c lung tumors, with 33% (2/6) of the hyperplasias, 58% (10/19) of the adenomas and 73% (8/11) of the carcinomas exhibiting point mutations at this gene locus. Similar incidences of Ki-ras mutations were previously found following transplacental exposure of [D2xB6D2F(1)]F(2) mice to MC and treatment of adult A/J mice with urethane. Interestingly, a strain-dependent difference was observed in the mutational spectrum. Sixty-two and 38% of the lung lesions in BALB/c mice exhibited G-->C and G-->T transversions, respectively, in contrast to the 13 and 84% incidences previously observed in [D2xB6D2F(1)]F(2) mice. SSCP analysis of the tumor suppressor gene p16Ink4a showed a 6% incidence of point mutations, consistent with that found in [D2xB6D2F(1)]F(2) mice. No mutations were found in exon 1beta of the p19ARF gene of either strain. BHT, a lung tumor promoter in adult mice, had no statistically significant effects on either tumor incidence, tumor multiplicity or the mutational spectrum produced in the Ki-ras gene by in utero MC treatment. However, though not significant, there was an observable trend in increased tumor multiplicity in mice co-treated with BHT. These data demonstrate the transplacental carcinogenic effect of MC in BALB/c mice and show that mutagenic damage to Ki-ras is a critical early event mediating murine lung tumorigenesis in both the tumor-sensitive and tumor-resistant strains. Unlike what occurs when adult BALB/c mice are treated with MC, BHT does not appear to significantly promote the formation of lung tumors following transplacental exposure to MC, possibly due to the rapid growth and cell proliferation in the developing organism. Strain-dependent differences in the Ki-ras mutational spectrum may be associated with their differential susceptibility to lung tumor initiation. | [
{
"begin_idx": "1297",
"end_idx": "1305",
"entity_id": "D000236",
"entity_type": "Disease",
"text_name": "adenomas"
},
{
"begin_idx": "1328",
"end_idx": "1338",
"entity_id": "D002277",
"entity_type": "Disease",
"text_name": "carcinomas"
},
{
"begin_idx": "1264",
"end_idx": "1276",
"entity_id": "D006965",
"entity_type": "Disease",
"text_name": "hyperplasias"
},
{
"begin_idx": "0",
"end_idx": "27",
"entity_id": "D008175",
"entity_type": "Disease",
"text_name": "Strain-dependent lung tumor"
},
{
"begin_idx": "451",
"end_idx": "461",
"entity_id": "D008175",
"entity_type": "Disease",
"text_name": "lung tumor"
},
{
"begin_idx": "680",
"end_idx": "690",
"entity_id": "D008175",
"entity_type": "Disease",
"text_name": "lung tumor"
},
{
"begin_idx": "992",
"end_idx": "1002",
"entity_id": "D008175",
"entity_type": "Disease",
"text_name": "lung tumor"
},
{
"begin_idx": "1229",
"end_idx": "1240",
"entity_id": "D008175",
"entity_type": "Disease",
"text_name": "lung tumors"
},
{
"begin_idx": "2072",
"end_idx": "2082",
"entity_id": "D008175",
"entity_type": "Disease",
"text_name": "lung tumor"
},
{
"begin_idx": "2767",
"end_idx": "2778",
"entity_id": "D008175",
"entity_type": "Disease",
"text_name": "lung tumors"
},
{
"begin_idx": "3027",
"end_idx": "3037",
"entity_id": "D008175",
"entity_type": "Disease",
"text_name": "lung tumor"
},
{
"begin_idx": "254",
"end_idx": "259",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumor"
},
{
"begin_idx": "632",
"end_idx": "638",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumors"
},
{
"begin_idx": "1863",
"end_idx": "1868",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumor"
},
{
"begin_idx": "2158",
"end_idx": "2163",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumor"
},
{
"begin_idx": "2175",
"end_idx": "2180",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumor"
},
{
"begin_idx": "2351",
"end_idx": "2356",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumor"
},
{
"begin_idx": "2597",
"end_idx": "2622",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumor-sensitive and tumor"
},
{
"begin_idx": "924",
"end_idx": "932",
"entity_id": "1029",
"entity_type": "Gene",
"text_name": "p16Ink4a"
},
{
"begin_idx": "937",
"end_idx": "943",
"entity_id": "1029",
"entity_type": "Gene",
"text_name": "p19ARF"
},
{
"begin_idx": "1885",
"end_idx": "1893",
"entity_id": "1029",
"entity_type": "Gene",
"text_name": "p16Ink4a"
},
{
"begin_idx": "2035",
"end_idx": "2041",
"entity_id": "1029",
"entity_type": "Gene",
"text_name": "p19ARF"
},
{
"begin_idx": "916",
"end_idx": "922",
"entity_id": "3845",
"entity_type": "Gene",
"text_name": "Ki-ras"
},
{
"begin_idx": "1170",
"end_idx": "1176",
"entity_id": "3845",
"entity_type": "Gene",
"text_name": "Ki-ras"
},
{
"begin_idx": "1408",
"end_idx": "1414",
"entity_id": "3845",
"entity_type": "Gene",
"text_name": "Ki-ras"
},
{
"begin_idx": "2237",
"end_idx": "2243",
"entity_id": "3845",
"entity_type": "Gene",
"text_name": "Ki-ras"
},
{
"begin_idx": "2516",
"end_idx": "2522",
"entity_id": "3845",
"entity_type": "Gene",
"text_name": "Ki-ras"
},
{
"begin_idx": "2940",
"end_idx": "2946",
"entity_id": "3845",
"entity_type": "Gene",
"text_name": "Ki-ras"
}
] | [
"Yes",
"Yes",
"No",
"No"
] | [
true,
false,
true,
true
] | [
{
"begin_idx": "916",
"end_idx": "922",
"entity_id": "3845",
"entity_type": "Gene",
"text_name": "Ki-ras"
},
{
"begin_idx": "916",
"end_idx": "922",
"entity_id": "3845",
"entity_type": "Gene",
"text_name": "Ki-ras"
},
{
"begin_idx": "2940",
"end_idx": "2946",
"entity_id": "3845",
"entity_type": "Gene",
"text_name": "Ki-ras"
},
{
"begin_idx": "2237",
"end_idx": "2243",
"entity_id": "3845",
"entity_type": "Gene",
"text_name": "Ki-ras"
}
] | [
{
"begin_idx": "0",
"end_idx": "27",
"entity_id": "D008175",
"entity_type": "Disease",
"text_name": "Strain-dependent lung tumor"
},
{
"begin_idx": "1297",
"end_idx": "1305",
"entity_id": "D000236",
"entity_type": "Disease",
"text_name": "adenomas"
},
{
"begin_idx": "254",
"end_idx": "259",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumor"
},
{
"begin_idx": "2351",
"end_idx": "2356",
"entity_id": "D009369",
"entity_type": "Disease",
"text_name": "tumor"
}
] | [
"Ki-ras",
"Ki-ras",
"Ki-ras",
"Ki-ras"
] | [
"Strain-dependent lung tumor",
"adenomas",
"tumor",
"tumor"
] |
10545596 | Expression analysis of four endoglin missense mutations suggests that haploinsufficiency is the predominant mechanism for hereditary hemorrhagic telangiectasia type 1. | ENDOGLIN codes for a homodimeric membrane glycoprotein that interacts with receptors for members of the TGF-beta superfamily and is the gene mutated in the autosomal dominant vascular disorder hereditary hemorrhagic telangiectasia type 1 (HHT1). We recently demonstrated that functional endoglin was expressed at half levels on human umbilical vein endothelial cells (HUVECs) and peripheral blood activated monocytes from HHT1 patients. Two types of mutant protein were previously analyzed, the product of an exon 3 skip which was expressed as a transient intracellular species and prematurely truncated proteins that were undetectable in patient samples. Here we report the analysis of four proteins resulting from point mutations, with missense codons G52V and C53R in exon 2, W149C in exon 4 and L221P in exon 5. Metabolic labeling of activated monocytes from confirmed, clinically affected patients revealed reduced expression of fully processed normal endoglin in all cases. Pulse-chase analysis with HUVECs from a newborn with the C53R substitution indicated that mutant endoglin remained intracellular as a precursor form and did not impair processing of the normal protein. Biotinylation of cell surface proteins, metabolic labeling and pulse-chase analysis revealed that none of the engineered missense mutants was significantly expressed at the surface of COS-1 transfectants. Thus, these four HHT1 missense mutations lead to transient intracellular species which cannot interfere with normal endoglin function. These data suggest that haploinsufficiency, leading to reduced levels of one of the major surface glyco-proteins of vascular endothelium, is the predominant mechanism underlying the HHT1 phenotype. | [
{
"begin_idx": "122",
"end_idx": "166",
"entity_id": "D013683",
"entity_type": "Disease",
"text_name": "hereditary hemorrhagic telangiectasia type 1"
},
{
"begin_idx": "361",
"end_idx": "405",
"entity_id": "D013683",
"entity_type": "Disease",
"text_name": "hereditary hemorrhagic telangiectasia type 1"
},
{
"begin_idx": "407",
"end_idx": "411",
"entity_id": "D013683",
"entity_type": "Disease",
"text_name": "HHT1"
},
{
"begin_idx": "590",
"end_idx": "594",
"entity_id": "D013683",
"entity_type": "Disease",
"text_name": "HHT1"
},
{
"begin_idx": "1572",
"end_idx": "1576",
"entity_id": "D013683",
"entity_type": "Disease",
"text_name": "HHT1"
},
{
"begin_idx": "1872",
"end_idx": "1876",
"entity_id": "D013683",
"entity_type": "Disease",
"text_name": "HHT1"
},
{
"begin_idx": "324",
"end_idx": "360",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal dominant vascular disorder"
},
{
"begin_idx": "28",
"end_idx": "36",
"entity_id": "2022",
"entity_type": "Gene",
"text_name": "endoglin"
},
{
"begin_idx": "168",
"end_idx": "176",
"entity_id": "2022",
"entity_type": "Gene",
"text_name": "ENDOGLIN"
},
{
"begin_idx": "455",
"end_idx": "463",
"entity_id": "2022",
"entity_type": "Gene",
"text_name": "endoglin"
},
{
"begin_idx": "1125",
"end_idx": "1133",
"entity_id": "2022",
"entity_type": "Gene",
"text_name": "endoglin"
},
{
"begin_idx": "1245",
"end_idx": "1253",
"entity_id": "2022",
"entity_type": "Gene",
"text_name": "endoglin"
},
{
"begin_idx": "1671",
"end_idx": "1679",
"entity_id": "2022",
"entity_type": "Gene",
"text_name": "endoglin"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "28",
"end_idx": "36",
"entity_id": "2022",
"entity_type": "Gene",
"text_name": "endoglin"
},
{
"begin_idx": "455",
"end_idx": "463",
"entity_id": "2022",
"entity_type": "Gene",
"text_name": "endoglin"
}
] | [
{
"begin_idx": "122",
"end_idx": "166",
"entity_id": "D013683",
"entity_type": "Disease",
"text_name": "hereditary hemorrhagic telangiectasia type 1"
},
{
"begin_idx": "324",
"end_idx": "360",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal dominant vascular disorder"
}
] | [
"endoglin",
"endoglin"
] | [
"hereditary hemorrhagic telangiectasia type 1",
"autosomal dominant vascular disorder"
] |
10545605 | Genetic epidemiology of the carnitine transporter OCTN2 gene in a Japanese population and phenotypic characterization in Japanese pedigrees with primary systemic carnitine deficiency. | Serum free-carnitine levels were determined in 973 unrelated white collar workers in Akita, Japan. Fourteen of these participants consistently had serum free-carnitine levels below the fifth percentile (28 microM for females and 38 microM for males). The OCTN2 (organic cation transporter) gene was sequenced for these 14 subjects, for 22 subjects whose carnitine levels were below the fifth percentile in the first screening but were normal in the second measurement and in 69 individuals with normal carnitine levels for two separate measurements. Polymorphic sequences defined three major haplotypes with equal frequency. Mutations were identified in nine subjects with low carnitine levels: Trp132X (three individuals), Ser467Cys (four), Trp283Cys (one) and Met179Leu (one). In vitro expression studies in HEK cells indicated that Ser467Cys and Trp283Cys, but not Met179Leu, significantly reduced L-carnitine uptake relative to the normal control. Trp132X and Ser467Cys were associated with specific haplotypes, suggesting a founder effect. A conservative estimate of the overall prevalence of heterozygotes was 1.01% in the Akita prefecture, Japan, giving an estimated incidence of primary systemic carnitine deficiency (MIM 212140) as 1 in 40 000 births. An echocardiographic study of the families of patients with primary carnitine deficiency revealed that the heterozygotes for OCTN2 mutations were predisposed to late onset benign cardiac hypertrophy (odds ratio 15.1, 95% CI 1.39-164) compared with the wild-types. Sequencing of DNA isolated from three deceased siblings (1.5-8 years) in two families retrospectively confirmed that all three deceased subjects were homozygous for the OCTN2 mutations. | [
{
"begin_idx": "145",
"end_idx": "182",
"entity_id": "C536778",
"entity_type": "Disease",
"text_name": "primary systemic carnitine deficiency"
},
{
"begin_idx": "1371",
"end_idx": "1408",
"entity_id": "C536778",
"entity_type": "Disease",
"text_name": "primary systemic carnitine deficiency"
},
{
"begin_idx": "1513",
"end_idx": "1533",
"entity_id": "C536778",
"entity_type": "Disease",
"text_name": "carnitine deficiency"
},
{
"begin_idx": "1617",
"end_idx": "1643",
"entity_id": "D006332",
"entity_type": "Disease",
"text_name": "benign cardiac hypertrophy"
},
{
"begin_idx": "245",
"end_idx": "274",
"entity_id": "D056784",
"entity_type": "Disease",
"text_name": "white collar workers in Akita"
},
{
"begin_idx": "50",
"end_idx": "55",
"entity_id": "6584",
"entity_type": "Gene",
"text_name": "OCTN2"
},
{
"begin_idx": "439",
"end_idx": "444",
"entity_id": "6584",
"entity_type": "Gene",
"text_name": "OCTN2"
},
{
"begin_idx": "1570",
"end_idx": "1575",
"entity_id": "6584",
"entity_type": "Gene",
"text_name": "OCTN2"
},
{
"begin_idx": "1878",
"end_idx": "1883",
"entity_id": "6584",
"entity_type": "Gene",
"text_name": "OCTN2"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "50",
"end_idx": "55",
"entity_id": "6584",
"entity_type": "Gene",
"text_name": "OCTN2"
},
{
"begin_idx": "1570",
"end_idx": "1575",
"entity_id": "6584",
"entity_type": "Gene",
"text_name": "OCTN2"
}
] | [
{
"begin_idx": "145",
"end_idx": "182",
"entity_id": "C536778",
"entity_type": "Disease",
"text_name": "primary systemic carnitine deficiency"
},
{
"begin_idx": "1617",
"end_idx": "1643",
"entity_id": "D006332",
"entity_type": "Disease",
"text_name": "benign cardiac hypertrophy"
}
] | [
"OCTN2",
"OCTN2"
] | [
"primary systemic carnitine deficiency",
"benign cardiac hypertrophy"
] |
10545612 | CBFA1 mutation analysis and functional correlation with phenotypic variability in cleidocranial dysplasia. | Cleidocranial dysplasia (CCD) is a dominantly inherited skeletal dysplasia caused by mutations in the osteoblast-specific transcription factor CBFA1. To correlate CBFA1 mutations in different functional domains with the CCD clinical spectrum, we studied 26 independent cases of CCD and a total of 16 new mutations were identified in 17 families. The majority of mutations were de novo missense mutations that affected conserved residues in the runt domain and completely abolished both DNA binding and transactivation of a reporter gene. These, and mutations which result in premature termination in the runt domain, produced a classic CCD phenotype by abolishing transactivation of the mutant protein with consequent haploinsufficiency. We further identified three putative hypomorphic mutations (R391X, T200A and 90insC) which result in a clinical spectrum including classic and mild CCD, as well as an isolated dental phenotype characterized by delayed eruption of permanent teeth. Functional studies show that two of the three mutations were hypomorphic in nature and two were associated with significant intrafamilial variable expressivity, including isolated dental anomalies without the skeletal features of CCD. Together these data show that variable loss of function due to alterations in the runt and PST domains of CBFA1 may give rise to clinical variability, including classic CCD, mild CCD and isolated primary dental anomalies. | [
{
"begin_idx": "82",
"end_idx": "105",
"entity_id": "D002973",
"entity_type": "Disease",
"text_name": "cleidocranial dysplasia"
},
{
"begin_idx": "107",
"end_idx": "130",
"entity_id": "D002973",
"entity_type": "Disease",
"text_name": "Cleidocranial dysplasia"
},
{
"begin_idx": "132",
"end_idx": "135",
"entity_id": "D002973",
"entity_type": "Disease",
"text_name": "CCD"
},
{
"begin_idx": "327",
"end_idx": "330",
"entity_id": "D002973",
"entity_type": "Disease",
"text_name": "CCD"
},
{
"begin_idx": "385",
"end_idx": "388",
"entity_id": "D002973",
"entity_type": "Disease",
"text_name": "CCD"
},
{
"begin_idx": "743",
"end_idx": "746",
"entity_id": "D002973",
"entity_type": "Disease",
"text_name": "CCD"
},
{
"begin_idx": "993",
"end_idx": "996",
"entity_id": "D002973",
"entity_type": "Disease",
"text_name": "CCD"
},
{
"begin_idx": "1322",
"end_idx": "1325",
"entity_id": "D002973",
"entity_type": "Disease",
"text_name": "CCD"
},
{
"begin_idx": "1496",
"end_idx": "1499",
"entity_id": "D002973",
"entity_type": "Disease",
"text_name": "CCD"
},
{
"begin_idx": "1506",
"end_idx": "1509",
"entity_id": "D002973",
"entity_type": "Disease",
"text_name": "CCD"
},
{
"begin_idx": "1272",
"end_idx": "1288",
"entity_id": "D014071",
"entity_type": "Disease",
"text_name": "dental anomalies"
},
{
"begin_idx": "1523",
"end_idx": "1547",
"entity_id": "D014071",
"entity_type": "Disease",
"text_name": "primary dental anomalies"
},
{
"begin_idx": "153",
"end_idx": "181",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "inherited skeletal dysplasia"
},
{
"begin_idx": "0",
"end_idx": "5",
"entity_id": "860",
"entity_type": "Gene",
"text_name": "CBFA1"
},
{
"begin_idx": "250",
"end_idx": "255",
"entity_id": "860",
"entity_type": "Gene",
"text_name": "CBFA1"
},
{
"begin_idx": "270",
"end_idx": "275",
"entity_id": "860",
"entity_type": "Gene",
"text_name": "CBFA1"
},
{
"begin_idx": "1433",
"end_idx": "1438",
"entity_id": "860",
"entity_type": "Gene",
"text_name": "CBFA1"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "0",
"end_idx": "5",
"entity_id": "860",
"entity_type": "Gene",
"text_name": "CBFA1"
},
{
"begin_idx": "0",
"end_idx": "5",
"entity_id": "860",
"entity_type": "Gene",
"text_name": "CBFA1"
}
] | [
{
"begin_idx": "82",
"end_idx": "105",
"entity_id": "D002973",
"entity_type": "Disease",
"text_name": "cleidocranial dysplasia"
},
{
"begin_idx": "1523",
"end_idx": "1547",
"entity_id": "D014071",
"entity_type": "Disease",
"text_name": "primary dental anomalies"
}
] | [
"CBFA1",
"CBFA1"
] | [
"cleidocranial dysplasia",
"primary dental anomalies"
] |
10545953 | Perlecan is essential for cartilage and cephalic development. | Perlecan, a large, multi-domain, heparan sulfate proteoglycan originally identified in basement membrane, interacts with extracellular matrix proteins, growth factors and receptors, and influences cellular signalling. Perlecan is present in a variety of basement membranes and in other extracellular matrix structures. We have disrupted the gene encoding perlecan (Hspg2) in mice. Approximately 40% of Hspg2-/- mice died at embryonic day (E) 10.5 with defective cephalic development. The remaining Hspg2-/- mice died just after birth with skeletal dysplasia characterized by micromelia with broad and bowed long bones, narrow thorax and craniofacial abnormalities. Only 6% of Hspg2-/- mice developed both exencephaly and chondrodysplasia. Hspg2-/- cartilage showed severe disorganization of the columnar structures of chondrocytes and defective endochondral ossification. Hspg2-/- cartilage matrix contained reduced and disorganized collagen fibrils and glycosaminoglycans, suggesting that perlecan has an important role in matrix structure. In Hspg2-/- cartilage, proliferation of chondrocytes was reduced and the prehypertrophic zone was diminished. The abnormal phenotypes of the Hspg2-/- skeleton are similar to those of thanatophoric dysplasia (TD) type I, which is caused by activating mutations in FGFR3 (refs 7, 8, 9), and to those of Fgfr3 gain-of-function mice. Our findings suggest that these molecules affect similar signalling pathways. | [
{
"begin_idx": "601",
"end_idx": "619",
"entity_id": "C535662",
"entity_type": "Disease",
"text_name": "skeletal dysplasia"
},
{
"begin_idx": "767",
"end_idx": "778",
"entity_id": "D009436",
"entity_type": "Disease",
"text_name": "exencephaly"
},
{
"begin_idx": "783",
"end_idx": "799",
"entity_id": "D010009",
"entity_type": "Disease",
"text_name": "chondrodysplasia"
},
{
"begin_idx": "1287",
"end_idx": "1310",
"entity_id": "D013796",
"entity_type": "Disease",
"text_name": "thanatophoric dysplasia"
},
{
"begin_idx": "1312",
"end_idx": "1314",
"entity_id": "D013796",
"entity_type": "Disease",
"text_name": "TD"
},
{
"begin_idx": "699",
"end_idx": "725",
"entity_id": "D019465",
"entity_type": "Disease",
"text_name": "craniofacial abnormalities"
},
{
"begin_idx": "1367",
"end_idx": "1372",
"entity_id": "2261",
"entity_type": "Gene",
"text_name": "FGFR3"
},
{
"begin_idx": "1405",
"end_idx": "1410",
"entity_id": "2261",
"entity_type": "Gene",
"text_name": "Fgfr3"
},
{
"begin_idx": "427",
"end_idx": "432",
"entity_id": "3339",
"entity_type": "Gene",
"text_name": "Hspg2"
},
{
"begin_idx": "464",
"end_idx": "469",
"entity_id": "3339",
"entity_type": "Gene",
"text_name": "Hspg2"
},
{
"begin_idx": "560",
"end_idx": "565",
"entity_id": "3339",
"entity_type": "Gene",
"text_name": "Hspg2"
},
{
"begin_idx": "738",
"end_idx": "743",
"entity_id": "3339",
"entity_type": "Gene",
"text_name": "Hspg2"
},
{
"begin_idx": "801",
"end_idx": "806",
"entity_id": "3339",
"entity_type": "Gene",
"text_name": "Hspg2"
},
{
"begin_idx": "934",
"end_idx": "939",
"entity_id": "3339",
"entity_type": "Gene",
"text_name": "Hspg2"
},
{
"begin_idx": "1107",
"end_idx": "1112",
"entity_id": "3339",
"entity_type": "Gene",
"text_name": "Hspg2"
},
{
"begin_idx": "1245",
"end_idx": "1250",
"entity_id": "3339",
"entity_type": "Gene",
"text_name": "Hspg2"
}
] | [
"Yes",
"Yes",
"No",
"No"
] | [
true,
true,
true,
true
] | [
{
"begin_idx": "427",
"end_idx": "432",
"entity_id": "3339",
"entity_type": "Gene",
"text_name": "Hspg2"
},
{
"begin_idx": "427",
"end_idx": "432",
"entity_id": "3339",
"entity_type": "Gene",
"text_name": "Hspg2"
},
{
"begin_idx": "738",
"end_idx": "743",
"entity_id": "3339",
"entity_type": "Gene",
"text_name": "Hspg2"
},
{
"begin_idx": "1405",
"end_idx": "1410",
"entity_id": "2261",
"entity_type": "Gene",
"text_name": "Fgfr3"
}
] | [
{
"begin_idx": "783",
"end_idx": "799",
"entity_id": "D010009",
"entity_type": "Disease",
"text_name": "chondrodysplasia"
},
{
"begin_idx": "699",
"end_idx": "725",
"entity_id": "D019465",
"entity_type": "Disease",
"text_name": "craniofacial abnormalities"
},
{
"begin_idx": "1287",
"end_idx": "1310",
"entity_id": "D013796",
"entity_type": "Disease",
"text_name": "thanatophoric dysplasia"
},
{
"begin_idx": "1287",
"end_idx": "1310",
"entity_id": "D013796",
"entity_type": "Disease",
"text_name": "thanatophoric dysplasia"
}
] | [
"Hspg2",
"Hspg2",
"Hspg2",
"Fgfr3"
] | [
"chondrodysplasia",
"craniofacial abnormalities",
"thanatophoric dysplasia",
"thanatophoric dysplasia"
] |
10546209 | [T174M polymorphism of angiotensinogen gene in Moscow population is associated with hypertension]. | [
{
"begin_idx": "84",
"end_idx": "96",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertension"
},
{
"begin_idx": "23",
"end_idx": "38",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "angiotensinogen"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "23",
"end_idx": "38",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "angiotensinogen"
}
] | [
{
"begin_idx": "84",
"end_idx": "96",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertension"
}
] | [
"angiotensinogen"
] | [
"hypertension"
] |
|
10547078 | Overexpression of insulin-like growth factor-I in hearts of rats with isoproterenol-induced cardiac hypertrophy. | Increased levels of plasma catecholamine lead to cardiac hypertrophy via the alpha-, beta-adrenergic receptors, and partially, type 1 angiotensin II (AT1) receptor. However, it remains unclear whether other factors are involved in catecholamine-induced cardiac hypertrophy. We investigated the expression of insulin-like growth factor (IGF)-I in hearts of male Wistar rats infused with a beta-adrenergic agent, isoproterenol (ISO) (3 mg/kg/day), with or without an AT1-receptor antagonist, TCV-116 (10 mg/kg/day). Cardiac myocytes became hypertrophied 1 day after the beginning of ISO administration. ISO induced a biphasic increase of cardiac myocytes positive for IGF-I protein in the early and late phases of the study period, whereas IGF-I gene expression was upregulated only in the late phase by ISO. TCV- 116 abolished the upregulation of IGF-I gene and protein expression in the late phase in association with the regression of cardiac hypertrophy. These results suggest that ISO-induced cardiac hypertrophy is mediated, at least in part, by IGF-I, the expression of which is upregulated through the activation of AT1 receptor. | [
{
"begin_idx": "92",
"end_idx": "111",
"entity_id": "D006332",
"entity_type": "Disease",
"text_name": "cardiac hypertrophy"
},
{
"begin_idx": "162",
"end_idx": "181",
"entity_id": "D006332",
"entity_type": "Disease",
"text_name": "cardiac hypertrophy"
},
{
"begin_idx": "366",
"end_idx": "385",
"entity_id": "D006332",
"entity_type": "Disease",
"text_name": "cardiac hypertrophy"
},
{
"begin_idx": "1049",
"end_idx": "1068",
"entity_id": "D006332",
"entity_type": "Disease",
"text_name": "cardiac hypertrophy"
},
{
"begin_idx": "1109",
"end_idx": "1128",
"entity_id": "D006332",
"entity_type": "Disease",
"text_name": "cardiac hypertrophy"
},
{
"begin_idx": "421",
"end_idx": "455",
"entity_id": "3479",
"entity_type": "Gene",
"text_name": "insulin-like growth factor (IGF)-I"
},
{
"begin_idx": "779",
"end_idx": "784",
"entity_id": "3479",
"entity_type": "Gene",
"text_name": "IGF-I"
},
{
"begin_idx": "851",
"end_idx": "856",
"entity_id": "3479",
"entity_type": "Gene",
"text_name": "IGF-I"
},
{
"begin_idx": "959",
"end_idx": "964",
"entity_id": "3479",
"entity_type": "Gene",
"text_name": "IGF-I"
},
{
"begin_idx": "1163",
"end_idx": "1168",
"entity_id": "3479",
"entity_type": "Gene",
"text_name": "IGF-I"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "421",
"end_idx": "455",
"entity_id": "3479",
"entity_type": "Gene",
"text_name": "insulin-like growth factor (IGF)-I"
}
] | [
{
"begin_idx": "92",
"end_idx": "111",
"entity_id": "D006332",
"entity_type": "Disease",
"text_name": "cardiac hypertrophy"
}
] | [
"insulin-like growth factor (IGF)-I"
] | [
"cardiac hypertrophy"
] |
10547998 | [Molecular variants of the human angiotensinogen gene associated with essential hypertension]. | [
{
"begin_idx": "80",
"end_idx": "92",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertension"
},
{
"begin_idx": "33",
"end_idx": "48",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "angiotensinogen"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "33",
"end_idx": "48",
"entity_id": "183",
"entity_type": "Gene",
"text_name": "angiotensinogen"
}
] | [
{
"begin_idx": "80",
"end_idx": "92",
"entity_id": "D006973",
"entity_type": "Disease",
"text_name": "hypertension"
}
] | [
"angiotensinogen"
] | [
"hypertension"
] |
|
10548319 | Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. | Prostate cancer incidence, clinical presentation, and mortality rates vary among different ethnic groups. A genetic variant of CYP3A4, a gene involved in the oxidative deactivation of testosterone, has been associated recently with prostate cancer development in Caucasians. To further investigate this variant, we evaluated its genotype frequencies in different ethnic groups and its association with clinical presentation of prostate cancer in African Americans. CYP3A4 genotypes were assayed in healthy male Caucasian (n = 117), Hispanic (n = 121), African-American (n = 116), Chinese (n = 46), and Japanese (n = 34) volunteers using the TaqMan assay. The association between CYP3A4 genotype and prostate cancer presentation was determined in 174 affected African-American men. Genotype frequency of the CYP3A4 variant differed substantially across ethnic groups, with African Americans much more likely to carry one or two copies than any other group (two-sided P < 0.0001). Among African Americans, 46% (80 of 174) of men with prostate cancer were homozygous for the CYP3A4 variant, whereas only 28% (32 of 116) of African-American healthy volunteers were homozygous (two-sided P < 0.005). A consistent positive association was observed between being homozygous for the CYP3A4 variant in African-American prostate cancer patients and clinical characteristics. Men homozygous for the CYP3A4 variant were more likely to present with higher grade and stage of prostate cancer in a recessive model [odds ratio (OR), 1.7; 95% confidence interval (CI), 0.9-3.4]. This association was even stronger for men who were >65 years of age at diagnosis (n = 103; OR, 2.4; 95% CI, 1.1-5.4). In summary, the CYP3A4 genotype frequency in different ethnic groups broadly followed trends in prostate cancer incidence, presentation, and mortality in the United States. African-American prostate cancer patients had a higher frequency of being homozygous for the CYP3A4 variant than healthy African-American volunteers who were matched solely based on ethnicity. Among the patients, those who were homozygous for the CYP3A4 variant were more likely to present with clinically more advanced prostate cancer. | [
{
"begin_idx": "91",
"end_idx": "106",
"entity_id": "D011471",
"entity_type": "Disease",
"text_name": "prostate cancer"
},
{
"begin_idx": "117",
"end_idx": "132",
"entity_id": "D011471",
"entity_type": "Disease",
"text_name": "Prostate cancer"
},
{
"begin_idx": "349",
"end_idx": "364",
"entity_id": "D011471",
"entity_type": "Disease",
"text_name": "prostate cancer"
},
{
"begin_idx": "544",
"end_idx": "559",
"entity_id": "D011471",
"entity_type": "Disease",
"text_name": "prostate cancer"
},
{
"begin_idx": "816",
"end_idx": "831",
"entity_id": "D011471",
"entity_type": "Disease",
"text_name": "prostate cancer"
},
{
"begin_idx": "1149",
"end_idx": "1164",
"entity_id": "D011471",
"entity_type": "Disease",
"text_name": "prostate cancer"
},
{
"begin_idx": "1427",
"end_idx": "1442",
"entity_id": "D011471",
"entity_type": "Disease",
"text_name": "prostate cancer"
},
{
"begin_idx": "1579",
"end_idx": "1594",
"entity_id": "D011471",
"entity_type": "Disease",
"text_name": "prostate cancer"
},
{
"begin_idx": "1894",
"end_idx": "1909",
"entity_id": "D011471",
"entity_type": "Disease",
"text_name": "prostate cancer"
},
{
"begin_idx": "1988",
"end_idx": "2003",
"entity_id": "D011471",
"entity_type": "Disease",
"text_name": "prostate cancer"
},
{
"begin_idx": "2282",
"end_idx": "2306",
"entity_id": "D011471",
"entity_type": "Disease",
"text_name": "advanced prostate cancer"
},
{
"begin_idx": "22",
"end_idx": "28",
"entity_id": "1576",
"entity_type": "Gene",
"text_name": "CYP3A4"
},
{
"begin_idx": "244",
"end_idx": "250",
"entity_id": "1576",
"entity_type": "Gene",
"text_name": "CYP3A4"
},
{
"begin_idx": "582",
"end_idx": "588",
"entity_id": "1576",
"entity_type": "Gene",
"text_name": "CYP3A4"
},
{
"begin_idx": "796",
"end_idx": "802",
"entity_id": "1576",
"entity_type": "Gene",
"text_name": "CYP3A4"
},
{
"begin_idx": "924",
"end_idx": "930",
"entity_id": "1576",
"entity_type": "Gene",
"text_name": "CYP3A4"
},
{
"begin_idx": "1189",
"end_idx": "1195",
"entity_id": "1576",
"entity_type": "Gene",
"text_name": "CYP3A4"
},
{
"begin_idx": "1392",
"end_idx": "1398",
"entity_id": "1576",
"entity_type": "Gene",
"text_name": "CYP3A4"
},
{
"begin_idx": "1505",
"end_idx": "1511",
"entity_id": "1576",
"entity_type": "Gene",
"text_name": "CYP3A4"
},
{
"begin_idx": "1814",
"end_idx": "1820",
"entity_id": "1576",
"entity_type": "Gene",
"text_name": "CYP3A4"
},
{
"begin_idx": "2064",
"end_idx": "2070",
"entity_id": "1576",
"entity_type": "Gene",
"text_name": "CYP3A4"
},
{
"begin_idx": "2218",
"end_idx": "2224",
"entity_id": "1576",
"entity_type": "Gene",
"text_name": "CYP3A4"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "22",
"end_idx": "28",
"entity_id": "1576",
"entity_type": "Gene",
"text_name": "CYP3A4"
}
] | [
{
"begin_idx": "2282",
"end_idx": "2306",
"entity_id": "D011471",
"entity_type": "Disease",
"text_name": "advanced prostate cancer"
}
] | [
"CYP3A4"
] | [
"advanced prostate cancer"
] |
10549825 | The L392V mutation of presenilin 1 associated with autosomal dominant early-onset Alzheimer's disease alters the secondary structure of the hydrophilic loop. | Autosomal dominant early-onset Alzheimer's disease results mainly from mutations of the presenilin 1 (PSEN1) gene, which codes for an integral membrane protein of 467 amino acids. The hydrophilic loop (amino acids 263-407) of PSEN1, in which many pathogenic mutations have been localized, appears to be crucial for the protein function since it includes the binding domains to different PSEN1 partners. Using circular dichroism (CD) we analyzed the structural effects of the pathogenic L392V mutation and compared them with those of the E318G substitution. This study revealed that, the L392V mutation, in a phospholipidic medium which mimics the in vivo membrane environment, reduces the alpha helix content of the PSEN1 loop, whereas the E318G substitution, considered as a polymorphism, does not. These results suggest that the pathogenic effect of some PSEN1 mutations within the hydrophilic loop could be the alteration of the interaction to the different binding proteins through a disruption of the secondary structure. | [
{
"begin_idx": "82",
"end_idx": "101",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "Alzheimer's disease"
},
{
"begin_idx": "189",
"end_idx": "208",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "Alzheimer's disease"
},
{
"begin_idx": "22",
"end_idx": "34",
"entity_id": "5663",
"entity_type": "Gene",
"text_name": "presenilin 1"
},
{
"begin_idx": "246",
"end_idx": "258",
"entity_id": "5663",
"entity_type": "Gene",
"text_name": "presenilin 1"
},
{
"begin_idx": "260",
"end_idx": "265",
"entity_id": "5663",
"entity_type": "Gene",
"text_name": "PSEN1"
},
{
"begin_idx": "384",
"end_idx": "389",
"entity_id": "5663",
"entity_type": "Gene",
"text_name": "PSEN1"
},
{
"begin_idx": "545",
"end_idx": "550",
"entity_id": "5663",
"entity_type": "Gene",
"text_name": "PSEN1"
},
{
"begin_idx": "874",
"end_idx": "879",
"entity_id": "5663",
"entity_type": "Gene",
"text_name": "PSEN1"
},
{
"begin_idx": "1015",
"end_idx": "1020",
"entity_id": "5663",
"entity_type": "Gene",
"text_name": "PSEN1"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "22",
"end_idx": "34",
"entity_id": "5663",
"entity_type": "Gene",
"text_name": "presenilin 1"
}
] | [
{
"begin_idx": "82",
"end_idx": "101",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "Alzheimer's disease"
}
] | [
"presenilin 1"
] | [
"Alzheimer's disease"
] |
10551543 | Association study between high and low activity polymorphism of catechol-O-methyltransferase gene and alcoholism. | Catechol-O-methyltransferase (COMT) is a key modulator of dopaminergic and noradrenergic neurotransmission. There is a functional polymorphism of the COMT gene, Val108Met in the soluble form of the enzyme (Val158Met in the membrane-bound form). Involvement of the dopaminergic systems in alcoholism has been suggested in mice and humans. We examined associations between this polymorphism and alcoholism in 175 Japanese alcoholics and 354 age- and gender-matched Japanese controls. No significant difference in the allelic distributions in alcoholics and controls and no significant associations between antisocial behaviors in alcoholics and this polymorphism were observed. Therefore, the COMT gene is not likely to play a significant role in alcoholism. | [
{
"begin_idx": "102",
"end_idx": "112",
"entity_id": "D000437",
"entity_type": "Disease",
"text_name": "alcoholism"
},
{
"begin_idx": "402",
"end_idx": "412",
"entity_id": "D000437",
"entity_type": "Disease",
"text_name": "alcoholism"
},
{
"begin_idx": "507",
"end_idx": "517",
"entity_id": "D000437",
"entity_type": "Disease",
"text_name": "alcoholism"
},
{
"begin_idx": "859",
"end_idx": "869",
"entity_id": "D000437",
"entity_type": "Disease",
"text_name": "alcoholism"
},
{
"begin_idx": "718",
"end_idx": "738",
"entity_id": "D001523",
"entity_type": "Disease",
"text_name": "antisocial behaviors"
},
{
"begin_idx": "64",
"end_idx": "92",
"entity_id": "1312",
"entity_type": "Gene",
"text_name": "catechol-O-methyltransferase"
},
{
"begin_idx": "114",
"end_idx": "142",
"entity_id": "1312",
"entity_type": "Gene",
"text_name": "Catechol-O-methyltransferase"
},
{
"begin_idx": "144",
"end_idx": "148",
"entity_id": "1312",
"entity_type": "Gene",
"text_name": "COMT"
},
{
"begin_idx": "264",
"end_idx": "268",
"entity_id": "1312",
"entity_type": "Gene",
"text_name": "COMT"
},
{
"begin_idx": "805",
"end_idx": "809",
"entity_id": "1312",
"entity_type": "Gene",
"text_name": "COMT"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "64",
"end_idx": "92",
"entity_id": "1312",
"entity_type": "Gene",
"text_name": "catechol-O-methyltransferase"
},
{
"begin_idx": "144",
"end_idx": "148",
"entity_id": "1312",
"entity_type": "Gene",
"text_name": "COMT"
}
] | [
{
"begin_idx": "102",
"end_idx": "112",
"entity_id": "D000437",
"entity_type": "Disease",
"text_name": "alcoholism"
},
{
"begin_idx": "718",
"end_idx": "738",
"entity_id": "D001523",
"entity_type": "Disease",
"text_name": "antisocial behaviors"
}
] | [
"catechol-O-methyltransferase",
"COMT"
] | [
"alcoholism",
"antisocial behaviors"
] |
10555044 | Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. | OBJECTIVE: To analyze the genotypes of the promoter region of the serotonin transporter gene (5-HTT) in patients with fibromyalgia (FM). METHODS: Genomic DNA from 62 patients meeting the American College of Rheumatology 1990 criteria for FM and 110 healthy controls was analyzed by polymerase chain reaction. Additionally, the psychopathologic state of 52 of the FM patients was evaluated using the Beck Depression Inventory (BDI) and the Symptom Checklist-90-Revised (SCL-90-R). RESULTS: The 5-HTTLPR genotypes in FM patients versus controls were distributed as follows: L/L 27% versus 34%, L/S 42% versus 50%, and S/S 31% versus 16%. FM patients with the S/S genotype had higher mean scores on the BDI and the SCL-90-R compared with those in the L/L and L/S groups. CONCLUSION: A higher frequency of the S/S genotype of 5-HTT was found in FM patients compared with healthy controls. The S/S subgroup exhibited higher mean levels of depression and psychological distress. These results support the notion of altered serotonin metabolism in at least a subgroup of patients with FM. | [
{
"begin_idx": "1044",
"end_idx": "1054",
"entity_id": "D003866",
"entity_type": "Disease",
"text_name": "depression"
},
{
"begin_idx": "24",
"end_idx": "36",
"entity_id": "D005356",
"entity_type": "Disease",
"text_name": "fibromyalgia"
},
{
"begin_idx": "228",
"end_idx": "240",
"entity_id": "D005356",
"entity_type": "Disease",
"text_name": "fibromyalgia"
},
{
"begin_idx": "242",
"end_idx": "244",
"entity_id": "D005356",
"entity_type": "Disease",
"text_name": "FM"
},
{
"begin_idx": "348",
"end_idx": "350",
"entity_id": "D005356",
"entity_type": "Disease",
"text_name": "FM"
},
{
"begin_idx": "473",
"end_idx": "475",
"entity_id": "D005356",
"entity_type": "Disease",
"text_name": "FM"
},
{
"begin_idx": "625",
"end_idx": "627",
"entity_id": "D005356",
"entity_type": "Disease",
"text_name": "FM"
},
{
"begin_idx": "746",
"end_idx": "748",
"entity_id": "D005356",
"entity_type": "Disease",
"text_name": "FM"
},
{
"begin_idx": "951",
"end_idx": "953",
"entity_id": "D005356",
"entity_type": "Disease",
"text_name": "FM"
},
{
"begin_idx": "1188",
"end_idx": "1190",
"entity_id": "D005356",
"entity_type": "Disease",
"text_name": "FM"
},
{
"begin_idx": "1059",
"end_idx": "1081",
"entity_id": "D020018",
"entity_type": "Disease",
"text_name": "psychological distress"
},
{
"begin_idx": "64",
"end_idx": "85",
"entity_id": "6532",
"entity_type": "Gene",
"text_name": "serotonin transporter"
},
{
"begin_idx": "176",
"end_idx": "197",
"entity_id": "6532",
"entity_type": "Gene",
"text_name": "serotonin transporter"
},
{
"begin_idx": "204",
"end_idx": "209",
"entity_id": "6532",
"entity_type": "Gene",
"text_name": "5-HTT"
},
{
"begin_idx": "932",
"end_idx": "937",
"entity_id": "6532",
"entity_type": "Gene",
"text_name": "5-HTT"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "64",
"end_idx": "85",
"entity_id": "6532",
"entity_type": "Gene",
"text_name": "serotonin transporter"
},
{
"begin_idx": "176",
"end_idx": "197",
"entity_id": "6532",
"entity_type": "Gene",
"text_name": "serotonin transporter"
}
] | [
{
"begin_idx": "24",
"end_idx": "36",
"entity_id": "D005356",
"entity_type": "Disease",
"text_name": "fibromyalgia"
},
{
"begin_idx": "1044",
"end_idx": "1054",
"entity_id": "D003866",
"entity_type": "Disease",
"text_name": "depression"
}
] | [
"serotonin transporter",
"serotonin transporter"
] | [
"fibromyalgia",
"depression"
] |
10556270 | Polymorphisms within the interleukin-10 receptor cDNA gene (IL10R) in Japanese patients with systemic lupus erythematosus. | OBJECTIVE: To assess the association between polymorphisms within the interleukin-10 receptor cDNA gene (IL10R) and systemic erythematosus (SLE) in Japanese people. METHOD: We examined the IL-10 receptor genotype of 109 SLE patients and 102 healthy subjects by the reverse transcription-polymerase chain reaction-restriction fragment length polymorphism (RT-PCR-RFLP) method. RESULTS: There was no difference in the IL10R genotype frequencies of these two groups. CONCLUSION: The IL10R genotype does not determine susceptibility to SLE in Japanese people. | [
{
"begin_idx": "93",
"end_idx": "121",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "systemic lupus erythematosus"
},
{
"begin_idx": "263",
"end_idx": "266",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "343",
"end_idx": "346",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "655",
"end_idx": "658",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
},
{
"begin_idx": "312",
"end_idx": "317",
"entity_id": "3586",
"entity_type": "Gene",
"text_name": "IL-10"
},
{
"begin_idx": "60",
"end_idx": "65",
"entity_id": "3587",
"entity_type": "Gene",
"text_name": "IL10R"
},
{
"begin_idx": "228",
"end_idx": "233",
"entity_id": "3587",
"entity_type": "Gene",
"text_name": "IL10R"
},
{
"begin_idx": "539",
"end_idx": "544",
"entity_id": "3587",
"entity_type": "Gene",
"text_name": "IL10R"
},
{
"begin_idx": "603",
"end_idx": "608",
"entity_id": "3587",
"entity_type": "Gene",
"text_name": "IL10R"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "312",
"end_idx": "317",
"entity_id": "3586",
"entity_type": "Gene",
"text_name": "IL-10"
},
{
"begin_idx": "539",
"end_idx": "544",
"entity_id": "3587",
"entity_type": "Gene",
"text_name": "IL10R"
}
] | [
{
"begin_idx": "93",
"end_idx": "121",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "systemic lupus erythematosus"
},
{
"begin_idx": "343",
"end_idx": "346",
"entity_id": "D008180",
"entity_type": "Disease",
"text_name": "SLE"
}
] | [
"IL-10",
"IL10R"
] | [
"systemic lupus erythematosus",
"SLE"
] |
10556299 | Severity of phenotype in cystinosis varies with mutations in the CTNS gene: predicted effect on the model of cystinosin. | Infantile nephropathic cystinosis is a rare, autosomal recessive disease caused by a defect in the transport of cystine across the lysosomal membrane and characterized by early onset of renal proximal tubular dysfunction. Late-onset cystinosis, a rarer form of the disorder, is characterized by onset of symptoms between 12 and 15 years of age. We previously characterized the cystinosis gene, CTNS, and identified pathogenic mutations in patients with infantile nephropathic cystinosis, including a common, approximately 65 kb deletion which encompasses exons 1-10. Structure predictions suggested that the gene product, cystinosin, is a novel integral lysosomal membrane protein. We now examine the predicted effect of mutations on this model of cystinosin. In this study, we screened patients with infantile nephropathic cystinosis, those with late-onset cystinosis and patients whose phenotype does not fit the classical definitions. We found 23 different mutations in CTNS; 14 are novel mutations. Out of 25 patients with infantile nephropathic cystinosis, 12 have two severely truncating mutations, which is consistent with a loss of functional protein, and 13 have missense or in-frame deletions, which would result in disruption of transmembrane domains and loss of protein function. Mutations found in two late-onset patients affect functionally unimportant regions of cystinosin, which accounts for their milder phenotype. For three patients, the age of onset of cystinosis was <7 years but the course of the disease was milder than the infantile nephropathic form. This suggests that the missense mutations found in these individuals allow production of functional protein and may also indicate regions of cystinosin which are not functionally important. | [
{
"begin_idx": "574",
"end_idx": "607",
"entity_id": "C565655",
"entity_type": "Disease",
"text_name": "infantile nephropathic cystinosis"
},
{
"begin_idx": "922",
"end_idx": "955",
"entity_id": "C565655",
"entity_type": "Disease",
"text_name": "infantile nephropathic cystinosis"
},
{
"begin_idx": "1148",
"end_idx": "1181",
"entity_id": "C565655",
"entity_type": "Disease",
"text_name": "infantile nephropathic cystinosis"
},
{
"begin_idx": "25",
"end_idx": "35",
"entity_id": "D003554",
"entity_type": "Disease",
"text_name": "cystinosis"
},
{
"begin_idx": "131",
"end_idx": "154",
"entity_id": "D003554",
"entity_type": "Disease",
"text_name": "nephropathic cystinosis"
},
{
"begin_idx": "354",
"end_idx": "364",
"entity_id": "D003554",
"entity_type": "Disease",
"text_name": "cystinosis"
},
{
"begin_idx": "498",
"end_idx": "508",
"entity_id": "D003554",
"entity_type": "Disease",
"text_name": "cystinosis"
},
{
"begin_idx": "979",
"end_idx": "989",
"entity_id": "D003554",
"entity_type": "Disease",
"text_name": "cystinosis"
},
{
"begin_idx": "1594",
"end_idx": "1604",
"entity_id": "D003554",
"entity_type": "Disease",
"text_name": "cystinosis"
},
{
"begin_idx": "1678",
"end_idx": "1690",
"entity_id": "D003554",
"entity_type": "Disease",
"text_name": "nephropathic"
},
{
"begin_idx": "307",
"end_idx": "341",
"entity_id": "D007674",
"entity_type": "Disease",
"text_name": "renal proximal tubular dysfunction"
},
{
"begin_idx": "166",
"end_idx": "193",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal recessive disease"
},
{
"begin_idx": "65",
"end_idx": "69",
"entity_id": "1497",
"entity_type": "Gene",
"text_name": "CTNS"
},
{
"begin_idx": "515",
"end_idx": "519",
"entity_id": "1497",
"entity_type": "Gene",
"text_name": "CTNS"
},
{
"begin_idx": "1094",
"end_idx": "1098",
"entity_id": "1497",
"entity_type": "Gene",
"text_name": "CTNS"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "65",
"end_idx": "69",
"entity_id": "1497",
"entity_type": "Gene",
"text_name": "CTNS"
},
{
"begin_idx": "1094",
"end_idx": "1098",
"entity_id": "1497",
"entity_type": "Gene",
"text_name": "CTNS"
}
] | [
{
"begin_idx": "131",
"end_idx": "154",
"entity_id": "D003554",
"entity_type": "Disease",
"text_name": "nephropathic cystinosis"
},
{
"begin_idx": "1148",
"end_idx": "1181",
"entity_id": "C565655",
"entity_type": "Disease",
"text_name": "infantile nephropathic cystinosis"
}
] | [
"CTNS",
"CTNS"
] | [
"nephropathic cystinosis",
"infantile nephropathic cystinosis"
] |
10558867 | Association of the estrogen receptor alpha gene polymorphisms with sporadic Alzheimer's disease. | Alzheimer's disease (AD) is a multifactorial disorder determined by the interaction of genetic, metabolic, and environmental factors. In the common late-onset familial and sporadic forms of AD apolipoprotein E type 4 allele (APOE-epsilon4) is now widely accepted as a major risk factor. The association of estrogen treatment with a reduction in the risk of AD together with the modulation by estrogen of the secretory metabolism of the amyloid precursor protein offers new possibilities for identification of other AD susceptibility genes, as those encoding for the estrogen receptors (ERs). A total of 193 patients with sporadic late-onset AD, meeting the NINCDS-ADRDA criteria, and a total of 202 control subjects, age and education matched, were included in this study. PvuII and XbaI ERalpha and HhaI APOE gene polymorphisms were evaluated in genomic DNA by Polymerase Chain Reaction (PCR). The frequency of the various ERalpha genotypes by the combination of P, p and X, x was calculated for controls and AD patients stratified based on ApoE typing. When the two ERalpha gene polymorphisms were analyzed in combination, 7 genotypes were recognized, with a significantly increased prevalence of PPXX genotype in AD patients compared to controls (P = 0.0001). Risk of AD increased by a factor of 7.6 (CI [1.10-62.3]) in homozygous APOE-epsilon4 individuals with PPXX ERalpha genotype. These results are consistent with a segregation of PPXX ERalpha genotype with a higher risk of developing late-onset sporadic AD in the Italian population. The ERalpha gene appears to interact with the APOE-epsilon4 genotype in determining AD susceptibility. | [
{
"begin_idx": "76",
"end_idx": "95",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "Alzheimer's disease"
},
{
"begin_idx": "97",
"end_idx": "116",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "Alzheimer's disease"
},
{
"begin_idx": "118",
"end_idx": "120",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "287",
"end_idx": "289",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "454",
"end_idx": "456",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "612",
"end_idx": "614",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "738",
"end_idx": "740",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "1107",
"end_idx": "1109",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "1313",
"end_idx": "1315",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "1368",
"end_idx": "1370",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "1602",
"end_idx": "1613",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "sporadic AD"
},
{
"begin_idx": "1725",
"end_idx": "1727",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "19",
"end_idx": "42",
"entity_id": "2099",
"entity_type": "Gene",
"text_name": "estrogen receptor alpha"
},
{
"begin_idx": "885",
"end_idx": "892",
"entity_id": "2099",
"entity_type": "Gene",
"text_name": "ERalpha"
},
{
"begin_idx": "1021",
"end_idx": "1028",
"entity_id": "2099",
"entity_type": "Gene",
"text_name": "ERalpha"
},
{
"begin_idx": "1165",
"end_idx": "1172",
"entity_id": "2099",
"entity_type": "Gene",
"text_name": "ERalpha"
},
{
"begin_idx": "1467",
"end_idx": "1474",
"entity_id": "2099",
"entity_type": "Gene",
"text_name": "ERalpha"
},
{
"begin_idx": "1541",
"end_idx": "1548",
"entity_id": "2099",
"entity_type": "Gene",
"text_name": "ERalpha"
},
{
"begin_idx": "1645",
"end_idx": "1652",
"entity_id": "2099",
"entity_type": "Gene",
"text_name": "ERalpha"
},
{
"begin_idx": "322",
"end_idx": "326",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "APOE"
},
{
"begin_idx": "902",
"end_idx": "906",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "APOE"
},
{
"begin_idx": "1139",
"end_idx": "1143",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "ApoE"
},
{
"begin_idx": "1431",
"end_idx": "1435",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "APOE"
},
{
"begin_idx": "1687",
"end_idx": "1691",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "APOE"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "19",
"end_idx": "42",
"entity_id": "2099",
"entity_type": "Gene",
"text_name": "estrogen receptor alpha"
},
{
"begin_idx": "1687",
"end_idx": "1691",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "APOE"
}
] | [
{
"begin_idx": "76",
"end_idx": "95",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "Alzheimer's disease"
},
{
"begin_idx": "1368",
"end_idx": "1370",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
}
] | [
"estrogen receptor alpha",
"APOE"
] | [
"Alzheimer's disease",
"AD"
] |
10559218 | Mutations in novel organic cation transporter (OCTN2), an organic cation/carnitine transporter, with differential effects on the organic cation transport function and the carnitine transport function. | Novel organic cation transporter (OCTN2) is an organic cation/carnitine transporter, and two missense mutations, L352R and P478L, in OCTN2 have been identified as the cause for primary carnitine deficiency. In the present study, we assessed the influence of these two mutations on the carnitine transport function and the organic cation transport function of OCTN2. The L352R mutation resulted in a complete loss of both transport functions. In contrast, the P478L mutation resulted in a complete loss of only the carnitine transport function but significantly stimulated the organic cation transport function. Studies with human OCTN2/rat OCTN2 chimeric transporters indicated that the carnitine transport site and the organic cation transport site were not identical. Because carnitine transport is Na(+)-dependent whereas organic cation transport is Na(+)-independent, we investigated the possibility that the P478L mutation affected Na(+) binding. The Na(+) activation kinetics were found to be similar for the P478L mutant and wild type OCTN2. We then mutated nine different tyrosine residues located in or near transmembrane domains and assessed the transport function of these mutants. One of these mutations, Y211F, was found to have differential influence on the two transport activities of OCTN2 as did the P478L mutation. However, the Na(+) activation kinetics were not affected. These findings are of clinical relevance to patients with primary carnitine deficiency because whereas each and every mutation in these patients is expected to result in the loss of the carnitine transport function, all of these mutations may not interfere with the organic cation transport function. | [
{
"begin_idx": "386",
"end_idx": "406",
"entity_id": "C536778",
"entity_type": "Disease",
"text_name": "carnitine deficiency"
},
{
"begin_idx": "1658",
"end_idx": "1678",
"entity_id": "C536778",
"entity_type": "Disease",
"text_name": "carnitine deficiency"
},
{
"begin_idx": "47",
"end_idx": "52",
"entity_id": "6584",
"entity_type": "Gene",
"text_name": "OCTN2"
},
{
"begin_idx": "235",
"end_idx": "240",
"entity_id": "6584",
"entity_type": "Gene",
"text_name": "OCTN2"
},
{
"begin_idx": "334",
"end_idx": "339",
"entity_id": "6584",
"entity_type": "Gene",
"text_name": "OCTN2"
},
{
"begin_idx": "560",
"end_idx": "565",
"entity_id": "6584",
"entity_type": "Gene",
"text_name": "OCTN2"
},
{
"begin_idx": "831",
"end_idx": "836",
"entity_id": "6584",
"entity_type": "Gene",
"text_name": "OCTN2"
},
{
"begin_idx": "841",
"end_idx": "846",
"entity_id": "6584",
"entity_type": "Gene",
"text_name": "OCTN2"
},
{
"begin_idx": "1243",
"end_idx": "1248",
"entity_id": "6584",
"entity_type": "Gene",
"text_name": "OCTN2"
},
{
"begin_idx": "1501",
"end_idx": "1506",
"entity_id": "6584",
"entity_type": "Gene",
"text_name": "OCTN2"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "47",
"end_idx": "52",
"entity_id": "6584",
"entity_type": "Gene",
"text_name": "OCTN2"
}
] | [
{
"begin_idx": "386",
"end_idx": "406",
"entity_id": "C536778",
"entity_type": "Disease",
"text_name": "carnitine deficiency"
}
] | [
"OCTN2"
] | [
"carnitine deficiency"
] |
10561141 | Detection of mutations in the COL4A5 gene in over 90% of male patients with X-linked Alport's syndrome by RT-PCR and direct sequencing. | X-linked Alport's syndrome is caused by mutations in the COL4A5 gene encoding the type IV collagen alpha5 chain (alpha5[IV]). Polymerase chain reaction-single-str and conformation polymorphism (PCR-SSCP) on genomic DNA has previously been used to screen for mutations in the COL4A5 gene, but this method was relatively insensitive, with mutations detected in less than 50% of patients. Here, we report a systematic analysis of the entire coding region of the COL4A5 gene, using nested reverse-transcription-polymerase chain reaction (RT-PCR) and the direct sequence method using leukocytes. This study examines twenty-two unrelated Japanese patients with X-linked Alport's syndrome showing abnormal expression of alpha5(IV) in the glomerular or epidermal basement membranes. Mutations that were predicted to be pathogenic were identified in 12 of the 13 male patients (92%) and five of the nine female patients (56%). Six patients had missense mutations, four had out-of-frame deletion mutations, three had nonsense mutations, and three had mutations causing exon loss of the transcript. The current study shows that nested RT-PCR and the direct sequence method using leukocytes are highly sensitive and offer a useful approach for systematic gene analysis in patients with X-linked Alport's syndrome. | [
{
"begin_idx": "76",
"end_idx": "102",
"entity_id": "D009394",
"entity_type": "Disease",
"text_name": "X-linked Alport's syndrome"
},
{
"begin_idx": "136",
"end_idx": "162",
"entity_id": "D009394",
"entity_type": "Disease",
"text_name": "X-linked Alport's syndrome"
},
{
"begin_idx": "791",
"end_idx": "817",
"entity_id": "D009394",
"entity_type": "Disease",
"text_name": "X-linked Alport's syndrome"
},
{
"begin_idx": "1410",
"end_idx": "1436",
"entity_id": "D009394",
"entity_type": "Disease",
"text_name": "X-linked Alport's syndrome"
},
{
"begin_idx": "30",
"end_idx": "36",
"entity_id": "1287",
"entity_type": "Gene",
"text_name": "COL4A5"
},
{
"begin_idx": "193",
"end_idx": "199",
"entity_id": "1287",
"entity_type": "Gene",
"text_name": "COL4A5"
},
{
"begin_idx": "411",
"end_idx": "417",
"entity_id": "1287",
"entity_type": "Gene",
"text_name": "COL4A5"
},
{
"begin_idx": "595",
"end_idx": "601",
"entity_id": "1287",
"entity_type": "Gene",
"text_name": "COL4A5"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "30",
"end_idx": "36",
"entity_id": "1287",
"entity_type": "Gene",
"text_name": "COL4A5"
}
] | [
{
"begin_idx": "76",
"end_idx": "102",
"entity_id": "D009394",
"entity_type": "Disease",
"text_name": "X-linked Alport's syndrome"
}
] | [
"COL4A5"
] | [
"X-linked Alport's syndrome"
] |
10563487 | Three novel mutations in the COL4A5 gene in Mexican Alport syndrome patients. | [
{
"begin_idx": "52",
"end_idx": "67",
"entity_id": "D009394",
"entity_type": "Disease",
"text_name": "Alport syndrome"
},
{
"begin_idx": "29",
"end_idx": "35",
"entity_id": "1287",
"entity_type": "Gene",
"text_name": "COL4A5"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "29",
"end_idx": "35",
"entity_id": "1287",
"entity_type": "Gene",
"text_name": "COL4A5"
}
] | [
{
"begin_idx": "52",
"end_idx": "67",
"entity_id": "D009394",
"entity_type": "Disease",
"text_name": "Alport syndrome"
}
] | [
"COL4A5"
] | [
"Alport syndrome"
] |
|
10563634 | APOE-epsilon4 is associated with less frontal and more medial temporal lobe atrophy in AD. | OBJECTIVE: To test the hypothesis that the e4 allele of APOE is associated with a region-specific pattern of brain atrophy in AD. METHODS: Volumes of the hippocampi, entorhinal cortices, and anterior temporal and frontal lobes were measured in 28 mild to moderate AD patients and 30 controls using MRI. Within the AD group, 14 patients were noncarriers (-/-), 9 were heterozygous (e4/-), and 5 were homozygous (e4/4) for the e4 allele. Dementia severity was similar across the three AD groups. RESULTS: Smaller volumes were found with increasing dose of the e4 allele in the hippocampus, entorhinal cortex, and anterior temporal lobes in AD patients. When compared with controls, the volume loss in the right and left temporal regions ranged from -15.3 to -22.7% in the -/- AD group, from -26.2 to -36.0% in the e4/- group, and from -24.0 to -48.0% in the e4/4 group (p < 0.0005). In contrast, larger volumes were found in the frontal lobes with increasing e4 gene dose. When compared with controls, volume differences of the right frontal lobe were -11.8% in the -/- AD group, -8.5 in the e4/- group, and -1.4% in the e4/4 group (p = 0.03). CONCLUSIONS: We found smaller volumes in the temporal lobe regions but larger volumes in the frontal lobes with increasing APOE-e4 gene dose in AD patients. These data suggest a region-specific biological effect of the e4 allele in the brains of AD patients. | [
{
"begin_idx": "200",
"end_idx": "213",
"entity_id": "C566985",
"entity_type": "Disease",
"text_name": "brain atrophy"
},
{
"begin_idx": "87",
"end_idx": "89",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "217",
"end_idx": "219",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "355",
"end_idx": "357",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "405",
"end_idx": "407",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "574",
"end_idx": "576",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "729",
"end_idx": "731",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "865",
"end_idx": "867",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "1159",
"end_idx": "1161",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "1377",
"end_idx": "1379",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "1479",
"end_idx": "1481",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "76",
"end_idx": "83",
"entity_id": "D001284",
"entity_type": "Disease",
"text_name": "atrophy"
},
{
"begin_idx": "527",
"end_idx": "535",
"entity_id": "D003704",
"entity_type": "Disease",
"text_name": "Dementia"
},
{
"begin_idx": "775",
"end_idx": "786",
"entity_id": "D034381",
"entity_type": "Disease",
"text_name": "volume loss"
},
{
"begin_idx": "0",
"end_idx": "4",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "APOE"
},
{
"begin_idx": "147",
"end_idx": "151",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "APOE"
},
{
"begin_idx": "1356",
"end_idx": "1360",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "APOE"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "0",
"end_idx": "4",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "APOE"
},
{
"begin_idx": "1356",
"end_idx": "1360",
"entity_id": "348",
"entity_type": "Gene",
"text_name": "APOE"
}
] | [
{
"begin_idx": "87",
"end_idx": "89",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "200",
"end_idx": "213",
"entity_id": "C566985",
"entity_type": "Disease",
"text_name": "brain atrophy"
}
] | [
"APOE",
"APOE"
] | [
"AD",
"brain atrophy"
] |
10564334 | Ichthyosis bullosa of Siemens resulting from a novel missense mutation near the helix termination motif of the keratin 2e gene. | Ichthyosis bullosa of Siemens (IBS) is an autosomal dominant disorder of keratinization. It is characterized by a mild epidermolytic ichthyosis which tends to localize to the flexures. Affected individuals are born with widespread blistering, which develops into large hyperkeratotic plaques over the extremities. Mutations in the K2e gene cause epidermolytic hyperkeratosis confined to the upper spinous and granular layers, as observed in IBS. In this report, we describe a novel mutation in the keratin 2e gene in a four-generation IBS kindred of German ancestry. The mutation resides within the 2B helix termination motif of the keratin 2e gene, and extends the body of evidence implicating keratin 2e gene mutations in IBS. | [
{
"begin_idx": "247",
"end_idx": "271",
"entity_id": "D017488",
"entity_type": "Disease",
"text_name": "epidermolytic ichthyosis"
},
{
"begin_idx": "474",
"end_idx": "502",
"entity_id": "D017488",
"entity_type": "Disease",
"text_name": "epidermolytic hyperkeratosis"
},
{
"begin_idx": "170",
"end_idx": "215",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal dominant disorder of keratinization"
},
{
"begin_idx": "0",
"end_idx": "29",
"entity_id": "D053560",
"entity_type": "Disease",
"text_name": "Ichthyosis bullosa of Siemens"
},
{
"begin_idx": "128",
"end_idx": "157",
"entity_id": "D053560",
"entity_type": "Disease",
"text_name": "Ichthyosis bullosa of Siemens"
},
{
"begin_idx": "159",
"end_idx": "162",
"entity_id": "D053560",
"entity_type": "Disease",
"text_name": "IBS"
},
{
"begin_idx": "569",
"end_idx": "572",
"entity_id": "D053560",
"entity_type": "Disease",
"text_name": "IBS"
},
{
"begin_idx": "663",
"end_idx": "666",
"entity_id": "D053560",
"entity_type": "Disease",
"text_name": "IBS"
},
{
"begin_idx": "852",
"end_idx": "855",
"entity_id": "D053560",
"entity_type": "Disease",
"text_name": "IBS"
},
{
"begin_idx": "111",
"end_idx": "121",
"entity_id": "3849",
"entity_type": "Gene",
"text_name": "keratin 2e"
},
{
"begin_idx": "459",
"end_idx": "462",
"entity_id": "3849",
"entity_type": "Gene",
"text_name": "K2e"
},
{
"begin_idx": "626",
"end_idx": "636",
"entity_id": "3849",
"entity_type": "Gene",
"text_name": "keratin 2e"
},
{
"begin_idx": "761",
"end_idx": "771",
"entity_id": "3849",
"entity_type": "Gene",
"text_name": "keratin 2e"
},
{
"begin_idx": "823",
"end_idx": "833",
"entity_id": "3849",
"entity_type": "Gene",
"text_name": "keratin 2e"
}
] | [
"Yes",
"No"
] | [
true,
true
] | [
{
"begin_idx": "111",
"end_idx": "121",
"entity_id": "3849",
"entity_type": "Gene",
"text_name": "keratin 2e"
},
{
"begin_idx": "761",
"end_idx": "771",
"entity_id": "3849",
"entity_type": "Gene",
"text_name": "keratin 2e"
}
] | [
{
"begin_idx": "0",
"end_idx": "29",
"entity_id": "D053560",
"entity_type": "Disease",
"text_name": "Ichthyosis bullosa of Siemens"
},
{
"begin_idx": "474",
"end_idx": "502",
"entity_id": "D017488",
"entity_type": "Disease",
"text_name": "epidermolytic hyperkeratosis"
}
] | [
"keratin 2e",
"keratin 2e"
] | [
"Ichthyosis bullosa of Siemens",
"epidermolytic hyperkeratosis"
] |
10566598 | Influence of TNF microsatellite polymorphisms (TNFa) on age-at-onset of insulin-dependent diabetes mellitus. | The TNF-alpha gene is located in the HLA region and has been implicated in the pathogenesis of Type I (insulin-dependent) diabetes mellitus (IDDM). We investigated the frequency of TNFa microsatellite alleles in 76 young-onset IDDM patients, 65 adult-onset IDDM patients, and 90 control subjects. We also examined the association of these TNFa alleles with HLA-DRB1 alleles, HLA-class I alleles, and TNF-alpha production. The frequency of the TNFa2 and TNFa9 alleles was increased in the young-onset IDDM patients compared to control subjects, but the increased frequency of TNFa2 was not significant after the correction for the number of comparisons was made. We did not find any association of TNFa2 or TNFa9 with any of the HLA-DRB1 alleles. In contrast, the frequency of the TNFa13 allele was decreased in both the young-onset and the adult-onset IDDM patients compared to the control subjects, but the difference lost significance after the correction was made in the adult-onset IDDM. The TNFa13 allele was strongly associated with DRB1*1502. Patients with TNFa2 or TNFa9 had greater TNF-alpha production, while those positive for TNFa13 had lower TNF-alpha production than patients with non-TNFa2, a9, and a13 alleles. These results suggest that TNFa polymorphisms are associated with age-at-onset of IDDM and influence the inflammatory process of pancreatic beta cell destruction in the development of IDDM. | [
{
"begin_idx": "72",
"end_idx": "107",
"entity_id": "D003922",
"entity_type": "Disease",
"text_name": "insulin-dependent diabetes mellitus"
},
{
"begin_idx": "204",
"end_idx": "248",
"entity_id": "D003922",
"entity_type": "Disease",
"text_name": "Type I (insulin-dependent) diabetes mellitus"
},
{
"begin_idx": "250",
"end_idx": "254",
"entity_id": "D003922",
"entity_type": "Disease",
"text_name": "IDDM"
},
{
"begin_idx": "336",
"end_idx": "340",
"entity_id": "D003922",
"entity_type": "Disease",
"text_name": "IDDM"
},
{
"begin_idx": "366",
"end_idx": "370",
"entity_id": "D003922",
"entity_type": "Disease",
"text_name": "IDDM"
},
{
"begin_idx": "609",
"end_idx": "613",
"entity_id": "D003922",
"entity_type": "Disease",
"text_name": "IDDM"
},
{
"begin_idx": "961",
"end_idx": "965",
"entity_id": "D003922",
"entity_type": "Disease",
"text_name": "IDDM"
},
{
"begin_idx": "1095",
"end_idx": "1099",
"entity_id": "D003922",
"entity_type": "Disease",
"text_name": "IDDM"
},
{
"begin_idx": "1418",
"end_idx": "1422",
"entity_id": "D003922",
"entity_type": "Disease",
"text_name": "IDDM"
},
{
"begin_idx": "1520",
"end_idx": "1524",
"entity_id": "D003922",
"entity_type": "Disease",
"text_name": "IDDM"
},
{
"begin_idx": "466",
"end_idx": "474",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "HLA-DRB1"
},
{
"begin_idx": "837",
"end_idx": "845",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "HLA-DRB1"
},
{
"begin_idx": "13",
"end_idx": "45",
"entity_id": "7124",
"entity_type": "Gene",
"text_name": "TNF microsatellite polymorphisms"
},
{
"begin_idx": "47",
"end_idx": "51",
"entity_id": "7124",
"entity_type": "Gene",
"text_name": "TNFa"
},
{
"begin_idx": "113",
"end_idx": "122",
"entity_id": "7124",
"entity_type": "Gene",
"text_name": "TNF-alpha"
},
{
"begin_idx": "290",
"end_idx": "294",
"entity_id": "7124",
"entity_type": "Gene",
"text_name": "TNFa"
},
{
"begin_idx": "448",
"end_idx": "452",
"entity_id": "7124",
"entity_type": "Gene",
"text_name": "TNFa"
},
{
"begin_idx": "509",
"end_idx": "518",
"entity_id": "7124",
"entity_type": "Gene",
"text_name": "TNF-alpha"
},
{
"begin_idx": "1200",
"end_idx": "1209",
"entity_id": "7124",
"entity_type": "Gene",
"text_name": "TNF-alpha"
},
{
"begin_idx": "1264",
"end_idx": "1273",
"entity_id": "7124",
"entity_type": "Gene",
"text_name": "TNF-alpha"
},
{
"begin_idx": "1363",
"end_idx": "1367",
"entity_id": "7124",
"entity_type": "Gene",
"text_name": "TNFa"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "13",
"end_idx": "45",
"entity_id": "7124",
"entity_type": "Gene",
"text_name": "TNF microsatellite polymorphisms"
},
{
"begin_idx": "466",
"end_idx": "474",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "HLA-DRB1"
}
] | [
{
"begin_idx": "204",
"end_idx": "248",
"entity_id": "D003922",
"entity_type": "Disease",
"text_name": "Type I (insulin-dependent) diabetes mellitus"
},
{
"begin_idx": "250",
"end_idx": "254",
"entity_id": "D003922",
"entity_type": "Disease",
"text_name": "IDDM"
}
] | [
"TNF microsatellite polymorphisms",
"HLA-DRB1"
] | [
"Type I (insulin-dependent) diabetes mellitus",
"IDDM"
] |
10566637 | A novel compound heterozygous mutation in the steroidogenic acute regulatory protein gene in a patient with congenital lipoid adrenal hyperplasia. | Congenital lipoid adrenal hyperplasia (CLAH) is an autosomal recessive disorder characterized by impaired synthesis of all adrenal and gonadal steroid hormones. Recently, it was reported that mutations in the steroidogenic acute regulatory protein (StAR) gene cause CLAH. In the present study, we have analyzed the StAR gene of a Japanese patient with CLAH. PCR amplification and subsequent nucleotide sequencing of the StAR gene and those of her parents revealed that the patient has a compound heterozygous mutation of this gene. In one allele, an undescribed G to C transversion in codon 217, which occurred at the last base of exon 5 and thus altered the splice donor site sequence, apparently resulted in a substitution of Arg to Thr (AGG to ACG: R217T), and in the other allele, a C to T transition in codon 218 caused a substitution of Ala to Val (GCG to GTG: A218V), which has been previously shown to abolish StAR activity. In vitro expression analysis of an allelic minigene that consists of exons 4-6 of the R217T mutant StAR gene showed that the G to C transversion in the splice donor site of exon 5 caused by the R217T mutation disrupts normal splicing, resulting in the complete skipping of exon 5, which alters the translation reading frame of exon 6, introduces a stop codon at amino acid position 174, and thus impairs the activity. A functional expression study of the R217T replacement mutant revealed that the mutant has no steroidogenesis-enhancing activity if the transcript of the R217T mutant allele is ever spliced normally and translated into the protein. From the genetic analysis of 50 healthy subjects, the novel R217T mutation was unlikely to be due to polymorphism. Together, these results indicate that this patient is a compound heterozygote for the mutation in the StAR gene (T217R and A218V) and that these mutations inactivate the StAR function and give rise to clinically manifest CLAH. | [
{
"begin_idx": "108",
"end_idx": "145",
"entity_id": "C537027",
"entity_type": "Disease",
"text_name": "congenital lipoid adrenal hyperplasia"
},
{
"begin_idx": "147",
"end_idx": "184",
"entity_id": "C537027",
"entity_type": "Disease",
"text_name": "Congenital lipoid adrenal hyperplasia"
},
{
"begin_idx": "186",
"end_idx": "190",
"entity_id": "C537027",
"entity_type": "Disease",
"text_name": "CLAH"
},
{
"begin_idx": "413",
"end_idx": "417",
"entity_id": "C537027",
"entity_type": "Disease",
"text_name": "CLAH"
},
{
"begin_idx": "499",
"end_idx": "503",
"entity_id": "C537027",
"entity_type": "Disease",
"text_name": "CLAH"
},
{
"begin_idx": "2066",
"end_idx": "2070",
"entity_id": "C537027",
"entity_type": "Disease",
"text_name": "CLAH"
},
{
"begin_idx": "198",
"end_idx": "226",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal recessive disorder"
},
{
"begin_idx": "46",
"end_idx": "84",
"entity_id": "6770",
"entity_type": "Gene",
"text_name": "steroidogenic acute regulatory protein"
},
{
"begin_idx": "356",
"end_idx": "394",
"entity_id": "6770",
"entity_type": "Gene",
"text_name": "steroidogenic acute regulatory protein"
},
{
"begin_idx": "396",
"end_idx": "400",
"entity_id": "6770",
"entity_type": "Gene",
"text_name": "StAR"
},
{
"begin_idx": "462",
"end_idx": "466",
"entity_id": "6770",
"entity_type": "Gene",
"text_name": "StAR"
},
{
"begin_idx": "567",
"end_idx": "571",
"entity_id": "6770",
"entity_type": "Gene",
"text_name": "StAR"
},
{
"begin_idx": "1065",
"end_idx": "1069",
"entity_id": "6770",
"entity_type": "Gene",
"text_name": "StAR"
},
{
"begin_idx": "1179",
"end_idx": "1183",
"entity_id": "6770",
"entity_type": "Gene",
"text_name": "StAR"
},
{
"begin_idx": "1947",
"end_idx": "1951",
"entity_id": "6770",
"entity_type": "Gene",
"text_name": "StAR"
},
{
"begin_idx": "2015",
"end_idx": "2019",
"entity_id": "6770",
"entity_type": "Gene",
"text_name": "StAR"
}
] | [
"Yes",
"No"
] | [
true,
false
] | [
{
"begin_idx": "46",
"end_idx": "84",
"entity_id": "6770",
"entity_type": "Gene",
"text_name": "steroidogenic acute regulatory protein"
},
{
"begin_idx": "1065",
"end_idx": "1069",
"entity_id": "6770",
"entity_type": "Gene",
"text_name": "StAR"
}
] | [
{
"begin_idx": "108",
"end_idx": "145",
"entity_id": "C537027",
"entity_type": "Disease",
"text_name": "congenital lipoid adrenal hyperplasia"
},
{
"begin_idx": "198",
"end_idx": "226",
"entity_id": "D030342",
"entity_type": "Disease",
"text_name": "autosomal recessive disorder"
}
] | [
"steroidogenic acute regulatory protein",
"StAR"
] | [
"congenital lipoid adrenal hyperplasia",
"autosomal recessive disorder"
] |
10566648 | Aromatase deficiency caused by a novel P450arom gene mutation: impact of absent estrogen production on serum gonadotropin concentration in a boy. | We identified a new point mutation in the CYP19 gene responsible for aromatase (P450arom) deficiency in a 46,XY male infant with unremarkable clinical findings at birth. This boy is homozygote for a 1-bp (C) deletion in exon 5 of the aromatase gene causing a frame-shift mutation. The frame-shift results in a prematurely terminated protein that is inactive due to the absence of the functional regions of the enzyme. Aromatase deficiency was suspected prenatally because of the severe virilization of the mother during the early pregnancy, and the diagnosis was confirmed shortly after birth. Four weeks after birth, the baby boy showed extremely low levels of serum estrogens, but had a normal level of serum free testosterone; in comparison with the high serum concentration of androstenedione at birth, a striking decrease occurred by 4 weeks postnatally. We previously reported elevated basal and stimulated FSH levels in a female infant with aromatase deficiency in the first year of life. In contrast, in the male infant, basal FSH and peak FSH levels after standard GnRH stimulation tests were normal. This finding suggests that the contribution of estrogen to the hypothalamic-pituitary gonadotropin-gonadal feedback mechanism is different in boys and girls during infancy and early childhood. In normal girls, serum estradiol concentrations strongly correlate with circulating inhibin levels, and thus, low inhibin levels may contribute to the striking elevation of FSH in young girls with aromatase deficiency. In contrast, estradiol levels are physiologically about a 7-fold lower in boys than in girls, and serum inhibin levels remain elevated even though levels of FSH, LH, and testosterone are decreased. | [
{
"begin_idx": "0",
"end_idx": "20",
"entity_id": "C537436",
"entity_type": "Disease",
"text_name": "Aromatase deficiency"
},
{
"begin_idx": "564",
"end_idx": "584",
"entity_id": "C537436",
"entity_type": "Disease",
"text_name": "Aromatase deficiency"
},
{
"begin_idx": "1094",
"end_idx": "1114",
"entity_id": "C537436",
"entity_type": "Disease",
"text_name": "aromatase deficiency"
},
{
"begin_idx": "1646",
"end_idx": "1666",
"entity_id": "C537436",
"entity_type": "Disease",
"text_name": "aromatase deficiency"
},
{
"begin_idx": "39",
"end_idx": "47",
"entity_id": "1588",
"entity_type": "Gene",
"text_name": "P450arom"
},
{
"begin_idx": "188",
"end_idx": "193",
"entity_id": "1588",
"entity_type": "Gene",
"text_name": "CYP19"
},
{
"begin_idx": "226",
"end_idx": "234",
"entity_id": "1588",
"entity_type": "Gene",
"text_name": "P450arom"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "39",
"end_idx": "47",
"entity_id": "1588",
"entity_type": "Gene",
"text_name": "P450arom"
}
] | [
{
"begin_idx": "0",
"end_idx": "20",
"entity_id": "C537436",
"entity_type": "Disease",
"text_name": "Aromatase deficiency"
}
] | [
"P450arom"
] | [
"Aromatase deficiency"
] |
10568518 | Risk for Alzheimer's disease in older late-onset cases is associated with HLA-DRB1*03. | The allele frequency of the HLA-DRB1 gene was compared between groups of 48 clinically diagnosed elderly Alzheimer's disease (AD) cases and 44 pathologically confirmed elderly control cases. Specific primers were used to PCR amplify the highly polymorphic second exon of HLA-DRB1 using DNA extracted from blood samples or frozen brain tissue. The allele type was identified using sequence specific oligonucleotide probes. The results showed an increased frequency of DRB1*03 (P < 0.006) and decreased frequency of DRB1*09 (P < 0.049) in the AD cases compared with the controls. The results suggest that DRB1*03 is associated with an increased risk and DRB1*09 a possible decreased risk for the development of late-onset AD with first detectable clinical symptoms occurring at age 75 years or greater. | [
{
"begin_idx": "9",
"end_idx": "28",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "Alzheimer's disease"
},
{
"begin_idx": "192",
"end_idx": "211",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "Alzheimer's disease"
},
{
"begin_idx": "213",
"end_idx": "215",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "628",
"end_idx": "630",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "807",
"end_idx": "809",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "AD"
},
{
"begin_idx": "74",
"end_idx": "82",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "HLA-DRB1"
},
{
"begin_idx": "115",
"end_idx": "123",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "HLA-DRB1"
},
{
"begin_idx": "358",
"end_idx": "366",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "HLA-DRB1"
},
{
"begin_idx": "554",
"end_idx": "558",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "DRB1"
},
{
"begin_idx": "601",
"end_idx": "605",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "DRB1"
},
{
"begin_idx": "690",
"end_idx": "694",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "DRB1"
},
{
"begin_idx": "739",
"end_idx": "743",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "DRB1"
}
] | [
"Yes"
] | [
true
] | [
{
"begin_idx": "74",
"end_idx": "82",
"entity_id": "3123",
"entity_type": "Gene",
"text_name": "HLA-DRB1"
}
] | [
{
"begin_idx": "9",
"end_idx": "28",
"entity_id": "D000544",
"entity_type": "Disease",
"text_name": "Alzheimer's disease"
}
] | [
"HLA-DRB1"
] | [
"Alzheimer's disease"
] |
10570779 | [Distributive shock and it's therapy by cardio-vascular acting drugs]. | Distributive shock is defined as circulatory insufficiency induced by excessive dilatation of the peripheral vasculature or maldistribution of cardiac output. Septicemia, systemic inflammatory response syndrome, anaphylaxis, injuries to the central nervous system, and drug intoxication are causative factors of shock. Circulatory derangements induced by bacterial infection have been divided into hyperdynamic and hypodynamic shock. Administration of inotropic drugs, vasopressors, and/or vasodilators are primary treatments in this type of shock. Continuous infusion of norepinephrine to maintain blood pressure or administration of inoptropes such as dopamine or dobutamine are recommended to improve tissue perfusion. High-dose intravenous epinephrine is required to reestablish cardiac function, followed by continuous infusion of norepinephrine in severe anaphylactic shock. Vasoconstrictors such as norepinephrine, vasopressin, or amaminone are administered to maintain vascular tone in shock caused by nerve damage or drug overdose. | [
{
"begin_idx": "283",
"end_idx": "294",
"entity_id": "D000707",
"entity_type": "Disease",
"text_name": "anaphylaxis"
},
{
"begin_idx": "426",
"end_idx": "445",
"entity_id": "D001424",
"entity_type": "Disease",
"text_name": "bacterial infection"
},
{
"begin_idx": "296",
"end_idx": "334",
"entity_id": "D002493",
"entity_type": "Disease",
"text_name": "injuries to the central nervous system"
},
{
"begin_idx": "1081",
"end_idx": "1093",
"entity_id": "D009422",
"entity_type": "Disease",
"text_name": "nerve damage"
},
{
"begin_idx": "1",
"end_idx": "19",
"entity_id": "D012769",
"entity_type": "Disease",
"text_name": "Distributive shock"
},
{
"begin_idx": "71",
"end_idx": "89",
"entity_id": "D012769",
"entity_type": "Disease",
"text_name": "Distributive shock"
},
{
"begin_idx": "242",
"end_idx": "281",
"entity_id": "D018746",
"entity_type": "Disease",
"text_name": "systemic inflammatory response syndrome"
},
{
"begin_idx": "230",
"end_idx": "240",
"entity_id": "D018805",
"entity_type": "Disease",
"text_name": "Septicemia"
},
{
"begin_idx": "1102",
"end_idx": "1110",
"entity_id": "D062787",
"entity_type": "Disease",
"text_name": "overdose"
},
{
"begin_idx": "993",
"end_idx": "1004",
"entity_id": "551",
"entity_type": "Gene",
"text_name": "vasopressin"
}
] | [
"Yes",
"No"
] | [
false,
false
] | [
{
"begin_idx": "993",
"end_idx": "1004",
"entity_id": "551",
"entity_type": "Gene",
"text_name": "vasopressin"
},
{
"begin_idx": "993",
"end_idx": "1004",
"entity_id": "551",
"entity_type": "Gene",
"text_name": "vasopressin"
}
] | [
{
"begin_idx": "1",
"end_idx": "19",
"entity_id": "D012769",
"entity_type": "Disease",
"text_name": "Distributive shock"
},
{
"begin_idx": "230",
"end_idx": "240",
"entity_id": "D018805",
"entity_type": "Disease",
"text_name": "Septicemia"
}
] | [
"vasopressin",
"vasopressin"
] | [
"Distributive shock",
"Septicemia"
] |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.